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ABSTRACT 
Leishmaniasis is a vector-borne disease caused by protozoan parasites of the genus 
Leishmania that affects millions of people worldwide. The disease can assume different 
clinical forms depending on the infectious species and also on the immune status of the 
host. Visceral leishmaniasis, caused by the members of the L. donovani complex, is the 
most severe form of the disease and is fatal if left untreated. Currently there is no effective 
vaccine available and the chemotherapeutic treatment that exists is expensive, toxic and 
lacks efficacy; moreover, drug resistance has emerged as a serious problem. Thus novel 
therapies are urgently required and this will be aided through characterization of the 
factors involved in parasite survival and virulence. 
 
Leishmania Thiol dependent reductase 1 (TDR1) is parasite-specific enzyme that 
presents some similarities with human omega glutathione-S-transferase, as demonstrated 
previously by its thiol transferase and dehydroascorbate reductase activities. This enzyme 
also catalyzes in vitro the conversion of pentavalent antimonials (SbV) into a trivalent form, 
an ability that could be important in the mechanism of action of this drug against 
Leishmania. Alternatively, it could be involved in drug resistance as reduction of SbV and 
conjugation with thiols is used by the parasite to extrude the drug out of the cell. 
 
TDR1’s high similarity with a T. cruzi enzyme named Tc52 which had been previously 
reported as a virulence factor led us to analyze the effect of recombinant TDR1 on the 
immune response in the context of infection with L. infantum promastigotes. Balb/c 
immunization with recombinant TDR1 led to an increase in the CD8-T cell splenic 
population and decrease in IL-10 production, although the reduction in parasite burden 
was not sufficient to consider TDR1 as a good antigen to be used in vaccination 
approaches. Interesting was the finding of an increase in CD8-T cells induced by 
immunization with TDR1, since CD8-T cell activation and the formation of memory T cells 
plays an important role against parasitic diseases. These CD8-T cells presented increase 
expression of memory surface markers, potentially involved in the partial protection 
obtained at the chronic phase of infection. 
 
In order to provide insights into the functional role of TDR1, attempts were made to delete 
the gene by homologous recombination in visceral Leishmania species (L. infantum and L. 
donovani). Unexpectedly, attempts to obtain the L. donovani null mutant after two rounds 
of gene deletion failed. Leishmania have been considered diploid organisms, although 
exceptions were reported and aneuploidy has arisen during attempts to delete essential 
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genes or in drug-resistant cell lines. The fact that a null mutant was previously obtained in 
L. major after two rounds of gene knockout suggested that the gene was unlikely to be 
essential in L.donovani. Thus we proceeded to the disruption of a third copy of the gene 
and a null mutant in L. donovani was obtained in this way. L. infantum TDR1 null mutants 
were obtained both after 2 and 4 rounds of gene deletion, showing that the gene occurs in 
variable copy number within the same cloned population. TDR1 null mutant generation 
has provided more evidence that the Leishmania genome has plasticity in terms of ploidy 
and recently reported genome sequence data for different Leishmania species supports 
this finding. Deletion of TDR1 did not affect L. donovani and L. infantum parasites’ 
virulence to macrophages. Further analysis of L. donovani null mutants revealed that the 
null mutants were not more susceptible to oxidative and nitrosative stress, although an 
increase in sensitivity to trivalent antimony and trivalent arsenite was observed, which 
could be related with TDR1 detoxification activities. Also, there were no changes in the 
susceptibility of intracellular parasites of the TDR1 null mutant in macrophages to SbV 
when compared with the WT parasites. Thus, the results obtained did not support the role 
of TDR1 in drug activation or in the involvement in resistance to SbV.  
Analysis of parasite’s metabolome, a new approach to detect differences between 
Leishmania null mutants and the WT parent line, revealed few but striking differences in 
metabolite levels involved in energy and amino acid metabolism. This was interpreted as 
a metabolic re-configuration in the absence of TDR1, implying the enzyme in the 
regulation of metabolism through S-glutathionylation. Metabolic re-configuration has been 
reported in a wide range of organisms and occurs due to inhibition or activation of 
enzymes activity. S-glutationylation, which occurs in response to oxidative stress or under 
physiological conditions as a regulatory mechanism, has not yet been reported in 
Leishmania although the effect of TDR1 deletion strongly suggests it existence. 
Furthermore, recombinant TDR1 has deglutathionylation activity towards protein and 
peptide substrates supporting the hypothesis postulated. 
Overall, the results presented here provide information on the potential role of TDR1 in 
vivo, through the regulation of enzymes activities by S-glutathionylation. Moreover, TDR1 
gene clearly shows that Leishmania copes well with aneuploidy; the challenge now is to 
understand how the parasite takes advantage of this genomic feature. Metabolomics 
analysis has shown to be an excellent tool for dissecting differences between mutant or 
natural lines of Leishmania. 
 
Keywords: Leishmania, Thiol dependent reductase 1, CD8-T cells, aneuploidy, 
deglutathionylation
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RESUMO 
A leishmaniose é uma doença parasitária causada por protozoários do género da 
Leishmania. Esta patologia afecta milhões de pessoas em todo o mundo, e pode assumir 
diferentes formas clínicas, dependendo da espécie de Leishmania que infecta e do 
estado imunológico do hospedeiro. A leishmaniose visceral, causada por parasitas do 
complexo L. donovani, representa a forma mais severa da doença, letal se não tratada. 
Actualmente não existe uma vacina contra a leishmaniose humana e os medicamentos 
disponíveis são dispendiosos, tóxicos, carecem de eficácia e verifica-se um número 
crescente de casos de resistência aos mesmos. 
 
A “Thiol dependent reductase 1 (TDR1)” é uma enzima especifica do parasita Leishmania 
que apresenta algumas semelhanças com a proteina humana omega glutationa-S-
transferase, tendo como actividades a redução do ácido dehidroascórbico e a 
transferência de tióis. Esta enzima também catalisa a conversão de compostos 
antimoniais pentavalentes (SbV) na sua forma trivalente, actividade que pode ser 
importante no mecanismo de acção deste medicamento contra o parasita ou estar 
envolvida na resistência ao mesmo, uma vez que a redução de SbV e posterior 
conjugação com tióis é usada pelo parasita como mecanismo de desintoxicação. 
A homologia observada entre a TDR1 e a enzima de T. cruzi, designada Tc52, 
previamente considerada como um factor de virulência, conduziu à análise do efeito da 
proteína recombinante TDR1 (rTDR1) na resposta imunológica no contexto da infecção 
com formas promastigotas da L. infantum. A imunização de ratinhos Balb/c com rTDR1 
induziu um aumento significativo no número das células T-CD8 do baço e uma 
diminuição na produção da citoquina IL-10 durante a fase crónica de infecção. No entanto 
a redução da carga parasitária não foi suficiente para considerar a TDR1 como um 
antigénio adequado para desenvolver uma vacina. Interessante foi o aumento das células 
T-CD8, uma vez que a activação destas e a formação de células T de memória 
desempenha um papel importante no controlo das doenças parasitárias. Verificou-se um 
aumento nos marcadores de superfície nas células T-CD8 característicos de células T 
centrais de memória, o que poderá ter contribuído para a protecção parcial obtida na fase 
crónica de infecção. 
 
Com o objectivo de investigar a função da proteína TDR1 nas espécies de Leishmania 
viscerais (L. donovani e L. infantum) realizaram-se tentativas para remover os alelos que 
codificam para esta proteína através de recombinação homóloga. A remoção do gene 
não foi possível após duas rondas de transfecção. A Leishmania tem sido considerada 
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um organismo diplóide, apesar de terem sido já identificadas excepções e casos de 
aneuploidia detectados durante tentativas para eliminar genes essenciais ou em parasitas 
resistentes a medicamentos. O facto de um mutante nulo ter sido produzido 
anteriormente na L. major, sugeriu a possibilidade de o gene não ser essencial na L. 
donovani, dada a sua proximidade filogenética. Assim, procedemos a uma terceira ronda 
de transfecção na qual foi possível remover o último alelo do gene TDR1. No caso da L. 
infantum, os mutantes nulos foram obtidos após 2 e 4 rondas de transfecção, mostrando 
que o gene apresenta um número de cópias variável dentro da mesma população. Estes 
resultados fornecem evidências de que o genoma da Leishmania tem plasticidade em 
termos de ploidia, suportado pelos recentes dados obtidos na sequenciação do genoma 
de diferentes espécies de Leishmania. A remoção do gene TDR1 não afectou a 
capacidade dos parasitas para infectar macrófagos. Uma análise detalhada dos mutantes 
nulos na L. donovani revelou que a remoção do gene alterou a susceptibilidade a 
compostos antimoniais trivalentes e arsénicos trivalentes, o que pode estar relacionado 
com a capacidade de desintoxicação da TDR1. Também não foram detectadas 
alterações na susceptibilidade ao stress oxidativo/nitrosativo e aos SbV pela forma 
intracelular do mutante nulo. Assim, os resultados experimentais não suportam a função 
da TDR1 na activação dos SbV ou na resistência a estes compostos. 
A análise do metaboloma dos mutantes nulos na L. donovani revelou importantes 
diferenças, nos níveis de metabolitos envolvidos na produção de energia e metabolismo 
de aminoácidos. Estas alterações foram interpretadas como uma re-configuração 
metabólica, na ausência da TDR1, implicando a enzima na regulação do metabolismo 
através da modificação pós-traducional designada de S-glutationação. A S-glutationação 
pode ocorrer em condições de stress oxidativo mas também em condições fisiológicas 
como um mecanismo de regulação, através da inibição ou activação de enzimas; esta 
modificação ainda não foi descrita na Leishmania, no entanto as alterações detectadas 
devido à remoção do gene TDR1 sugerem a sua existência. Além disso, rTDR1 é capaz 
de reverter a S-glutationação de diferentes substratos, proteínas e péptidos, suportando a 
hipótese acima descrita. Em suma, os resultados deste estudo fornecem informações 
sobre a potencial função da proteína TDR1 in vivo, como reguladora da actividade 
enzimática na célula através de S-glutationação. A análise do metaboloma mostrou ser 
uma excelente ferramenta para investigar as diferenças tanto entre linhas celulares 
mutantes como selvagens de Leishmania. 
 
Palavras-chave: Leishmania, Thiol dependent reductase 1, células T-CD8, aneuploidia, 
glutationação. 
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1.1 The Leishmania parasite 
 
 1.1.1 History and taxonomy 
 
Leishmania parasite was first described in 1885 by Cunningham in India from a tissue 
taken from a sore called the Delhi boil, which at the time was thought to have fungal 
origin. Later, in 1898, Borovsky reported that the causative agent was a protozoan and 
described the anatomy of the organism. William Leishman and Charles Donovan were the 
first to attribute to the parasite the etiology of the disease, after independently discovering 
the parasite in the spleens of patients with kala azar, nowadays called visceral 
leishmaniasis1. In 1904, the organism responsible for the disease was recognised as 
being protozoan in nature, named “Leishman-Donovan bodies” and received the 
taxonomic designation of Leishmania donovani. In 1924, John Sinton proposed the theory 
that the sand fly was the vector of the Kala-azar parasite, L. donovani and only later, 
Robert Knowles and scientists at the Calcutta School of Tropical Medicine gave evidence 
to support Sinton’s theory, by detection of Leishmania parasites in sand flies that had 
been fed on patients. The first experimental evidence of transmission of leishmaniasis by 
the bite of sand flies was by Shortt et al in 1931, who achieved the transmission of L. 
donovani to hamsters by the bite of Phlebotomus argentipes2. Since then, Leishmania has 
been found to be a complex grouping of species, more than 20 species transmitted to 
humans by species of phlebotomine sandflies, which cause several diverse clinical 
manifestations3. Currently there are two groups of Leishmania parasites, subgenera 
Leishmania and Vianna, classified based on which part of the sand fly gut is colonized by 
the parasite4. This separation was also supported by DNA sequence-based phylogenetic 
analysis5 (Figure 1.1).  
 
 
Figure 1.1 The main species of Leishmania that affect humans (adapted from WHO6). 
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Members of the subgenus Leishmania undergo suprapylarian development taking place 
exclusively in the midgut and foregut of the vector whereas members of the subgenus 
Viannia also undergo a period of peripylarian development in the hindgut5, 7. 
 
 1.1.2 Morphology and ultrastructure  
 
Leishmania has a dimorphic life cycle and two main forms can be distinguished: an 
extracellular promastigote stage that develops within the digestive tract of sand flies and 
an intracellular amastigotes, which proliferate and multiply within the phagolysosome of 
mammalian macrophages. The promastigotes have a fusiform shape (5-15µM) while 
amastigote forms are smaller and present an ovoid shape (3-5µM); both forms possess a 
specialized invagination of the plasma membrane, named flagellar pocket, at the anterior 
end of the parasite that encloses the base of the flagellum that in amastigotes is greatly 
reduced or barely emergent8, the reason why amastigotes are non-motile forms (Figure 
1.2).  
 
 
Figure 1.2 Scanning electron microscope images of Leishmania main 
morphological forms: promastigotes and amastigote (adapted from Besteiro et al.9). 
 
In 1950s, a report by Chang has described the ultrastructure of L. donovani as follow: 
“The structure of the intracellular form of Leishmania donovani as seen by the light 
microscope consists of a nucleus and usually a rod-like kinetoplast within a homogeneous 
mass of cytoplasm, while the extracellular or culture form has, in addition to these 
structures, an anterior flagellum” and concluded “intra- and extracellular phases of the 
parasite possess the same basic structures”10. There are considerable variations between 
different species of kinetoplastids and even between different life cycle stages within a 
specie; ultrastructure features such as the overall dimension, flagelar morphology and 
position of kinetoplast (mitochondrial) and flagellar basal body relative position to the 
nucleus have been used to distinguish the different forms11. Nevertheless, research work 
through the years has shown that the different developmental stages can be distinguished 
from each other based also on their growth rates, nutritional requirements and the 
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regulated expression of surface proteins. Moreover, parasite differentiation is often 
marked by dramatic changes in the morphology and function of organelles in the secretory 
and endocytic pathways that regulate many of these processes. A schematic 
representation of the main intracellular organelles from promastigotes and amastigote 
forms (Figure 1.3) reveals differences between the two forms such as the absence of 
flagellum in the amastigote form and the presence of multi-vesicular tubule (MVT) 
lysosome or megasomes in the promastigotes and amastigote form, respectively. 
 
 
Figure 1.3 Schematic representation of the main intracellular organelles from 
Leishmania promastigote (left) or amastigote (right) forms (adapted from Besteiro et 
al.9). 
 
Surface membrane of Kinetoplastids, including Leishmania, is divided into 3 
morphological distinct subdomains: (i) the flagellum, (ii) the flagellar pocket and (iii) a 
pellicular plasma membrane12, which surrounds the body of the cell and is attached to an 
array of subpeculiar microtubules that underlie the plasma membrane13. The flagellum is 
responsible for parasite motility, but is also involved in the attachment of the parasite to 
the sand fly12 and may have a role in environmental sensing, as many nutrients and 
signaling proteins are targeted to the flagellar membrane14. The single flagellum emerges 
from a deep invagination, named flagellar pocket, which is an important zone of 
interaction between the parasite and its environment because it is the only site in the cell 
for endocytosis and exocytosis being responsible for crucial exchanges such as uptake of 
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nutrients via receptor-mediated endocytosis15 for secretion of proteins into the 
extracellular medium, and for integration of membrane proteins into the cell surface12, 16, 
which is supported by the fact that the structure is surrounded  by several organelles of 
the secretory and endocytic pathways13. Besides the flagellar pocket, Leishmania contains 
other specialized organelles such as the kinetoplast and glycosomes. 
 
The mitochondrial DNA is enclosed in an unusual structure known as the kinetoplast 
(kDNA), considered one of the unusual characteristic of trypanosomatids. kDNA is a 
network of thousands of catenated circular DNAs of two types, maxicircles and 
minicircles. There are several thousand minicircles, which range in size from about 0.5 to 
2.5 kb (depending on the species), and a few dozen maxicircles, which usually vary 
between 20 and 40 kb17, 18. The maxicircles are structurally and functionally analogous to 
the mitochondrial DNA from higher eukaryotes, and they encode rRNAs and subunits of 
the respiratory complexes. Minicircles encode guide RNAs that modify the maxicircle 
transcripts by extensive uridylate insertion or deletion in a process known as RNA 
editing19. 
 
Another unique feature of trypanosomatids is the compartmentalization of several 
important metabolic pathways, such as glycolysis, in organelles designated glycosomes20. 
Compartmentation of glycolytic enzymes in T. brucei prevents the toxic accumulation of 
glycolysis metabolism intermediates, as the parasite lacks a feedback regulation of the 
early steps of glycolysis21. The sequestering of pathways of carbohydrate metabolism 
within the glycosomes may allow a rapid adaptation of parasites to new nutritional 
conditions during their life cycle20.  
 
 1.1.3 Life cycle 
 
The life cycle of Leishmania alternates between a mammalian host and a phlebotomine 
sand fly (Figure 1.4). Phlebotomies sand flies are the vectors responsible for the 
transmission to mammalian hosts ranging from desert rats to humans22, who are often an 
accidental host. Female sand flies become infected when they feed on an infected host, 
as free amastigotes or amastigote-infected mononuclear cells are ingested along with the 
blood meal. Once in the vector, amastigotes will transform into motile and replicative 
forms called procyclic promastigotes. This development is triggered by a change in 
environmental conditions such as decrease in temperature and increase in pH7, 23. The 
Leishmania procyclic promastigote will differentiate into the infective, non-dividing 
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metacyclic promastigote, a form characterized by a smaller body and a longer flagellum 
that undergo significant changes for a successful transmission to the mammalian host. 
 
 
 
Figure 1.4 The life cycle of Leishmania parasites. Leishmania metacyclic 
promastigotes are delivered to the mammalian host through the bite of an infected sandfly 
(1) followed by the promastigote attachement to the macrophage. Once phagocytised by 
the macrophage (2), the parasite-containing phagosomes fuse with lysosomes, forming 
phagolysosomes, where the promastigotes forms differentiate into amastigotes (3), 
replicate (4), and are released by lysis of the infected macrophages (5), leading to 
infection of other cells (6). Following ingestion of the parasite by the sandfly during a 
bloodmeal (7), amastigotes differentiate into procyclic promastigotes (8), which then 
undergo several changes and develop into the infective metacyclic stage (9) (adapted 
from Kaye et al.24). 
During another blood feeding, the sandfly regurgitates the metacyclic promastigotes, 
which are phagocytosed by macrophages or other cell types, such as neutrophils, 
dendritic cells or fibroblasts found in the local environment. Once inside the macrophage, 
the promastigotes undergo significant biochemical and metabolic changes, which result in 
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the intracellular aflagellate amastigote form, which can replicate within the macrophage 
parasitophorous vacuoles. 
 
 1.1.4 Leishmania-sand fly interactions 
 
There are approximately 1000 species of sand flies, from which only 70 are proven or 
probable vectors of Leishmania25. Leishmania vectors are small insects of the order 
Diptera, subfamily Phlebotominae commonly called phlebotomie sand flies, with a body 
length of approximately 2−3 mm (Figure 1.5)26, 27. There are 3 features that make sand 
flies easy to recognize as described by Killick-Kendrick et al : "when at rest, they 
characteristically hold their wings at an angle above the abdomen; they are hairy; and, 
when coming to engorge, they typically hop around on the host before settling down to 
bite”26. The activity of sand flies is crepuscular or nocturnal and diurnal resting places are 
comparatively cool and humid26, 28. Both male and females sand flies feed on natural 
sugar sources but only females also feed on blood which provides nutrition for the 
production of eggs26. 
 
 
Figure 1.5 A blood-sucking phlebotomine sand fly (adapted from Kato et al.27). 
 
Many factors can account for the low number of sand fly species that participate in the 
transmission of leishmaniasis such as a different distribution from that of the reservoir 
host, inability to support the development of Leishmania. To be considered as a 
Leishmania vector, a sand fly must be anthropophilic, bite the reservoir host(s), infected in 
the nature with the same Leishmania as occurs in humans, support the growth of the 
parasite and be able to transmit the parasite by bitting26. Thus Leishmania species are 
restricted to two genera of phlebotomie sand flies: Phlebotomus, divided into 12 
subgenera, and Lutzomyia, divided into 25 subgenera and species groups26. The vectors 
can be further divided into specific or permissive considering the vector competence to 
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support the growth of only one or more species of Leishmania. Some phlebotomine 
species are considered specific as they can support the growth of only those species of 
Leishmania with which they are infected in nature, such as Phlebotomus papatasi and 
Phlebotomus sergenti; other species such as Lutzomyia longipalpis and Phlebotomus 
argentipes are permissive vectors since they are able to develop mature transmissible 
infections when infected with several Leishmania species29-32. Vectorial competence is 
influenced mainly by 3 factors: parasite resistance to the action of digestive enzymes 
produced in the sand fly midgut, which may inhibit the early growth of parasites in the 
bloodmeal33; the presence on the inner surface of the gut of the vector of the appropriate 
lipophosphoglycan-binding sites that match the lipophosphoglycan on the surface of the 
promastigotes, enabling them to attach to the inner surface of the sandfly gut33, 34 and the 
complete development of the parasite to produce metacyclic promastigotes, the only form 
of the parasite that can survive in the vertebrate host2. Besides the digestive enzymes, 
other potential barriers to the complete development of the parasite in the sand fly, such 
as, the peritrophic membrane (physical barrier to parasite migration out of the abdominal 
midgut), the excretion of the digested bloodmeal (may result in loss of infection from the 
gut) and the anatomy and physiology of the anterior gut (may prevent the forward 
movement of metacyclic promastigotes and their egestion during blood feeding) have 
likely forced the parasite to express specific molecules in order to survive in the sand fly2. 
 
In the sand fly, can be distinguished 4 major development forms: procyclic, nectomonad, 
leptomonad and metacyclic promastigotes. Leishmania development in the sand fly is 
often simplified to two main forms, procyclic and metacyclic, however promastigotes 
undergo a sequential transformation that is dependent on the nutrient availability and 
occurs as they migrate from the posterior midgut to the stomodeal valve5, 7. These 
different forms should be taken into account to understand promastigote cell biology and 
differentiation to the infective stage, metacyclics forms (metacyclogenesis). The time-
dependent location of these distinct morphological forms of Leishmania promastigotes 
within the sand fly are shown in Figure 1.6. First, amastigotes differentiate into procyclic 
promastigotes, the replicative form that multiplies in the bloodmeal and is confined to the 
peritrophic matrix (PM); PM is produced by epithelial cells and lines the gut lumen of most 
insects, protecting against rough food particles and pathogens and composed of chitinous 
microfibrils, proteoglycans and proteins35. Procyclic promastigotes will then differentiate 
into a non-dividing form, nectomonad promastigotes that are responsible for the infection 
establishment2 and anterior migration36 beyond the bloodmeal phase. As soon as 
nectomonads are released into the midgut lumen they attach between microvilli of 
epithelial cells to avoid elimination from the midgut during digestion. It was shown for L. 
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major that the abundant surface molecule lipophosphoglycan (LPG) specifically binds to 
the midgut galectin receptor PpGalec of the sand fly vector P. papatasi37. Surface 
molecules such LPG and proteoglycans protect the parasite from the proteolytic activities 
of the blood-fed midgut besides being responsible for the attachment in order to maintain 
infection during excretion of the bloodmeal2. 
 
 
Figure 1.6 Main developmental forms of Leishmania promastigotes in the sand fly 
vector (adapted from Kamhawi et al.7). 
 
Nectomonads migrate towards the anterior midgut and differentiate into the shorter 
leptomonads, which go through the second round of multiplication in the insect host called 
the sugarmeal phase, leading to a massive infection of the anterior midgut. Leptomonads 
produce the promastigote secretory gel (PSG), a matrix structure composed mainly of 
filamentous proteophosphoglycan, which is thought to trigger metacyclogenesis and plays 
an important role in the transmission phase, being responsible for the ‘blocked fly’ effect36. 
The transformation of leptomonads into non-dividing metacyclics occurs at the stomodeal 
valve, which separates the midgut from the foregut and the proboscis. Metacyclic forms 
are highly motile, present a small cell body compared to the elongated flagellum and are 
resistant to complement-mediated lysis. The other parasite form found at the stomodeal 
valve, the haptomonad, forms a parasite plug at the stomodeal valve7. 
 
 1.1.5 Reservoirs and transmission modes 
 
According to the source of human infection, leishmaniasis can be an anthroponosis, 
parasites essentially circulate between humans, or a zoonosis, in which the reservoir 
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hosts are wild animals and the parasites circulate essentially between those and the sand 
fly, humans being an accidental host6. A reservoir is, from a pratical point of view, a host 
that fulfills some attributes that favor the maintenance and dissemination of a given 
disease agent38. Many mammals have been described as important reservoirs of 
Leishmania 38-42, including dogs, which are the main reservoir hosts of L. infantum, playing 
an important role in the epidemiology of zoonotic visceral leishmaniasis38. 
 
 1.1.6 Reproduction mode: clonality versus sexuality 
 
In eukaryotes, genetic exchange is crucial for adaptation to new environmental conditions. 
Since the discovery of Leishmania there has been a debate about how these parasites 
reproduce: clonality versus sexuality43. For many years, the “clonal theory” has been 
accepted as the main mechanism of parasite reproduction44-47. The ‘clonal theory’ of 
parasitic protozoa which suggests that offsprings are genetically identical to their parents 
has been based in several criteria (ex. fixed heterozygosity, absence of recombinant 
genotypes, deviation from Hardy-Weinberg expectations, widespread identical 
genotypes). The hypothesis of clonality does not rule out the possibility of occasional 
genetic recombination, but suggests that is not important enough to change the 
predominant pattern of  clonal population structure47. However, this theory was challenged 
over the years by the observation of interspecific, intraspecific hybrids,  recombinant 
genotypes43, 48-52 and by other studies based on molecular karyotype analysis and 
multilocus microsatellite typing that argued for a predominance of autogamy (a sexual 
reproductive mode where zygotes are produced by the fusion of two gametes that were 
produced by the same parental individual)53,54, 55 or possible existence of selfing (a sexual 
reproductive mode where an individual self-fertilizes its own ovules with its own 
spermatozoids)53. The impossibility to obtain clear evidences to support sexuality in 
Leishmania, in part due to technical limitations as the low reliability of the genetic markers 
used, sampling or data interpretation53 allowed the clonal theory to persist and be 
accepted as the main mode of reproduction, with infrequent genetic recombination, until 
new evidences emerged from experimental data. Using transgenic Leishmania strains 
resistant to different selective drugs, Akopyants et al 56 were able to isolate parasites from 
naturally infected sand fly that result from recombination between the two strains as they 
contain full genomic complements from both parents, but with kinetoplast DNA maxicircles 
from only one parent. The generation of a hybrid progeny occurred just in the sand fly 
vector and the parasites were transmitted to the mammalian host by sand fly bite56. This 
study demonstrated for the first time that genetic exchange occurs during Leishmania 
promastigotes development in the sand fly vector. Although genetic exchange in T. brucei 
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has been demonstrated a long time ago57, a similar approach was used previously to 
show that genetic exchange in T. brucei takes place in the salivary glands of the tsetse fly 
vector involving meiosis58, but the precise mechanism remains unknown. In order to 
understand the impact of genetic exchange in Leishmania epidemiology it is necessary to 
gain more insights into the process such as when, where (in which part of sand fly gut) 
and the frequency of hybrids. It may not have much relevance in parasites with 
exponential growth in an ideal environment, but could become crucial when parasites face 
changes in the environment59 as it can potentiate a successful adaptation to new niches, 
vectors and hosts. A genetic exchange consequence is clearly shown by the fact that L. 
infantum/L. major hybrids were transmited by sand fly vector Phlebotomus papatasi, 
which is normally only competent to transmit L. major60. 
 
 
1.2 Leishmaniasis 
 
 1.2.1 Clinical manifestations 
 
Clinical manifestations of Leishmania infection range from self-healing cutaneous and 
mucocutaneous forms to visceral leishmaniasis, which is fatal if left untreated. The clinical 
outcome is mainly dependent on the infectious species, but other factors such as the host 
immune status also play a role3, 61. Leishmaniasis is classified based on symptomatology 
in 3 main forms as follows: 
 
 Visceral leishmaniasis  
 
Visceral leishmaniasis (VL) is characterized by fever, weight loss, enlargement of the 
spleen and liver, anemia and this form of the disease is fatal if left untreated62. A frequent 
complication of VL is post-kala-azar dermal leishmaniasis (PKDL) characterized by a 
macular, maculo-papular or nodular rash, which are highly infectious as the nodular 
lesions may contain many parasites, being consider as potential reservoirs  for 
anthroponotic VL62. 
 
 Cutaneous leishmaniasis  
 
Cutaneous leishmaniasis (CL) is characterized by the presence of one or several ulcers or 
nodules in the skin, which heal spontaneously but cause disfiguring scars. Thus CL is not 
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a life-threatening condition however lesions can lead to significant disfigurement and 
disability63, 64. 
 
 Mucocutaneous leishmaniasis  
 
Mucocutaneous leishmaniasis (ML) is characterized by destructive ulcerations of the 
mucosa, which extend from the nose and mouth to the pharynx and larynx. These lesions 
are not self-healing and are usually caused by inadequate treatment of a primary CL 
lesion64, 65. 
 
 1.2.2 Disease burden and geographical distribution 
 
Leishmaniasis is still one of the world’s most neglected diseases, widely dispersed, with 
transmission to humans in five continents (endemic in 98 countries or territories), affecting 
mainly developing countries; 350 million people are considered at risk of contracting the 
disease, with an estimated incidence of 2 million new cases per year. Leishmaniasis is 
associated with nearly 2.4 million disability-adjusted life years and 50000 deaths annually, 
however this numbers may be underestimated mainly due failure to account for secondary 
effects, such as stigma and the economic effect on households and their treatment, that 
leads to millions of disable people6. Leishmaniasis is also found as an opportunistic 
disease associated with human immunodeficiency virus (HIV). Leishmania–HIV 
coinfection had been reported in 35 endemic countries, intensifying the burden of 
leishmaniasis by causing severe forms6. Depending on the geographic region the infection 
is acquired, leishmaniasis have traditionally been classified as “Old World” forms (Asia, 
Europe and Africa) and “New World” forms (Americas)65.  
 
Visceral leishmaniasis is caused by parasites of the L. donovani complex, L.donovani and 
L. infantum depending on the geographical area. There are an estimated 0.5 million new 
cases of VL, over 50,000 deaths each year and more than 90% of the cases are 
concentrated in Bangladesh, Brazil, Ethiopia, India, Nepal and the Sudan6 (Figure 1.7). 
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Figure 1.7 Worlwide distribution of visceral (VL) and post kala-azar dermal (PKDL) 
leishmaniasis (adapted from Duthie et al.66). 
 
CL is endemic in more than 70 countries worldwide and up to 90% of cases occur in 
Afghanistan, Algeria, the Islamic Republic of Iran, Saudi Arabia and the Syrian Arab 
Republic and in Bolivia, Brazil, Colombia, Nicaragua and Peru6 (Figure 1.8). The 
distribution of ML is tightly linked to CL. CL is predominantly caused by L. major and L. 
tropica, while ML cases are mainly caused by L. braziliensis and L. panamensis. 
 
 
Figure 1.8 Worldwide distribution of cutaneous (CL) and mucocutaneous (ML) 
leishmaniasis (adapted from Duthie et al.66). 
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 1.2.3 Diagnosis 
 
The diagnosis of leishmaniasis is considered a complex challenge due to the wide 
spectrum of clinical manifestations and also the difficulty to distinguish the condition from 
other diseases as many of the clinical signs is shared with malaria, schistosomiasis, 
tuberculosis or other systemic infections. Thus, Leishmania specific laboratory tests are 
required for diagnosis confirmation and can be grouped into 3 categories: (i) parasite 
detection; (ii) antibody-detection tests and (iii) antigen-detection tests67, 68.  
 
(i) Parasite detection: demonstration of parasite in tissue samples by light microscopic 
examination, detection of parasite DNA in tissue samples by PCR. The commonly used 
method for diagnosing VL is the visualization of the amastigote form of the parasite by 
microscopy examination in tissues aspirates. This method is highly specific; however, 
sensitivity varies greatly depending on the source62, 69, 70. Detection of parasites in blood, 
serum or organs by PCR71, 72 offers several advantages over the microcope examination: 
it is highly specific and sensitive irrespective of species or genus, quick to perform, may 
allow host tissue quantification of parasites and is able to detect more asymptomatic 
infections73. 
 
(ii) Antibody-detection tests: methods based on the presence of specific humoral 
response74. Serological tests based on indirect fluorescent antibody test (IFAT), enzyme 
linked immunosorbent assay (ELISA) and immunoblotting have shown high accuracy, but 
are not adapted to field settings. Thus to overcome that problem were specifically 
developed two tests for field use: direct agglutination test (DAT - based on antigen-
antibody reaction) and the rK39 antigen-based immunochromatographic test (a rapid 
dipstick test based on the recombinant K39 protein)68, 75, 76. Although, high sensitivity and 
specificity were obtained77, both tests suffer from 2 limitations: specific antibodies remain 
detectable up to several years after cure so relapse cannot be reliable diagnosed and a 
significant proportion of healthy people living in endemic areas are positive76. 
Nevertheless, a phase III trial for diagnostics of VL in India have confirmed DAT and rK39 
strip tests has an excellent diagnostic tool, with high sensitive and excellent specificity, 
being rK39 strip test most suitable for the diagnosis of VL in the field conditions as it is 
easier to perform than DAT78.  
 
(iii) Antigen-detection tests: detection of parasite antigen in tissue, blood or urine 
samples, by detection of nonspecific or specific antileishmanial antibodies 
(immunoglobulin), or by assay for Leishmania-specific cell-mediated immunity 67. 
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 1.2.4 Control strategies 
 
The lack of an effective human vaccine or chemotherapy limits the options to prevent 
leishmaniasis. Thus, control strategies include the elimination of reservoir populations and 
reduction or interruption of disease transmission through vector control. 
 
Vector control methods available include chemicals, environmental management and 
personal protection, and although they can have a strong effect when use independently, 
sand fly control should involve more than one method;  vector control “packages” should 
take into account parameters such as the species involved, habitats, host feeding 
preferences and resting sites among others6. The efficacy of these measure was well 
demonstrated by almost disappearance of VL in the Indian subcontinent after a large-
scale anti-malarial insecticide (dichloro-diphenyl-trichloroethane (DDT)) spraying 
campaigns implementation in the 1950s and 1960s; the disease quickly re-emerged when 
the spraying  campaigns were discontinued6, 62. The main methods for controlling sandflies 
with insecticides are indoor residual spraying, spraying of resting sites, use of insecticide-
impregnated materials such as bednets and curtains, and pyrethroid impregnated dog 
collars6, 79. Vector control through environmental management involves for example the 
relocation of human settlements away from sandfly habitats and physical modification of 
the habitats and personal protection measures, such as application of insect repellents on 
exposed skin and avoiding times of sand fly activity, should be used by people entering or 
living in highly endemic foci to avoid bites by sandfly vectors of leishmaniasis6. 
 
In the regions where the dog is the main reservoir, a canine vaccine would be the better 
solution as it would reduce this reservoir and interrupt transmission of Leishmania to 
humans. Treatment of infected dogs is not effective and canine treatment is performed 
with the same drugs used in humans increasing the risk of the emergence of drug 
resistant parasites80; the deltamethrin-impregnated collars have been shown to be 
effective in reducing the risk of infection in dogs81. Dog vaccination with Leishmune82 has 
shown positives results, with a good correlation in the decrease of both canine and human 
VL with the increase of the number of vaccinated dogs83. Thus it is a promising tool to 
reduce parasite reservoir and protecting dogs. 
 
 1.2.5 Antileishmanial drugs 
 
The lack of vaccines against human leishmaniasis implies that chemotherapy is the only 
way available to fight the disease. However, the current drugs are far from being 
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satisfactory with associated high costs and an alarming increase in drug resistance84-86. 
Drug discovery and development has been mainly directed towards treatment of VL since 
this form of disease is fatal if left untreated. Pentavalent antimonials remain the first-line 
treatment in most parts of the world despite the requirement for long treatment duration, 
toxic effects and the development of resistance, particularly in the region of Bihar (India), 
where 60% of patients do not respond to the treatment85. Miltefosine, different 
formulations of amphotericin B, paromomycin among others are available to use in 
addition to pentavalent antimonials. Combination therapy for VL is now seen as a way to 
increase treatment efficacy and tolerance, reduce treatment duration and cost, and reduce 
the probability of selection for drug resistant parasites. Studies have shown that treatment 
with oral miltefosine can be shortened when it is combined with single-dose liposomal 
amphotericin B87-89.  
 
 Pentavalent antimonials 
  
Pentavalent antimonials (SbV) are available in two formulations: meglumine antimoniate 
and sodium stibogluconate (SSG). The full mechanism of action of antimonials is not 
known but the drug inhibits the activity of the glycolytic and fatty acid oxidative pathways 
in amastigote forms85. Antimonials are administered as a produg in pentavalent form, 
which needs to be reduced to its trivalent form (SbIII) in order to be active against the 
parasite. Tis reduction can either occur in the macrophage, in the amastigote, or both85 
and it was shown to be catalyzed in vitro by parasite-specific enzymes namely thiol 
dependent reductase 1 (TDR1)90 and arsenate reductase 2 (ACR2)91 or non-enzymatically 
by thiols. In antimonial-sensitive cell lines was observed an accumulation of the trivalent 
form, which is reduced in resistant cell lines92. Resistance to antimonial drugs is thought to 
be multifactorial but one of the key factors is the concentration of active drug within the 
parasite, which can be modulated by decreased uptake and increased inactivation of the 
drug by the parasite. Inactivation can be achieved by the conjugation of SbIII with 
glutathione or trypanothione, leading to extrusion of the drug out of the cell93. Indeed, an 
increase in total thiols92 and overexpression of associated enzymes are often observed in 
metal resistant Leishmania94. This leads to an imbalance in thiol homeostasis and a 
consequent accumulation of reactive oxygen species95, 96. The mode of action of 
pentavalent antimonials is also dependent on T-cell subsets and cytokines. SSG was 
found to inhibit protein tyrosine phosphatases, which leads to an increase in cytokine 
responses. Also treatment with meglumine antimoniate leads to an increase in the 
phagocytic capacity of monocytes and neutrophils, suggesting an important role of the 
host response in the activity of these drugs97-99. 
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 Amphotericin B 
 
Amphotericin B is available in four different formulations: amphotericin B deoxycholate, 
liposomal amphotericin, cholesterol dispersion amphotericin and lipid complex 
amphotericin. The primary target of this drug is membrane ergosterol, which constitute the 
major surface sterol in Leishmania in contrast with cholesterol in human cells100. Thus, 
amphotericin B kills the parasite by destroying the surface membrane, without having to 
enter it. Given this, resistance to amphotericin B seems unlikely to occur as Leishmania 
parasites would need to generate a new biochemical pathway to replace surface 
ergosterol101. A single-dose of liposomal amphotericin B was considered by the WHO 
appointed expert committee on control of leishmaniasis the best available therapy for 
anthroponotic VL in the Indian subcontinent as it is effective and is safer than any other 
treatment6. 
 
 Pentamidine 
 
Pentamidine is a dicationic drug that interferes with Leishmania DNA synthesis, leads to 
the condensation and disruption of the kinetoplast DNA core and promotes fragmentation 
of the mithocondrial membrane, killing the parasite102-104. Pentamidine has been used with 
success to treat cutaneous leishmaniasis or ML in some regions of the New World with 
same efficacy as antimonials105.  
 
 
 Paramomycin 
 
Paromomycin, is an aminoglycoside that inhibits protein synthesis and modifies 
membrane fluidity and permeability106. Recently was shown that paromomycin drastically 
alters the accuracy of protein synthesis in Leishmania; defective proteins might cause 
deleterious effects on parasite survival. Paramomycin binds to the parasite ribosomal 
decoding site, modifying the codon-anticodon recognition process; the effectiveness 
against leishmaniasis is believed to be due to the ability of paramomycin to discriminate 
between ribosomes of Leishmania and mammalian cells107. L. donovani promastigotes 
selected in vitro for paramomycin resistance showed reduced accumulation of drug and a 
significant reduction in the initial binding of drug to the cell surface. Paromomycin resistant 
cells retained sensitivity to other drugs indicating that if resistance emerge in the field 
other drugs can be used108. 
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 Miltefosine 
 
Miltefosine (hexadecylphosphocholine) is an alkyl phospholipid which was first developed 
as an anticancer agent and the first orally administered drug for VL to be developed. 
Miltefosine induces an apoptosis-like death in L. donovani promastigotes and 
amastigotes109, 110. The mechanism of action involves interaction with lipids and in 
particular membrane lipids - phospholipids and sterols. Reduction in the membrane sterol 
content led to a reduction in miltefosine activity of 40%; Leishmania lipid rafts, 
microdomains enriched in sphingolipids, sterols, LPG and GP63111, are used as 
miltefosine reservoirs at the membrane level, contributing for the constant supply of the 
miltefosine transporter (LdMT), which is responsible for the internalization of the drug 
within the parasite112. In vitro resistance to miltefosine was shown to occur through 
decreased uptake or increased efflux of the drug; experimental mutations at LdMT and its 
specific beta subunit LdRos3, rendered the parasites less sensitive to miltefosine113, 114. 
Miltefosine resistance induces modifications in C-24 sterol alkylation and fatty acid 
elongation and saturation. These changes interfere with membrane fluidity and 
consequently affect drug-membrane interactions115, essential for an effective action of the 
drug. 
 
 1.2.6 Vaccine development 
 
Studies on antileishmanial vaccine candidates have increased remarkably in the recent 
years, largely due to a better understanding of the mechanisms necessary to induce 
immunity and the availability of Leishmania genome sequences. Several vaccine 
formulations provided partial protection, however there is no fully effective vaccine against 
leishmaniasis. An ideal vaccine should meet several attributes such as safety, low cost, 
be effective against species causing CL and VL, induce CD8- and CD4-T cell responses 
and long-term immunological memory116. In addition, an effective vaccine should 
efficiently stimulate dendritic cells as they play a key role in inducing both humoral and 
cellular responses117. In the search for a vaccine against leishmaniasis have been used 
different strategies, including killed, live attenuated parasites, recombinant proteins or 
vaccines based on recombinant DNA among others118.  
 
First generation vaccines 
Tthe administration of live virulent parasites, process known as Leishmaniazation 
constitute the first vaccine against Leishmania. This has been used for over 60 years in 
several countries, since 1940s but discontinued due to safety issues. In the 1970s and 
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1980s vaccine trials involving whole and killed parasites were conducted. Recent trials 
have used inactivated whole parasites, in some cases a mixture of strains, or in the 
presence of adjuvants but none of those demonstrated protection119. However, in Brazil 
similar vaccines have been used successful for immunotherapy of human CL, leading to 
the register of a first generation vaccine as an adjunct to antimony therapy120. The first 
generation vaccines also include the use of live attenuated parasites, which are infectious 
but not pathogenic, an important advantage over the vaccination with live or killed 
parasites116. The ability to manipulate Leishmania genome to create genetically modified 
parasites by introducing or eliminating genes offered a new alternative to develop a 
vaccine against leishmaniasis. L. major parasites lacking dhfr-ts- gene induced substantial 
protection against a virulent L. amazonensis and L. major infection in a murine model, 
although it failed to induce protective immunity in a primate model121-123. Immunization with 
L. major parasites lacking the lpg2- gene yield different results depending on the 
susceptibility of the murine model used124-126. Deletion of one allele of SIR2 gene in L. 
infantum affected the development of the intracellular amastigote stage and immunization 
of Balb/c mice with these mutants induced a high degree of protection against a virulent 
challenge127. Another example involves the disruption of L. donovani centrin which also 
affects the growth of the amastigote stage of the parasite. Mice immunized with centrin 
null mutant showed early clearance of virulent parasite challenge associated with a 
significant increase in IFN-γ, IL-2, and TNF production by CD4+T cell population; 
sustained immunity and cross-protection against infection with L. braziliensis, indicates 
that these live attenuated parasites are effective and a potentially candidate vaccine 
against VL as well as ML128. The use of live parasites is considered important for 
vaccination as it mimics the natural course of infection, although the possibility that the 
parasite may revert back to a virulent form or reactivation in immunosupressed individuals 
is a major concern limiting the use of live attenuated vaccines129. Also their large scale 
distribution represents a major concern. 
 
Second generation vaccines 
Second generation vaccines, such as parasite fractions, recombinant proteins or 
expression in heterologous microbial vector, represent a more feasible option than the first 
generation vaccines, as they can be produced in a large scale and responses elicited can 
be potentiated with the use of an adjuvant130, 131. Different approaches have been used to 
identify proteins potentially suitable to be tested as a vaccine candidate118; several 
Leishmania proteins were selected including GP63, Leishmania homologue of receptor for 
activated C kinase (LACK), parasite surface antigen 2 (PSA-2), fucose mannose ligand 
(FML), cysteine proteinase (CP)A and CPB, amastigote antigen 2 (A2), hydrophilic 
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acylated surface protein B1 (HASPB1), kinetoplastid membrane protein 11 (KMP-11), L. 
major homologue of the eukaryotic thiol-specific-antioxidant (TSA), L. major homologue of 
the eukaryotic stress-inducible protein 1 (LmSTI1) Leishmania elongation and initiation 
factor (LeIF) among others, although only a few formulations have entered clinical or 
veterinary testing (reviewed by Nagill et al.118, Duthie et al.66, Kaye et al.132, Costa et 
al.133). Analysis of the overall results obtained with these antigens in vaccinations 
experiments revealed in some cases contradictory results that could be due to different 
eign-keys><key app="EN" db-id="eevzatx0madrtoeadsections, challenge dose, adjuvants 
animal model. Also, failure to protect against the different forms of the disease was 
observed as in the case of LACK immunizations which failed to protect against VL134. 
Another issue with the use of recombinant proteins is that alone they induce weak T cell 
responses and only the addition of certain adjuvants leads to the generation of effective 
and durable T cell responses66. 
Currently, there is only one defined vaccine against leishmaniasis entering phase II 
clinical testing in humans designated LEISH-F1 (also designated as Leish-111f)135, 136. 
LEISH-F1 is a fusion protein of three relatively conserved Leishmania proteins (TSA, 
LmSTI1 and LeIF) formulated with MPL-SE (monophosphoryl lipid A - stable emulsion)137. 
This vaccine candidate protects mice, hamsters, rhesus macaques137-140. In mice infected 
with L. infantum, LEISH-F1 + MPL-SE vaccine administration induced a strong humoral 
and T cell responses; a significant increase in CD4+ T cells producing IFN-γ, IL-2 and 
TNF was detected, indicative of a Th1-type immune response137. Recently was reported 
that LEISH-F1 + MPL-SE vaccine is safe and immunogenic in human healthy subjects 
with and without history of previous infection with L. donovani136. Moreover, the vaccine 
was considered safe and immunogenic against CL when administered alone140 or in 
conjugation with antimonials in human clinical trials135, 141. The effect of LEISH-F1 vaccine 
was also investigated in naturally exposed dogs. As dogs are a very important reservoir, a 
canine vaccine with the aim to prevent or treat the animals would have beneficial effects 
through the interruption of the transmission of Leishmnaia parasites to humans. However, 
vaccination with LEISH-F1 did not protected dogs in an extremely high L. infantum 
endemic region142. On the other hand, the administration of the fucose mannose ligand 
(FML)-vaccine induced high levels of protection, since only 8% of the vaccinated dogs 
showed mild signs of canine leishmaniasis after 2 year, while 33% of the non-vaccinated 
animals developed clinical or fatal disease associated with L. donovani infection143. This 
vaccine is commercially available since 2004 under the name of Leishmune82 and is 
considered a transmission blocking vaccine likely due to the fact that vaccinated dogs do 
not have parasites in their skin even when infected144 and antibodies raised against 
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Leishmume are able to block the parasite development in the sand fly rendering the vector 
non-infectious 145, 146. 
 
Third generation vaccines: DNA vaccines  
DNA vaccines are an attractive alternative to conventional methods of vaccination due to 
several features that include the ability to elicit humoral and cellular immune responses, 
which can be modulated by the addition of adjuvants such as cytokines or CpG147, 148. 
Prime boosting strategies that involve priming with DNA and boosting with the respective 
recombinant protein or other antigen delivery systems have also been used149-152, since 
heterologous prime-boost leads to a synergistic enhancement of immunity to the target 
antigen153. DNA compared to recombinant protein vaccines present some advantages, 
largely due to stability and low cost of production. Moreover DNA vaccines may provide 
better protection as they can induce the expression of Leishmania antigens folded in its 
native conformation and normal posttranslational modifications to occur similar to natural 
infection and potentially with unaltered antigenecity147. Induction of both humoral and 
cellular immune responses by DNA vaccines is due to the ability of DC to present the 
encoded antigen in the context of MHC class I and MHC class II (known as cross-priming) 
as they can be directly transfected with the plasmid or take up soluble proteins and debris 
from apoptotic transfected cells117. Moreover has been suggested that this form of antigen 
delivery induces longer lasting immune responses154. There are many reports involving 
vaccination with DNA encoding Leishmania antigens, some of them tested previously as 
recombinant proteins, including GP63155, LACK156, 157, LmST11 and TSA158, cysteine 
proteinases159, ORFF160 among others with a wide range of success rate161, 162.Preclinical 
experience in other models of leishmaniasis with recombinant adenovirus, vaccinia virus 
and attenuated Salmonella suggest that these carriers should also be explored against 
VL132. 
 
 
1.3 Leishmania-host interactions 
 
Intracellular parasitism poses substantial challenges and to be successful the parasites 
must be able to enter and/or invade the host cell and escape the mechanisms used by the 
host to clear the intracellular parasites, such as apoptosis, autophagy, production of 
oxidative and nitrosative species and recognition by Toll-like receptors163. Leishmania 
parasites have adapted to colonize different host cells as a way to invade and evade the 
host immune response, taking advantage of the interaction between the different cells to 
establish and promote disease. Moreover, Leishmania-host interactions are even more 
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complex due to the diversity between the parasites themselves and the differences in 
human versus mouse host cell responses experimentally studied. 
 
Leishmania infection of a mammalian host initiates after a sand fly bite, in which 
promastigotes are injected into the skin where the parasite uptake by phagocytic cells 
occurs. The sand fly inoculate has an active role in the modulation of immune response of 
the host to Leishmania and may have a role in the influx of potential host cells. Besides 
delivering a high number of parasites highly enriched in metacyclic promastigotes, the 
infective form of the parasite30, 164, was detected the presence of apoptotic parasites that 
through the production of TGF-β seems to mediate the silencing of phagocytes and lead 
to survival of viable parasites165. In addition, the infectious inoculum also contains sand fly 
salivary components and parasite derived molecules such as the filamentous 
proteophosphoglycan (fPPG), which is a component of the promastigote secretory gel that 
blocks the anterior midgut of infected Lutzomyia longipalpis sand flies30. 
 
The earliest Leishmania interactions with the host take place in the whole blood as the 
sand fly bite create a hemorrhagic pool in the host skin for feeding. This first contact 
between Leishmania and the mammalian host induces tissue damage, a process that 
initiates a strong local inflammatory response and the recruitment of neutrophils and 
monocytes. Parasites react with natural antibodies and are opsonized by complement, 
binding to erythrocytes through complement receptor 1 (CR1) and after few minutes of 
infection transferred and internalized by neutrophils and monocytes166. Several recent 
studies have highlighted and reviewed the role of neutrophils in the initial phase of 
Leishmania infection both as a safe target that protects Leishmania from the extracellular 
hostile environment before entering macrophages but also is an important player in the 
development and modulation of an immune reponse against the parasite167-175. The 
neutrophils classical function is considered to be the capacity to phagocytose and kill 
microorganisms, contributing to the “first line of defense” against infectious agents176. 
However, the role of neutrophils in Leishmania infection goes further as they have been 
established as early host cells for promastigotes177 and may also contribute to the 
development and modulation of immune response against the parasite through the 
release of chemokines and cytokines178-183. Leishmania can transiently survive within 
neutrophils due to the development of protective mechanisms including the prevention of 
oxidative burst activation, avoiding the generation of toxic ROS177 and also the ability to be 
targeted to non-lytic compartment of neutrophils as reported for L. donovani173.  
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Recruitment of neutrophils to the local of infection occurs as early as 30 min post infection 
and after 1 day of infection parasites localize mainly inside neutrophils. During the first 
week, the proportion of infected neutrophils drops and as parasites are released from 
apoptotic neutrophils they become localized in macrophages. The crucial role of 
neutrophils after sand fly transmission of Leishmania is also shown by reduction of local 
incidence of infection observed when this cell population was depleted, suggesting that 
parasite can hide in the neutrophil until the host cell apoptosis forces the parasite to infect 
a macrophage171. On the other hand, passage through neutrophils can render the parasite 
more infective, as host recognition of phosphatidylserine (PS) on the surface of unicellular 
parasites is an important feature of the process and progression of infection184.  
 
The way parasites are transferred from neutrophils to macrophages is not yet clear. A 
model named “Trojan horse” whereby macrophage can uptake apoptotic neutrophils 
containing viable Leishmania parasites has been shown to occur in vitro and considered a 
mechanism for “silent” entry of parasites into macrophages175. However, dynamic intravital 
microscopy have not shown the phagocytosis of infected neutrophils but that Leishmania 
parasites can escape neutrophils before infecting macrophages171. Also arrival of 
macrophages to the local of infection can induce neutrophils apoptosis. Thus another 
strategy called “Trojan rabbit” was proposed, in which the parasite hides outside the 
apoptotic neutrophil to infect the macrophage169.  
 
Engulfment of apoptotic neutrophils by macrophages can have immunoregulatory or 
pathogenic roles. BALB/c neutrophils induce a biochemical cascade that deactivates 
macrophage through the production of TGF-β and increase growth of L. major in a 
manner dependent on PGE2 and TGF-β. In contrast resistant B6 mice interaction of dead 
neutrophils with macrophage promoted parasite killing185. Susceptible Balb/c mice are 
also less efficient in mediating neutrophil apoptosis as these cells persist much longer in 
Balb/c than in the resistant B6 mice, suggesting an important role for neutrophil 
accumulation in the differences observed between the two species186.  Clearance of 
neutrophils can have a proinflammatory effect mediated by soluble factors and neutrophil 
elastase, which activate infected macrophages to eliminate Leishmania parasites via 
TLR4 signaling187. Besides the role of neutrophils in the killing of parasites through the 
activation of macrophages, they have their own microbicidal mechanism such as the 
release of neutrophil extracellular traps (NETs), which are composed of DNA, histone 
proteins and antimicrobial peptides188. Indeed, L. amazonensis induced NET release by 
human neutrophils in a parasite number- and dose-dependent manner, which in turn led 
to decrease in parasite viability; the disruption of neutrophil NETs interaction with 
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Leishmania led to an increase in parasite survival that supports the possible contribution 
of NETs in the decrease of parasite burden at the site of inoculation189. In contrast, 
another study have shown that L. donovani is able to evade the microbicidal effect of 
NETs, a mechanism dependent on LPG biosynthesis as mutant parasites were highly 
susceptible to the antimicrobial activity of NETs. As the parasites are only trapped by 
NETs and not killed, it was proposed that these structures may contribute to the 
containment of L. donovani promastigotes at the site of inoculation, facilitating their uptake 
by macrophages190.  
Intradermal infection with L. infantum chagasi, a visceralizing species, leads to the 
recruitment of neutrophils to the dermis even later after inoculation and parasites were 
trafficked through the neutrophils, suggesting that neutrophils may play a role in visceral 
leishmaniasis191. Also, neutrophils seem to have a crucial role during the first weeks of 
infection with L. donovani, as mice in which neutrophils were selectively depleted have 
shown a significant increase in parasite burden in spleen and bone marrow172. Both 
studies highlight the importance of neutrophils in visceral leishmaniasis and how they may 
influence the development of a protective response.  
 
Leishmania spp. have also found a way to interfere and/or control neutrophils functions. 
The infectious inoculum is composed of non-apoptotic and apoptotic cells, the last ones 
shown to be necessary in the survival of non-apoptotic parasites that were rapidly killed if 
phagocytosed in the absence of apoptotic promastigotes. This is explained by the 
induction of higher levels of TGF-β and low levels of TNF-α by apoptotic parasites than 
non-apoptotic cells, directly related with PS exposure on the parasite surface. The PS 
recognition is known to suppress phagocytic functions through the release of and down-
regulation of TNF-α; TGF-β is likely involved in the silent entry of the parasite and survival 
in the neutrophils165. Leishmania is also able to interfere with IFN-γ signaling in 
neutrophils, working as a potent inhibitor mechanism of the host cell activation174. Another 
strategy of survival used by Leishmania is to delay apoptosis of neutrophils, since they are 
short-lived cells that undergo rapidly spontaneous apoptosis. Infection with L. major led to 
an increase up to 2 days in life span of neutrophils revealing that the parasite can actively 
modulate the host apoptosis which will probably allow the parasite to adapt and survive 
before engulfment by macrophages186. Infected neutrophils secrete high levels of MIP-1β 
which attracts macrophages180, that due to the recognition of PS on the neutrophil surface 
will proceed to a “silent” clearance of apoptotic neutrophils, since ingestion of apoptotic 
cells does not result in the activation of antimicrobial effector functions. Leishmania-
infected neutrophils are able to deactivate the functions of macrophages as the amount of 
TGF-β secreted by macrophage following the uptake of infected neutrophils was higher 
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than direct uptake of L. major promastigotes, with no significant release of TNF 175. The 
ability of the Leishmania to survive and maintain infectivity in neutrophils seems to have a 
crucial role in the establishment of a productive infection in macrophages174. 
 
Although, in situ imaging has shown that most infected neutrophils release the parasites 
before being phagocytosed by macrophages and also that parasites numbers in the 
macrophages of mice did not change after neutrophil depletion171. Thus, the contribution 
of parasites uptake by neutrophils to Leishmania infectivity is still controversial and not 
clear. Indeed reported work suggests that the effects of neutrophil depletion are mouse 
strain dependent185. 
Another type of cells may be involved in the initiation of a protective immune response 
directed to Leishmania, as infection with L. major induced the secretion of 
immunomodulatory mediators such as IL-12, IL-1 IL-4 and IL-6 by keratinocytes192. There 
still some controversy in the role of DC during early infection, whether these cells are able 
to uptake the parasite193-195. However, recent studies have shown using an intradermal 
infection model that dermal DCs, a sub-type of dendritic cells found on the dermis, are 
able to uptake L. major parasites shortly after infection196. Both infected and non-infected 
dermal DCs became non-migratory at the inoculation site, suggesting that the 
inflammatory environment induces the change in dermal DC migratory behavior. However, 
20h post-infection the number of parasite-containing dermal DC decreased, suggesting 
that infected dermal DC leave the dermis in order to migrate to draining lymph nodes196, 
supporting previous studies which have shown that DC arrival in draining lymph nodes 
occurs around 24 hours post-infection197.  
 
Although Leishmania parasites can be found in different types of cells, the macrophage is 
considered the principal site of parasite proliferation and dissemination. Metacyclic 
promastigotes can be phagocytised indirectly by macrophages through the uptake of 
infected neutrophils as detailed above. Macrophages can also be directly phagocytised 
promastigotes that attach to the host cell via a receptor-mediated mechanism and are 
taken up via CR3-dependent mechanism, by which Leishmania is able to avoid 
complement mediated lysis. This occurs in part through the activity of Leishmania surface 
protease GP63, which cleaves host complement component C3b into iC3b, preventing 
complement mediated parasite lysis and, in addition the iC3b deposited on the 
promastigote surface promotes receptor-mediated uptake through CR1 and CR3198, 199 . 
Parasite phagocytosis by macrophage in vitro is rapid and can be completed within 10-20 
minutes of parasite attachment, occurring similarly when performed by neutrophils or 
dermal DC171, 196, 200. 
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2.1 Leishmania “omics” 
 
Leishmania represents a very diverse group of organisms. In order to characterize 
Leishmania diversity whole-genome sequencing, transcriptomic studies based on whole 
genome-based DNA arrays and global proteomic studies have already been carried 
out201. Suprisingly, the comparative genomic studies between L. major, L. infantum and L. 
braziliensis showed a highly conserved gene synteny and a small number of species-
specific genes202, despite an estimated divergence of 46-36 million years43. These findings 
were unexpected as they contrast with the major phenotypic differences caused by each 
species. Recently, new sequencing technologies allowed a more powerful study of 
different Leishmania species genomes demonstrating that the apparent genetic 
homogeneity contains features such as aneuploidy, expansion and contraction of genes in 
tandem arrays and episomes that contributes to genomic diversity and/or plasticity203, 204. 
Transcriptomic studies have been used to determine differences in gene expression 
between different species and life cycles or associated with drug resistance and clinical 
polymorphism. Although, due to the fact that regulation in Leishmania appears to occur at 
a post-transcriptional level it was found that the vast majority of the genes are 
constitutively expressed in all developmental stages and thus transcriptomics alone might 
not be useful to describe coordinate expression in Leishmania. On the other hand, 
proteomic studies have been useful in the identification of stage specific proteins and 
have reported a higher percentage of the predicted proteome as stage-specifically 
regulated at the translational or post-translational level contrary to the data obtained with 
transcriptomics201. Both genomic and proteomic approaches play a role in revealing 
differences between Leishmania species, but are limited in providing contextual and 
integrative information that is necessary to decipher the mechanisms of cellular function. 
Metabolites are key in linking together the web of complex interactions, cellular pathways, 
molecular participants and environmental stimuli. Metabolomics has gained increasing 
interest in drug discovery, disease diagnostics and treatment, as it allows the measure of 
metabolites fluctuation that can occur very quickly205 and is now being applied in parasite 
research206-209.  
 
 
2.2 Leishmania genome: gene content and structure 
 
The Leishmania genome is composed of nuclear and kinetoplast DNA, that constitute a 
unique feature of trypanosomatids. The L. major genome was the first to be sequenced210, 
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however before the whole-genome sequencing was completed previous studies have 
already revealed an unusual pattern of gene distribution, in which the genes are aligned in 
long arrays that appear to be transcribed as a single unit prior to trans-splicing and 
polyadenylation211. L. major Friendlin genome is 32.8 Mb in size with a karyotype of 36 
chromosomes, with 8272 protein encoding genes, of which 36% can be ascribed with a 
putative function210. Comparative genomic analysis of L. major, L. infantum and L. 
braziliensis showed a high degree of conserved synteny for more than 99% of the genes. 
Conservation within coding sequences is also high, with an average amino acid identity 
between L. major and L. infantum of 92% and between L. braziliensis and L. infantum or 
L. major of 77%202. Despite a similar DNA content among all Leishmania species 
analyzed, differences were detected in the karyotype, confirming data previously observed 
by linkage group analysis212. L. infantum has a haploid content of 36 chromosomes as 
does L. major, while the New World species have 35 or 34 chromosomes, L. braziliensis 
and L. mexicana respectively202. These differences are due to chromosome fusion events 
that in L. braziliensis involved chromosome 20 with 34 and in L. mexicana the 
chromosome 8 with 29, and 20 with 36203, 204. An update on Leishmania genomes 
obtained by recent genome re-sequencing projects, using the Illumina Genome Analyser 
plataform and the iterative mapping algorithm iCORN204 is shown in Table 2.1.  
 
Table 2.1 Summary of Leishmania genomes 
 
 L. major L. infantum L. braziliensis L. mexicana 
Size (Mb) 32.855 32.101 31.997 32.108 
Chromosomes 36 36 35 34 
GC% 59.7 59.6 57.8 59.7 
Predicted protein coding genes 8412 8241 8357 8250 
Predicted specific genes 14 19 67 2 
 
(adapted from Rogers et al.204) 
 
This together with new alignments allowed an update in the number of unique genes in 
each species (Table 2.1) that is even more restricted than the first data provided by the 
comparative genomic analysis of L. major, L. infantum and L. braziliensis202 . An 
interesting finding was that species-specific genes are conserved in isolates from within 
the same complex (L. donovani versus L. infantum) and between strains of the same 
species isolated from different or similar geographical locations204. The identification of 
specie-specific genes is thought to be crucial to determine the possible role of those in the 
variety of clinical outcomes caused by different Leishmania species, particularly the L. 
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donovani genes required for visceral infection. Experimental approaches to identify the 
role of specie-specific genes have been mainly achieved through the generation of 
transgenic parasites, such as L. major parasites expressing L. donovani specific genes213. 
The A2 gene is an example of a L. donovani specific gene that encodes an amastigote-
specific protein. A2 L. donovani deficient amastigotes were severely compromised in their 
ability to infect mice, indicating the requirement of A2 for survival in the mammalian 
host214, 215. Introduction of A2 gene into L. major by genetic transfection led to an increase 
of parasite survival in visceral organs, conferring a change in the virulence phenotype216. 
Furthermore, genome sequencing analysis revealed significant sequence diversity and 
structural variation at the A2 locus in L. donovani203, in contrast with the conservation 
observed at the same locus in L. major203, suggesting  and re-enforcing the possible role 
of the gene in infection visceralization. Other examples of potentially interesting specie-
specific genes are the cyclopropane fatty acyl phospholipid synthase (CFAS) gene 
present in L. infantum and L. braziliensis but not in L. major and the SEC14-like originally 
identified in L. infantum202, but which has now been identified also in L. mexicana204. 
CFAS orthologue in Mycobacterium tuberculosis has been shown to modify cell surface 
glycolipids and is associated with increased virulence and persistence203, while Sec14 
cytosolic factor has been implicated in the release of secretory vesicles from the 
transgolgi network217. There were no differences in growth and in the ability to infect 
macrophages between SEC14-like null mutants and the L. infantum WT204. Other species-
specific genes can result from insertions/deletions and sequence rearrangements that 
contribute to gene degeneration218 as demonstrated by the identification of Pfp1 gene, 
which is expressed in L. major, but present in L. infantum and L. braziliensis as a 
pseudogene219. Unexpected was the fact that genes ubiquitously present in different 
Leishmania species could also have a dramatic effect on parasite tropisms213. Zhang and 
co-workers found that the expression of L. donovani Li1040 ortholog gene in L. major, 
which does not belong to the group of specie-specific genes, dramatically increase L. 
major parasite numbers in the liver and spleen213. This finding highlight that the factors 
controlling tropism and virulence are not only related to the species-specific genes, but 
also to post-transcriptional regulation and gene polymorphisms. 
 
 
2.3 Genomic features that contribute to Leishmania diversity and plasticity 
 
Given the small number of species-specific genes identified, differential gene expression 
has been investigated as another potential explanation for disease phenotypic differences. 
DNA microarrays, of varying size and composition, have been used to determine the 
2. Leishmania: From Genome to Metabolome 
32 
 
global Leishmania gene expression, revealing that the vast majority of Leishmania 
genome is constitutively expressed and that only a limited number of genes, ranging from 
0.2 to 5.7% depending on the microarray study, showed differential regulation when 
comparing promastigote and amastigote forms220-225. Analysis of L. major promastigotes 
and lesion-derived amastigotes gene expression showed that over 94% of the genes were 
expressed in both stages, with just 1.5% differential mRNA expression221. These results 
suggest that Leishmania is constitutively pre-adapted for survival and replication in 
different hosts, the constitutive expression of the genome being an advantage of 
adaptation to the different environments using an appropriate set of genes as 
necessary226. Comparison of L. donovani axenic and intracellular amastigotes revealed 
substantial differences in gene expression regulation, with 40% more genes up-regulated 
in axenic than in intracellular amastigotes and just 12% of the differential regulated genes 
were common to both amastigotes preparations225. Also for L. major the differences 
obtained when comparing promastigotes to axenic (3.5%) or lesion derived amastigotes 
(0.2%)220 point out that the axenic culture conditions may alter the amastigote 
transcriptomic abundance and that the importance of the host macrophage as a driving 
force to specific adaptations cannot be disregarded. Indeed, a quantitative proteomic 
analysis of axenic and splenic L. donovani amastigotes revealed important differences, 
such as in cell volume and nuclear size, A2 protein expression and parasite infectivity, 
between both amastigote sources227. Reduction in A2 expression in the hamster-derived 
amastigotes suggests that these parasites are adapted to survive under stress conditions, 
as the A2 protein has been considered a virulence factor required for L. donovani 
intracellular survival and resistance to stress215; this is in agreement with the hypothesis 
suggested by the results obtained when comparing mRNA levels of axenic and 
intracellular amastigotes, showing that the ones collected from the host are adapted to 
growth in different environments. This demonstrates that results obtained with axenic 
amastigotes should be carefully considered as they represent a host free system.  
 
The constitutive expression of the Leishmania genome is consistent with the unusual 
gene organization detected in trypanosomatids. The Leishmania genome is organized into 
large polycistronic gene clusters, comprising of up to hundreds of genes, in the same 5’-3’ 
direction along the chromosome DNA strand210. These long arrays are transcribed into 
polycistronic RNA precursors and further processed into individual mRNAs with a 39-nt 5’ 
capped spliced leader sequence and a 3’ poly(A) tail generated from the polycistronic pre-
mRNAs via 5’ trans-splicing and 3’ cleavage polyadenylation reactions228. Polycistronic 
transcription and the lack of RNA polymerase II promotors for protein-coding genes imply 
that most of the gene regulation occurs post-transcriptionally. Indeed, numerous 
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sequences located in the 3’UTRs were described as being involved in the control of 
mRNA stability and translation, even before the Leishmania genome sequence was 
available229-234. Advances in the discovery and characterization of these elements 
occurred due to the complete annotation of L. major genome210. Stage-specific post-
transcriptional regulation is described as being mediated through specific regions (cis-
elements) within 3’UTRs of mRNAs235. These elements are widely distributed in the 3’UTR 
and are classified as U-rich instability elements (UREs), short interspersed degenerated 
retroposons (SIDERs)236 and individual cis-elements237. SIDER elements represent the 
most abundant transposable elements characterized so far in trypanosomatid genomes; 
two functional distinct families were described in Leishmania: SIDER1, which is implicated 
in stage-specific translational control and SIDER2 that promotes mRNA destabilization. 
SIDER2 are cis-acting components of a regulatory pathway that generally down regulates 
gene expression to ensure rapid turnover of a specific subset of Leishmania mRNAs.  
 
Rapid mRNA turnover may be a strategy that allows the parasite to easily adapt its pattern 
of protein synthesis to the different environments236. A well known example of stage-
specific regulation in Leishmania through conserved elements in the 3′UTR is the amastin 
gene family, which is expressed preferentially in the mammalian stage238. Thus, 
Leishmania genome organization and regulation explains why limited stage-specific 
differences in mRNA levels are detected. In fact the weak correlation of protein expression 
with the corresponding mRNA levels, as reported in many other organisms239-241, confirm 
the importance of regulation of protein levels in Leishmania by mechanisms such as 
stage-specific translational control or protein stability. A combined proteomic and 
transcriptomic analysis of L. infantum parasites have confirmed the striking lack of 
correlation in promastigotes between mRNA and protein levels, while for amastigotes it 
was found to be over 50%242. Moreover, a higher number of promastigote- or amastigote-
specific protein isoforms were found to be differentially regulated, respectively 6.1% and 
12.4%, when comparing with the data obtained from mRNA levels, for which the fold 
changes observed were more modest than at a protein level. Furthermore, multiple 
protein spots were found for a single gene and also different isoforms of the same protein 
are detected as stage-specific, clearly suggesting that protein post-translational 
modifications occurs playing an essential role on the parasite adaptation to different 
environments, which might explain the considerable degree of discrepancies between 
transcriptomics and proteomics as well as the limited number of stage-specific genes. 
Many other proteomic studies with L. infantum, L. donovani, L. mexicana and L. 
panamensis have also highlighted differences between different life stages: there are 
subtle differences based on the identification of protein isoforms from the same gene, but 
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also major differences in protein expression, up- or down regulation of expression, with 
some being stage-specific221, 243-248. 
 
Despite considering that different mechanisms of post-transcriptional and post-
translational regulation are crucial for species-specific differences, it is still intriguing how 
an apparent genetic homogeneity between different Leishmania species due to the 
constitutive expression of the genome generates such enormous diversity in disease 
outcome. The recent re-sequencing genome projects have increased our knowledge 
about Leishmania genome structure and highlighted some features that can contribute for 
genome diversity and/or plasticity, the most notable being the chromosome copy number 
variation between Leishmania species and strains203, 204 changing the assumption until 
now accepted that the Leishmania genome was generally diploid249, since that only two 
exceptions had been reported in L. major, with the detection of triploidy and tetraploidy in 
chromosome 1250 and 3156, respectively. Thus it is clear that the emergence of new and 
powerful molecular technology will reveal important features of the genome that were 
likely to be masked by previous approaches, showing that evolutionary changes to reach 
an adaptive phenotype reflects changes in the karyotype such as gene rearrangement 
and chromosomal size variation251. Several studies, either associated with attempts to 
knockout essential genes252-254 or dealing with the mechanisms associated with drug 
resistance, have highlighted the plasticity of Leishmania genome255, 256. DNA microarrays 
have been used to screen for differentially expressed genes in Leishmania parasites 
selected in vitro for drug resistance and proven suitable to detect gene amplification 
events256-258. Overexpression of genes such as gamma-glutamylcysteine synthetase 
(GSH1), ABC transporter MRPA (PGPA), pterin reductase 1 (PTR1) and dihydrofolate-
reductase thymidylate synthase (DHFR-TS) was found to be due to DNA amplification, a 
strategy that seems to be used by Leishmania parasites to increase expression of certain 
genes in order to survive under drug pressure258. Modulation of gene copy numbers and 
consequent up or down regulation of gene expression in resistant lines was described as 
involving gene deletion, extrachromosomal circular or linear amplicons and 
supernumerary chromosomes255, 256. Gene amplification has been described in drug 
resistant parasites selected in vitro for resistance to methotrexate (MTX), in which the 
target gene DHFR-TS or PTR1 were amplified as part of extrachromosomal circular or 
linear amplicons258-260; also in vitro selection of antimony resistance L. infantum parasites 
led to the generation of several supernumerary chromosomes and two haploid 
chromosomes 255, 256. Although, a clear pattern of aneuploidy was observed in L. donovani 
clinical lines, isolated from visceral leishmaniasis patients, it was not possible to establish 
a clear link between supernumerary chromosomes and drug resistance phenotypes203. 
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Clearly further work is needed to confirm the generation of aneuploidy with drug 
resistance emergence in clinical strains, however there are some indications that gene 
rearrangements and chromosome aneuploidy make part of the mechanisms used in 
response to drug pressure, demonstrating the plasticity of the Leishmania genome and 
how well these parasites cope with changes that include duplication or deletion of a whole 
chromosome. Most surprising is the fact that chromosome copy number variation does not 
occur only under drug pressure. It was revealed by the new sequencing genome projects 
that included the annotation of L. mexicana and L. donovani reference genomes for the 
first time and also the refined versions of L. major, L. infantum and L. braziliensis, to be a 
natural genetic feature of Leishmania species and apparently the major source of genomic 
diversity203, 204. Variation in chromosome organization and copy number is a common 
mechanism used by pathogenic fungi to rapidly generate diversity in response to stressful 
growth conditions 261 This plasticity includes the types of genomic changes frequently 
observed with cancer cells, including chromosomal rearrangements, aneuploidy, and loss 
of heterozygosity. Aneuploidy in human cancer cells is very prevalent and increasingly 
common during the acquisition of drug resistance in cancer cells262, 263. Chromosome copy 
number variation was found in all Leishmania species and large differences were detected 
among the strains and species analyzed, as shown in Table 2.2.  
The only supernumerary chromosome found to be common to all species was 
chromosome 31204, which has been previously identified as tetraploid in L. major56. 
Furthermore, identified in L. mexicana and L. braziliensis were chromosomes with an 
intermediate read depth, being neither disomic or trisomic, suggesting a mixture of ploidy 
in the cloned population as reported for seven chromosomes from individual L. major 
parasites by fluorescent in-situ hybridisation (FISH)264. Sterkers and co-workers have, for 
the first time, shown variable ploidy within the same L. major population suggesting that 
every chromosome was observed in at least two ploidy stages and also that chromosome 
ploidy distribution was variable among clones and strains264. This phenomenon, named 
chromosomal mosaicism, appeared to be constitutive and potentially responsible for the 
generation of phenotypic variability from genomic plasticity264. Suprisingly, was the 
observation that L. braziliensis strain M2904 is predominantly triploid contrary to what was 
observed for the other species, containing several tetrasomic chromosomes and six 
copies of chromosome 31204.  
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Chromosome ploidy variation was validated for LinJ36.0640 and LinJ31.3030 genes of L. 
infantum JPCM5 (MCAN/ES/98/LLM-887)204 by gene deletion, with no differences in 
growth or infectivity between the null mutants and wild type strains. As shown by the 
analysis of 17 strains of L. donovani, the pattern of aneuploidy is unique for each cell line, 
impossible to link a given pattern to sodium stibogluconate drug resistance, showing 
clearly that Leishmania genomic plasticity and diversity is a complex phenomenon. It’s 
noteworthy to mention the huge difference in the number of single nucleotide 
polymorphisms (SNPs) detected in L. major (297 SNPs) and L. infantum (629 SNPs) 
compared with L. mexicana (12531 SNPs) and L. braziliensis (44588 SNPs), revealing a 
remarkably high level of heterozygosity in L. braziliensis. SNPs are the most frequent 
variation in the human genome, which consist of single base-pair substitutions that occur 
within and outside genes265. As mentioned above, the recent genome sequence revealed 
that chromosome copy number variation is the major source of genomic diversity in 
Leishmania203, 204. Besides chromosome copy number variations, expansion and 
contraction of genes in tandem arrays also contributes to gene dosage differences203, 204. 
The total number of arrays and the number of gene copies in each array varied among 
species, with 56 protein-coding genes found to be multicopy in all 4 species studied: L. 
major, L. infantum, L. donovani and L. braziliensis and L. mexicana. Interesting was the 
fact that multicopy genes were found preferentially on disomic and not in supernumerary 
chromosomes204. The authors of the study suggested that disomic chromosomes 
containing genes in tandem array are not among those that underwent whole 
chromosome duplications due to the presence of a higher proportion of dose-sensitive 
genes204. As reported previously drug selection in vitro induced the amplification of genes 
as part of extrachromosomal amplicons255. Although the presence of episomal DNA 
corresponding to the amplification of the MAPK locus in L. donovani clinical lines, and the 
fact that more copies of the MAPK-locus were found in SSG-resistant lines, is evidence 
for Leishmania genomic plasticity and the potentially different mechanisms used to 
regulate gene dosage. Furthermore, it was shown that the gene dosage in the L. donovani 
reference line strongly correlates with transcription levels and thus the implications of this 
need to be evaluated at proteome and metabolome levels203. 
  
 
 
 
 
 
 
2. Leishmania: From Genome to Metabolome 
38 
 
2.4 Proteomics meets metabolomics: an integrative approach to understand 
Leishmania metabolism 
 
 
In Leishmania, mRNA levels can be a misleading indication of the protein expression as 
parasite genome is constitutively expressed and consequently regulation of gene 
expression in these organisms is post-transcriptional266. Thus, mRNA stability, translation 
rate and post-translation modifications affecting protein function and stability contribute to 
gene expression modulation. Both changes in transcripts and protein levels are reflected 
in functionally relevant variation at a metabolite level, making the metabolome the closest 
“picture” of the phenotype201. Metabolic levels are tightly regulated and the unclose of the 
complex Leishmania metabolic network and its associated dynamic will allow the 
determination of basic biological processes and to be relevant to understand the 
mechanisms underlying drug resistance, since drugs such as amphotericin B and  
miltefosine target metabolic processes, ergosterol biosynthesis and phospholipid 
metabolism, respectively267, 268. The annotation of the Leishmania genome together with 
several proteomic and biochemical studies on promastigotes and amastigote forms 
allowed the prediction of Leishmania metabolic potential and also the inference of a wide 
range of metabolic pathways269-271.  
 
Proteomics analysis of Leishmania spp. have been used to identify stage-specific, 
immunogenic or secreted/excreted proteins, contributing to an understanding of the 
changes and/or adaptations underlying, for example, parasite differentiation or drug 
resistance. Moreover, proteomics has provided crucial data for the prediction of the 
metabolic pathways present in Leishmania spp. Several proteomic studies have been 
published, reporting the comparison between promastigote and axenic amastigote 
proteome profile, grown in in vitro conditions, which mimic the sand fly and 
phagolysosome environments, while others have been focused on the analysis of the 
proteome during differentiation221, 242-248, 272-279. All studies revealed differences in protein 
expression, up-or down- regulation and stage specific expression; however an interesting 
result was the fact that different protein spots were originated in the same gene, likely due 
to post-translational modifications (PTM) and consequent detection of different protein 
isoforms in the different Leishmania life stages. PTMs such as phosphorylation, 
methylation, acetylation and glycosylation are important regulators of protein function, 
stability and turnover rate280. In Leishmania, little information is available about PTMs, 
although recently proteomic approaches have been used to identify sites of PTM in 
promastigotes and amastigotes, with the aim of determining the changes that occur during 
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axenic differentiation and also gain insight into the role of these modifications in the 
regulation of Leishmania development272, 281, 282. Both phosphorylation and methylation 
PTMs were more common latter than during the initial differentiation, and in the case of 
protein methylation, such modification was followed by an increase in protein abundance 
suggesting a role in protein stability. The notable increase in β-tubulin glycosylation 
observed 15h post differentiation signals support for the possible role of this modification 
in parasite cytoskeletal remodeling, since glycosylation of tubulin was reported to inhibit 
GTP-dependent polymerization281. Furthermore, Morales and co-workers have identified 
phosphoproteins implicated in stress and heat shock response, RNA/protein turnover, 
metabolism, and signalling. They have reported that in amastigotes relatively more 
proteins were phosphorylated compared to promastigotes, 4% and 2.6% of total protein 
content, respectively272. Phosphorylation appears to be extremely important in the 
regulation of Leishmania response to stress, as amastigotes phosphoproteins with 
increasing abundance were almost exclusively protein chaperones such as the HSP90 
family member HSP83, various HSP70 family members and the stress induced protein 
STI1/HOP282, for which have been shown a largely constitutive expression, not induced by 
elevated temperatures across promastigotes and amastigotes stages245. The importance 
of chaperone phosphorylation in L. donovani viability was shown by mutation of STI1/HOP 
phosphorylation sites, since a “conditional” STI1 null mutant required the presence of a 
functional STI1/HOP copy when a mutated copy was added as an episome282. Thus, 
phosphorylation as well as other PTMs constitute an extremely important adaptation of 
Leishmania parasites to constitutive gene expression and absence of transcriptional 
regulation.  
 
Proteome profiling comparison of promastigote and amastigote forms provide important 
information, as they represent two different life stages, although the search for differences 
in protein expression during parasite differentiation and preparation to infect the 
mammalian host is also of utmost interest. The most comprehensive analysis of protein 
expression was carried out across seven time points during in vitro differentiation of L. 
donovani promastigotes, in order to highlight how promastigotes retool themselves to 
survive and replicate as an amastigote245. This study, used a novel proteomics approach, 
in which peptides were labeled by the isobaric tags for the relative and absolute 
quantification (iTRAQ) method, allowing a coverage of 21% of the predicted Leishmania 
proteome, that resulted in the detection of 969 proteins at all time-points, grouped into an 
amastigote (289 proteins) and promastigote (310 proteins) specific cluster; major changes 
in protein abundance occurred at 10–15 h post differentiation signals245. Many enzymes of 
the major metabolic pathways were identified and analysis of their pattern provided a 
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comprehensive view of parasite metabolic and physiological adjustments during 
differentiation. Parasites down-regulate glycolysis and simultaneously up-regulate 
gluconeogenesis, in agreement with the scarce availability of glucose in the 
phagolysosome283 and the necessary production of sugars from glycerol and amino acids; 
also notorious is the parasite shift from glucose to fatty acid oxidation as the main source 
of metabolic energy, by the up-regulation of the majority of the enzymes involved in β-
oxidation and down-regulated expression of acetyl-CoA carboxylase, the enzyme that 
synthesizes a key inhibitor of β-oxidation, 15h after differentiation. Also, enzymes involved 
in the tricarboxylic acid cycle, mitochondrial respiration and oxidative phosphorylation 
were up-regulated throughout differentiation, supporting the increase in metabolic energy 
production, that the authors of the study propose to be necessary to maintain amastigote 
pH homeostasis281.  
 
The availability of the Leishmania genome sequence and all the information gathered by 
transcriptomic, proteomic and biochemical studies allowed the construction of a database 
named LeishCyc, which describes L. major genes, gene products, metabolites, their 
relationships and biochemical organization into metabolic pathways, providing a useful 
tool for integration of Leishmania -omics data (transcriptomics, proteomics, metabolomics) 
in the context of metabolic pathways271.  
 
Analysis of the metabolome, the total collection of metabolites in a cell provides a read-out 
of the metabolite levels in biological samples. Thus, metabolomics gives access to 
information that both genomics and proteomics do not cover, enabling the analysis of 
small molecules that reveal new insights into the molecular pathways underlying biological 
processes. Metabolomics have been applied to the discovery of new biomarkers and also 
to provide a “fingerprint” that allow the distinction between healthy and unhealthy cells284, 
considered as being an excellent tool in the discovery of metabolites and metabolic 
pathways central to biological regulation, with important applications in the study of 
disease including the regulation of disease. Metabolomics applied to parasites is now 
emerging due to availability of new and improved techniques for extraction and 
identification of metabolites. Some studies have examined the effect of parasite infection 
in vivo by analysis of host biofluids in order to elucidate the metabolic modulation induced 
by the parasite and identify biomarkers for a variety of diseases caused by Schistosoma, 
Trichinella and Plasmodium209, 285, 286. Other experiments have analyzed the parasite in 
vitro, revealing important aspects of T. brucei carbon metabolism287 or changes in 
metabolism that may be involved in the generation of Leishmania drug resistance207. 
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2.5 Leishmania metabolome   
 
During its digenetic life cycle, Leishmania alternates between the alimentary tract of the 
sandfly vector and the acidic phagolysosomes of mammalian macrophages. In order to 
survive in such different environments, Leishmania has adapted to exploit multiple carbon 
sources, possesses a complex transport and salvage pathways to acquire essential 
nutrients, for which lack the pathways of de novo synthesis, is able to synthesize 
metabolites involved in cellular oxidative defence, to modulate the host cell metabolic and 
signalling pathways for their own profit288, 289. As a promastigote, Leishmania experience 
nutrient-rich conditions in the digestive tract of the sand-fly either during digestion of the 
blood meal or sugar meal phase. Although, the parasite has to survive in a nutrient poor 
environment during the initial phagocytosis by the neutrophils and adapt to the poor 
content of sugars within the macrophage phagolysosome, where the nutrient composition 
is heavily dependent on the host immune and activation state of the host cell283. 
The pathways of core metabolism in Leishmania occur between two organelles: 
glycosome and mithocondrion (Figure 2.1). Glycolysis, gluconeogenesis, pentose 
phosphate and succinate fermentation, that are involved in carbohydrate metabolism take 
place partially or exclusively in the glycosome while the tricarboxylic acid (TCA) cycle 
occurs in the mitochondria269, 290, 291. 
 
Leishmania can use an amylase, many sugar kinases and a sucrose like protein for the 
digestion of plant starch and disaccharides, likely to be present in the nectar taken by 
sand flies269. Thus, Leishmania parasites are well adapted to develop in a glucose rich 
environment, a fact observed in vitro by the preference of glucose and other sugars as 
carbon sources by both promastigotes and axenic amastigotes292. Although, the sugar 
content in the phagolysosome, in which the amastigote form resides is likely to be scarce 
and the parasite have adapted to use other sources of carbon such as amino acids and 
fatty acids, Leishmania is still highly dependent on hexoses. Exogenous hexoses may be 
needed to sustain essential pathways such as the pentose phosphate pathway (PPP), 
RNA/DNA synthesis, N-glycosylation and myo-inositol synthesis293, 294. Hexose 
transporter-deficient L. mexicana mutants could not survive inside macrophages295. Also, 
fructose-1,6-bis-phosphatase (FBP) L. major mutants were able to infect but failed to 
generate normal lesions in mice, revealing the essential role of gluconeogenesis296. 
Indeed, analysis of parasite proteome during in vitro differentiation has shown that 
glycolysis is down-regulated during late differentiation while gluconeogenesis enzymes 
expression was up-regulated. Co-localization and co-expression of gluconeogenic and 
glycolytic enzymes may allow the parasites to rapidly adapt to different environments.  
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Figure 2.1 Central carbon metabolism in Leishmania. 
Boxed metabolites are end-products (in black) of metabolism; dotted arrows represent 
multiple step reactions. Abbreviations: Ala, alanine; Asp, aspartic acid; DHAP, 
dihydroxyacetone phosphate; Glc, glucose; Fru, fructose; Fru1,6BP, fructose-1,6-
bisphosphate; GAP, glyceraldehyde-3-phosphate; G1,3P2, 1,3-biphosphoglycerate; GlcN, 
glucosamine; GlcNAc, N-acetyl-glucosamine; Glu, glutamic acid; Gln, glutamine; Man6P, 
mannose-6-phosphate; ManPc, Man1,4-cyclic-phosphate; Mann, mannogen oligomers 
(Manβ1-2Man)n; PGL, phosphogluconolactone; PG, phosphogluconate; PGA, 
phosphoglycerate; PEP, phosphoenolpyruvate; Pro, proline; SDL, S-D-lactoyl-conjugate. 
Enzymes: 1, hexokinase; 2, glucose-6-phosphate dehydrogenase, 3, 6-
phosphogluconolactonase; 4, phosphoglucose isomerase; 5, phosphofructokinase; 6, 
fructose biphosphate aldolase; 7, triosephosphate isomerase; 8, glycerol-3-phosphate 
dehydrogenase; 9, glycerol kinase; 10, glyceraldehyde-3-phosphate dehydrogenase; 11, 
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phosphoglycerate kinase; 12, phosphoglycerate mutase; 13, enolase; 14, pyruvate 
kinase; 15, alanine aminotransferase; 16, pyruvate dehydrogenase; 17, citrate lyase; 18, 
aconitase; 19, isocitrate dehydrogenase; 20, glutamatedehydrogenase; 21, α-
ketoglutarate dehydrogenase; 22, succinyl-CoA ligase; 23, succinate dehydrogenase; 24, 
fumarate hydratase; 25, malate dehydrogenase; 26, acetate-succinate CoA transferase; 
27, malic enzyme; 28, acetyl-CoA synthethase; 29, phosphoenolpyruvate carboxykinase; 
30, aspartate aminotransferase; 31, fructose-1,6-bis-phosphatase; 32, glucosamine-6-
phosphate deaminase; 33, N-acetylglucosamine-6-phosphate deacetylase; 34, 
glutamine:Fru6P aminotransferase; 35, glucosamine-6-phosphate acetylase; 36, pyruvate 
phosphate dikinase; 37, NADH-dependent fumarate reductase; 38, glutamine synthetase; 
39, FAD-dependent glycerol-3-phosphate dehydrogenase; 41, glyoxalase I; 42, 
glyoxalase II. 
 
Recently, hexosamine uptake by amastigote was shown to be important, since parasites 
in which the enzyme responsible for the conversion of glucosamine to fructose-6-
phosphate was deleted showed an attenuated virulence phenotype in mice. This study 
also suggests that hexosamine sugars may be more abundant in the host cell in the 
earlier stages of infection, while later other sugars will constitute the major source297, 
probably due to an active gluconeogenesis pathway298. However, amastigotes are able to 
accumulate a unique intracellular carbohydrate reserve material named mannogen, 
despite living in a sugar poor niche. Mannogen is composed of short chains of β1-2 linked 
mannose, accumulates exclusively in the cytosol and is degraded under sugar-limiting 
conditions, suggesting that due to this reserve of de novo synthesis or uptake of sugars 
not to be limiting for amastigotes growth299. In L. mexicana promastigotes was detected 
the incorporation of glucose into mannogen at a similar rate as into the glycolytic 
intermediates, suggesting that excess of glucose/fructose-6-phosphate is converted to 
mannose-6-phosphate and GDP-Man300. 
 
The end-products of glucose catabolism in insect forms of trypanosomatids include 
succinate, pyruvate, acetate, alanine, ammonia, urea and lactate269, 301-303.  Recently, a 
study using gas chromatography-mass spectrometry and 13C-NMR has shown that 
glucose is rapidly catabolized to CO2, partially oxidized to succinate, acetate, alanine and 
also a low level of glutamate, consistent with the operation of a succinate fermentation 
pathway, the conversion of acetyl-CoA to acetate and substantial flux of glycolytic end-
products into the TCA cycle300. Acetate is produced by the mitochondrial enzyme 
acetate:succinyl-CoA transferase304, 305 and alanine results of pyruvate transamination. 
Lactate is a metabolic end product of methylglyoxal, a toxic by-product of glycolysis 
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detoxified via glyoxalase pathway; this pathway is composed of two enzymes that use 
T(SH)2 as cofactor in contrast with the GSH-dependent enzymes present in mammalian 
cells306, 307. Succinate production occurs through the succinate fermentation pathway, in 
which succinate is produced from phosphoenolpyruvate (PEP) involving two glycosomal 
NADH-dependent oxidoreductases, malate dehydrogenase and fumarate reductase, 
providing a means for the re-oxidation of NADH produced in the glycosome by the 
glycolytic glyceraldehyde-3-phosphate dehydrogenase (GADPH), resulting in the 
synthesis of one ATP and two molecules of NAD+ for each PEP imported. Other pathways 
for regeneration of glycosomal ATP and NAD+ have been described including a glycerol-
3-phosphate/dihydroxyacetone shuttle and reactions catalyzed by a glycerol-3-phosphate 
kinase, glycosomal isoforms of 3 phosphoglycerate kinase and/or a pyruvate dikinase20. In 
T. brucei procyclic stages, succinate fermentation appears to be the major pathway for 
regenerating glycosomal pools of ATP/NAD+, being responsible for a tightly balanced 
consumption and production of NADH within the glycosomes necessary to maintain the 
organellar redox (NAD+/NADH) balance, while the other pathways are only activated in 
the case of succinate fermentation inhibition308. In contrast with T. brucei, Leishmania 
succinate fermentation may not be only essential to maintain the glycosome redox 
balance but also have an important role in TCA cycle anaplerosis (replenishment of TCA 
cycle intermediates). The majority of the C4 dicarboxylic acids, such as malate and 
fumarate, generated during glycosomal succinate fermentation are subsequently used for 
TCA cycle anaplerosis, suggesting that metabolic fluxes in the glycosome and 
mitochondria are intimately linked300. These findings are supported by previous 
observations that hexose uptake and catabolism is essential for amastigote survival in the 
mammalian host, despite the relatively high levels of amino acids in the phagolysosome, 
which can be used as the carbon source. Thus the hexose uptake may be needed to 
replenish the TCA cycle intermediates in order to sustain the synthesis of glutamate and 
related amino acids, such as proline and glutamine. Indeed, TCA cycle activity may 
increase markedly in the amastigote stages, likely exposed to low levels of glucose but 
relatively high levels of amino acids and lipids296. Furthermore, TCA cycle enzymes 
activity is up-regulated during differentiation, likely a consequence of up-regulation in β-
oxidation, already reported in vivo as Leishmania starts to use fatty acids as carbon 
source 292, which leads to an increase production of acetyl-CoA units handled by TCA 
cycle in the mitochondria and then the generated reducing equivalents oxidized by the 
mitochondrial respiratory chain245. Mitochondrial function seems to be essential for 
Leishmania amastigote viability, as deletion of both alleles of the gene encoding a 
mitochondrial protein, named MIX was not achieved and just the deletion of one allele 
induced abnormalities in cell morphology, mitochondrial segregation and loss of virulence 
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in mice309; a similar phenotype was observed when MIX gene in T. brucei was targeted by 
RNAi310. Another Leishmania mitochondrial protein (Ldp27) was shown to be important as 
gene deleted parasites have less cytochrome c oxidase activity and ATP synthesis and 
were less virulent both in human macrophages and in BALB/c mice311. 
 
Besides glycolysis, glucose is also metabolized via PPP, which is found in most cell types 
and provides the major source of NADPH for anabolic reactions and regeneration of 
antioxidant systems. The pathway also provides phosphorylated carbohydrate 
intermediates including ribulose-5-phosphate that is incorporated into nucleotides for 
biosynthesis of nucleic acids and nucleotide cofactors312, 313. PPP is also active in 
Leishmania species containing all enzymes of the classical pathway in promastigotes314; 
the oxidative branch of PPP is compartmentalized inside glycosomes. Sugars such as 
ribose and erythrose are formed from glucose-6-phosphate via glucose-6-phosphate 
dehydrogenase and 6-phosphogluconate dehydrogenase315. It’s noteworthy to mention 
that 13C-glucose incorporation into the PPP intermediates has shown slower kinetics than 
the glycolytic intermediates, indicating a reduced flux into this pathway, but a 
simultaneous rapid labeling of several nucleotides supporting the crucial role of PPP 
pathway for nucleotide biosynthesis300. The major product of the pathway is ribose-5-
phosphate (R5P), however PPP is not the only source of R5P as this metabolite can also 
be produced from free ribose activated by phosphorylation with ribokinase or released 
from nucleosides through the action of nucleoside hydrolase314, that has been shown to 
accumulate via a specific carrier-protein in Leishmania316. PPP has an important role in 
defense against oxidative stress as shown by the fact that L. infantum mutants adapted to 
nitric oxide expressed high levels of the PPP enzyme 6-phosphogluconate 
dehydrogenase317. Also a higher PPP oxidative branch enzymatic activity was detected in 
L. mexicana promastigotes when compared with insect forms of T. brucei proposed to be 
due to a higher demand of NADPH to counteract the oxidative stress suffered by 
Leishmania promastigotes in the initial phase of infection314. 
 
Proteomic and biochemical studies have suggested that Leishmania intracellular forms 
are able to use lipids as a carbon source for energy generation through the β-oxidation of 
fatty acids. The higher activity of enzymes that catalyze β-oxidation of fatty acids in L. 
mexicana amastigotes292 and protein up-regulation in this pathway during late 
differentiation of L. donovani parasites with simultaneously down-regulation of 
glycolysis245, support the change in carbon sources as the parasite differentiate and 
colonize niches with different nutrient composition suggesting a more important role for 
fatty acid as a carbon source in intracellular amastigotes. Leishmania, as well as other 
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intracellular pathogens, can use fatty acids derived from complex host lipids, such as 
lipoproteins internalized by infected macrophages318, 319; lipid exchange between 
amastigote plasma membrane and the PV membrane may also occur, in a way that the 
host glycosphingolipids become intercalated into the amastigote membrane283, 320, 321. 
Leishmania can also a in defined medium lacking lipid moieties, since it is able to 
synthesize fatty acids de novo. Indeed, as observed in T. brucei and in T.cruzi, L. major 
encodes a type II FA synthase, however this does not seem to be the major pathway for 
fatty acid de novo synthesis. Trypanosomatids use a new mechanism involving 
endoplasmic reticulum-based elongases (ELOs) to make the bulk of their fatty acids, while 
other organisms use ELOs to make long chain fatty acids even longer318. 
 
Phospholipids (PLs) account for ~70% of total cellular lipids in Leishmania and are 
classified according to the “head group” as phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidyinositol (PI) and phosphatidylserine (PS). 
Leishmania parasites also synthesize low levels of phosphatidyglycerol (PG), cardiolipin 
and phosphatidic acid. The most abundant PL in Leishmania is PC with unusually long 
and unsaturated fatty acid species322. PC function is not yet known, but their 
polyunsaturated fatty acid chains could modulate membrane physiology by reducing the 
melting point and confer resistance to host derived oxidants323. PI is found in the anchors 
of surface glycoconjugates including glycosylinositolphospholipids (GIPLs), 
glycosylphosphatidylinositol (GPI)-containing membrane proteins and lipophosphoglycan 
(LPG)324, 325. In Leishmania it is not yet known if PS is synthesized by the parasite or 
acquired from the host, despite the presence of putative enzymes involved in PS 
metabolism. PS exposure on the outer surface of cells may trigger the removal of 
apoptotic cells by phagocytes326, 327. Leishmania has been reported to mimic such PS 
exposure acting as a “deactivating” signal for host cells, used as a strategy of silent entry 
into the macrophage165, 328, 329. PLs as the major components of Leishmania membranes 
are likely to be determinant in membrane permeability, fluidity and also have a profound 
impact in vesicular trafficking, nutrients acquisition through endocytosis and cell 
differentiation, which involves an extensive membrane remodeling. Furthermore, the fact 
that PLs diversity between Leishmania and mammals is quite different has been explored 
as a drug target by the use of lysophospholipid analogs including miltefosine, edelfosine 
and ilmofosine330, 331. Miltefosine effects described in L. donovani promastigotes include 
perturbations on lipid metabolism, specifically phospholipid content, fatty acid and sterol 
content332. Recently mitochondria and specifically the cytochrome c oxidase have been 
implicated as targets of miltefosine in L. donovani promastigotes333. 
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The majority of spingolipids (SLs) in Leishmania belong to unglycosylated 
inositolphosphorylceramide (IPC) and ceramide. IPC are abundant, constituting nearly 
10% of the total membrane phospholipids and are generated by the transfer of a 
phosphorylinositol headgroup from PI to ceramide, a process catalyzed by the IPC 
synthase, demonstrating that a functional SL pathway is present in these parasites334. SLs 
are not required for growth of Leishmania, since parasites that completely lack SLs grew 
normally in logarithmic phase and were still able to make “lipid rafts”. However, deletion of 
SPT2, the gene that encodes the key de novo biosynthetic enzyme serine 
palmitoyltransferase subunit 2, resulted in parasites deficient in de novo SLs synthesis 
that once in the stationary phase were not able to differentiate into metacyclic forms335. 
SLs are considered essential membrane components in all eukaryotes, mediating many 
signaling pathways including those key for apoptosis, growth and differentiation 336. 
However, in Leishmania the primary role of SLs appears to be the provision of 
ethanolamine, as ethanolamine supplementation was able to overcome the phenotype 
observed in the SL-deficient mutant parasites337. Ethanolamine and choline are essential 
nutrients, and when available exogenously they can be salvaged by Leishmania via 
membrane transporters338, 339. Thus the significance of SL biosynthesis is likely to be 
stage-specific, being important in those stages in the sand fly that cannot rely upon 
salvaged ethanolamine. Indeed, amastigotes deficient in de novo SLs synthesis recovered 
from a mammalian host showed normal levels of IPC and thus amastigotes seems to be 
able to perform SLs salvage or use host lipids as precursors for synthesis of IPC340. 
Interesting is also the fact that SLs may play an important role in the modulation of host 
responses, given that the increase in ceramide levels detected in Leishmania-infected 
macrophages in vitro leads to the suppression of NF-kB activation in host 
macrophages341. 
 
Besides PLs and SLs Leishmania lipid composition also includes sterols that play an 
important role in the structure and function of cellular membranes and are essential for 
parasite growth and viability, revealed by the effect of antifungal compounds which inhibit 
the reactions of sterol biosynthesis342. In contrast with mammalian cells, Leishmania 
parasites synthesize ergosterol instead of cholesterol100, 343, being able to incorporate 
cholesterol either from an infected host or culture medium; cholesterol uptake was 
observed in miltefosine resistant parasites115. Sterol biosynthesis in Leishmania parasites 
has received much attention as it may constitute a good drug target, due to the fact that 
parasites synthesize ergosterol derivatives instead of cholesterol as in mammalian cells. 
There are already some drugs reported to interfere with sterol biosynthesis, such as 
amphotericin B344, atavaquone345, synthetic quinuclidines346, 347 and chalcones348. 
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Moreover, sterols probably play a significant role in miltefosine action against the parasite, 
since membrane sterol depletion led to a decrease in drug susceptibility, suggesting that 
sterols can serve as a reservoir for miltefosine providing a constant supply to the 
respective transporter112. Drug effectiveness is mainly dependent on the interaction with 
the Leishmania membrane, thus it is clear that the ability of the parasite to change the 
lipid membrane composition inherent to its life cycle should be taken into consideration in 
the finding of new formulations. 
Leishmania ability to synthesize amino acids is limited to nonessential ones plus threonine 
and methionine269. Cysteine can be produced either by de novo synthesis from serine or 
from homocysteine by the trans-sulfuration pathway349; aspartate and asparagine can be 
formed from oxaloacetate, while glycine can be formed from serine and alanine via 
transamination of pyruvate289. Methionine can be salvaged or synthesized by methionine 
synthase, which uses methyl- tetrahydrobiopterin (H4F) and homocysteine to produce 
methionine and H4F; methionine plays a crucial role as an essential amino acid and for 
formation of S-adenosylmethionine (SAM), which is required for methylation reactions and 
the synthesis of polyamines. Aromatic amino acids (phenylalanine, tyrosine or 
tryptophan), the branched amino acids (leucine, isoleucine or valine), lysine and histidine 
cannot be synthesized by Leishmania269. On the other hand, the Leishmania encodes 
several putative amino acid permeases. A high affinity arginine-specific transporter, 
named LdAAP3 was the first permease to be identified in L. donovani350. Arginine is an 
essential amino acid in Leishmania parasites and must be taken up from the host as it is 
used not only for protein synthesis as well as the precursor for synthesis of polyamines269, 
351. Arginine starvation resulted in the increase of both mRNA and LdAAP3 protein levels, 
which were abrogated by supplementing amino acid-starved parasites with arginine. 
LdAAP3 expression and activity increased whenever the cellular level of arginine 
decreased, suggesting that the parasites sense the intracellular level of arginine and 
adjust the transport to maintain homeostasis352. Recently, a lysine-specific transporter in 
L. donovani (LdAAP7) was also identified and shown to be essential given the 
impossibility to delete the gene, suggesting that this is the only lysine transporter in L. 
donovani353. Leishmania parasites also contain several peptidases that are likely to play 
an important role in degrading proteins taken up from the environment, some of them 
being up-regulated in the amastigote stage. Moreover, cysteine proteinases L. mexicana 
mutants are attenuated in vivo, consistent with a role in parasite nutrition9. The fact that 
amino acid uptake was shown to be increased in L. mexicana amastigotes292 and also the 
up-regulation of enzymes such as branched chain aminotransferase, alanine 
aminotransferase, glutamate dehydrogenase isoenzymes involved in the catabolism of 
certain amino acids (isoleucine, valine, alanine, glutamate, glycine) during 
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differentiation245, give good indications of amino acid use as a carbon source, however 
there is no direct evidence for a dependency of amastigotes on amino acid catabolism in 
vivo, similar to the essential requirement for hexoses295, 296. Besides the use in protein 
biosynthesis, proline and glutamate may serve as important energy substrate for 
Leishmania.  Proline is oxidized to glutamate, which will be incorporated into the TCA 
cycle269, while leucine metabolized through 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) 
can be incorporated directly into Leishmania’s sterol biosynthetic pathway354. A recent 
study by Saunders and co-workers using L. mexicana promastigotes has shown that only 
a limited number of amino acids such as aspartate and alanine were used as carbon 
sources, during in vitro culture. Also, several pathways of amino acid synthesis were 
repressed in the presence of exogenous amino acids, revealing that key enzymes 
involved in the amino acid biosynthesis are constitutively expressed but under tight control 
to ensure that exogenous nutrients are used first300. Moreover, glutamate identified as the 
most abundant amino acid in promastigotes stages is internalized at a low rate under 
standard culture conditions, a fact that may be explained by the high rate of glutamate 
synthesis through the incorporation of aspartate and alanine into the TCA cycle, where 
major anabolic function is likely to be the synthesis of glutamate300. 
 
Purines and pyrimidines are essential to all living organisms, performing many vital 
functions such as nucleic acids (DNA and RNA) synthesis and ATP which serves as the 
major energy source within the cell to drive a number of biological processes. Leishmania 
parasites, like other trypanosomatids, need to acquire purines from the medium, as they 
are incapable of de novo purine synthesis. Thus, the parasite has evolved a number of 
unique purine salvage enzymes that enables it to scavange host purines by 
interconversion and metabolism to phosphorylated nucleotides355. The parasites only 
present one of the 10 enzymes, adenylosuccinate, required to make inosine 
monophosphate (IMP) from phosphoribosyl pyrophosphate that participates in purine 
salvage by converting IMP to adenine monophosphate (AMP)289, 356. Purines, such as 
hypoxanthine and xanthine are essential for parasite growth and hence the need to add 
those to in vitro cultures; purine withdrawal from L. donovani promastigotes culture led to 
a dramatic and rapid increase of endogenous purine transport proteins and purine salvage 
componentes as well as to changes in the parasite morphology357, 358. It was established 
that L. donovani salvages purines primarily through hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT) and xanthine phosphoribosyltransferase (XPRT)359, 
genetic disruption of individual transporters had little impact on intracellular growth, 
suggesting a significant redundancy in the purine salvage; only deletion of both HGPRT 
and XPRT in the same cell line resulted in severely attenuated parasites in vivo. It is 
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noteworthy to mention, that a marked amplification and over-expression of the adenine 
phosphoribosyltransferase (APRT) gene was observed in the null mutant parasites 
recovered from animals, implying that APRT was capable of phosphoribosylating 
hypoxanthine and promote cell growth360, despite being previously reported that it 
exclusively recognize adenine as a substrate361, 362. On the other hand, Leishmania is able 
to synthesize pyrimidines de novo from glutamine, bicarbonate and aspartate289. 
 
Other Leishmania metabolic requirements include, polyamines, such as putrescine, 
essential for Leishmania growth and survival as a precursor of spermidine that together 
with glutathione is the substrate for synthesis of T(SH)2363, an essential thiol that 
constitutes with trypanothine reductase the unique antioxidant system present in these 
parasites364. Polyamine production is dependent on arginine, an essential amino acid that 
the parasite is not able to synthesize269; disruption of the gene that encodes arginase, the 
initial enzyme in arginine catabolism led to severely restricted growth of intracellular 
amastigotes and growth of promastigotes only possible in the presence of ornithine, 
putrescine or spermidine, showing that amastigotes are dependent on the de novo 
polyamine biosynthesis as well as on the salvage of polyamines from the 
phagolysosome365. A polyamine transporter with high affinity for putrescine and 
spermidine has been identified in L. major366 and pentamidine, a drug used in the 
treatment of leishmaniasis, was shown to inhibit putrecine and spermidine transport367. 
Moreover, deletion of the ornithine decarboxylase (ODC) gene in L. donovani, which 
encodes the enzyme that catalyzes the reaction of ornithine to putrescine, resulted in the 
generation of cells that can only survive in the presence of putrescine or spermidine and 
were not able to scavenge polyamines from the host in sufficient amounts to sustain an 
infection, confirming the essential role of polyamine biosynthesis368, 369. Thus, ODC has 
been validated as a drug target and the anti-Leishmania activity of DL-α-
difluoromethylornithine (DFMO), a drug that irreversible inactivates the T. brucei enzyme, 
was also shown to be effective in killing Leishmania parasites370.  
 
Leishmania parasites are auxotrophic for both folate and unconjugated pteridins and thus 
need to salvage these metabolites from the host371; folates are acquired via active 
transport372, 373. DHFR-TS is a bifunctional enzyme that catalyzes the reduction of folate 
and biopterin to tetrahydroderivatives. The inability to delete DHFR-TS gene in L. major, 
led to the consideration that it as an essential gene and a potential good drug target252. 
However, PTR1, an enzyme that can reduce both folates and unconjugated pterins can 
act as a metabolic bypass of DHFR-TS inhibition leading to the antifolate drugs 
inefficacy260, 374. PTR1 seems also to be essential to the parasite375. Leishmania seems 
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well adapted to the lack of folate de novo synthesis as the parasites possess a reduced 
number of folate-dependent metabolic reactions, although the loss of several folate 
metabolic pathways results in attenuation or loss of virulence371. 
 
Leishmania are also haem auxotrophs and need to obtain these molecules or precursors 
directly from the host376. The Leishmania genome possess homologues for the three last 
enzymes of haem pathway likely to be functional, since these parasites can grow in 
medium in which hemin is replaced by protoporphyrin IX377-379. Haem is present in 
trypanosomatids hemoproteins such as peroxidases, cytochromes P450, which are 
involved in the oxidative stress response, detoxification, synthesis of polyunsaturated fatty 
acids and sterol biosynthesis380-385. Also, the presence of a fully functional mitochondria in 
these parasites315, require haem for oxidative phosphorylation and other cellular 
processes382, 383, 386. 
 
Overall, Leishmania parasites have been able to survive due to the nutritional complex 
environment that encounter in the different hosts, which seems to fulfill the parasite 
metabolic requirements. In order to efficiently use the potential carbon sources and 
essential nutrients available, the parasite has evolved numerous mechanisms for salvage 
and conversion of host molecules. 
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3.1 Thiol metabolism and antioxidant defense 
 
During metabolic activity of organisms, the imbalance between the production of reactive 
oxygen species (ROS)/reactive nitrogen species (RNS) and antioxidants will lead to 
oxidative stress. To protect against it, cells have developed both enzymatic and non-
enzymatic antioxidant defenses. Non-enzymatic defenses include ascorbate, glutathione 
(GSH) and polyamines among others, while catalase, superoxide dismutase, glutathione 
peroxidase belong to the enzymatic mechanisms that protect by directly scavenging toxic 
species converting them to less reactive species387.  
 
Contrary to other organisms, trypanosomatids lack genes for glutathione reductase (GR) 
and thioredoxin reductase (TR) as well as catalase and selenocysteine-containing 
glutathione peroxidases364. Instead, these parasites possess a redox metabolism that is 
based on the low molecular mass dithiol trypanothione (N1,N8-bis(glutathionyl)spermidine, 
T(SH)2) and trypanothione reductase (TryR)388. The unique T(SH)2/TryR system is 
responsible for the maintenance of the intracellular thiol redox homeostasis similar to the 
GSH/GR and thioredoxin(Trx)/TR systems in eukaryotic cells364. Besides kinetoplastids, 
T(SH)2 and/or TryR also occur in some other protists389-391. Trypanosomatids can cope 
successfully with the oxidative burst during host infection due to the well organized and 
complex T(SH)2/TryR system, involved at least in three important biological functions: 
hydroperoxide detoxification, regulation of replication and DNA synthesis392-394.  
 
In addition to T(SH)2, trypanosomatids contain three other major low molecular mass 
thiols: GSH, mono-glutathionylspermidine (Gsp) and ovothiol (OvSH); T(SH)2 can 
spontaneously reduce GSH and OvSH395, 396. A significant amount of GSH is present as 
T(SH)2, formed by the conjugation of two GSH molecules linked by the polyamine 
spermidine in a two step reaction catalyzed by trypanothione synthetase (TryS)397-399. 
Another enzyme thought to be involved in T(SH)2 biosynthesis, glutathionylspermidine 
synthetase (GspS) was identified but proven not necessary. GspS as well as TryS has 
amidase activity, being able to cleave T(SH)2398, 400, leading to the hypothesis that this 
activity may contribute to maintain a balance between GSH, Gsp, T(SH)2 and 
spermidine364. However, TryS amidase activity was shown not to be required for parasite 
viability while the synthetase activity is essential since T. brucei TryS conditional double 
knockout lost the ability to produce T(SH)2 with simultaneous accumulation of GSH and 
were unable to infect mice, validating TryS as a drug target401. Despite a quite similar 
redox potential, at a physiological pH T(SH)2 it is more reactive than GSH396. Both the 
dithiol character of T(SH)2, which favors its ability as a reductant of intramolecular 
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disulfides402 and lower pK values in T(SH)2 compared to GSH coinciding with the 
intracellular pH of the parasites403 are responsible for the unique properties of T(SH)2. It’s 
still not understood why T(SH)2 has evolved in trypanosomatids, however recently was 
shown that T(SH)2 has a much higher capacity to neutralize toxic NO as it is able to 
sequester NO and iron in a free harmless dinitrosyl-iron complex, that in other organisms 
is found to be associated with glutathione S-transferases (GST)404. TryR, a flavoprotein 
oxidoreductase, plays an important role in the parasite redox state as it is responsible for 
keeping T(SH)2 in the reduced form. As trypanosomatids lack GR, TryR is the only 
enzyme that connects the NADPH- and the thiol-based redox systems in these parasites. 
TryR is an essential enzyme as deletion of one allele was easily achieved but disruption of 
the second one was not possible or a genomic re-arrangement occurred to maintain a 
copy of the gene254, 405. Also down-regulation of TryR activity to 15% led to a significant 
impairment of parasite ability to regenerate T(SH)2, but cells kept the capacity to 
metabolize H2O2. Although, parasites were not able to survive inside the activated 
macrophage406. Thus TryR, already characterized in L. donovani, L. infantum and T. 
cruzi407-409, is a promising target for Leishmania-specific drug design. Indeed, recent 
studies are an example of the efforts being made to obtain TryR inhibitors410, 411. 
 
The reducing capacity of T(SH)2 is strongly enhanced in the presence of tryparedoxins 
(TXNs), small dithiol redox proteins functional similar to glutaredoxins (Grxs) and Trxs. 
TXNs are oxidoreductases that in analogy with Grxs, are reduced by a low molecular 
mass thiol (T(SH)2) and can reduce glutathione-mixed disulfides386. Indeed T(SH)2 and 
TXN have a central role in the thiol metabolism of trypanosomes taking part in parasite-
specific cascades (Figure 3.1) that catalyze the reduction of hydroperoxides and 
ribonucleotides392, 393, 412. 
 
 
Figure 3.1 Trypanothione-mediated detoxification of hydroperoxides in 
trypanosomatids. Trypanothione reductase (TryR) regenerates trypanothione disulfide 
(TS2) to trypanothione (T(SH)2), which will reduce tryparedoxin (TXN). TXN will deliver 
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electrons to tryparedoxin peroxidase (TXNPx) or non-selenium glutathione peroxidase like 
enzymes (nsGPx), which will then metabolize hydroperoxides (ROOH) to an alcohol 
(ROH). The subscripts red and ox refer to the redox state of the proteins, dithiol and 
disulfide, respectively (adapted from Krauth-Siegel et al.364). 
 
TXNs are specifically reduced by T(SH)2. The reducing equivalents obtained from T(SH)2 
are transferred by TXNs to tryparedoxin peroxidases (TXNPxs) and also non-selenium 
glutathione peroxidase like enzymes (nsGPxs)413-416. Reduced TXN also delivers electrons 
to the ribonucleotide reductase (RR)392, the universal minicircle sequence binding protein 
(UMSBP) involved in the initial step of replication of the kinetoplast417 and to a monothiol 
GRx (1-Cys Grx)418, 419. Cytosolic TXN knock down in T. brucei resulted in impaired 
viability and increased sensitivity to hydroperoxides, demonstrating the essential role of 
cytosolic TXN and its pivotal function in the parasite defense against oxidative stress420, 
while mitochondrial TXNs do not seem to be important for both T. brucei and L. 
infantum421, 422. TXNPxs are 2-Cys peroxiredoxins that primarily detoxify H2O2 and a wide 
range of organic hydroperoxides. These enzymes are highly conserved and present in 
various Leishmania species394, 423, 424, with distinct subcellular localization, cytosolic and 
mitochondrial425. Cytosolic TXNPx was demonstrated to be essential in T. brucei and L. 
infantum, while deletion of mitochondrial TXNPx in L. infantum yields a less virulent 
parasite but no obvious phenothype detected in T. brucei386, 422, 426. The nsGPxs differ from 
the selenoenzymes found in mammals and some other organisms as the active site 
selenocysteine has been replaced by a cysteine residue being fuctionally similar to 
TXNPxs413, 414, 427. Besides, 2-Cys peroxiredoxins and nsGPxs the parasites possess a 
third family of enzymes involved in hydroperoxide detoxification, the ascorbate peroxidase 
(APx)386. APx is a heme containing peroxidase first identified in L. major that localizes in 
the intermembrane of the mitochondrial inner membrane of the parasite428. APx 
expression is up-regulated in the presence of increasing concentrations of H2O2 and 
deletion of the APx gene in L. major rendered the cells more sensitive to ROS in vitro, 
demonstrating the important role of APx in H2O2 detoxification428, 429. However, the 
parasite seems to be able in part to compensate for the effect of APx deletion by 
increasing the expression of nsGPx and also TXNPx, suggestting a high degree of 
redundancy in ROS detoxifying mechanisms in Leishmania. On the other hand, the null 
mutant cells exhibit hyper virulence after infection with macrophages as well as 
inoculation into BALB/c mice, which may be explained by the higher numbers of 
metacyclics, suggesting a role of APx in the control of parasite differentiation and survival 
in macrophages429. 
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Overall, cellular redox homeostasis is maintained by biosynthesis of T(SH)2, which is kept 
reduced by TryR, the enzyme that represents the only connection between the NADPH- 
and the thiol-based redox metabolism. Figure 3.2 gives an overview of parasite thiol 
metabolism and antioxidant defense. Contrary to other organisms no role has been 
attributed to GSH besides precursor of T(SH)2 and thus remains the doubt about the 
importance of the free GSH presence in cells that do not possess GR. Given this, it is 
crucial to understand the possible role of proteins such as TDR1, which contain motifs 
characteristics of Trx and GST families. 
 
 
Figure 3.2 Thiol metabolism in trypanosomatids. 
1-C-Grx1, a monothiol glutaredoxin; dSAM, decarboxylated S-adenosyl-L-methionine; 
dNTP, GSH1, γ-glutamylcysteine; GSH2, glutathione synthetase; GSSG, glutathione 
disulfide; GSH, glutathione; ODC, ornithine descarboxylase; Prx, 2-Cys-peroxiredoxins 
(also named TXNPX) ; Px, glutathione-peroxidase-type enzymes (also named nsGPx); 
RS2, disulfide proteins; ROOH, hydroperoxides; ROH, alcohol; RR, ribonucleotide 
reductase Sp, spermidine; SpS, spermidine synthase; TryS, trypanothione synthetase, 
Trx, thioredoxin; TXN, tryparedoxin; TyrR, trypanothione reductase; T(SH)2, 
trypanothione; TS2, trypanothione disulfide; UMSBP, universal minicircle sequence 
binding protein; ISC, iron sulfur clusters; C, cytosol; K, kinetoplast; M, mitochondrion; N, 
nucleus. Proteins that were experimentally shown to be essential and dispensable for T. 
brucei are highlighted with black and light grey background, respectively (adapted from 
Krauth-Siegel et al.364). 
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3.2 Glutathione S-transferases  
 
GSTs catalyze nucleophilic attack by reduced glutathione on non polar compounds that 
contain an electrophilic carbon, nitrogen or sulphur atom. GSTs are versatile enzymes 
able to inactivate a wide range of exogenous toxic molecules, including naturally occurring 
compounds, industrial chemicals, drugs, herbicides, and pesticides; these phase II 
detoxification reactions produce generally less reactive and more polar compounds, which 
can be actively extruded from the cytosol430, 431. In addition, GSTs are also important in the 
detoxification of endogenous reactive species produced during oxidative stress, such as 
lipid hydroperoxides432 or reactive aldehydes433. In addition, GSTs can also serve as 
peroxidases, isomerases, thiol transferases or have a role in signalling processes. 
Therefore, GSTs are not solely detoxification enzymes and are also involved in other 
pathways such as leukotriene and prostaglandin biosynthesis and the catabolism of 
aromatic amino acids434. On the other hand, GSTs have been reported to be involved in 
the development of drug resistance towards chemotherapy agents, insecticides, 
herbicides, and microbial antibiotics, likely related to detoxification abilities431, 435. GSTs 
have been purified from a wide range of organisms and are classified into 3 major families 
according to their cellular localization: cytosolic, mitochondrial and microsomal 
(microsomal GSTs are also referred to as membrane associated proteins in eicosanoid 
and glutathione metabolism). All 3 families contain members that catalyze the conjugation 
of GSH with 1-chloro-2,4-dinitrobenzene (CDNB) and exhibit glutathione peroxidase 
activity towards cumene hydroperoxide431. Cytosolic GSTs are, generally, biologically 
active as dimers of subunits of 23-30 kDa and an average length of 200–250 
aminoacids434. There are seven classes of cytosolic GSTs recognized in mammalian 
species: alpha, mu, pi (GSTPi), sigma, theta, omega (GSTO) and zeta431. Other classes 
such as lambda and tau have been identified in other organisms436. Each monomer in 
GSTs has a catalytic active site with two domains: G-site, responsible for GSH binding 
and H-site, which binds hydrophobic substrates. The H-site or substrate binding site is 
more variable in structure and is largely formed from residues at the C-terminal; the G-site 
is highly conserved and composed of amino acid residues found in the N-terminal domain; 
different amino acids (tyrosine, serine or cysteine) according to the class allow 
conjugation or thiol transfer431. The tyrosine or serine hydroxyl group acts as a hydrogen 
bond donor to the thiol group of GSH, promoting the formation and stabilization of the 
highly reactive thiolate anion which is the target for nucleophilic attack of an electrophilic 
substrate. By site directed mutagenesis, the serine or tyrosine residues have proven 
catalytically essential in GSTs of different organisms434. GSTOs, unlike other GSTs, have 
a cysteine residue in their active site, which promotes the formation of mixed disulphides 
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with glutathione rather than the formation of the thiolate anion. Therefore, GSTOs catalyze 
a range of thiol transferase and reduction reactions that are not catalyzed by members of 
other GSTs classes437, 438. This feature is also common to beta and lambda GSTs, 
dehydroascorbate reductases (DHARs), Grxs and chloride intracellular channel proteins. 
GSTOs have glutathione-dependent thiol transferase activity and can also catalyze 
dehydroascorbate (DHA) reduction, activities characteristics of Grxs437. Besides the 
detoxification of exogenous compounds through the conjugation with GSH, GSTs are also 
responsible for the detoxification of products of oxidative stress. ROS such as superoxide 
radical (O2˙−), hydrogen peroxide (H2O2), hydroxyl radical (OH˙) and RNS such as nitric 
oxide (NO˙) and peroxynitrite (ONOO−) radicals are extremely reactive being inevitably 
associated with toxicity, causing damage in various biological molecules: lipids (causing 
lipid peroxidation and membrane damage), DNA (causing DNA breaks), and proteins 
(oxidation of various amino acids and inactivation of essential enzymes)387. In several 
organisms, GSTs are up-regulated by exposure to pro-oxidants indicating that induction of 
GSTs is an evolutionarily conserved response of cells to oxidative stress439-445. GST 
activity has been detected in parasitic nematodes, trematodes, ticks and malarial 
parasites and the identified GSTs assigned to the classes identified in mammalian cells 
based on the substrate specificity (in particular with the universal substrate CDNB) or 
sensitivity to inhibitors, such as bromosulphthalein, 1,2-dichloro-4-nitrobenzene, 
ethacrynic acid and cumene hydroperoxide among others438, 446-452. In helminths GSTs 
represent the major phase II detoxification system required for the parasite survival in the 
host, since these parasites contain very low levels of other detoxification enzymes such as 
catalase, superoxide dismutase and cytochrome P450, GST may provide the primary 
defense against electrophilic and oxidative damage453. Therefore helminth GSTs have 
been proposed as a potential drug target or for a vaccine candidate’s development, as the 
enzyme differs in its primary amino acid sequence and gene structure from the host 
GST454. GST activity has also been detected in all Plasmodium species studied so far as 
well as in all intraerythrocytic stages of the parasite446, 455-458. Plasmodium falciparum GST 
may be essential for parasite survival by protecting the parasite against oxidative stress 
and/or acting as a buffer for detoxification of heme-binding compounds in vivo446, 455. 
Moreover, P. falciparum possesses only one GST, which is highly abundant and its 
activity is increased in parasites resistant to chloroquine, an anti-malarial drug456, 458. Thus 
inhibition of P. falciparum GST, whose structure presents features distinctive of human 
GSTs, is expected to impair detoxification processes, enhance levels of cytotoxic 
peroxides among other effects, being considered as a highly promising target for anti-
malarial drug development459, 460. No GST activity has been reported in Trypanosoma or 
Leishmania parasites, apart from TDR1 that contain domains of the GSTO and uses GSH 
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as the reductant90. Although, in L. major a protein named eEF1B, with trypanothione S-
transferase activity, was able to catalyze the aromatic nucleophilic substitution reactions 
between T(SH)2 and CDNB461, in agreement with the redox system used by 
trypanosomatids, based on T(SH)2 and TR364. 
 
 
3.3 Thioredoxins and Glutaredoxins  
 
The thioredoxins (Trxs) family is defined by a structural motif named the Trx fold, common 
to a variety of functionally different proteins as thiol-disulfide oxidoreductases, disulfide 
isomerases, glutathione S-transferases, thiol dependent peroxidases and chloride 
intracellular channels462. The family of proteins with a Trx fold includes Trxs and Grxs, 
small ubiquitous proteins with conserved CysXXCys/Ser (CXXC/S) active sites, where X 
represents various amino acids. Both are able to regulate several processes through 
reduction of disulfide bridges in target proteins in a reaction taking place in two steps: the 
N-terminal thiol of the CXXC motif attacks the disulfide bridge of the target protein, 
releasing a free thiol and forming a disulfide bridge with the second Cys of the target. 
Then the C terminal thiol of the CXXC motif breaks the Trx-target disulfide bridge, 
releasing the reduced target and oxidized redoxin protein463. The midpoint redox potential 
differs between Trxs and Grxs, being close to -300mV for Trx and -200mV for Grx. In the 
cytosol and mitochondria, Trxs are reduced via NADPH and an NADPH-dependent 
thioredoxin reductase (TR) and Grxs via NADPH-dependent GR and GSH as shown in 
Figure 3.3464. 
 
 
Figure 3.3 Thioredoxin and Glutaredoxin systems. Thioredoxin (Trx) and glutaredoxin 
(Grx) are reduced by NADPH-dependent enzymes, thioredoxin reductase (TR) and 
glutathione reductase (GR) respectively. Both Trx and Grx can serve as electron donors 
for metabolic enzymes, represented by P, being P(SH)2 a reduced form and PS2 an 
oxidized form (adapted from Ghezzi et al.465) 
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The first Trx was originally discovered in Escherichia coli as an electron donor for RR, an 
enzyme required for DNA synthesis and later the identification of a glutathione dependent 
reductase able to restore the growth of E. coli in a mutant lacking Trx led to the discovery 
of Grx466, 467. Trxs are ubiquitous proteins, with molecular weight around 10-12 kDa, 
present in all forms of life. Mammalian cells contain two Trxs, one cytosolic (Trx1) and 
another localized in the mitochondria (Trx2); E. coli and yeast also contain two Trxs each 
and plants contain a variety of Trxs with highly specialized functions468-471. For example, 
Arabidopsis thaliana possesses multiple Trxs isoforms, and in vitro experiments have 
shown that some of them exhibit substrate specificity, suggesting that multiple Trxs may 
serve as a backup measure to cope with redox stress, it being likely that some cellular 
processes use preferentially one Trx472. Trxs are essential cofactors for DNA synthesis, 
sulfur assimilation and several antioxidant enzymes, such as peroxiredoxins, arsenate 
reductases and methionine sulfoxide reductase463. Trxs regulate the activity of several 
transcription factors, such as NF-κB in mammals473 and OxyR in E.coli474, and enzymes 
involved in different metabolic pathways475, 476. Grxs, also called thiol transferases, are 
small, GSH-dependent oxidoreductases with low molecular weights ranging from 9-15 
kDa, which play a crucial role in biological processes such as regulation of transcription 
factors, protecting cells from oxidative stress and catalyzing reversible protein S-
glutathionylation462. Based on the active site sequence, Grxs are divided into two 
categories: dithiol and monothiol. Dithiol Grxs have the characteristic Cys-Pro-Tyr-Cys 
active site motif, while monothiol Grxs lack the C-terminal active site thiol in its Cys-Gly-
Phe-Ser active site but contains all structural and functional elements to bind and utilize 
GSH as a substrate462, 477. Dithiol glutaredoxins catalyze GSH-dependent reduction of 
disulfide bonds using either a monothiol or dithiol mechanism. Protein disulfides are 
reduced by a dithiol mechanism requiring both active cysteines while mixed disulfides 
between GSH and proteins or low molecular mass thiols are mainly reduced by a 
monothiol mechanism that involves only the more N-terminal redox active Cys478. 
Versatility of Grxs includes the reduction of a compound devoid of thiol groups, DHA, 
which results from the oxidation of ascorbate. Ascorbate can be regenerated by a variety 
of oxidoreductases including Grxs, protein disulfide isomerase, but not Trxs, through 
mechanisms similar to the monothiol and dithiol reactions479, 480. All organisms have an 
individual set of Grxs isoforms that occur in the cytosol, mitochondria, or nucleus of 
different cells. For example, E.coli contains four Grxs, two dithiols (Grx1, Grx2 and Grx3) 
and one monothiol (Grx4) Grxs. In Sacharomyces cerevisiae were descrided seven Grxs 
and human cells contain four Grxs. In plants, Grxs constitute a rapidly growing family at 
least when the identification is based on sequence similarity; in Arabidopsis there are 
about 50 genes encoding Grxs or Grx-like proteins, suggesting considerable functional 
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Grxs diversity in these organisms481. E. coli Grx1 can serve as electron donors for 
metabolic enzymes such as RR and phosphoadenylsulfate reductase (PAPS) and is also 
active in monothiol mechanism reactions. Despite structural similarity to Grx1, Grx3, the 
most abundant in the cell, is not efficient in the reduction of the same substrates; although 
genetic mutations in Grx3 led to an increase in the reduction activity thought to be due to 
an  improved affinity for RR482. Grx2 is an unusual dithiol Grx as it is structural similar to 
GSTs family of proteins and lacks activity as hydrogen donors for RR483. The monothiol 
Grx4 does not exhibit classical Grx activity, but can be reduced by TR484. In mammalians 
Grx1, which is localized in the cytosol with small amounts in the nucleus, is a functional 
homologue of E. coli Grx1, while a modification in the active site of mammalian Grx2 
enables the protein to receive electrons from GR485. Moreover, Grx2 is also able to 
coordinate an iron sulfur cluster and may play a role in iron–sulfur cluster 
assembly/biogenesis, activity also detected in chloroplastic Grxs486-489. Grxs are highly 
conserved in all organisms, although in malaria parasites besides the presence of a 
classical Grx and a glutaredoxin-like protein, which shares similarities with PICOT-HD-
containing proteins490, was also identified a novel functional redox active protein, named 
Plasmoredoxin (Plrx). Plrx was found exclusively in malaria parasites and is a member of 
the thioredoxin superfamily able to provide electrons for RR, an activity detected both in 
Trxs and Grxs491.  
 
All trypanosomatids organisms lack GR and thioredoxin reductase, as their redox 
metabolism is based on T(SH)2 and TR364. The T(SH)2 system has been shown to deliver 
the reducing equivalents for the synthesis of DNA percursores by RR392 as well as the 
detoxification of hydroperoxides catalyzed by 2-Cys-peroxiredoxins and the glutathione 
peroxidase-type enzymes, which in these parasites act as trypanothione-dependent 
tryparedoxin peroxidases394, 413, 414, 416, 420, 427, 492. Despite the absence of TR, 
trypanosomes encode a thioredoxin gene, which results in very low protein levels and 
thus it may be compensated by tryparedoxins, present in the cell in much higher 
concentrations493, 494. Trypanosoma brucei possesses three genes for monothiol Grxs and 
two genes for dithiol Grxs. The three monothiol Grxs occur in both life stages, with the 
highest levels found in the stationary phase and distinct cellular functions. One of the 
monothiol Grxs, named 1-C-Grx1 is an abundant protein with a mitochondrial localization, 
able to form an iron-sulfur center using GSH as the non protein-ligand and thus may play 
an essential role in the iron and redox homeostasis of the parasite418, 495; the dithiol Grx1 
also coordinates iron-sulfur clusters496, as shown for other Grxs, human Grx2  and poplar 
Grx1C1489, 497. T. brucei Grx1 is a cytosolic protein that efficiently catalyzes the reduction 
of protein-GSH mixed disulfides; Grx1 can supply electrons for reduction of RR, while 
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Grx2 was able to reduce insulin disulfide, indicating that the two oxidoreductases have a 
high specificity toward distinct protein disulfides. On the other hand, Grx2 occurs in the 
mitochondrial intermembrane space and seems to be essential for procyclic parasites, as 
RNA interference against Grx2 resulted in growth retardation496. T. brucei Grx1 and Grx2 
were able to catalyze the reduction of GSSH by T(SH)2, suggesting a participation of 
those in the trypanothione metabolism. Thus besides a T(SH)2 percursor GSH, in the 
absence of a GR, it may be involved in protein glutathionylation or as a reducing agent of 
Grxs. Indeed, recently was also identified a dithiol Grx in T.cruzi, which showed a typical 
thioltransferase activity and in vitro assays suggested a possible role in reduction of  
glutathione disulfide as well as in deglutathionylation of target proteins498. L. infantum, L. 
mexicana and L. braziliensis genomes revealed the presence of genes encoding two 
putative monothiol Grx, 1 putative Grx and one putative Grx-like protein; in L. major was 
detected an extra gene encoding for a putative monothiol Grx. However, none of those 
was yet characterized. TDR1 is the only protein characterized in Leishmania that contains 
an active site characteristic of Grxs and the thioltransferase activity typical of this family of 
proteins90. 
 
 
3.4 Protein S-glutathionylation as a mechanism of regulation in various 
cellular processes 
 
All living organisms are exposed to various oxidants, resulting from their own metabolism 
or generated under oxidative stress. The levels of ROS and RNS in a cell are normally 
tightly regulated by antioxidant defense mechanisms. In a situation of oxidative stress, 
when ROS and/or RNS concentrations exceed the antioxidant capacity of the cell, cellular 
homeostasis is affected leading to disruption of redox signaling and/or molecular damage. 
ROS and/or RNS can cause specific, reversible or irreversible oxidative modifications on 
sensitive proteins, which may interfere with function of the oxidized protein387. 
 
Proteins can undergo different types of oxidation including carbonylation (introduction of a 
carbonyl group into proteins by oxidation of amino acid side chains such as lysine, 
arginine, histidine), oxidation of aromatic amino acids to various hydroxy derivatives and 
oxidation of methionine and cysteine to sulfoxides or sulfones. Methionine and cysteine 
residues are particularly sensitive to oxidation by almost all forms of ROS499. The thiol 
groups of Cys residues within the proteins act as redox-sensitive switches, as they are 
particularly susceptible to oxidative modifications and undergo various reversible and 
irreversible redox alterations as shown in Figure 3.4500. The vast majority of Cys residues, 
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in a reducing environment, remain almost completely protonated at a physiological pH and 
unlikely to be reactive with ROS/RNS. The Cys residues present in redox-sensitive 
proteins exist as thiolate anions at neutral pH, due to a lower pKa value that results from 
charge interactions with neighboring positively charged amino acids, therefore being more 
vulnerable to oxidation501. Thus the thiolate anion of redox-sensitive Cys residues can 
undergo a diverse spectrum of oxidative modifications. Sequential oxidation of Cys thiols 
yields sulfenic (–SOH), sulfinic (–SO2H), or sulfonic (–SO3H) acid derivatives. Reaction of 
protein thiols with low-molecular weight thiols such as GSH can yield mixed disulfides. 
Alternatively, oxidation by ROS and RNS can result in a disulfide bridge forming between 
two thiols either within a protein chain or between protein chains502. 
 
 
Figure 3.4 Oxidation fates of protein cysteines. Protein thiols, particularly low pKa 
cysteines, upon reaction with H2O2 form a sulfenic acid (SOH), which can react with a 
second cysteine resulting in intramolecular or intermolecular protein disulfide. SOH can 
also react with GSH (pink circle) to form a disulfide (S-glutathionylation). The irreversible 
sulfinic (SO2H) and sulfonic (SO3H) acids result from further reactions of SOH with H2O2. 
In the absence of a second cysteine or GSH, the amide nitrogen of the neighbouring 
residue can attack the SOH to form a sulfonamide (adapted from Paulsen et al.500). 
 
Oxidation to sulfinic and sulfonic acid are irreversible and thus other means of oxidation 
named S-thiolation, such as the formation of mixed disulfides may prevent thiols over-
oxidation and either protects and/or also modulates protein function. It’s noteworthy that 
the Cys residue does not necessarily need to be part of the active site of the protein to 
alter its function, since modification of thiols may also cause conformational changes that 
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alter protein activity or even interaction with other proteins501. As GSH represents the 
major thiol in almost all organisms, with the exception of Trypanosomatids364, protein S-
glutathionylation (the covalent addition of glutathione to cysteine residues on target 
proteins) represents the most abundant form of reversible thiol modification; S-
cysteinylation also occurs but the availability of free cysteine in the cell is much lower than 
GSH and thus this type of modification occurs at a lower rate than S-glutathionylation503. 
The reversible nature of S-glutathionylation and the fact that it occurs during oxidative 
stress but also under physiological conditions make it an important regulatory mechanism 
of biological processes504. In addition, S-glutathionylation may also serve as a storage 
form of GSH, which otherwise would be rapidly extruded from the cell under oxidative 
conditions505. S-glutathionylation is a dynamic process that can occur through several 
reactions (Figure 3.5): direct interaction between partially oxidized (activated) protein 
sulfhydryls (thiyl radical, sulfenic acid or protein S-nitrosothiol) and GSH; thiol/disulfide 
exchange reactions between protein thiols and GSSG or S-glutathionylated proteins; 
reaction between protein thiols and intermediate S-nitrosothiols such as S-
nitrosoglutathione (GSNO), which is able to modify protein sulfhydryl groups by both 
protein S-nitrosation and S-glutathionylation and direct interaction between a free protein 
cysteinyl residue and GSH triggered by oxidants506. Also, glutathionylated proteins can 
result from the reaction catalyzed by Grx between the thiyl radical of GSH (formed by 
reaction with hydroxyl radicals) and proteins. Indeed, intracellular GSSG concentrations 
would need to change 100-fold, due to the redox potential of most cysteine residues, to 
induce S-glutathionylation through thiol exchange mechanism and thus unlikely to occur 
intracellularly464. However, the role of Grx seems to be primarily in the catalysis of protein 
deglutathionylation (S-glutathionylation reverse reaction). Human GSTPi was reported to 
catalyse S-glutathionylation reactions, for which contribute the high expression levels 
detected in many drug resistant tumours, not related to detoxification as GSTPi has a 
modest activity with of a number of identified substrates, particularly anticancer drugs507.  
 
To consider protein glutathionylation as a regulatory mechanism it was proposed that S-
glutathionylation must change the protein activity and function in the cell, occur in intact 
cells in response to a physiological stimulus, occur at physiological GSH:GSSG ratios, 
and exhibit rapid and efficient mechanisms of specificity towards certain cysteine 
residues, and reversibility of protein-SSG508. 
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Figure 3.5 Potential mechanisms of protein S-glutathionylation. Modification of 
cysteine residues to protein–SSG mixed disulide can occur through several mechanisms: 
(1) thiol-disulfide exchange; (2) sulfenic acid intermediates; (3) sulfenylamide 
intermediates; (4) thiyl radical intermediates; (5) thiosulfinate intermediates; (6) S-nitrosyl 
intermediates (adapted from Mieyal et al.506). 
 
Many proteins involved in a wide range of biological processes have been identified as 
potentially regulated by reversible S-glutathionylation, either inhibited or activated. 
However, the exact mechanism or importance of this type of modification in vivo remains 
unclear. Detection of S-glutathionylation targets have been reported in a wide range of 
organisms including animals, plants, fungi, and bacteria, through the analysis of purified 
proteins in vitro or large-scale proteomic studies. Two major strategies have been used to 
detect glutathionylated proteins: labeled GSH, which allows the detection of GSH adducts 
on S-thiolated proteins and anti-GSH antibodies or thiol alkylation after deglutathionylation 
by Grxs509. Other approach have been the identification of Trx- or Grx-interacting proteins 
through the use of mutant Trx or Grx immobilized in a resin that are able to catch target 
proteins as a mixed disulfide intermediate510-512. The putative target proteins are involved 
in many processes, including redox homeostasis, nitrogen, sulfur and carbon 
metabolisms, protein biosynthesis and protein folding476, 502, 511-519. Several metabolic 
enzymes were reported has susceptible to S-glutathionylation. The glycolitic enzyme, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which plays a primary role in 
energy production, is inactivated by S-gluathionylation520-522. Other enzymes such as 
ketoglutarate dehydrogenase523, aldolase and triose phosphate isomerase can undergo S-
glutathionylation both in human cells and plants516, 524 suggesting an important role for this 
oxidative modification in the modulation of energy production. In E.coli, cobalamin-
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independent methionine synthase, the enzyme that catalyses the final step of methionine 
biosynthesis is also inactivated by S-glutationylation during oxidative stress525. S-
glutathionylation also plays a role in cell signaling, being involved in the regulation of the 
kinase activity of protein tyrosine phosphatase 1B (PTPB1) in response to oxidative 
stress526, 527, among others; interferon regulatory factor 3 (IRF3) is an example of the 
crucial role of S-glutathionylation in the control of cell signaling pathways. IRF3 is an 
essential transcriptional regulator of the interferon genes and is S-glutathionylated in non 
infected cells, but after viral infection IRF3 undergoes deglutathionylation necessary for 
transcriptional activation of the interferon genes528. Activation of the NF-kB pathway is 
also dependent on the redox state of the cell as the transcription factor NF-kB is a target 
for oxidative inactivation by S-glutathionylation529. S-glutathionylation also plays a role in 
the regulation of redox homeostasis as shown by the inhibition of human and plants Trxs. 
In chloroplasts only f-type of Trxs (Trxfs) are required for activation of Calvin-cycle 
enzymes. Thus inactivation of Trxf will affect the activity of other enzymes such as NADP-
malate dehydrogenase and GAPDH, which is strongly decreased when Trxfs are 
glutathionylated. As Trxfs are involved in the regulation of carbon-fixation enzymes by 
light, S-glutathionylation may constitute a mechanism of regulation of photosynthetic 
metabolism under oxidative stress530. Also, S-glutathionylation of human Trx abolished its 
enzymatic activity as insulin disulfide reductase in the presence of NADPH and TR 
suggesting that the redox state of the cell can regulate Trx functions reversibly through 
thiol-disulfide exchange reactions531. Concerning the detection of glutathionylated proteins 
in parasites, the malaria parasite P. falciparum has also been reported to have proteins 
redox regulated through S-glutathionylation being targeted by Trx, Grx and Plrx511, 532, 533. 
Proteins involved in antioxidant defense (peroxiredoxins) were identified specifically as 
potential Trx targets and proteins involved in carbohydrate metabolism were also found to 
interact with Trx, Grx and Plrx proteins511. Among the identified targets of protein S-
glutathionylation in P. falciparum, as observed in other organisms, both GADPH and 
pyruvate kinase were reversible inhibited by S-glutathionylation and not only Grx1 but also 
Trx1 and Plrx were able to efficiently catalyze protein deglutathionylation532. In the case of 
trypanosomatids, there are no reports of glutathionylation of Leishmania proteins, 
although the related organism Trypanosoma uses GSH for the glutathionylation of thiol 
redox proteins as shown by the specific and reversible glutathionylation of Grx1, Trx and 
glutathione peroxidase type tryparedoxin peroxidase III of T. brucei419. In addition in 
T.cruzi was also identified a dithiol Grx with typical thioltransferase activity that may be 
involved in the reduction of  glutathione disulfide as well as in deglutathionylation of target 
proteins498. These data suggest that free GSH in these parasites that do not possess a 
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GR may have other roles beside being a trypanothione precursor, such as protein 
glutathionylation and deglutathionylation or as a reducing agent of Grxs364.  
Interesting is the fact that S-glutathionylation occurs not only in response to oxidative 
stress but was demonstrated through the detection of glutathionylated proteins under 
physiological conditions517, 534. For example, constitutive S-glutathionylation has been 
shown in hemoglobin in red blood cells535, 536 and actin in human fibroblasts and epidermal 
cells537, 538. Another example is P. falciparum GAPDH protein glutathionylation which 
occurs in the presence of low concentration of GSH, likely to reflect physiological 
conditions419, 532. 
 
The reverse reaction called deglutathionylation consists of the removal of the GSH moiety 
from protein mixed disulfides and can be efficiently catalyzed by Grx or Trx via a dithiol 
exchange mechanism, once the intracellular redox balance has been restored470, 539-541. 
Human sulfiredoxin has also been reported to catalyze deglutathionylation of a number of 
distinct proteins in response to oxidative and/or nitrosative stress, such as actin and 
PTP1B542. It has been shown that Grxs are very efficient glutathionyl mixed disulfide 
reductases, whereas Trxs are more specific for reduction of protein disulfide bonds and 
much less efficient than Grxs to catalyze deglutathionylation reactions543, 544. C. reinhardtii 
isocitrate lyase can be inactivated by glutathionylation and reactivated by Grx, while Trx 
does not appear to regulate protein activity541. Identification of S-glutathionylated proteins 
is based on the enzymatic reduction of S-glutathionylated proteins by Grx. Grx activity is 
often measured using the artificial substrate 2-hydroxyethyldisulphide (HEDS) or through 
deglutathionylation of radiolabeled protein-GSH mixed disulfides545, 546. More recently was 
developed a new real-time fluorescence-based method for measuring the 
deglutathionylation activity of Grxs using a glutathionylated peptide as a substrate, which 
measures the formation of the deglutathionylated product rather than indirectly the 
consumption of NADPH as in the classical HEDS assay547.  
 
 
3.5 Thiol Dependent Reductase 1 
 
TDR1 is a parasite-specific enzyme, first identified in L. major, with an unusual two 
domain nature, where the N-terminal domain contains a CXXC motif characteristic of Grxs 
and Trxs, while the C-terminal active site is characteristic of GSTO; the protein is 
functional as a trimer90. TDR1 possesses thioltransferase and DHAR enzymatic activities, 
shown by the ability of using GSH as an electron donor to reduce HEDS (Figure 3.6) and 
DHA, respectively, with specific activities significantly higher than those reported for the 
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human GSTO90. Although, the conjugation of GSH with the generic GST substrate CDNB 
occurred at a low rate and no activities were detected with other GST substrates90. CDNB 
is a good substrate for all other classes of GSTs, which are able to catalyze the 
conjugation of free radicals, metals and other electrophilic compounds with GSH and play 
a major role in the detoxification of many reactive metabolites. Human GSTO instead has 
activities similar to Grxs, with thioltransferase activity being the most prominent437. 
 
 
Figure 3.6 HEDS reduction by TDR1. Reactions involved in the thioltransferase in vitro 
assay using the artificial substrate HEDS. TDR1 is able to transfer electrons to 2-
hydroxyethyldisulphide HEDS after glutathione (GSH) oxidation. Glutathione reductase 
(GR) is used to regenerate glutathione disulfide (GSSG) to GSH. The subscripts “red” and 
“ox” refer to the redox state of the proteins, dithiol and disulfide, respectively. 
 
In addition, TDR1 is able to reduce the antileishmanial drug pentavalent antimonial (SbV) 
to a trivalent form (SbIII), the active form against Leishmania intracellular amastigotes. 
Spontaneous conversion of pentavalent antimonials in the presence of GSH has been 
reported to occur in vitro548, 549, however the rate of the reaction is much lower than when 
catalyzed by TDR1, suggesting a role for the enzyme in the anti-leishmanial activity of 
antimonial drugs90. Although, generally accepted that amastigotes are the susceptible 
form of the parasite to antimonials550, 551, it is not yet known if activation occurs within the 
parasite or outside, leading to the question whether the TDR1 role in drug activation is 
biologically relevant. The fact that TDR1 levels of expression are 10-fold higher in the 
amastigotes90 plus the observation that the conditions found within the phagolysosome, in 
which Leishmania resides (acidic pH and elevated temperature), favour this conversion 
support the hypothesis of a role in the activation of antimonials; however it can also, 
instead, play a part in the detoxification of the drug90, consistent with the finding of several 
products of stibogluconate in L. donovani amastigotes552. Besides antimonial reduction, it 
has also been suggested that TDR1 may play a role in the detoxification of arsenic, due to 
its similarity with the arsenate reductases90. As observed for SbV, arsenate (AsV) can also 
be reduced to arsenite (AsIII) nonenzymatically, although the process is too slow to be 
physiologically significant and, so organisms use enzymes that catalyze AsV reduction553. 
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Arsenical resistant Leishmania strains are frequently cross-resistant to antimonials, 
justified by the fact that these compounds are related metalloids. This is supported by the 
identification and characterization of a  an arsenate reductase in L. major, namely ACR2, 
capable of reducing SbV to SbIII, that when over-expressed leads to an increase in 
susceptibility to sodium stibogluconate (SSG)91. 
 
TDR1 is conserved among Leishmania spp. and have also been characterized in L. 
donovani and L. infantum, with 100% homology between this two species and levels of 
thiol trasferase activity similar to those obtained with L. major enzyme (Silva et al, 
unpublished results). Moreover, a protein similar to TDR1 was identified on the related 
parasite T.cruzi, named Tc52, with an overall identity of 45.7%; the putative active-site 
residues of the two proteins are identical in the N-terminal domains (CPFC) but differ in 
the C-terminal domain, which contains the CPF motif similar to GSTO in TDR1 but in Tc52 
the cysteine residue is replaced by a serine. Both possess thioltransferase activity and 
DHAR activity90, 554. In Leishmania, GST activity was not detectable, but a related 
trypanothione S-transferase activity was observed, L. major eEF1B was able to catalyze 
the aromatic nucleophilic substitution reactions between T(SH)2 and CDNB461,  which 
correlates with the fact that Leishmania parasites rely on the T(SH)2/TR system and lack 
GR and thioredoxin reductase364. Thus, given the data available on TDR1, Denton and co-
workers have suggested the possibility that the two domains of TDR1 could function 
together as electron donor and reductase, providing Grx-like activities for Leishmania90. 
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4.1 Objectives 
 
The identification and characterization of a parasite-specific enzyme, named TDR1, in L. 
major by Denton et al.90 with interesting similarity to an enzyme known as Tc52 of the 
related parasite T. cruzi which had previously been reported as an important factor in the 
modulation of the host immune reponse to infection with T. cruzi 554-557, prompted this 
study. It had as main aims the objectives of determining whether TDR1 has a similar 
effect during Leishmania infection as Tc52 does during infection with T. cruzi and 
assessing the potential of the protein in vaccination approaches. An additional interesting 
aspect of TDR1 is that it possesses an intriguing two domain nature, with motifs 
characteristic of Grx and GSTO proteins90. This feature, added to the fact that TDR1 
shows high conservation within the different Leishmania species and has the ability to 
catalyze the reduction of pentavalent antimonials which is necessary for effective action of 
the drug against the parasite, suggested an interesting and important role for the enzyme 
in the parasite. In order to provide insights into the role of TDR1 in visceral Leishmania 
species (L. infantum and L. donovani), we investigated the essentiality of the gene for 
parasite survival and virulence through the generation and characterization, including the 
use of untargeted metabolomics analysis, of TDR1 null mutants.   
 
 
The experimental results obtained in this study are organized in 6 sections within this 
thesis as follows: 
 
4.2 Characterization of TDR1 expression, localization of TDR1 in L. infantum, and 
evaluation of the immune response induced by recombinant TDR1 in the context of L. 
infantum infection using a murine model;  
 
4.3 Generation of a TDR1 null mutant in L. infantum; 
 
4.4 Elucidation of the role of TDR1 in L. donovani, through the generation of a null mutant 
and characterization of the generated cell lines in the context of oxidative stress, drug 
resistance and redox regulation; 
 
4.5 Determination of the structure of L. donovani TDR1; 
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4.6 Analysis of the changes that occur at the metabolome level during L. donovani wild-
type promastigote growth from logarithmic to stationary phase of in vitro culture, using an 
untargeted metabolomics approach; 
 
4.7 Evaluation of potential differences between visceral (L. donovani) and cutaneous (L. 
major) Leishmania species through an untargeted metabolomics analysis.  
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4.2  Immunological role of Leishmania infantum Thiol Dependent 
 Reductase 1 
 
 
The need to develop an effective vaccine against leishmaniasis to prevent the 2 million 
new cases each year led to the search for antigens able to elicit protection against 
infection with Leishmania.  
In this study we have evaluated the immune response induced by a recombinant parasite-
specific protein of L. infantum, Thiol dependent reductase 1 (rTDR1) as well as the ability 
of this antigen to protect against experimental challenge using a murine model. rTDR1 
immunization led to an expansion of CD8-T cell population and a decrease in IL-10 
production. However, immunization with rTDR1 did not elicit high levels of protection, 
despite the maintenance of a significant decrease in IL-10 production. Nevertheless, 
immunization with rTDR1 induced an increase in CD8-T cell number during the chronic 
phase of infection, suggesting the generation of memory CD8-T cells. Indeed, analysis of 
CD8-T cells from rTDR1 immunized mice showed an increase in cells with characteristics 
of central memory T cells, while no differences were observed in the CD4-T cells from the 
same animals. Thus, the expansion of CD8-T cell induced by immunization with rTDR1 
although insufficient to protect Balb/c mice, highlighted the potential importance of these 
cells in a vaccination strategy. 
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Summary  
 
The need to develop an effective vaccine against leishmaniasis to prevent the 2 million 
new cases each year led to the search for antigens able to elicit protection against 
infection with Leishmania.  
In this study we have evaluated the immune response induced by a recombinant parasite-
specific protein of L. infantum, Thiol dependent reductase 1 (rTDR1) as well as the ability 
of this antigen to protect against experimental challenge using a murine model. rTDR1 
immunization led to an expansion of CD8-T cell population and a decrease in IL-10 
production. However, immunization with rTDR1 did not elicit high levels of protection, 
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despite the maintenance of a significant decrease in IL-10 production. Nevertheless, 
immunization with rTDR1 induced an increase in CD8-T cell number during the chronic 
phase of infection, suggesting the generation of memory CD8-T cells. Indeed, analysis of 
CD8-T cells from rTDR1 immunized mice showed an increase in cells with characteristics 
of central memory T cells, while no differences were observed in the CD4-T cells from the 
same animals. Thus, the expansion of CD8-T cell induced by immunization with rTDR1 
although insufficient to protect Balb/c mice, highlighted the potential importance of these 
cells in a vaccination strategy. 
 
 
1. Introduction 
 
The leishmaniases remain a major public health problem with 350 million people at risk 
worldwide and 2 million estimated new cases every year in 88 countries. Clinical 
manifestations of Leishmania infection range from self-healing cutaneous (CL) and 
mucocutaneous (MCL) forms to visceral leishmaniasis (VL) which, if left untreated, is 
fatal1. Leishmaniasis is also found as an opportunistic disease associated with human 
immunodeficiency virus (HIV). HIV infection increases the risk of developing active VL by 
between 100 and 2320 times2. Unfortunately, there is no effective vaccine against this 
parasite, thus control of disease relies on chemotherapy. However, there are limitations in 
the use of available drugs due to high cost, toxicity, long courses of treatment and, in 
particular, the emergence of drug resistance3. The clinical outcome of infection is 
determined by a combination of several factors including parasite pathogenicity, 
determined by the Leishmania species, and the host’s immune status4. 
 
In order to discover new therapeutic or preventative measures to control the disease, it is 
necessary to dissect the factors involved in the parasite-host interactions. Leishmania is 
able to modulate the immune response, facilitating the invasion and establishment of 
infection5. Recently, Silverman and co-workers described a new exosome-based 
mechanism for the release of Leishmania proteins into the host’s cytoplasm6. Previously, 
a wide range of Leishmania proteins including GP637, A28, cysteine proteinases9 and 
CRK310 have been implicated in the survival of the parasite in the mammalian host and 
consequently considered virulence factors11. Recombinant proteins of Leishmania such as 
LACK12, HASPB113 and LeIF14 have been assayed for their immunogenicity and protective 
potential in murine models; they elicited different degrees of protection. So far, despite 
many antigens being identified as vaccine candidates only the LEISH-F1+MPL-SE 
polyprotein vaccine seems promising; this was considered safe and immunogenic against 
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CL when administered alone15 or in conjugation with antimonials in human clinical trials16, 
17. Protection against challenge with L. infantum in Leish-F1+MPL-SE-immunized animals 
appears to be associated with a Th1-type immune response18. Moreover, Leish-F1+MPL-
SE protective effect against L. major is also associated with memory cells that are capable 
of antigen-specific restimulation for at least 6 months19.  
 
An ideal vaccine against leishmaniasis should be able to elicit long-lasting immunity20. 
This involves the generation of CD4-T and CD8-T effector and memory T cells, which 
depends on the strength and duration of antigenic stimulation. CD4-T cells mediate their 
effector functions through the production of IFN-γ and IL-4, while CD8-T cells response 
involve both cytokine production and cytolytic mechanisms21, 22. Moreover, expansion of T 
cell populations in the context of infection will lead to an increase of antigen-specific T 
cells that ultimately result in the formation of T cell memory23. Maintenance of protective T 
cell memory against leishmaniasis has been difficult to achieve, despite different 
vaccination strategies being used including live attenuated parasites, recombinant 
antigens and DNA vaccines1, 20. Zaph et al. established that CD4- memory T cells provide 
effective and long-lasting protection against L. major infection, involving two population’s 
of effector and central memory T cells. This study also showed that central memory T 
cells do not require the presence of the parasite to maintain the pool of memory cells24. 
CD4-T cells are critical for the development of CD8-T-cell memory25. Host protection 
against Leishmania infection has been reported to be associated with CD8-T cells26-29. 
CD8-T cells are required for resistance to re-infection, as shown by the enhanced levels of 
IFN-γ released during a memory response to L. major by antigen-specific CD8-T cells 
from the lymph nodes and spleen cells of immune re-infected mice30. 
 
The current study was undertaken to investigate the role of L. infantum Thiol dependent 
reductase 1 (TDR1) in the parasite-host interaction. TDR1 was first identified in L. major 
as a parasite-specific enzyme by Denton and co-workers31. This enzyme has some 
similarities to human omega-GST, including its thiol transferase and dehydroascorbate 
reductase activities31. This is an interesting feature given the fact that Leishmania 
parasites do not possess the classical redox system based on glutathione and rely on the 
trypanothione system for protection against oxidant damage and toxic heavy metals32. 
Alignment of the predicted amino acid sequences also revealed a considerable identity 
(45.7%) between TDR1 and a T. cruzi protein named Tc52 and very high identity (95%) 
with L. infantum, which could suggest an important and conserved role for this protein31. 
Tc52 is an excreted/secreted protein of  T. cruzi which has been reported to be important 
in modulation of the mammalian host’s immune response by the suppression of T cell 
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proliferation33. Moreover, Tc52 targeted gene deletion gave evidence for a crucial 
importance of this protein in the survival and virulence of T. cruzi34. Similarly to TDR1, 
Tc52 also possesses thiol transferase and dehydroascorbate reductase enzymatic 
activity35. Thus, in this study we have evaluated the immune response induced by 
recombinant TDR1 when administered to Balb/c mice as well as the ability to induce 
protection against challenge with virulent L. infantum promastigotes. The data showed 
that recombinant TDR1 of L. infantum only elicited partial protection against chronic 
Leishmania infection, despite a decrease in IL-10 production and expansion in CD8-T 
cells with characteristics of central memory T cells.  
 
 
2. Materials and Methods 
 
2.1. Leishmania parasites  
Leishmania infantum (clone MHOM/MA/67/ITMAP263) promastigotes were grown at 27ºC 
in RPMI complete medium (RPMI 1640, BioWhittaker) supplemented with 10% (v/v) heat 
inactivated fetal bovine serum (FBS, Gibco), 2 mM L-glutamine (Sigma), 20 mM Hepes 
(Gibco), 100 U/ml penicillin and 100 mg/ml streptomycin (BioWhittaker). Cultures were set 
up initially at a concentration of 1 x106 parasites/ml and sub-passaged every 5 days. 
 
To obtain promastigotes in the different phases of growth, parasites were first 
synchronized by five daily passages of 1x106 parasites/ml and then harvested at days 1 
(early log phase), 2  (late log phase) and 6 (stationary phase). Axenic amastigotes were 
grown at 37ºC with 5% CO2 in MAA/20 medium. MAA/20 consists of modified medium 199 
(GIBCO) with Hank’s balanced salt supplemented with 0.5% trypto-casein (Oxoid), 15 mM 
D-glucose (Sigma), 5 mM L-glutamine, 4 mM NaHCO3 (Sigma), 0.023 mM bovine hemin 
(Fluka), and 25 mM Hepes to a final pH of 5.8 and supplemented with 20% (v/v) FBS36. 
The differentiation process was initiated by incubation of stationary phase promastigotes 
in MAA/20 medium at 37°C with 5% CO2. Parasites were harvested after 1, 3, 5, 10, 24, 
48 and 72 h of incubation.  
 
2.2. Cloning and purification of TDR1 
The L. infantum TDR1 was PCR amplified using L. infantum genomic DNA as template 
and the following forward (5’-GCCATATGGCCGCCCGCGCGCTAAAGCTATACGTG-3’) 
and reverse (5’-GATCTAGATTACCCGCTCTGGGCCCTCCGTTGACGC-3’) primers 
containing NdeI and XbaI restriction sites (underlined), respectively. Amplification 
conditions were as follows: 94ºC, 2 min; 30 cycles of 94ºC, 15 sec; 55ºC, 30 sec; 72ºC, 90 
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sec and 72ºC, 10 min. The PCR product (1349bp) was cloned into pGEM-T Easy vector 
(Promega). All the transformants were identified by restriction analysis and one of the 
clones chosen to be confirmed by sequencing (Eurofins MWG Operon). The insert was 
excised by digestion with NdeI-XbaI (New England Biolabs) and sub-cloned into the 
Escherichia coli expression vector pET28a+ in frame with an amino-terminal six-histidine 
tag (pET28a+ TDR1). Briefly, 500 ml cultures of recombinant E. coli BL21 (DE3) were 
induced to express TDR1 by the addition of 2 mM of isopropyl β D-thiogalactoside (IPTG), 
overnight at 15ºC. The induced culture was harvested and resuspended in 20 mM 
Tris/500 mM NaCl, pH 7.9 (Buffer A) containing 10 mM imidazole. The cells were lysed by 
sonication and the resulting suspension was centrifuged at 15000 x g for 30 min at 4 °C to 
remove cell debris. The clear supernatant containing soluble protein was applied on to a 
pre-equilibrated nickel-nitrilotriacetic acid (Ni-NTA) column (Qiagen). The column was 
washed with Buffer A containing 60 mM imidazole to remove the non-binding proteins and 
the His-tagged recombinant protein was eluted with Buffer A containing 250 mM of 
imidazole. After purification, the eluted fractions were pooled and buffer-exchanged into 
20 mM Tris, 250 mM NaCl, pH 7.9 using a PD10 desalting column (GE Healthcare) and 
stored at -80ºC. The recombinant protein was designated rTDR1. To eliminate endotoxins, 
the recombinant protein was passed through an EndoTrap®red column (Profos, 
Germany) following manufacturer’s instructions. Polyclonal antiserum against TDR1 was 
generated in mice by intraperitoneal (i.p.) injection of recombinant protein in incomplete 
Freund’s adjuvant. 
 
2.3. Immunofluorescence analysis of sub-cellular location of TDR1 
L. infantum promastigotes and axenic amastigotes were pelleted by centrifugation at 1500 
x g for 10 min, washed with phosphate buffered saline (PBS) and fixed to slides in a PBS 
solution containing 4% paraformaldehyde, for 20 min at room temperature. Fixed 
parasites were permeabilised with 0.1% (v/v) Triton X-100 in PBS. Slides were washed 
several times with PBS and blocked in PBS containing 1% bovine serum albumin (PBS-
BSA) for 30 min at room temperature. Incubation with the anti-TDR1 mouse serum (1:100 
in PBS-BSA) was made in a humid chamber, for 1 h at room temperature. After several 
washes in PBS, slides were blocked once more in PBS-BSA for 15 min at room 
temperature. Alexa Fluor® 488 goat anti-mouse IgG (Molecular Probes) diluted 1:100 in 
PBS-BSA was used as secondary antibody. Washed parasites were mounted in 
Vectashield (Vector Laboratories) and analyzed with a fluorescent microscope (Axioskop-
Carl Zeiss, Germany) at 1000x magnification. A negative control with parasites treated 
only with secondary antibody was used. 
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2.4. Digitonin fractionation 
Promastigote fractionation was done according to Häusler et al.37. Aliquots of  5x107 cells 
(~100 μg of total protein), resuspended in 1.125 ml of 25 mM Tris pH 7.5, 0.6 M sucrose, 
1 mM DTT, 1 mM EDTA and a cocktail of protease inhibitors, were permeabilized with 125 
µl of pre-diluted digitonin (Calbiochem) to final concentrations of 0-10 mg of digitonin per 
mg of cellular protein. Upon incubation at 37ºC for 2 min, the samples were mixed in a 
vortex and centrifuged at 12000 x g at 4ºC for 10 min. Protein in the supernatants were 
concentrated by trichloroacetic acid precipitation and supernatant and pellet fractions 
corresponding to 1.125 x 107 ml promastigotes were run in SDS-PAGE and analyzed by 
Western Blot. 
 
2.5. SDS-PAGE and Western Blot analysis 
Lysates of L. infantum promastigotes and amastigotes were prepared by freeze-thaw lysis 
of parasite pellets. Insoluble cellular debris was removed by centrifugation at 12000 x g for 
20 min at 4ºC, the proteins separated by SDS-PAGE (12%) and blotted to nitrocellulose 
for Western Blot analysis. Western blots were probed with a polyclonal mouse anti-TDR1 
and goat anti-mouse IgG peroxidase-conjugated (SouthernBiotech) used as the 
secondary antibody. Antibodies raised against L. infantum cTXNPx and mTXNPx sera 
were used as control. Development was performed with an ECL detection system 
(Amersham). 
 
2.6. Immunization and challenge infection 
Balb/c mice were obtained from Charles River (Spain) and maintained at the animal 
facilities of the Instituto de Biologia Molecular e Celular (IBMC, Porto, Portugal). Mice 
were kept six per cage and allowed food and water ad libitum. 
Balb/c mice (3 animals per group) were inoculated three times i.p. at 1 week intervals 
either with 25 µg of rTDR1 or just PBS. Two weeks after the last immunization, spleen and 
sera were collected. Additional groups were immunized following the scheme described 
above and two weeks after the last boost challenged i.p. with 108 L. infantum 
promastigotes in PBS. Mice were bled and sacrificed at 2, 5, 7 and 9 weeks post-infection 
and spleen, liver and sera were collected. The spleen from each individual mouse was 
gently dissected to obtain single cell suspensions for cell population and cytokine 
production analysis. Splenocytes were washed and resuspended in RPMI complete 
medium to a concentration of 107 cells/ml. Mice groups were designated as follows: TDR1, 
immunized with rTDR1; PBS, injected with PBS; TDR1 INF, immunized with TDR1 and 
infected; INF, injected with PBS and infected. 
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2.7. Assessment of parasite load 
Parasite quantification in the spleen and liver was performed by limiting dilution as 
previously described38. Briefly, organs were removed, homogenised and resuspended in 
RPMI medium. Two-fold serial dilutions were prepared in flat bottom 96-well microtiter 
plates (Immune Plate Maxisorp; Nunc). After incubation for 15 days at 27ºC, plates were 
examined and the positive (presence of motile parasites) and negative (absence of motile 
parasites) wells were determined using an inverted microscope. The number of parasites 
per gram of organ (parasite load) was calculated as follows: parasite load = [(geometric 
mean of reciprocal titer from each quadruplicate cell culture/weight of homogenized 
organ) x reciprocal fraction of the homogenized organ inoculated into the first well]. 
 
2.8. Flow cytometry analysis 
A total of 106 splenocytes resuspended in PBS supplemented with 10% (v/v) FBS were 
distributed into a 96-well microtiter culture plate and washed with PBS-2% FBS. For 
spleen cell population determinations, cells were incubated with saturating concentrations 
of fluorescein isothiocyanate (FITC)-conjugated rat anti-mouse CD8 (Ly-2) monoclonal 
antibody, FITC-conjugated rat anti-mouse CD4 (L3T4) from BD Pharmingen or FITC-
conjugated goat anti-mouse IgM from Southern Biotechnology. After 30 min incubation on 
ice, the cells were washed three times with PBS-2% FBS and examined in a FACSCalibur 
(Becton Dickinson) using propidium iodide 0.25 μg/ml (BD Pharmingen) for cell death 
exclusion. For phenotypic characterization of spleen cells, CD8 and CD4 subsets were 
double stained with phycoerythrin (PE)-conjugated rat anti-mouse CD44 (clone IM7, BD 
Pharmingen) and APC-conjugated rat anti-mouse CD62L (clone MEL-14, BD 
Pharmingen). Data files were analyzed using FlowJo software (Tree Star, Inc.). 
 
2.9. Cytokine ELISAs 
Spleen cells were seeded at a density of 2×105 cells/well in the presence of rTDR1 (10 
µg/ml), concanavaline A (Con A, 6 µg/ml) or medium alone. Plates were incubated for 24h 
(for detection of IL-2), 48 h (for detection of IL-10 and IL-4) or 72 h (for detection of IFN-γ) 
at 37ºC in 5% CO2. The IFN-γ, IL-10 and IL-4 production in supernatants of splenocyte 
cultures was measured by two-site sandwich enzyme-linked immunosorbent assay 
(ELISA), as previously described39 
 
2.10. Detection of specific rTDR1 antibodies 
Serum samples from animals immunized with rTDR1 were analyzed by ELISA for specific 
IgG and IgG1, IgG2a, IgG2b subclasses to rTDR1 2 weeks after the last boost and also 2, 
5, 7 and 9 weeks post-infection, as previously described40. 
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2.11. Statistical analysis 
Statistical analysis was performed using Student’s T test. A p value smaller than 0.05 
(p<0.05) was considered significant. GraphPad Prism 4 was used for plotting the graphs. 
 
The L. infantum TDR1 sequence was submitted to the NCBI sequence database under 
the accession number JF767498. 
 
 
3. Results 
 
3.1. Molecular cloning, expression and purification of L. infantum TDR1 
L. infantum TDR1 is predicted to encode a protein with a theoretical molecular weight of 
49.9 kDa. Fig. 1 shows the LiTDR1 amino acid sequence and compares it with LmTDR1 
and Tc52. The sequence analysis revealed that LiTDR1 shares a high identity with 
LmTDR1 (95.8%), as predicted by Denton and co-workers31. Moreover, LiTDR1 shares 
with Tc52 the putative  active site positioned in the N-terminal region while the CPF motif, 
characteristic of omega GSTs, occurring in the C-terminal region of the Leishmania 
proteins is absent from Tc52. The CXXC sequence, where X represent any amino acid, is 
also characteristic of glutaredoxins41. 
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Figure 1. Amino acid alignment of L. infantum TDR1, L. major TDR1 and T. cruzi 
Tc52. The amino acid sequences of L. infantum TDR1 and  L. major TDR1 (EBI 
accession no.AJ582069) were aligned and compared with T. cruzi Tc52 (EBI accession 
no. Q26950). Alignment was performed with AlignX (VectorNTI, Invitrogen). Identical 
amino acids in all sequences are shaded in black, identical amino acids in the Leishmania 
sequences are shaded in dark grey and light grey indicates similarity between amino 
acids. The putative active-sites are underlined. 
 
In order to obtain TDR1 as a recombinant protein, TDR1 was cloned into pET28a+ and 
expressed in E. coli with a N-terminal 6x Histidine-tag. As shown in Fig. 2, rTDR1 is a 
highly soluble recombinant protein with a yield of approximately 20 mg per liter of E. coli 
culture. 
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Figure 2. Expression and purification of L. infantum TDR1 in E. coli. Protein samples 
were separated in 12% SDS-PAGE gel followed by Coomassie staining. Molecular mass 
standards (lane 1), lysate (lane 2) and supernatant (lane 3) of E. coli expressing 
recombinant protein; flow-through (lane 4); washes with Buffer A 60 mM imidazole (lanes 
5 and 6) and purified recombinant protein eluted with Buffer A 250 mM imidazole (lanes 7 
- 10). Estimated molecular masses and recombinant protein (arrowed) are indicated on 
the left and right, respectively 
 
3.2. L. infantum TDR1 is constitutively expressed and is present in the cytosol of 
both parasite stages 
 
To analyze the protein expression throughout the life cycle of L. infantum, promastigotes 
were synchronized to obtain the cells in different developmental stages (early log, late log 
and stationary phase of in vitro cultures), as well as differentiated into amastigotes. As 
shown in Fig. 3A, TDR1 expression is up-regulated in the axenic amastigote form and 
kept constant during exponential growth of promastigote stage.  
 
Figure 3. Expression of TDR1 throughout L. infantum development. (A) Western Blot 
analysis of TDR1 expression in total protein extracts from early log (lane 1), late log (lane 
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2) and stationary phase (lane 3) promastigotes and from axenic amastigotes (lane 4) 
using anti-TDR1 polyclonal antibody. (C) Western Blot analysis of TDR1 expression in 
total protein extracts resulting from differentiation of promastigotes into amastigotes. 
Expression was analyzed, using anti-TDR1 polyclonal antibody, 1, 3, 5, 10, 24, 48 and 72 
h after initiation of incubation of promastigotes in MAA/20 medium at 37ºC. Coomassie 
blue staining of identical gel run in parallel (B, D) is shown as a loading control. Estimated 
molecular masses and TDR1 protein (arrowed) are indicated on the left and right, 
respectively.   
 
This result was also confirmed by FACS analysis (Fig. S1 in supporting information). 
Furthermore, TDR1 expression increased in response to the temperature elevation and 
acidic pH in MAA/20 medium (Fig. 3C). The protein expression increased continuously 
until full differentiation to the amastigote form (Fig. 3C).  
 
In order to gain insight into the localization of TDR1 in L. infantum, an 
immunofluorescence assay was performed with both promastigote and axenic amastigote 
forms (Fig. 4A). Immunostaining revealed a cytosolic localization with a punctate 
morphology. Cell fractionation by digitonin titration was carried out to further check the 
protein localization. Increasing concentrations of digitonin will permeabilise the different 
cellular membranes with the release of the proteins present in each cellular 
compartment37. Release of mitochondrial and cytosolic contents was monitored using a 
mitochondrial (LimTXNPx) and cytosolic (LicTXNPx) tryparedoxin peroxidases, 
respectively. As shown in Fig. 4B, TDR1 was released at very low concentrations of 
digitonin (0.1-0.5 mg digitonin/mg protein) in agreement with a cytosolic localization 
observed by immunofluorescence.  
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Figure 4. Sub-cellular localization of TDR1 in L. infantum promastigotes and axenic 
amastigotes. (A) Early log, late log, stationary phase promastigotes and axenic 
amastigotes were stained by immunofluorescence with mouse anti-TDR1 polyclonal 
antibody. A second antibody Alexa Fluor-488 goat anti-mouse IgG was used to detect the 
immune complex. Parasites were analyzed under a fluorescent microscope (Axioskop-
Carl Zeiss, Germany) at 1000× magnification. (B) Western blot analysis, using anti-TDR1 
polyclonal antibody, of supernatant (S) and pellet (P) fractions resulting from 
promastigotes permeabilisation with increasing concentrations of digitonin. Anti-cTXNPx 
and anti-mTXNPx were used as cytosolic and mitochondrial markers, respectively. 
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Given the fact that TDR1 has high homology with Tc52, an excreted/secreted protein from 
T. cruzi33, we assessed the possibility of L. infantum TDR1 belong to the group of 
excreted/secreted molecules. TDR1 secretion was evaluated by immunoprecipitation of 
[35S] methionine-labelled L. infantum promastigotes and axenic amastigotes antigens after 
pulse chase experiments, using anti-TDR1 antibodies. We found that the protein is 
released by promastigotes and axenic amastigotes into the culture medium at low levels 
(Fig. S2 in supporting information). Moreover, TDR1 was detected in vesicles purified from 
spent medium of L. infantum promastigote cultures, revealing the possible release of the 
protein by an exosome-based mechanism (N. Santarém et al., unpublished data). 
 
3.3. TDR1 immunization leads to an increase in B and CD8-T cell numbers and a 
marked increase in specific IgG1 production 
The effect of TDR1 on the immune response was investigated in Balb/c mice after 
administration of rTDR1. Two weeks after the last immunization, spleen cells were used to 
analyze the humoral and cellular responses. As shown in Fig. 5A, immunization with 
rTDR1 led to a significant increase in the total number of B cells (p=0.006) and CD8-T 
cells (p=0.0009). As a control Balb/c mice were immunized with two other Leishmania 
recombinant proteins, namely tryparedoxin 1 (TXN1) and mTXNPx, which were produced 
following the same procedure used to obtain rTDR1. Both TXN1 and mTXNPx are 
involved in Leishmania hydroperoxide metabolism42 and TXN1 has been reported to up-
regulate IL-10 secretion through activation of B cells43. There were no differences in the 
numbers of CD8-T cell population between mice only injected with PBS and mice 
immunized with rTXN1 or rmTXNPx (Fig. S3 in supporting information), suggesting that 
TDR1 induces specifically CD8-T cells expansion in vivo. Increase in B cell numbers 
induced both by rTDR1 and mTXNPx immunization could be related with polyclonal B cell 
activation reported to occur in response to Leishmania infection, although analysis of 
polyclonal antibodies against for example whale skeletal muscle type II myoglobulin (Myo) 
and native double-stranded DNA (DNA) in the sera of TDR1- or rmTXNPx-immunized 
Balb/c mice did not confirm it as were detected very low levels similar to the ones 
observed in the control animals. In vitro experiments showed no significant increase in 
CD69 surface expression, an early activation marker, by B or T cells in response to 
treatment with rTDR1. The latter suggest that TDR1 may need to be processed and 
presented in vivo to have an effect on the immune response.  
 
In order to examine the in vivo effect of TDR1 on the cytokine production, splenocytes of 
rTDR1-immunized or PBS-injected Balb/c mice were stimulated with rTDR1 or Con A. Cell 
supernatants were collected and production of IFN-γ (Fig. 5B), IL-10 (Fig. 5C), IL-2 and 
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IL-4 (Fig. S4 in supporting information) were measured by ELISA. No significant 
differences were observed in the cytokines production from cells cultured in the presence 
or absence of rTDR1. However, spleen cells from TDR1 immunized mice stimulated with 
Con A showed a significant decrease in the IL-10 production (p=0.0073) when compared 
with cells from PBS-injected mice. This resulted in an increase in the IFN-γ/IL-10 ratio in 
the rTDR1 immunized mice (52) when compared with PBS-injected mice (39). 
Immunization of Balb/c mice with rTXN1 used as control did not induce any significant 
change in IL-10 production by spleen cells stimulated ex-vivo with Con A (data not 
shown).  
 
 
 
Figure 5. Cellular and humoral immune responses induced by immunization with 
rTDR1. Balb/c mice were immunized i.p. with 25 µg of rTDR1 three times with an interval 
of one week between each injection. The control group received PBS injections. Two 
weeks after the last immunization, the mice were sacrificed and spleens recovered. (A) 
Spleen cells were analyzed by flow cytometry to determine the percentage of B cells, 
CD4- and CD8-T cells. The number of each cell subpopulation was calculated based on 
the total viable cells determined by trypan blue exclusion and the percentage of cell bound 
to the specific cell marker (anti-CD4, anti-CD8, anti-µ). Cytokine production was quantified 
in the supernatant of spleen cells cultures by ELISA. Spleen cells (2.5x105) were 
stimulated with rTDR1 protein (10 μg/ml) or Con A (6 μg/ml) for 48 and 72 h for 
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quantification of IL-10 (C) and INF-γ (B) production, respectively. (D) Sera obtained from 
PBS- or TDR1-immunized mice were used to determine the levels of TDR1-specific IgM, 
IgG, IgG1, IgG2a, IgG2b and IgG3 by ELISA. The sera were diluted 1/100 in PBS-1% 
gelatin. The data represent the mean and standard deviations of three animals analyzed 
individually and are representative of three experiments carried out independently. 
Statistically significant differences between TDR1 and PBS groups are indicated ** p<0.01, 
*** p<0.001. 
 
To evaluate the humoral response induced by TDR1 immunization, the levels of TDR1-
specific isotypes in the sera of rTDR1 or PBS immunized mice were determined by 
ELISA. Fig. 5D shows that sera from rTDR1 immunized mice contained elevated levels of 
TDR1-specific IgG, with predominant IgG1 antibody isotype. Previously the IgG2a/IgG1 
ratio has been used as a predictive measure for Th1 and Th2 responses since IgG2a 
levels are dependent on IFN-γ and IgG1 levels correlate with IL-444. Based on the humoral 
response, rTDR1 immunization induced high levels of IgG1 compared with IgG2a 
revealing a tendency toward Th2 response, with a TDR1-specific IgG2a/IgG1 ratio of 0.37. 
 
3.4. Expansion of CD8-T cells and decrease in IL-10 production elicited by rTDR1 
immunization was insufficient to protect Balb/c mice against L. infantum infection 
 
In order to investigate the effect of rTDR1 immunization to elicit protection against 
leishmaniasis, rTDR1 immunized mice were challenged with L. infantum promastigotes. 
The parasite load in the spleen and liver was evaluated by limiting dilution at 2, 5, 7 and 9 
weeks post-infection. Fig. 6A shows that animals immunized with rTDR1 presented a 
lower parasite load in the spleen compared with PBS immunized animals during 
experimental infection, except for 2 weeks after infection. Significant differences were 
observed at 7 (p=0.023) and 9 weeks (p=0.002) post-infection. No significant differences 
were detected in the liver parasite load between the groups used in this study (Fig. 6B). 
An attempt to improve the protection levels induced by rTDR1 immunization using CpG as 
an adjuvant or protein delivery as a DNA vaccine proved unsuccessful (data not shown).  
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Figure 6. Parasite load in the spleen (A) and liver (B) of Balb/c mice immunized with 
rTDR1 after challenge with L. infantum promastigotes. Groups of mice were 
immunized i.p. with 25 µg rTDR1 (TDR1) or with PBS and challenged with 1x108 L. 
infantum promastigotes and groups designated as TDR1 INF (immunized and infected) 
and INF (infected). Limiting dilution analysis was performed 2, 5, 7 and 9 weeks after 
infection on the cells isolated from the spleen and liver of each individual mouse and 
cultured in quadruplicate for 2 weeks at 27º C. The cultures were then assessed 
microscopically for L. infantum viable parasites. The data represent the mean and 
standard deviations of three animals analyzed individually and are representative of three 
experiments carried out independently. Statistically significant differences between TDR1 
INF and INF groups are indicated * p<0.05, ** p<0.01 
 
Analysis of rTDR1-specific IgG isotypes in the sera of rTDR1 immunized mice during the 
course of experimental infection (Fig. 7) revealed the maintenance of high levels of 
specific IgG1 over IgG2a, as observed when analysing the humoral response after 
immunization with rTDR1. Sera from animals receiving PBS were essentially negative for 
TDR1-specific immunoglobulins.  
 
Figure 7. Levels of TDR1-specific antibodies in sera from Balb/c mice immunized 
with rTDR1 and infected with L. infantum promastigotes. (A) Levels of TDR1-specific 
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IgG, IgG1, IgG2a and IgG2b were determined by ELISA during L. infantum infection (2, 5, 
7, and 9 weeks) in sera from Balb/c mice immunized with rTDR1. The sera were diluted 
1/100 in PBS-1% gelatin. (B) Ratio between TDR1-specific IgG2a and IgG1 levels at 2, 5, 
7 and 9 weeks post-infection. The data represent the mean and standard deviations of 
three animals analyzed individually and are representative of three experiments carried 
out independently. 
 
Although rTDR1 immunization was only able to induce a small degree of protection, the 
cellular response of immunized and infected mice was assessed to determine whether the 
protection levels achieved resulted from a cell-mediated process. Production of IFN-γ, IL-
10 and IL-4 was determined by ELISA after ex-vivo stimulation of spleen cells with rTDR1 
or Con A. There was no significant difference in the profiles of IFN-γ and IL-4 production 
between rTDR1 immunized and infected mice and control group during the course of 
Leishmania infection (Fig. 8A and 8C).  
 
 
 
Figure 8. Cytokine production by spleen lymphocytes from Balb/c mice immunized 
with rTDR1 and challenged with L. infantum promastigotes. Spleen cells from Balb/c 
mice immunized with rTDR1 (TDR1) or PBS and challenged with 1x108 L. infantum 
promastigotes (groups designated as TDR1 INF (immunized and infected) and INF 
(infected)), were recovered at 2, 5, 7 and 9 weeks post-infection. Cells were stimulated 
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with 6 µg/ml of Con A for 72 h to determine INF-γ production (A) and for 48 h to determine 
IL-10 (B) and IL-4 (C) production by ELISA. (D) Ratio of INF-γ/IL-10 production by spleen 
cells stimulated with 6 µg/ml of Con A at 2, 5, 7 and 9 post-infection. The data represent 
the mean and standard deviations of three animals analyzed individually and are 
representative of three experiments carried out independently. Statistically significant 
differences between TDR1 INF and INF groups are indicated * p<0.05, ** p<0.01. 
 
In contrast, a significant decrease in the production of IL-10 was observed in the case of 
spleen cells from rTDR1-immunized and infected mice at 7 (p=0.038) and 9 (p=0.0056) 
weeks post-infection upon their ex-vivo stimulation with Con A compared with the controls 
(Fig. 8B). This fact contributes to the increase in the ratio of IFN-γ/IL-10 in the rTDR1 
immunized mice at 7 (30) and 9 weeks (48) post-infection while in the PBS immunized 
mice it remains at comparable levels (15 at 7 weeks and 16 at 9 weeks) during the course 
of infection (Fig. 8D). In Leishmania infection, IL-10 limits the magnitude of the immune 
response by inhibiting APC functions, such as IFN-γ secretion, which are essential for the 
parasite clearance45. Moreover, IL-10 produced by T regulatory cells has been shown to 
play an important role in disease chronicity 46, thus the decrease in IL-10  production may 
contribute to the reduction in the parasite load observed at 7 and 9 weeks post-infection in 
Balb/c immunized with rTDR1 but was not enough to induce high levels of protection. 
 
As reported above, rTDR1 immunization induced an increase of splenic B cells and CD8-
T cells. To investigate if the same occur in the context of Leishmania infection, spleen cell 
populations obtained from immunized mice challenged with L. infantum promastigotes 
were analyzed by flow cytometry. As shown in Table 1, two weeks post-infection spleens 
from mice immunized with rTDR1 show a significant increase in the number of CD8-T 
cells (p=0.003) when compared with the control. This is also observed at 9 weeks after 
infection (p=0.008), confirming the maintenance of an increase in the CD8-T cell 
population even in the context of Leishmania infection.  
 
CD8-T cells upon antigenic stimulation up-regulate the expression of granzymes, perforin, 
IFN-γ secretion and become cytolytic, leading to the death of infected cells47. Thus, we 
tested the cytolytic capacity of spleen cells from mice immunized with rTDR1 or PBS and 
challenged with L. infantum. Spleen cells were stimulated ex-vivo with rTDR1 or 
Leishmania antigens and then put in contact with macrophage infected cells to determine 
the percentage of death induced in the infected population. No differences were observed 
between the control and the immunized mice, therefore the CD8-T cells number increase 
in the mice immunized with TDR1 do not seem to be involved in the death of infected cells 
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by a cytotoxic mechanism (Fig. S5 in supporting information). The maintenance of 
increase numbers of CD8-T cells in mice immunized with rTDR1 even in a chronic phase 
of the disease led us to hypothesize the generation of T cell memory induced by rTDR1 
immunization.  
 
Table 1. Analysis of spleen cell populations from Balb/c mice immunized with 
rTDR1 and challenged with L. infantum promastigotes 
 
  Cell number (x107)  
 
week  
TDR1 
treatment 
CD4 CD8 B 
2 - 1.732 ± 0.063 0.684 ± 0.033 3.392 ± 0.028 
 + 2.327 ± 0.039 1.008 ± 0.043** 3.772 ± 0.114 
5 - 2.397 ± 0.028 1.220 ± 0.055 3.303 ± 0.218 
 + 2.388 ± 0.099 1.267 ± 0.039 3.998 ± 0.316 
7 - 1.920 ± 0.097 0.777 ± 0.101 4.307 ± 0.496 
 + 2.017 ± 0.034 1.146 ± 0.170 4.012 ± 0.106 
9 - 2.944 ± 0.420 0.990 ± 0.060 4.224 ± 0.541 
 + 2.942 ± 0.590   1.422 ± 0.023** 5.287 ± 0.118 
 
The percentage of B cells, CD4- and CD8-T cells were determined by flow cytometry analysis in the spleen of 
Balb/c mice immunized with rTDR1 (TDR1) or with PBS 2, 5, 7 and 9 weeks post-infection The number of 
each cell subpopulation was calculated based on the total viable cells determined by trypan blue exclusion 
and the percentage of cell bound to the specific cell marker (anti-CD4, anti-CD8, anti-µ). The data represent 
the mean and standard deviation of three animals analyzed individually and are representative of three 
experiments carried out independently. Statistically significant differences between TDR1 and PBS groups are 
indicated ** P<0.01. 
 
In order to characterize T cells after immunization and challenge with L. infantum, spleen 
cells were labeled with antibodies that recognized T cell expression markers - allowing the 
distinction of different subsets of memory T cells. CD44, a surface protein required for 
lymphocyte extravasation to inflammatory sites48, and CD62L, a lymph node homing 
receptor49, were used since up-regulation of these markers is a hallmark of memory T 
cells. The combination of surface staining for CD44 and CD62L separates between two 
functionally distinct memory cell subsets, central memory T cells (CD44high and CD62Lhigh) 
and effector memory T cells (CD44high and CD62Llow). The stained splenocytes were 
analyzed by flow cytometry, and only CD8-T or CD4-T cells are shown in the analyses 
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(Fig. 9A). Analysis of spleen cells from TDR1-immunized mice 9 weeks post-infection 
revealed a significant difference in the CD8+ central memory subset with an increase in 
the percentage of CD8+CD44highCD62Lhigh cells (p=0.0085) when compared with 
splenocytes from PBS-immunized mice (Fig. 9B). CD4-T cells did not show any changes 
in the percentage of cells in the central memory subset when comparing the 2 groups 
analyzed (Fig. 9C).  
 
 
Figure 9. Representative three-color FACS contour plots of splenocytes. CD4+ and 
CD8+-gated cells were analyzed for CD44 and CD62L expression and the percentages for 
each subset are shown (A). Percentages of total spleen CD8- (B) and CD4- (C) T cells 
were obtained for CD44highCD62Llow, CD44highCD62Lhigh, CD44lowCD62Lhigh subsets as 
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defined in (A). Spleens from rTDR1- or PBS-immunized Balb/c mice were harvested 9 
weeks post-infection (groups designated as TDR1 INF (immunized and infected) and INF 
(infected)). and splenocytes stained with CD8 or CD4 monoclonal antibodies plus CD44 
and CD62L. Results shown are representative of two experiments carried out 
independently. Statistically significant differences between TDR1 INF and INF groups are 
indicated * p<0.05, ** p<0.01. 
Memory cell phenotype was checked during the course of infection with L. infantum based 
in the expression of high levels of CD62L on CD44highCD8+ and CD62L on CD44highCD4+ 
as shown in Table 2. Spleen cells from TDR1-immunized mice showed a significant 
increase in the percentage of CD62Lhigh on CD44highCD8+ cells (p=0.005), the central 
memory subset, only at 9 weeks post-infection. Altogether, these observations suggest 
that generation of central memory T cells may be induced by TDR1 in the context of 
Leishmania infection, however not in a significant magnitude which could result in higher 
levels of protection against Leishmania infection. 
 
Table 2. Expression of memory markers on splenic CD8+ and CD4+ T cells before 
and after challenge of rTDR1-immunized Balb/c mice with L. infantum 
promastigotes 
  % CD62Lhi 
week treatment CD44hiCD8+ CD44hiCD4+ 
0 PBS 53.61 ± 3.62 47.48 ± 4.09 
 TDR1 49.67 ± 7.75 51.48 ± 0.72 
1 PBS 52.27 ± 7.50 42.39 ± 3.77 
 TDR1 INF 54.83 ± 1.59 44.56 ± 5.75 
7 INF 48.02 ± 3.27 44.09 ± 5.2 
 TDR1 INF 47.33 ± 7.08 45.69 ± 8.0 
9 INF 49.06 ± 3.5 58.89 ± 7.5 
 TDR1 INF      60.27 ± 2.38** 61.22 ± 1.6 
 
The results shown are percentage ± standard deviation of CD62Lhigh on CD44highCD8+ 
and CD62Lhigh on CD44highCD4+ cells. Spleen cell suspensions from each mouse 
harvested before (0) or 1, 7 and 9 weeks post-infection were individually stained with CD8 
or CD4 monoclonal antibodies plus CD44 and CD62L. Groups used were named as 
follow: TDR1-immunized mice before (TDR1) and after infection (TDR1 INF) and PBS-
immunized before (PBS) and after infection (INF). Results shown are representative of 
two experiments carried out independently. Statistically significant differences between 
TDR1 INF and INF groups are indicated ** p<0.01. 
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4. Discussion 
 
Leishmania have efficiently developed measures to survive in the sand fly and also inside 
the mammalian host, where the conditions are hostile. Among the different mechanisms is 
the secretion/excretion or release of molecules important in the initial steps of infection as 
well as in the manipulation of the hosts’ immune responses. The search for parasite 
antigens able to induce a protective immune response in the mammalian host has lead to 
the identification of proteins that may constitute putative vaccine candidates7-10, 13, 14. The 
characterization of proteins involved in the parasite-host interactions has also contributed 
to understanding the biology of the parasite and its metabolic needs inside its hosts. 
 
In this study, we characterized the immune response to a L. infantum recombinant protein 
named Thiol Dependent Reductase 1 (TDR1). The interesting feature of this protein that 
prompted our study was the observation of a high identity between L. major TDR1 and 
Tc5231. Tc52 has been previously demonstrated to be a virulence factor of T. cruzi and 
disruption of one allele of the gene encoding Tc52 resulted in a mutant which gave 
attenuated disease in mice34. We confirmed that TDR1 is highly conserved between 
Leishmania species and that L. infantum TDR1 is highly homologous with TDR1 of L. 
major. This observation was not unexpected as previous studies have shown a highly 
conserved gene content and synteny across the Leishmania genus50. The expression 
profile of TDR1 in L. infantum showed an increase expression in the amastigote stage, 
suggesting a role of TDR1 in adaptation to the mammalian host. Immunostaining analysis 
revealed that TDR1 is cytosolic in both stages of Leishmania parasites. However, we 
detected TDR1 in the spent medium of both promatigote and amastigote cultures and this 
could be relevant to the protein role in the parasite-host interaction. TDR1 protein lacks an 
N-terminal signal sequence that could facilitate secretion but it is known that the parasite 
has alternative pathways of secretion or release of molecules important for a successful 
infection6, 51. Such exosomes may explain the presence of many proteins with known 
intracellular functions in the spent medium of Leishmania cells, a finding reported through 
applying a proteomic analysis52, 53. 
 
Several Leishmania antigens have been used as vaccine candidates, with considerable 
differences in the parasite load reduction obtained. The outcome of leishmaniasis is 
dependent on the type of immune response generated. In visceral leishmaniasis, caused 
by L. infantum or L. donovani species, the Th1/Th2 dichotomy is not as important to the 
outcome of the disease in murine models as it is for L. major infection. Th1 responses are 
suppressed by IL-10 and TGF-β, contrary to what is described in the case of L. major 
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where infection is promoted by the expansion of Th2 cells producing IL-4, IL-10 and IL-
1354. 
In this study, the ability of rTDR1 to induce protection against challenge with L. infantum in 
susceptible Balb/c mice was evaluated. Partial protection in the spleen was observed in 
mice immunized with rTDR1 whereas no difference was detected in the liver parasite load. 
Despite the partial protection obtained with rTDR1 immunization, two significant 
differences should be highlighted: the decrease in IL-10 and increase in CD8-T cell 
population with characteristics of central memory cells observed in a chronic phase of the 
disease. IL-10 decrease after ex-vivo stimulation of spleen cells with Con A was observed 
after immunization with rTDR1 but also in the context of rTDR1 immunization and infection 
with L. infantum. IL-10 is a regulatory cytokine that in visceral leishmaniasis has been 
described as a key factor in immunosupression. This was shown by the enhanced 
resistance to L. donovani infection observed in IL-10 deficient mice55. Increase in IFN-γ/IL-
10 ratio in the context of L. infantum infection has been shown to allow an effective 
clearance of the parasite40. Also, Leishmania chronic infection is associated with 
expansion or accumulation of IL-10 producing regulatory T cells (Tregs). In cutaneous 
leishmaniasis naturally, Tregs modulate the development of effector responses and 
prevent complete elimination of the parasite. Nevertheless, in active cases of human 
visceral leishmaniasis Tregs did not accumulate at the site of infection, being disease 
progression-associated with IL-10 production by splenic CD4+CD25- (Tr1 cells)46. Tr1 cells 
are a second type of regulatory T cells that are generated following exposure to antigen45. 
In the case of TDR1 immunization, the decrease in IL-10 only occurs in a chronic phase of 
the disease and is not accompanied by an IFN-γ increase that could account for 
enhancing the protection levels, since IFN-γ is required for protection against visceral 
leishmaniasis. It is possible to hypothesize that in Balb/c mice immunized with rTDR1 the 
decrease in IL-10 was due to a decrease in Tregs or Tr1 cells accumulation. CD8-T cells 
can be responsible for the suppression of regulatory CD4-T cells detrimental effects. 
Martin and co-workers have shown that CD8-T cells can work as contra-Treg, however 
these CD8-T cells are susceptible to IL-10-induced apoptosis and were unable to keep 
Treg in check 21 days after infection with L. donovani56. Therefore, this last observation 
does not support our data since the IL-10 decrease was observed in a later stage of 
infection. On the other hand, rTDR1 immunization induced an increase in CD8-T cells, to 
which we could attribute the contra-Treg role, however these did not show an increase 
ability to kill infected cells through cytotoxic mechanisms in vitro when compared with 
control cells.  
Although, immunization with rTDR1 did not induce high levels of protection, the decrease 
in parasite load observed in a chronic phase of L. infantum infection after Balb/c can be 
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due to CD8-T cells, in particular to the generation or maintenance of memory T cells. After 
exposure to Leishmania antigens, there is a strong clonal expansion of antigen-specific 
CD8-T cells needed to control the infection and that will determine the magnitude of the 
memory response. However, Leishmania is able to evade the attack from CD8-T cells by 
suppressing their expansion and effector function inducing functional exhaustion and cell 
death. This was confirmed when in vivo B7-H1 blockade during chronic L. donovani 
infection increased survival of dysfunctional CD8-T cell leading to a significant reduction in 
the splenic parasite burden26. The rTDR1 immunization that led to an increase in CD8+ 
central memory T cells 9 weeks post-infection may be due to the ability of TDR1 to induce 
a greater CD8-T cells expansion to generate memory cells or to maintain the memory T 
cell population. This possibility should be further explored by determination of cytokines, 
such as IL-7 and IL-15, which are essential for long term-maintenance of CD8-T cell 
population and also through adoptive transfer of CD8-T cell population into naive recipient 
mice to evaluate the levels of protection induced.  
 
The role of antibodies during Leishmania infection has been controversial, however recent 
work have shown that IgG1 can be detrimental to an infected host contributing to disease 
progression. Mice lacking IgG1 are more resistant to L. mexicana, developing earlier and 
stronger IgG2a and IgG3 responses57. The inability to obtain higher protection levels when 
using rTDR1 immunization in the context of L. infantum infection may be related with the 
high levels of TDR1-specific IgG1 detected in all experiments performed.  
 
In summary, our study with rTDR1 from L. infantum has shown the ability of this antigen to 
induce expansion of CD8-T cells, decrease in IL-10 production, although not enough to 
confer high levels of protection against infection in Balb/c mice. Nevertheless, the 
induction of CD8-T cells with characteristics of central memory T cells highlights the 
importance of these cells in a vaccination strategy against leishmaniasis. 
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Material and Methods 
 
Flow cytometry determinations 
L. infantum promastigotes and axenic amastigotes were washed twice in PBS-BSA and 
permeabilized before incubation for 30 min at 4ºC with mouse anti-LiTDR1 serum. After 
two washes with PBS–BSA, the parasites were incubated for 30 min at 4ºC with Alexa 
Fluor®-488 goat anti-mouse IgG (Molecular Probes). Labelled parasites were washed 
twice and resuspended in PBS–BSA followed by analysis in a FACSCalibur (Becton 
Dickinson). 
 
Immunoprecipitation 
L. infantum promastigotes and axenic amastigotes were incubated in methionine-free 
medium (Sigma) at 27ºC or 37ºC, respectively. After 1h, the parasites were washed twice 
at 2000 x g for 5min and resuspendend in medium containing 6.25µl of 500 µCi [35S] 
methionine (Amersham) per ml. After 1h incubation as above, the parasites were washed 
two times and resuspended in RPMI complete medium or MAA/20 medium. Aliquots of 
1mL were harvested by centrifugation at 3 or 6h, the pellet was subjected to lysis for 1h at 
4ºC and the supernatant incubated for 3 h at 4ºC with serum against TDR1 or pre-immune 
serum. The immunocomplexes were captured by the addition of 100 µl protein G 
sepharose (Sigma), overnight at 4°C. After incubation the protein G sepharose was 
collected by centrifugation, washed, resuspended in 2x SDS sample buffer and incubated 
1h at 56ºC. The beads were collected by centrifugation and supernatant subjected to 
SDS-PAGE analysis. After running, the gel was fixed, dried and exposed to X-ray film for 
2 days at -80ºC. 
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In vitro cytotoxicity assays 
In vitro cytotoxicity assay was performed by flow cytometry using a LIVE/DEAD cell-
mediated cytotoxicity kit (Molecular Probes) according to the manufacturer’s protocol. 
Spleen cells were stimulated with 50µg/ml of soluble Leishmania antigens (SLA) for 7 
days (effector cells); as target cells were used J774 macrophages infected with L. 
infantum. Briefly, effector cells were incubated for 4h with 3,3-
dioctadecylloxacarbocyanine (DIOC18) target cells at different effector/target (E/T) cell 
ratios (5:1, 20:1 and 50:1) in the presence of propidium iodide. Cells were analyzed in a 
FACSCalibur (Becton Dickinson). The percentage of specific lysis was calculated as 
follows: [(dead target cells/all target cells)+ effectors – (dead target cells/all target cells)-effectors] 
x 100. 
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Figure S1. Flow cytometry analysis of TDR1 expression in L. infantum 
promastigotes and axenic amastigotes. L. infantum parasites were incubated with 
mouse anti-TDR1 polyclonal antibody and Alexa Fluor®-488 goat anti-mouse IgG was 
used as secondary antibody (TDR1). Parasites labeled just with secondary antibody were 
used as control (Control). TDR1 labelled parasites: early log phase promastigotes (1), late 
log phase promastigotes (2), stationary phase promastigotes (3) and axenic amastigotes 
(4); Control labelled parasites: early log phase promastigotes (5), late log phase 
promastigotes (6), stationary phase promastigotes (7) and axenic amastigotes (8). The 
results are representative of two experiments carried out independently.  
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Figure S2. Identification of L. infantum TDR1 as an excreted/secreted antigen. L. 
infantum promastigotes (A) or axenic amastigotes (B) were metabolically labelled with 
[35S] methionine for 3h and 6h, respectively. TDR1 protein from parasite lysate (L) or 
supernatant (S) was immunoprecipitated with a specific antibody (T) and the 
immunocomplexes were analyzed by 10% SDS-PAGE, followed by autoradiography of 
the dried gels. A pre-immune serum (P) was used as control. Estimated molecular 
masses and TDR1 protein (arrowed) are indicated on the left and right, respectively. 
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Figure S3. Splenic cell populations in Balb/c mice immunized either with (A) rTXN 
or (B) rmTXNPx. Balb/c mice were immunized i.p. with rTXN1 or rTXNPx three times with 
an interval of one week between each injection. The control group received PBS 
injections. Two weeks after the last immunization, the mice were sacrificed and spleens 
recovered. Spleen cells were analyzed by flow cytometry to determine the percentage of 
B cells, CD4- and CD8-T cells. The number of each cell subpopulation was calculated 
based on the total viable cells determined by trypan blue exclusion and the percentage of 
cell bound to the specific cell marker (anti-CD4, anti-CD8, anti-µ). The data represent the 
mean and standard deviations of three animals analyzed individually. Statistically 
significant differences between TDR1 and PBS groups are indicated * p<0.05. 
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Figure S4. IL-2 and IL-4 cytokine production induced by immunization with rTDR1. 
Balb/c mice were immunized i.p. with 25µg of rTDR1 three times with an interval of one 
week between each injection. The control group received PBS injections. Two weeks after 
the last immunization the mice were sacrificed and spleen recovered. Cytokine production 
was quantified in the supernatant of spleen cells cultures by ELISA. Spleen cells (2.5x105) 
were stimulated with rTDR1 protein (10µg/ml) or ConA (6µg/ml) during 24 and 48h for 
quantification of IL-2 (A) and IL-4 (B) production, respectively. The data represent the 
mean and standard deviations of three animals analyzed individually and are 
representative of three experiments carried out independently. 
  
4. Objectives and Results 
 
114 
 
 
Figure S5. In vitro cytotoxicity of spleen cells from L. infantum rTDR1 immunized 
and infected mice. Lysis of L. infantum-infected J774 macrophages (target cells) by SLA 
stimulated splenocytes (effector cells) isolated from infected (INF) or rTDR1-immunnized 
infected (TDR1 INF) Balb/c mice 9 weeks post-infection with L. infantum.  Effector cells 
were incubated with target cells at different effector/ target cells ratio (E/T) - 5:1, 20:1 and 
50:1. The data represent the mean and standard deviations of three animals analyzed 
individually. 
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DNA vaccine encoding TDR1 do not protect Balb/c mice from infection with 
Leishmania infantum 
 
 
Abstract 
 
Parasitic protozoa, such as Leishmania spp., are responsible for several medically 
important tropical diseases, like visceral leishmaniasis, considered an important health 
problem that affects millions of people worldwide. Due to drug inefficacy and increase 
resistance is urgent to develop new vaccine candidates. DNA vaccination seems to be a 
promising tool and may offer a new alternative for the control of infectious diseases, once 
it is able to induce a complete immune response against the encoded antigen. Previously, 
we have shown that a Leishmania enzyme named Thiol Dependent Reductase 1 (TDR1) 
in the context of infection could induce some protection, through the increase of CD8-T 
cells population and decrease in IL-10 production, despite the high production of specific 
IgG1 that correlates with a Th2 profile. In order to enhance the levels of protection 
induced by TDR1, particularly the cellular response, we have produced a DNA vaccine 
encoding TDR1 protein (pVAX1-TDR1). Intramuscular immunization of Balb/c mice with 
pVAX1-TDR1 was able to induce a high production of specific IgG2a that was maintained 
2, 5 and 9 weeks after infection with L. infantum promastigotes. However, no protection 
was observed in mice immunized with the DNA vaccine. Prime-boost vaccination with the 
recombinant protein led to a lower IgG2a/IgG1 ratio due to an increase in IgG1 specific 
production and didn’t induce protection at 5 and 9 weeks after L. infantum infection, 
lacking as before the induction of a cellular response. Delivery of TDR1 as a DNA vaccine 
did not improve the protection observed after administration of the recombinant protein. 
This highlights the fact that not all DNA vaccines will lead to successful results, due to 
several factors such as the encoding gene, the plasmid backbone and the route of 
delivery necessary to obtain the activation of the immune response and consequent 
protection. 
 
 
 
Unpublished results 
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Introduction 
 
Leishmaniasis is a disease caused by the protozoan parasites of the genus Leishmania. 
More than 20 species of Leishmania are responsible for complex clinical manifestations, 
which range from self-healing cutaneous ulcers to fatal visceral disease (22). The clinical 
outcome depends mainly on the infecting specie: cutaneous leishmaniasis (CL) is caused 
by infection with L. major, L. braziliensis among others whereas visceral leishmaniasis 
(VL) caused by infection with species from the L. donovani complex (8, 34). Leishmaniasis 
remains a major public health problem making part of the neglected tropical diseases (14), 
with 350 million people at risk worldwide and 2 million estimated new cases every year in 
88 countries (22). CL predominates in Latin America, central Asia and north Africa (34) 
while 90% of the world’s VL occurs in India, Bangladesh, Nepal, Sudan and Brazil (8). 
Moreover, leishmaniasis is complicated by human immunodeficiency virus (HIV) co-
infection, which increases the risk of developing active VL by between 100 and 2320 
times (1). There is still no effective vaccine for use in humans against leishmaniasis and 
the drugs available (36) are costly, toxic, limited and increase in drug resistance has been 
reported (11). Currently, a licensed vaccine, named Leishmune, based on fucose-
mannose ligand antigen, present on the surface of the parasite throughout parasite life 
cycle, plus a saponin adjuvant is being used against canine visceral leishmaniasis. This 
vaccine is considered a transmission blocking vaccine since antibodies raised against 
Leishmume are able to block the parasite development in the sand fly rendering the vector 
non-infectious (4, 35). 
 
Studies on antileishmanial vaccine candidates have increased remarkably in the recent 
years, largely due to a better understanding of the mechanisms necessary to induce 
immunity and the availability of Leishmania genome sequences. Several vaccine 
formulations provided partial protection, however there is no fully effective vaccine against 
leishmaniasis. An ideal vaccine should meet several attributes such as safety, low cost, 
be effective against species causing CL and VL, induce CD8-T and CD4-T cell responses 
and long-term immunological memory (23). In addition, an effective vaccine should 
efficiently stimulate dendritic cells (DC) as they play a key role in inducing both humoral 
and cellular responses (47). In the search for a vaccine against leishmaniasis have been 
used different strategies, including killed, live attenuated parasites, recombinant proteins 
or  DNA vaccination among others (reviewed in (29)). 
Live attenuated vaccines are considered a good strategy as the use of parasites that are 
infectious but not pathogenic closely mimics a natural infection (38), which may lead to 
parasite persistence that seems to be important for an effective protective response (21, 
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31). Examples of two successful live attenuated vaccines in murine models are L. 
infantum Sir2-deficient (40) and L. donovani centrin null mutants (37) parasites, protection 
correlated with an increase in the IFN-γ/IL-10 ratio. However, vaccination with genetically 
modified parasites should be used carefully because the attenuated parasites may revert 
back to a virulent form. 
Several Leishmania antigens have been tested as possible vaccine candidates, chosen 
based in the protein expression, localization and involvement in parasite survival. These 
include LACK (27), HASPB1 (41), PSA-2 (18) among many others, administered alone or 
with adjuvants (reviewed in (29)) such as CpG (20, 46) , IL-12 (16, 41) or encapsulated in 
liposomes (2, 3, 28).  Vaccination with recombinant proteins led to a variety of protection 
levels through the induction of a Th1 response involving the generation of specific INF-γ 
producing CD4-T and CD8-T cells. Although necessary for protection the Th1 response 
may not be sufficient to induce protection against Leishmania challenge. Leish-F1+MPL-
SE consists of three recombinant Leishmania proteins (TSA, LmSTI1 and LeIF), together 
with the adjuvant monophosphoryl lipid and squalene in a stable emulsion (MPL-SE) (10). 
Leish-F1+MPL-SE was considered safe and immunogenic against CL when administered 
alone (48) or in conjugation with antimonials in human clinical trials (25, 30). In recent 
study was reported that  LEISH-F1 + MPL-SE vaccine is safe and immunogenic in healthy 
subjects with and without history of previous infection with L. donovani (7). 
 
DNA vaccines are an attractive alternative to conventional methods of vaccination due to 
several features that include the ability to elicit humoral and cellular immune responses, 
which can be modulated by the addition of adjuvants such as cytokines or CpG (28, 39). 
Prime boosting strategies that involve priming with DNA and boosting with the respective 
recombinant protein or other antigen delivery systems  have also been used (12, 26, 33, 
45), since heterologous prime-boost leads to a synergistic enhancement of immunity to 
the target antigen (49). DNA compared to recombinant protein vaccines present some 
advantages, largely due to stability and low cost of production. Moreover DNA vaccines 
may provide better protection as they can induce the expression of Leishmania antigens 
folded in its native conformation and normal posttranslational modifications to occur 
similar to natural infection and potentially with unaltered antigenecity (39). Induction of 
both humoral and cellular immune responses by DNA vaccines is due to the ability of DC 
to present the encoded antigen in the context of MHC class I and MHC class II (known as 
cross-priming) as they can be directly transfected with the plasmid or take up soluble 
proteins and debris from apoptotic transfected cells (47). Moreover has been suggested 
that this form of antigen delivery induces longer lasting immune responses (15). There are 
many reports involving vaccination with DNA encoding Leishmania antigens, some of 
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them tested previously as recombinant proteins, including GP63 (50), LACK (16, 43), 
LmST11 and TSA (6), cysteine proteinases (32), ORFF (44) among others with a wide 
range of success rate (13, 29).  
 
In this study we have evaluated the potential of TDR1 to protect Balb/c mice against 
leishmaniasis when delivered as a DNA vaccine or used in a heterologous prime-boost 
strategy. Previously we have shown that mice immunized with recombinant TDR1 were 
partial protected against infection with L. infantum promastigotes (Silva et al, unpublished 
data). Thus, in order to enhance the protection levels induced by recombinant protein 
against Leishmania infection, Balb/c mice were immunized with a plasmid DNA encoding 
TDR1. Despite, the induction of high levels of specific IgG’s neither DNA vaccination 
alone or combined with the recombinant protein were able to protect Balb/c mice against 
Leishmania infection. 
 
Material and Methods 
 
Leishmania parasites  
Leishmania infantum (clone MHOM/MA/67/ITMAP263) promastigotes were grown at 27ºC 
in RPMI medium (BioWhittaker) supplemented with 10% (v/v) heat inactivated fetal bovine 
serum (FBS, Gibco), 2 mM L-glutamine (Sigma), 20 mM Hepes (Gibco), 100 U/ml 
penicillin and 100 mg/ml streptomycin (BioWhittaker). Cultures were set up initially at a 
concentration of 1 x106 parasites/ml and sub-passaged every 5 days. 
 
Plasmid constructs and DNA preparation 
The L. infantum TDR1 gene was PCR amplified using L. infantum genomic DNA as 
template and the following forward (5’-CGAAGCTTAATATGGCCGCCCGCGCGCT 
AAAGCTATACGTC-3’) and reverse (5’-GATCTAGATTACCCGCTCTGGGCCCTC 
CGTTGACGC-3’) primers containing HindIII and XbaI restriction sites (underlined), 
respectively. Cycling conditions were as follows: 94ºC, 2 min; 30 cycles of 94ºC, 15 sec; 
55ºC, 30 sec; 72ºC, 90 sec and 72ºC, 10 min. The PCR product (1368 bp) was cloned 
into pGEM-Teasy vector (Promega). All the transformants were identified by restriction 
analysis and one of the clones chosen to be confirmed by sequencing (Eurofins MWG 
Operon). The insert was excised by digestion with HindIII-XbaI (New England Biolabs) 
and sub-cloned into pVAX1 vector, resulting the construct pVAX1-TDR1, under the control 
of CMV promoter, inserted downstream of a kozak consensus sequence and in frame with 
an initiation codon. The DH5α E. coli strain was used as a host during cloning 
experiments and to propagate the plasmid. All the transformants were identified by 
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restriction analysis. Plasmid DNA was purified using Endofree Plasmid Megakit (Quiagen) 
according to the commercial protocol. DNA concentration was estimated in a Qubit 
fluorometer with Quant-IT DNA Assay Kit (Invitrogen). 
 
In vitro expression of pVAX1-TDR1 in L929 cells 
L929 cells were transfected with 5 µg of pVAX1-TDR1 or with the empty plasmid (pVAX1) 
using the TransFast Transfection reagent (Promega) according to the manufacturer's 
protocol. Briefly, 2.5 x 105 cells were seeded on 6-well plates in RPMI medium 
(BioWhittaker) supplemented with 10% FBS (Gibco), 2 mM L-glutamine (Sigma) and 20 
mM Hepes (Gibco), the DNA/TransFast reagent mixture added and cells incubated at 
37ºC, 5% CO2. Seventy two hours after transfection the cells were washed with phosphate 
buffered saline (PBS) and fixed in a PBS solution containing 4% paraformaldehyde, for 20 
min at room temperature. After permeabilisation with 0.1% (v/v) Triton X-100 in PBS, cells 
were washed several times with PBS and blocked in PBS containing 1% bovine serum 
albumin (PBS-BSA) for 30 min at room temperature. Incubation with a polyclonal mouse 
anti-TDR1 (1:100 in PBS-BSA) was made in a humid chamber, for 1 h at room 
temperature. After several washes in PBS, cells were incubated with a secondary 
antibody, Alexa Fluor® 488 goat anti-mouse IgG (Molecular Probes) diluted 1:100 in PBS-
BSA. Washed cells were mounted in Vectashield (Vector Laboratories) and analyzed with 
a fluorescent microscope (Axioskop-Carl Zeiss, Germany) at 1000x magnification.  
For detection of TDR1 expression by western blot, seventy two hours after transfection 
L929 cells were harvested, washed two times with ice-cold PBS and lysed by the addition 
of 50 mM Tris/HCl pH 8.0, 0.25% (v/v) Triton X-100, 20% (v/v) glycerol, 2 mM EDTA, 10 
μM E-64, 400 μM 1,10-phenanthroline, 2 μM pepstatin A and 1 mM PMSF. Insoluble 
cellular debris was removed by centrifugation at 12000 x g for 20 min at 4ºC, proteins 
separated by SDS-PAGE (12%) and blotted to nitrocellulose for Western Blot analysis. 
Western blots were probed with a polyclonal mouse anti-TDR1 and goat anti-mouse IgG 
peroxidase-conjugated (Southern Biotech) used as the secondary antibody. Development 
was performed with an ECL detection system (Amersham). 
 
Cloning, expression and purification of recombinant TDR1  
The L. infantum TDR1 was PCR amplified using L. infantum genomic DNA as template 
and the following forward (5’GCCATATGGCCGCCCGCGCGCTAAAGCTATACGT 
G-3’) and reverse (5’-GATCTAGATTACCCGCTCTGGGCCCTCCGTTGACGC-3’) primers 
containing NdeI and XbaI restriction sites (underlined), respectively. Amplification 
conditions were as follows: 94ºC, 2 min; 30 cycles of 94ºC, 15 sec; 55ºC, 30 sec; 72ºC, 90 
sec and 72ºC, 10 min. The PCR product (1349bp) was cloned into pGEM-T Easy vector 
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(Promega). All the transformants were identified by restriction analysis and one of the 
clones chosen to be confirmed by sequencing (Eurofins MWG Operon). The insert was 
excised by digestion with NdeI-XbaI (New England Biolabs) and sub-cloned into the 
Escherichia coli expression vector pET28a+ in frame with an amino-terminal six-histidine 
tag (pET28a+ TDR1). Briefly, 500 ml cultures of recombinant E. coli BL21 (DE3) were 
induced to express TDR1 by the addition of 2 mM of isopropyl β D-thiogalactoside (IPTG), 
overnight at 15ºC. The induced culture was harvested and resuspended in 20 mM 
Tris/500 mM NaCl, pH 7.9 (Buffer A) containing 10 mM imidazole. The cells were lysed by 
sonication and the resulting suspension was centrifuged at 15000 x g for 30 min at 4 °C to 
remove cell debris. The clear supernatant containing soluble protein was applied on to a 
pre-equilibrated nickel-nitrilotriacetic acid (Ni-NTA) column (Qiagen). The column was 
washed with Buffer A containing 60 mM imidazole to remove the non-binding proteins and 
the His-tagged recombinant protein was eluted with Buffer A containing 250 mM of 
imidazole. After purification, the eluted fractions were pooled and buffer-exchanged into 
20 mM Tris, 250 mM NaCl, pH 7.9 using a PD10 desalting column (GE Healthcare) and 
stored at -80ºC. The recombinant protein was designated rTDR1. To eliminate endotoxins, 
the recombinant protein was passed through an EndoTrap®red column (Profos, 
Germany) following manufacturer’s instructions. Polyclonal antiserum against TDR1 was 
generated in mice by intraperitoneal (i.p.) injection of recombinant protein in incomplete 
Freund’s adjuvant. 
 
Immunization of mice and parasite challenge 
Balb/c mice were obtained from Charles River (Spain) and maintained at the animal 
facilities of the Instituto de Biologia Molecular e Celular (IBMC, Porto, Portugal). Mice 
were kept six per cage and allowed food and water ad libitum. 
Balb/c mice (8 or 9 animals/group and in the case of mock control 3 animals/group) were 
immunized with DNA or DNA plus rTDR1 as follow: a) three times intramuscularly (i.m.) at 
2 weeks intervals with 100 µg of pVAX1-TDR1 or pVAX1 (mock control); b) two times 
intramuscularly (i.m.) at 2 weeks intervals with 100 µg of pVAX1-TDR1 or pVAX1; c) two 
times intramuscularly (i.m.) at 2 weeks intervals with 100 µg of pVAX1-TDR1 or pVAX1 
plus 25 µg of rTDR1 2 weeks after the last DNA boost. Two weeks after the last 
immunization, mice were challenged i.p. with 108 L. infantum promastigotes in PBS. Mice 
immunized as described in a) were bled and sacrificed 2 weeks post infection and mice 
immunized as described in b) and c) were bled and sacrificed at 5 and 9 weeks post-
infection; spleen, liver and sera were collected. The spleen from each individual mouse 
was gently dissected to obtain single cell suspensions for cell population and cytokine 
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production analysis. Splenocytes were washed and resuspended in RPMI complete 
medium to a concentration of 107 cells/ml.  
 
Evaluation of parasite burden 
Parasite quantification in the spleen and liver was performed by limiting dilution as 
previously described (5). Briefly, organs were removed, homogenised and resuspended in 
RPMI medium. Two-fold serial dilutions were prepared in flat bottom 96-well microtiter 
plates (Immune Plate Maxisorp; Nunc). After incubation for 15 days at 27ºC, plates were 
examined and the positive (presence of motile parasites) and negative (absence of motile 
parasites) wells were determined using an inverted microscope. The number of parasites 
per gram of organ (parasite load) was calculated as follows: parasite load = [(geometric 
mean of reciprocal titer from each quadruplicate cell culture/weight of homogenized 
organ) x reciprocal fraction of the homogenized organ inoculated into the first well]. 
 
Flow cytometry analysis 
A total of 106 splenocytes resuspended in PBS supplemented with 10% (v/v) FBS were 
distributed into a 96-well microtiter culture plate and washed with PBS-2% FBS. For 
spleen cell population determinations, cells were incubated with saturating concentrations 
of fluorescein isothiocyanate (FITC)-conjugated rat anti-mouse CD8 (Ly-2) monoclonal 
antibody, FITC-conjugated rat anti-mouse CD4 (L3T4) from BD Pharmingen, FITC-
conjugated goat anti-mouse IgM from Southern Biotechnology and phycoerythrin (PE)-
conjugated rat anti-mouse MAC-1. After 30 min incubation on ice, the cells were washed 
three times with PBS-2% FBS and examined in a FACSCalibur (Becton Dickinson) using 
propidium iodide 0.25 μg/ml (BD Pharmingen) for cell death exclusion. 
 
Cytokine ELISAs 
Spleen cells were seeded at a density of 2×105 cells/well in the presence of rTDR1 (10 
µg/ml), concanavalin A (Con A, 6 µg/ml) or medium alone. Plates were incubated for 48 h 
(for detection of IL-10 and IL-4) or 72 h (for detection of INF-γ) at 37ºC in 5% CO2. The 
IFN-γ, IL-12p40 and IL-10 production in supernatants of splenocyte cultures was 
measured by two-site sandwich enzyme-linked immunosorbent assay (ELISA). 
Immunosorbent ninety-six-well flat-bottom microtiter plates (Immune Plate Maxisorp, 
Nunc) were coated overnight at 4º C with unlabeled rat antibodies to the cytokines: IFN-γ 
(R4-6A2 cell line), IL-12p40 (BVD4-1D11 cell line) and IL-10 (JES5-2A5 cell line) in 
carbonate buffer (pH 8.2). The plates were washed with PBS containing 0.1% Tween 20 
(PBS-T) and blocked with PBS–1% BSA (200 µl/well) for 2 h at room temperature. The 
plates were incubated with serial dilutions of each supernatant for 2 h at room 
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temperature. After being washed with PBS-T, the plates were incubated for 1 h at room 
temperature with biotinylated rat antibodies (BD Pharmingen) to the following cytokines: 
IFN-γ (XMG1.2 cell line), IL-12p40 (JES6- 5H4 cell line) and IL-10 (SXC-1 cell line). After 
a subsequent wash with PBS-T, the plates were incubated for 1 h at room temperature 
with streptavidin-peroxidase (Sigma) and developed with o-phenylenediamine (OPD, 
Sigma) in citrate buffer (0.1 M citrate acid and 0.2 M Na2HPO4, pH 5.4) The optical 
densities were recorded at 450 nm. The concentration of specific interleukins was 
determined by comparison with a standard curve generated with different recombinant 
interleukins: rIFN-γ; rIL-12; and rIL10 (R&D Systems). 
 
Detection of specific rTDR1 antibody response 
Serum samples from animals immunized with pVAX1-TDR1 or pVAX1-TDR1 plus rTDR1 
were analyzed by ELISA for TDR1-specific IgG, IgG1 and IgG2a subclasses before each 
immunization or challenge with L. infantum promastigotes and 2, 5, and 9 weeks post-
infection. Ninety-six-well flat-bottom microtiter plates (microtiter immunoplates, Greiner 
Bioscience) were coated with rTDR1 (5 µg/ml) in carbonate buffer (pH 8.5) and incubated 
overnight at 4º C. The plates were washed with PBS-T and blocked with PBS-1% gelatin 
(200 µl/well) for 1 h at room temperature. The plates were incubated with 1/100 dilutions 
of each serum sample in triplicate for 1 h at 37ºC. After being washed with PBS-T, the 
plates were incubated for 30 min at room temperature with peroxidase-labeled goat anti-
mouse immunoglobulin isotypes (anti-IgG, anti-IgG1, anti-IgG2a and anti-IgG2b) and 
developed with OPD (Sigma) in citrate buffer. Reactions were stopped with 3 M HCl and 
the absorbance was measured at 492 nm in an automatic ELISA reader. 
 
Statistical analysis 
Statistical analysis was performed using Student’s T test. A p value smaller than 0.05 
(p<0.05) was considered significant. GraphPad Prism 4 was used for plotting the graphs. 
 
 
Results 
 
Construction of DNA vaccine and transient expression in L929 cells 
 
We have already shown that Leishmania TDR1 recombinant protein is able to induce 
partial protection in Balb/c mice challenged with L. infantum (Silva et al, unpublished 
data). In order to improve the protection levels we tested the administration of TDR1 in a 
DNA format, as an alternative mean of antigen delivery. TDR1 gene was sub-cloned into 
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the eukaryotic expression vector pVAX1 for expression under the control of a strong 
cytomegalovirus (CMV) promoter (Fig. 1). To assess the expression of TDR1 in 
mammalian cells, L929 cells were transiently transfected with pVAX1-TDR1 or with the 
empty vector (pVAX1) as a control and after 72h protein expression was evaluated by 
immunofluorescence (Fig. 2) and western blot (data not shown). Despite a low 
transfection efficacy was possible to detect L929 cells expressing TDR1, which shows that 
the plasmid leads to the correct expression of the protein in mammalian cells.  
 
 
 
Figure 1. DNA vaccine construction. (A) Schematic representation of pVAX1-TDR1 
plasmid. The restriction sites used to sub-clone TDR1 gene into pVAX1 were HindIII and 
XbaI. DNA vaccine transcription unit comprises of a CMV promoter (human 
cytomegalovirus immediate-early promoter), TDR1 gene and a polyadenylation signal 
sequence (BGH pA, bovine growth hormone polyadenylation signal). A bacterial origin of 
replication (pUC ori) and an antibiotic resistance gene (Kan, kanamycin) are also 
incorporated in the vector backbone to allow growth and selection of the plasmid in 
bacteria (15). (B) pVAX1-TDR1 plasmid analysis by double digest with HindIII and XbaI 
The samples were analysed in a 0.8% agarose gel and stained with ethidium bromide: 
1Kb plus DNA ladder (lane 1) and pVAX1-TDR1 plasmid (lane 2). DNA fragment identity 
and size (in kilobase pairs) are indicated on the right and left, respectively.  
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Figure 2. Transient expression of TDR1 gene in L929 cells. 
L929 cells transiently transfected with 5 µg of pVAX1-TDR1 or with empty vector (pVAX1) 
were stained by immunofluorescence with anti-TDR1 polyclonal antibody. A second 
antibody Alexa-Fluor-488 goat anti-mouse IgG was used to detect the immune complex. 
Parasites were analyzed under a fluorescent microscope (Axioskop-Carl Zeiss, Germany) 
at 1000x magnification. 
 
Humoral response induced by DNA vaccination before and after challenge with L. 
infantum promastigotes. 
 
Antigen-specific immune response induced by DNA vaccination was used as a measure 
to monitorize the immunization efficacy, thus humoral responses were examined during 
immunization and after infection. First, we choose to immunize intramuscularly Balb/c 
mice three times with DNA before challenge (Fig. 3A), to evaluate if the third boost was 
necessary to induce a strong immune response, as in previous studies different protocols 
of immunization were used varying also the route of administration and the interval 
between the immunizations. Serum samples to evaluate the response induced by the 1st, 
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2nd and 3rd immunizations with DNA were collected and TDR1-specific IgG, IgG1 and 
IgG2a antibodies levels determined for each animal by ELISA. Fig. 3B-E shows the 
isotype profile obtained during immunization and also 2 weeks after infection. It is 
particular relevant the fact that for some animals after the second immunization was not 
detected the production of TDR1-specific antibodies (Fig. 3B-C) and in the case of animal 
1 that was just detected after infection (Fig. 3D-E). This variability can be linked with the 
route and protocol of administration that can result in low and variable expression of the 
injected gene and influence the vaccination outcome, despite the high amount of DNA 
used to immunize mice. After the 2nd DNA immunization, 3 mice out of 6 showed high 
levels of TDR1-specific antibodies, with a high predominance of IgG2a levels, which 
suggests the induction of a Th1 response normally judged by the IgG2a/IgG1 ratio. 
IgG2a/IgG1 ratio has been used as a predictive measure for Th1 and Th2 responses 
since IgG2a levels are dependent on IFN-γ and IgG1 levels correlate with IL-4 (42). 
Induction of high levels of IgG2a is not unexpected since DNA vaccines have an intrinsic 
adjuvant effect because of the presence of immune stimulatory CpG motifs. Unmethylated 
CpG dinucleotides in bacterial DNA or synthetic oligonucleotides (ODNs) cause B cell 
proliferation and preferentially elicit a Th1 type immune response by stimulating 
production of IL-12 and IFN-γ (17, 24). 
The humoral response induced after the 3rd immunization was similar to the levels 
obtained after the 2nd boost, at least in the animals that already showed high levels of 
antibodies, suggesting that 2 immunizations with DNA should be enough to trigger an 
immune response due to TDR1 production. Accordingly to the humoral response 
observed during immunization in the analysis of further experiments mice were grouped 
into responders (R) and non-responders (NR), NR being mice for which is not detected 
the production of TDR1-specific antibodies. Infection with L. infantum leads to a switch in 
the specific-IgG production, since IgG2a predominance fades out in sera collected from 
mice 2 weeks after infection, while a large increase in the levels of IgG1 specific 
antibodies is detected leading to a decrease in IgG2a/IgG1 to levels near 1(Table 1). 
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Figure 3. Analysis of specific humoral response induced by pVAX1-TDR1 
immunization in Balb/c mice before and after challenge with L. infantum 
promastigotes. (A) pVAX1-TDR1 vaccination scheme. Mice were immunized 3 times 
intramuscularly (i. m.) with 100 µg of pVAX1-TDR1  and control groups with the 100 µg of 
pVAX1 or with the correspondent volume of PBS. Mice were bled 2 weeks after first (B), 
second (C), third (D) immunizations and challenge with 1x108 L. infantum promastigotes 
(E). A serum from each mouse immunized with pVAX1-TDR1 (1-6) was tested individually 
at each time point by ELISA for IgG, IgG1 and IgG2a specific TDR1 antibodies production; 
sera from control groups showed no reactivity (data not shown). 
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Table 1 – Specific IgG2a and IgG1 responses in immunized mice before and after 
challenge 
 IgG2a/IgG1 
 weeks after immunization weeks after infection 
Mice identification 2 4 6 2 
1 0 0 0 2.5 
2 0 3 1.3 0.9 
3 0 0.6 0.6 0.7 
4 5.8 3.7 4.7 1.1 
5 10.7 3.9 2.1 0.9 
6 3 8.2 4.6 1.0 
 
Mice were immunized as described in Material and Methods. IgG2a/IgG1 levels represent 
the ratio of the absorbance at 490nm of specific antibodies for each animal (1-6) 2 weeks 
after the 1st, 2nd, 3rd DNA immunization and after infection with L. infantum promastigotes. 
 
 
DNA vaccination failed to confer protection against L. infantum infection  
 
To test the ability of immunization with a plasmid encoding TDR1 to protect Balb/c mice 
against Leishmania infection, mice were immunized with pVAX1-TDR1 and challenged 
two weeks after the last boost. No differences were detected both in splenic and hepatic 
parasite load between vaccinated animals and control groups (pVAX1 or PBS) (Fig. 4).  
 
 
Figure 4. Parasite load in the spleen and liver of Balb/c mice immunized with 
pVAX1-TDR1 determined 2 weeks after challenge with L. infantum promastigotes. 
Mice were immunized 3 times intramuscularly (i. m.) with 100 µg of pVAX1-TDR1  and 
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control groups with 100 µg of pVAX1 or with the correspondent volume of PBS followed 
by challenge with 1x108 L. infantum promastigotes. Limiting dilution analysis was 
performed 2 weeks after infection on the cells isolated from the spleen and liver of each 
individual mouse and cultured in quadruplicate for 2 weeks at 27º C. The cultures were 
then assessed microscopically for L. infantum viable parasites. 
 
Nevertheless, we have reported before that rTDR1 protein is able to elicit partial 
protection in a chronic stage of Leishmania infection (Silva et al, submitted), thus we have 
assessed the ability of DNA vaccination to induce protection after longer periods of 
infection, 5 and 9 weeks after challenge with L. infantum promastigotes. Prime-boost 
vaccination regimens which includes the immunization with the DNA plasmid and boost 
with the recombinant protein are usually used to improve DNA vaccine immunogenicity, 
as DNA vaccination induces a strong Th1 immune response and thus is attractive as a 
priming strategy (19). In our study, we have performed in parallel the immunization with 
DNA and also the prime-boost vaccination, in which after two immunizations with the DNA 
vaccine, Balb/c mice were boosted with rTDR1 protein (Fig. 5A). However, 5 weeks post-
infection, both vaccination regimens pVAX1-TDR1 (Fig. 5B) or pVAX1-TDR1+rTDR1 
(Fig.5C) failed to protect Balb/c mice against L. infantum infection, as there was no 
differences in splenic and hepatic parasite load between vaccinated and control groups, 
with exception of one animal from the DNA vaccine group (NR) that presents a 
considerable decrease in splenic parasite load and no parasites were detected in the liver.  
 
Analysis of humoral response during immunization and after challenge (Fig. 6) reveals 
that as in the first experiment (Fig. 3) there are animals that do not produce TDR1-specific 
antibodies (Fig. 6A-B, E-F) and two weeks after the first DNA immunization was just 
detected the production of IgG2a specific antibodies, which increase in the second boost 
(Fig. 6B). Again, before infection the IgG2a/IgG1 ratio is higher than 5 weeks after the 
challenge (Fig. 6D), showing that infection with Leishmania leads to a change in the 
immunoglobulins profile, with a large increase in IgG1, thought to be detrimental for the 
infection resolution (9). In the case of animal 11 from the group vaccinated only with 
pVAX1-TDR1 that showed a high level of protection, production of specific antibodies was 
only detected after infection, with IgG2a/IgG1 ratio levels near 1. However, other animals 
considered also as non-responders (animals 8, 9 and 10) even after infection did not 
produce TDR1-specific antibodies. Animals from the prime-boost regimen showed also 
high levels of IgG2a during immunization, sustained after the boost with the recombinant 
protein (Fig. 6F); nevertheless, immunization with rTDR1 led to an increase in IgG1 
production to similar or higher levels than those observed for IgG2a (Fig. 6E). Figs. 6C 
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and 6G show the levels of TDR1-specific antibodies after infection induced by both 
vaccinations regimens. It is noteworthy to mention that one immunization with rTDR1 was 
enough to induce production of specific antibodies, since in animals considered as non-
responders (animals 4, 8, 10 and 12) was only detected the production of specific 
antibodies after rTDR1 immunization and just 1 animal out of 4 presented higher levels of 
IgG2a than IgG1. In fact, we have already reported that immunization of Balb/c mice with 
rTDR1 induces preferentially the production of IgG1 with low levels of IgG2a specific 
antibodies (Silva et al, submitted). 
 
Figure 5. DNA vaccination or prime-boost regimens with pVAX1-TDR1 do not 
protect Balb/c mice against L. infantum at 5 weeks post-infection. (A) DNA (pVAX1-
4. Objectives and Results 
130 
 
TDR1) and prime-boost (pVAX1-TDR1+rTDR1) vaccination schemes. Mice were 
immunized i.m. twice with 100 µg of plasmid DNA followed by challenge with 1x108 L. 
infantum promastigotes or after the second DNA immunization boosted with 25µg of 
rTDR1 and 2 weeks later challenged with L. infantum promastigotes. Mice were grouped 
into non-responders (NR) or responders (R) taking into account the specific-TDR1 
response produced during DNA immunization. Spleen and liver parasite load of 
immunized pVAX1-TDR1 (B) or pVAX1-TDR1+rTDR1 (C) Balb/c mice 5 weeks after 
infection with L. infantum was determined by limiting dilution asssay. Limiting dilution 
analysis was performed on cells isolated from the spleen and liver of each individual 
mouse and cultured in quadruplicate for 2 weeks at 27º C. The cultures were then 
assessed microscopically for L. infantum viable parasites. 
Indeed, a high level of IgG2a specific antibodies per se do not necessarily correlates with 
protection as animals with higher levels of IgG2a/IgG1 ratio than animal 11 were not 
protected. The differences observed could be potentially explained by the cellular immune 
response. Analysis of splenic cell populations (CD8- and CD4-Tcells, B cells and 
macrophages) did not reveal any differences in cell number (Table 2).  
 
Spleen cells from vaccinated animals, either with pVAX1-TDR1 or pVAX1-TDR1+rTDR1, 
included in the responders group, stimulated ex-vivo with rTDR1 produced higher 
amounts of IFN-γ than animals immunized with the empty vector (Fig. 7A-B). IL-10 levels 
were very low or undetectable although, in the case of pVAX1-TDR1 immunization spleen 
cells from the control group when stimulated with rTDR1 produced higher levels of IL-10 
than those from the vaccinated groups (Fig. 7C); no differences were observed in the IL-
10 levels in the groups from the prime-boost regimen, except when cells were stimulated 
with ConA (Fig. 7D) and a similar profile among the different groups was observed in the 
levels of IL-12 with higher production by cells stimulated with rTDR1 than with SLA (Fig. 
7E-F). Analysis of splenic parasite load 9 weeks post challenge with Leishmania, using 
the same immunization strategies described above (Fig. 8A) showed that DNA 
vaccination was not effective in protecting Balb/c mice from infection. Neverthless, DNA 
vaccination strategy seems slightly better that the prime boost regimen (Fig. 8B), although 
it is evident a high variability among the animals in the pVAX1-TDR1(R); there was no 
differences in liver parasite load. The immunoglobulins profile 9 weeks after infection was 
similar to the one observed in the earlier time point of infection analyzed, with IgG2a/IgG1 
ratio around 1 in the prime boost regimen but higher in the DNA vaccination alone (Fig. 9); 
once again were detected animals that did not produce TDR1 antibodies, suggesting 
lower or no protein production at all. Given the fact that the protection was not achieved, 
parameters such as the cytokine production were not determined. 
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Figure 6. DNA vaccine elicits higher levels of IgG2a-specific TDR1 antibodies which 
decrease after rTDR1 immunization or Leishmania infection. Kinetics of specific 
isotype profile of antibody induced by immunization with pVAX1-TDR1 (left panel) or 
pVAX1-TDR1+rTDR1 (right panel)  after first (2 weeks) and second (4 weeks) 
immunizations, rTDR1 boost (6 weeks) and 5 weeks after challenge with L. infantum (9 or 
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11 weeks after first DNA immunization for the DNA vaccination or prime boost regimen, 
respectively). Left panel: animals 4, 5, 6 and 7 were included in pVAX1-TDR1(R) group 
and 8, 9, 10 and 11 in pVAX1-TDR1(NR) group; right panel: animals 5, 6, 7, 9 and 11 
were included in pVAX1-TDR1(R) group and 4, 8, 10 and 12 in pVAX1-TDR1(NR) group. 
The sera from each individually mice collected during vaccination was used to monitorize 
the production of TDR1 specific IgG1 (A,E) and IgG2a (B,F) antibodies and 5 weeks after 
challenge (C, G). Ratio between TDR1-specific IgG2a and IgG1 levels during vaccination 
and 5 weeks post-infection (D, H). 
 
Table 2- Analysis of immunized Balb/c mice spleen cell populations 5 weeks post-
infection with L. infantum promastigotes 
 
Mice were immunized as described in Material and Methods. Five weeks after infection with L. infantum 
promastigotes, spleens from Balb/c mice immunized with pVAX1-TDR1, pVAX1-TDR1 plus rTDR1 or 
pVAX1 were removed and single cell suspensions of each stained with monoclonal antibodies and 
analyzed on a FACScalibur flow cytometer. SD, standard deviation.   
 
 
 Cell number ± SD (x107) 
 CD4 CD8 B MAC 
pVAX1-TDR1     
pVAX1 2.85 ± 0.304 1.03 ± 0.052 5.13 ± 0.358 0.309 ± 0.030 
pVAX1-TDR1(R) 2.56 ± 0.314 1.02 ± 0.156 5.11 ± 0.548 0.328 ± 0.044 
pVAX1-TDR1(NR) 2.28 ± 0.494 1.03 ± 0.250 4.94 ± 0.648 0.266 ± 0.029 
pVAX1-TDR1 + rTDR1     
pVAX1 + rTDR1 2.17 ± 0.150 0.779 ± 0.032 3.71 ± 0.260 0.376 ± 0.022 
pVAX1-TDR1(R) + rTDR1 2.08 ± 0.227 0.809 ± 0.091 4.12 ± 0.247 0.497 ± 0.056 
pVAX1-TDR1(NR) + 
rTDR1 1.88 ± 0.139 0.751 ± 0.011 3.40 ± 0.574 0.372 ± 0.055 
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Figure 7. Cytokine production by spleen cells from Balb/c mice immunized with 
pVAX1-TDR1 (left panel) or pVAX1-TDR1+rTDR1 (right panel) 5 weeks after infection 
with L. infantum. Mice were immunized i.m. twice with 100 µg of plasmid DNA followed 
by challenge with 1x108 L. infantum promastigotes or after the second DNA immunization 
boosted with 25µg of rTDR1 and 2 weeks later challenged with L. infantum promastigotes. 
Five weeks post-infection mice were sacrificed and cells isolated from each individual 
mouse were stimulated with ConA (6µg/ml), rTDR1 (10µg/ml) and soluble Leishmania 
antigens (SLA) (10µg/ml) for quantification of INF-γ (A, B) production during 72 h, and for 
48 h for quantification of IL-10 (C, D) and IL-12p40 (E, F) production. The data represent 
the mean ± SD of triplicate samples of three mice analyzed independently. Statistically 
significant differences between pVAX1-TDR1 or pVAX1-TDR1+rTDR1 and pVAX1 groups 
are * p<0.05, ** p<0.01, *** p<0.001. 
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Figure 8. Parasite load in the spleen and liver of Balb/c mice immunized with 
pVAX1-TDR1 determined 9 weeks after challenge with L. infantum promastigotes. 
(A) DNA (pVAX1-TDR1) and prime-boost (pVAX1-TDR1+rTDR1) vaccination schemes. 
Mice were immunized i.m. twice with 100 µg of pVAX1-TDR1 and control groups with 100 
µg of pVAX1 followed by challenge with 1x108 L. infantum promastigotes. Spleen parasite 
load of immunized pVAX1-TDR1 (B) or pVAX1-TDR1+rTDR1 (C) Balb/c mice 9 weeks 
after infection with L. infantum was determined by limiting dilution asssay.  Mice were 
grouped into non-responders (NR) or responders (R) taking into account the specific-
TDR1 response produced during DNA immunization. Limiting dilution analysis was 
performed on cells isolated from the spleen of each individual mouse and cultured in 
quadruplicate for 2 weeks at 27º C. The cultures were then assessed microscopically for 
L. infantum viable parasites.  
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Figure 9. TDR1 specific immunoglobulin’s profile of Balb/c mice immunized with 
pVAX1-TDR1 or pVAX1-TDR1+rTDR1 9 weeks after infection with L. infantum 
promastigotes. Mice were immunized i.m. twice with 100 µg of pVAX1-TDR1 (A), 100 µg 
of pVAX1-TDR1+rTDR1 (B) or pVAX1 (control group) followed by challenge with 1x108 L. 
infantum promastigotes. Sera from each individually mice (1-3, control group; 4-12, 
vaccinated group (4-7, R and 8-12, NR)) collected 9 weeks after challenge was tested 
individually for IgG, IgG1 and IgG2a specific TDR1 antibodies production. 
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Conclusion 
 
In this study, we have evaluated the ability of a TDR1 based DNA vaccine to elicit 
protection against Leishmania infection. Previously, we have shown that recombinant 
TDR1 is able to induce partial protection. The results presented here clearly show that the 
immunization with a DNA vaccine encoding TDR1 does not confer protection against 
challenge with L. infantum promastigotes, an unexpected outcome since many studies 
using this strategy have proven to be successful (reviewed in (29)). This demonstrates 
that different strategies based on the same antigen leads to different results, although 
DNA vaccines due to its characteristics are generally accepted to give better results. DNA 
vaccination failure may be attributed to other factors rather than the potency of the 
encoded antigen such as number of immunizations, immunization route and low levels of 
DNA uptake and/or in vivo transfection. 
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4.3  Deletion of the TDR1 gene provides evidence of variable ploidy in 
 Leishmania infantum  
 
 
 
The occurrence of aneuploidy in Leishmania has been widely documented as a response 
to attempts to delete essential genes or overcome drug pressure, but naturally occurring 
and variable (‘mosaic’) aneuploidy has been realized only recently. Here we show that the 
TDR1 gene of L. infantum, of which there is just one in the haploid genome, occurs in 
variable copy number suggestive of both diploid and tetraploid cells within the same 
cloned population. Two rounds of transfection were sufficient to generate a null mutant for 
TDR1 but other cloned transfectants required four rounds of transfection to achieve the 
same. This clear demonstration of variation of gene copy number within a cloned line has 
implications for understanding the biology of Leishmania. 
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Abstract 
 
The occurrence of aneuploidy in Leishmania has been widely documented as a response 
to attempts to delete essential genes or overcome drug pressure, but naturally occurring 
and variable (‘mosaic’) aneuploidy has been realized only recently. Here we show that the 
TDR1 gene of L. infantum, of which there is just one in the haploid genome, occurs in 
variable copy number suggestive of both diploid and tetraploid cells within the same 
cloned population. Two rounds of transfection were sufficient to generate a null mutant for 
TDR1 but other cloned transfectants required four rounds of transfection to achieve the 
same. This clear demonstration of variation of gene copy number within a cloned line has 
implications for understanding the biology of Leishmania. 
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Introduction  
 
Leishmaniasis is still one of the world’s most neglected diseases and novel therapies are 
urgently required (WHO, 2010). One avenue in drug discovery is the identification of 
essential genes encoding ‘druggable’ target proteins (Handman, et al., 2008). A 
mechanism for demonstrating gene essentiality is targeted gene replacement, an 
extremely powerful method that allows investigation of the role of a gene and its encoded 
protein by a loss of function strategy (Beverley, 2003). Leishmania have in the past been 
considered to be diploid organisms generally (Cruz & Beverley, 1990), although 
aneuploidy has been known to occur naturally, established examples being chromosome 
1 trisomy (Sunkin, et al., 2000) and chromosome 31 tetrasomy (Akopyants, et al., 2009) in 
L. major, and has frequently arisen during attempts to delete essential genes and been 
interpreted as chromosome reorganization occurring to ensure retention of the gene 
(Cruz, et al., 1993, Mottram, et al., 1996, Ilgoutz, et al., 1999, Dubessay, et al., 2002, 
Martinez-Calvillo, et al., 2005, Vergnes, et al., 2005, Mukherjee, et al., 2009, Murta, et al., 
2009, Romao, et al., 2009). In these cases, additional evidence for gene essentiality can 
be provided through the generation of a ‘conditional’ null mutant in the presence of an 
extrachromosomal (also known as episomal) copy of the gene (Cruz, et al., 1993, 
Mottram, et al., 1996, Ilgoutz, et al., 1999, Vergnes, et al., 2005, Mukherjee, et al., 2009, 
Murta, et al., 2009, Romao, et al., 2009), which is used to prove that under these 
circumstances the endogenous locus can be deleted and so is not refractory to genetic 
manipulation. Recently, however, it was reported that the ploidy of Leishmania was less 
constant with the concept of mosaicism, with cells in a population having different ploidy, 
being postulated (Sterkers, et al., 2010). Moreover, detailed genome analyses using the 
latest technologies have revealed that the ploidy of different lines of Leishmania species 
are not the same, with individual chromosomes being apparently diploid in one line and 
triploid or tetraploid in others (Downing, et al., 2011, Rogers, et al., 2011).  
 
We report here variation in ploidy between cells in a population of L. infantum. The overall 
study aimed to define the precise role of an enzyme called thiol dependent reductase 1 
(TDR1), which is trypanosomatid-specific and first identified in L. major (Denton, et al., 
2004). Our approach was to investigate the function of TDR1 in L. infantum via generation 
of null mutants for the gene encoding it (TDR1). We have been able to generate a null 
mutant with just two rounds of transfection, but also have isolated clones that required 
four rounds of transfection to achieve deletion of all gene alleles. Thus this approach has 
shown that within a cloned line there can be variable ploidy in a gene, even one that is 
144 
 
4. Objectives and Results 
non-essential, but also that the ploidy cannot be super-variable in that gene deletions 
using differing numbers of allele deletions were possible.  
 
 
Materials and methods 
 
Leishmania parasites 
Leishmania infantum promastigotes (clone MHOM/MA/67/ITMAP-263) were grown at 
26ºC in RPMI 1640 (PAA Laboratories) supplemented with 20 mM Hepes, 2 mM L- 
glutamine, 100U mL-1 penicillin, 100 mg mL-1 streptomycin (PAA Laboratories) and 10% 
(v/v) heat inactivated fetal calf serum (FCS, PAA Laboratories). Cultures were set up 
initially at 2.5 x 105 parasite mL-1 and sub-passaged every 6 days. 
 
Transfection constructs 
To generate the constructs for deletion of L. infantum TDR1 by homologous 
recombination, the 3’and 5’ untranslated regions (UTR) of TDR1 were PCR amplified 
using the primers P1 and P2 or P3 and P4, respectively, (Table 1) and L. infantum 
genomic DNA as template, which was isolated from L. infantum promastigotes as 
described previously (Medina-Acosta & Cross, 1993). Each resulting PCR product (1.0Kb) 
was cloned directly at the T/A cloning site of pGEM-T Easy (Promega). The 5’UTR was 
digested with HindIII and SalI and cloned into the corresponding sites of plmcpb-hyg 
(Mottram, et al., 1996), yielding pldtdr1-hyg5’, followed by the 3’UTR ligated to the SmaI 
and BglII sites of pldtdr1-hyg5’ to give pldtdr1-hyg5’3’ (construct 1). The hygromycin 
phosphotransferase resistance gene (HYG) was replaced either with bleomycin (BLE) , 
streptothricin acetyltransferase (SAT), blasticidin deaminase (BLA) resistance genes by 
digestion with SpeI-BamHI and ligation to the SpeI and BamHI sites of pldtdr1-hyg5’3’ 
yielding construct 2, 3 and 4, , respectively. Before transfection, constructs 1-4 were 
linearised with HindIII and BglII restriction enzymes.  
 
For complementation studies, the TDR1 open reading frame (ORF) was cloned into the 
pRIB vector for chromosomal integration (Misslitz, et al., 2000) or into pXG, an episomal 
vector (Ha, et al., 1996). The TDR1 ORF was PCR amplified using P5 and P6 or P7 and 
P8, respectively (Table 1) and L. infantum genomic DNA as template. The resulting PCR 
products were sub-cloned into pGEM-T Easy (Promega) and confirmed by sequencing 
analysis before cloning into ClaI- and AgeI-digested pRIB or BamHI- and SmaI-digested 
pXG. The integration cassette from the pRIB plasmid containing the TDR1 ORF was 
released by digestion with PacI and PmeI before transfection. 
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Table 1 – Primers used in this study 
 
P1 3’UTR TDR1  5’ -CCCGGGAGGCTCGTCGAGGGGATCGACGTG- 3’ 
P2 3’UTR TDR1  5’ -AGATCTGGGGAGGGAGGGAATGTAGTAGTCCTCTGTGCCTGT- 3’ 
P3 5’UTR TDR1  5’ -AAGCTTTGTGCAGCGTTTCTTAGTACCGCTGTGCAGTTTTG- 3’  
P4 5’UTR TDR1  5’ - GTCGACCCTCGACGCCAGGCACGCAGTGGCTTAGTT- 3’  
P5 TDR1  5’ - GATCCATATGGCCGCCCGCGCGCTAAAGCTATAC- 3’ 
P6 TDR1  5’ -CTACCGGTTTACCCGCTCTGGGCCCTCCGTTG- 3’ 
P7 TDR1 5’ -GACCCGGGATGGCCGCCCGCGCGCTAAAGCTATAC- 3’ 
P8 TDR1 5’ -CTGGATCCTTACCCGCTCTGGGCCCTCCGTTG- 3’ 
 
For each oligonucleotide the restriction sites included are underlined; UTR, untranslated region. 
 
Transfection and selection of L. infantum promastigotes 
Late logarithmic phase promastigotes were resuspended at 5 x 107 cells mL-1 in 
nucleofector solution (Amaxa nucleofector kit, Lonza). 100 µl of cell suspension was either 
mixed with 10 µg of linearised or circular DNA or 10 µl of water as control and 
electroporated in a disposable cuvette using an Amaxa electroporation device (Lonza). 
Cells were immediately transferred to RPMI medium supplemented with 20% (v/v) FCS 
and 24 h later the antibiotic required for transfectant selection added as follows: 
hygromycin B (Sigma) at 50 µg mL-1; phleomycin (Jena Bioscience) at 40 µg mL-1; 
nourseothricin (Jena Bioscience) at 50 µg mL-1; neomycin (G418, Sigma) at 50 µg mL-1 
and puromycin (Calbiochem) at 100 µg mL-1. 
 
Southern blot analyses 
To verify the correct integration events, genomic DNA from wild type (WT) and mutant L. 
infantum promastigotes was analyzed by Southern blot. Briefly, 2 µg DNA were digested 
with XhoI, SalI or NotI, electrophoresed through a 0.7% or 0.8% agarose gel and blotted 
onto Hybond-N+ membrane (Amersham Bioscience). The 3´UTR of TDR1 generated from 
genomic DNA by PCR with primers P1 and P2 was labelled with the AlkPhos Direct 
Labelling kit (Amersham Bioscience) and used to probe the blot. After overnight 
hybridization at 55ºC, the blot was washed, drained and developed using CDP-Star 
Detection reagent and Hyperfilm ECL (Amersham Biosciences) according to the 
manufacturer’s instructions. 
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Western blot analyses 
L. infantum promastigotes were lysed by the addition of 0.25 M sucrose, 0.25% (v/v) 
Triton X-100, 10 mM EDTA, 10 μM E-64, 2 mM 1,10-phenanthroline, 4 μM pepstatin A 
and 1 mM PMSF. Insoluble cellular debris was removed by centrifugation at 12000 x g for 
20 min at 4ºC, proteins separated by SDS-PAGE (12%) and blotted to nitrocellulose for 
Western blot analysis. Western blots were probed with polyclonal sheep anti-TDR1 serum 
or, as a loading control, rabbit anti-CS (cysteine synthase) and rabbit anti-sheep or goat 
anti-rabbit secondary antibodies coupled to peroxidase (Pierce) followed by 
chemiluminescence using ECL detection system (Pierce). 
 
 
Results and Discussion  
 
In order to elucidate the role of TDR1 in L. infantum, we attempted to generate null 
mutants for TDR1, a single copy gene, using homologous gene replacement. Most gene 
deletions reported previously with Leishmania species required just two rounds of gene 
replacement, which is consistent with the organism being diploid, although aneuploidy has 
been reported (Sunkin, et al., 2000, Akopyants, et al., 2009). 
 
Southern blot analysis of XhoI-digested genomic DNA of selected clones after the first 
round of transfection confirmed the successful deletion of a first allele of TDR1 and 
integration of the HYG selectable marker (to give TDR1/tdr1). The two hybridizing bands 
detected (1.71 and 4.27 kb) with the 3’UTR TDR1 probe represented, respectively, the 
endogenous TDR1 (WT) gene and the correct integration of the HYG replacement 
cassette (Fig. 1B, lanes 1 and 2). The TDR1/tdr1 clone was then transfected with either 
construct 2 or 3 (Fig. 1A) with the aim of deleting the remaining WT allele.  
 
Deletion of the second and remaining allele of the TDR1 gene was confirmed by Southern 
blot analysis, the hybridizing band of 3.60 kb corresponding to the replacement of the 
remaining WT allele of the gene by the BLE cassette, showing that a null mutant (∆tdr1) 
had been obtained (Fig. 1B, lane 3). Western blot analysis confirmed the deletion of the 
gene by the absence of TDR1 protein expression in ∆tdr1 (Fig. 2A, lane 1). To be able to 
have definitive evidence that any phenotypic differences between the WT parasite and the 
∆tdr1 null mutant were directly related to the gene deletion, ∆tdr1 was complemented 
either with a ribosomal or an episomal Leishmania expression vector containing the TDR1 
ORF. Analysis of both generated lines by western blot showed successful re-expression 
of TDR1 in the null mutant (Fig. 2A). We selected two clones resulting from independent 
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transfections in the case of ∆tdr1[pXGTDR1] (Fig. 2A, lanes 5 and 6) and independent 
selection post-transfection in the case of ∆tdr1::PRRNATDR1 clones (Fig. 2A, lanes 8 and 
9); each have similar levels of TDR1 expression. 
 
 
Figure 1 – Targeted replacement of the TDR1 gene of L. infantum reveals variable 
ploidy (A) Schematic representation of the TDR1 locus and the constructs used to 
replace the gene alleles and to provide episomal expression of TDR1. Expected sizes of 
the XhoI, SalI and NotI fragments revealed by Southern blot analysis are shown. UTR, 
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untranslated region; DHFR, dihydrofolate reductase gene; HYG, hygromycin 
phosphotransferase gene; BLE, bleomycin acetyltransferase gene; SAT, streptothricin 
acetyltransferase gene; BLA, blasticidin deaminase gene; NEO, neomycin 
phosphotransferase gene. (B) Southern blot analysis of genomic DNA digested with XhoI, 
separated on a 0.8% agarose gel and blotted onto a nylon membrane. DNA from the wild 
type L. infantum (WT, lane 1), a single allele replacement clone (TDR1/tdr1, lane 2), the 
TDR1 null mutant (∆tdr1, lane 3) and a double allele replacement clone that still has 
present the WT gene (TDR1/tdr1/tdr1, lane 4). (C) Southern blot analysis of genomic DNA 
digested with NotI and SalI, separated on a 0.7% agarose gel and blotted onto a nylon 
membrane. DNA from the WT (lane 1), WT[pXG TDR1] (to allow the distinction of the 
gene in the episome from the other expected bands, lane 2 ), TDR1/tdr1 (lane 3), a single 
allele replacement clone transfected with episomal construct (TDR1/tdr1[pXG TDR1], lane 
4), clones that resulted from transfection of TDR1/tdr1 [pXG TDR1] with construct 2, in 
which the WT gene is still present (TDR1/tdr1/tdr1 [pXG TDR1], lanes 5, 6 and 7). (D) 
Southern blot analysis of genomic DNA digested with XhoI, separated on a 0.8% agarose 
gel and blotted onto a nylon membrane. DNA from the WT (lane 1), TDR1/tdr1 (lane 2), 
TDR1/tdr1/tdr1 (lane 3); a triple allele replacement clone, that resulted from transfection of 
TDR1/tdr1/tdr1 with construct 2, in which the WT gene is still present (TDR1/tdr1/tdr1/tdr1, 
lanes 4, 5 and 6). (E) Southern blot analysis of genomic DNA digested with XhoI, 
separated on a 0.8% agarose gel and blotted onto a nylon membrane. DNA from the WT 
(lane 1), TDR1/tdr1/tdr1/tdr1 (lane 2) and the ∆tdr1 obtained after 4 rounds of transfection 
(lane 3). Membranes were hybridized with an alkaline phosphatase-labeled DNA probe 
comprising the 3’UTR of the TDR1 gene. The positions of the molecular size markers (kb) 
and identity of the bands are shown on the left and on the right, respectively. The box 
below summarizes which genes are present. TDR1epi refers to the gene present in the 
episomal construct. 
 
Although we were able to generate a TDR1 null mutant as detailed above, we did obtain 
just the one null mutant clone. In this, the TDR1 alleles were replaced by the HYG and 
BLE resistance genes. All of the clones resistant to hygromycin and nourseothricin still 
had the WT gene present in the genome, despite the correct integration of SAT and HYG 
replacement cassettes (Fig. 1B, lane 4). The successful replacement of two alleles of the 
endogenous gene by resistance markers being accompanied by retention of a copy of the 
WT gene has been reported on multiple occasions in attempts to target essential genes in 
Leishmania, the mechanisms involved in retaining the WT gene are uncertain although 
changes in chromosome ploidy, translocation of a chromosomal segment to another 
chromosome, and intrachromosomal tandem duplication have been reported (Cruz, et al., 
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1993, Mottram, et al., 1996, Dumas, et al., 1997, Martinez-Calvillo, et al., 2005, 
Mukherjee, et al., 2011). As we wished to have more than one null mutant clone, and as a 
further approach to obtaining null mutants to cover the possibility that the gene may be 
hard to delete due to its importance, we transfected TDR1/tdr1 with a plasmid carrying 
TDR1 for episomal expression (Fig. 1A, episomal construct) before the second round of 
transfection aimed at endogenous gene replacement using the BLE construct (Fig. 1A, 
construct 2). This strategy has been commonly applied successfully when attempting to 
delete essential genes, with the second allele of the endogenous gene being easily 
deleted after such complementation with an extrachromosomal gene copy (Cruz, et al., 
1993, Mottram, et al., 1996, Ilgoutz, et al., 1999, Vergnes, et al., 2005, Mukherjee, et al., 
2009, Murta, et al., 2009, Romao, et al., 2009). Southern blot analysis of SalI and NotI-
digested genomic DNA of clones subsequently selected resulted in detection of the 
episomal construct itself (8.14 kb) and a new hybridizing band of 3.60 kb, corresponding 
to the integration of the BLE cassette (Fig. 1C, lanes 5, 6 and 7). This confirmed the 
successful replacement of the second endogenous TDR1 allele. However, the selected 
clones still had the WT gene as well as the episomal copy and western blot analysis 
confirmed the overexpression of TDR1 by the episomal plasmid in the generated lines 
(Fig. 2B, lanes 4 and 5). This result was an indication that TDR1 is a potential case of 
aneuploidy and clearly raised the possibility of variable ploidy within the L. infantum 
cloned population. 
 
Occurrence of aneuploidy in Leishmania has frequently been reported, but it has usually 
emerged as described above in response to attempts to knockout essential genes (Cruz, 
et al., 1993, Mottram, et al., 1996, Ilgoutz, et al., 1999, Vergnes, et al., 2005, Mukherjee, 
et al., 2009, Murta, et al., 2009, Romao, et al., 2009) or to drug pressure (Grondin, et al., 
1996, Ubeda, et al., 2008, Leprohon, et al., 2009). However, the fact that we had 
generated a TDR1 null mutant in L. infantum after just two rounds of transfection, albeit 
getting just a single clone, and the findings that TDR1 null mutants of L. major were 
obtained after just two rounds of transfection (J. McGregor and G.H. Coombs, 
unpublished data) whereas the TDR1 gene in L. donovani required three rounds of 
transfection to generate null mutant clones (which are viable although they show a 
phenotype, A.M. Silva, G.D. Westrop, S. Müller, A. Cordeiro-da-Silva and G.H. Coombs, 
submitted), made us consider that TDR1 was unlikely to be essential for L. infantum. The 
recent reports of naturally occurring aneuploidy in Leishmania, especially L. donovani, 
suggested to us that aneuploidy at the TDR1 locus may be a natural genomic feature of 
the L. infantum line used in this study. Moreover, Sterkers and co-workers had recently 
reported that every chromosome was observed in at least two ploidy stages in a 
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population and that chromosome ploidy distribution was variable among clones and 
strains; a phenomenon that they named mosaicism and postulated could might explain 
the genomic plasticity observed in Leishmania (Sterkers, et al., 2010). Thus in order to 
determine whether this was the case in the L. infantum line used in this study, we 
attempted to delete the remaining TDR1 allele(s) in one of the clones obtained after two 
rounds of transfection with constructs 1 and 3 that still had a WT TDR1 allele present. In a 
third round of transfection we found that TDR1 gene replacement by the BLE cassette 
was effected, as clearly shown in hybridization studies with the 3’UTR TDR1 probe, but an 
endogenous TDR1 allele also remained intact as the 1.7 kb genomic XhoI fragment was 
still present in the triple targeted mutants (Fig. 1D, lanes 4, 5 and 6). Western blot analysis 
of the clones generated after three rounds of transfection confirmed the presence of the 
gene by protein expression (Fig. 2B, lanes 7 and 8). This suggested the presence of more 
than three copies of the TDR1 gene.  
 
With the concept that this inability to generate a TDR1 null mutant in L. infantum after 3 
rounds of transfection was due to the presence of a fourth allele of the gene, construct 4, 
containing BLA (Fig. 1A), was used to transfect the clone in which three TDR1 alleles 
have been replaced by HYG, SAT and BLE cassettes (Fig. 1D). Of the multiple clones 
selected and analyzed by PCR, just two were negative for TDR1 and subsequent 
Southern blot analysis of one of these revealed the correct integration of BLA replacement 
cassette and the successful deletion of a fourth and final TDR1 allele (Fig. 1E, lane 3), 
also confirmed by the absence of TDR1 expression (Fig. 2C, lane 3), and so confirmation 
of null mutant status.  
 
Phenotypic analyses of promastigotes of the two ∆tdr1 null mutants, one generated after 
two rounds of transfection and one after four, revealed no substantive differences from the 
WT, confirming that TDR1 is not essential to L. infantum promastigotes (data not shown). 
We have recently shown that TDR1 apparently plays a part in redox regulation through 
glutathionylation/deglutathionylation of key enzymes of L. donovani (A.M. Silva, G.D. 
Westrop, S. Müller, A. Cordeiro-da-Silva and G.H. Coombs, submitted), it remains for 
investigation whether TDR1 plays the same role in L. infantum. All of the data for L. 
infantum, L. donovani and L. major, however, confirm that TDR1 is not essential to 
promastigotes. 
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Figure 2 – TDR1 expression in the cell lines generated after targeted gene 
replacement. Western blot analysis of cell lysate from stationary phase promastigotes of 
(A) ∆tdr1 generated after two rounds of tranfection (lanes 1 and 7), WT (lanes 2 and 4), 
TDR1/tdr1 (lane 3), the episomal add-back (Δtdr1[pXGTDR1], lanes 5 and 6) and the 
ribosomal add-back (∆tdr1::PRRNATDR1, lanes 8 and 9); (B) WT (lane 1), TDR1/tdr1 (lane 
2), TDR1/tdr1[pXGTDR1] (lane 3), TDR1/tdr1/tdr1[pXGTDR1] (lanes 4 and 5), 
TDR1/tdr1/tdr1 (lane 6) and TDR1/tdr1/tdr1/tdr1 (lanes 7 and 8). (C) WT (lane 1), 
TDR1/tdr1/tdr1/tdr1 (lane 2), ∆tdr1 generated after four rounds of transfection (lane 3), the 
episomal add-back (∆tdr1[pXGTDR1], lane 4). Cell extracts were separated using 12% 
SDS-PAGE and immunoblotted with polyclonal sheep anti-TDR1 serum. Anti-serum 
raised in rabbit against cysteine synthase (CS) was used to confirm equivalent protein 
loading; molecular masses are indicated on the left (kDa) and identity of the bands is 
shown on the right. 
 
Thus our results show that we generated TDR1 null mutant parasites from cells with 
different ploidy at the TDR1 locus even though they were in the same L. infantum cloned 
population. This leads us to conclude the TDR1 locus in L. infantum is diploid in at least 
some cells but tetraploid in others. These findings of the existence of supernumerary 
TDR1 allelles in L. infantum and apparent variable ploidy within the same population are 
consistent with the finding of mosaic ploidy in L. major using FISH analysis (Sterkers, et 
al., 2010) and the data arising from the analyses, just reported, of the genome structures 
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of different Leishmania species and lines; the application of new sequence technology 
that allows read depth coverage across all the Leishmania chromosomes revealed ploidy 
variation (Downing, et al., 2011, Rogers, et al., 2011). These recent studies report the 
existence of supernumerary chromosomes in Leishmania, differences in chromosome 
copy number variations between species and strains, and also that the variation is 
chromosome specific with stable disomy, stable tetrasomy or variable ploidy. In addition, 
Rogers and co-workers were able to validate the chromosome copy number through the 
generation of LinJ.36.0640 and LinJ.31.3030 null mutants, genes which reside in disomic 
and tetrasomic chromosomes, respectively (Rogers, et al., 2011). These findings together 
point to chromosome copy number variations as a major source of genomic diversity 
(Downing, et al., 2011, Rogers, et al., 2011). Interestingly, Rogers and co-workers have 
also found chromosomes with “intermediate” read depth, being neither disomic or trisomic 
in L. mexicana, L. braziliensis and L. donovani, potentially due to a mixture of individual 
cells within a population with monosomic, disomic and trisomic chromosomes. This 
situation is similar to the chromosome copy number mosaicism in a population as 
previous described for L. major by (Sterkers, et al., 2010). In these studies, all L. donovani 
lines and L. infantum JPCM5 (MCAN/ES/98/LLM-887), a different line from the one used 
in this study, had chromosome 33, on which TDR1 resides, among the supernumerary 
chromosomes. The data that we have generated with L. donovani 
(MHOM/NP/03/BPK206/0clone10) (A.M. Silva, G.D. Westrop, S. Müller, A. Cordeiro-da-
Silva and G.H. Coombs, submitted) and now with L. infantum in this study provide 
additional evidence for the variability between species and lines, but also, importantly, 
within a population of L. infantum. Our findings are consistent with aneuploidy of TDR1 
being due to variation in chromosome copy number. Although genes can reside on 
extrachromosomal DNA in Leishmania, this seems to occur as a mechanism of 
maintaining essential genes (Mottram, et al., 1996, Genest, et al., 2005), which is clearly 
not the case with TDR1 as we were able to delete it.  
 
The findings in this study reiterate the occurrence of natural genomic plasticity in 
Leishmania species and importantly have shown that there is variation even within a 
cloned population. This includes non-essential genes such as TDR1. Our findings support 
the concept of mosaic aneuploidy as described by Sterkers  et al. (2010), but also show 
that the ploidy cannot be super-variable within cells because in that case gene deletions 
such as we have achieved would not be possible. Clearly Leishmania cope well with 
aneuploidy, and it seems likely that it provides a mechanism to generate the diversity that 
allows the parasite to survive and take advantage of the different host environments. It 
also has implications for many experimental studies on the parasites and, in particular, in 
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deciding upon essentiality of genes and so their suitability for inclusion in drug discovery 
programmes. 
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4.4  Thiol Dependent Reductase 1 of Leishmania is implicated in the 
 regulation of central metabolism via deglutathionylation 
 
 
 
Thiol Dependent Reductase 1 (TDR1) of Leishmania donovani is a parasite-specific 
enzyme with a two domain structure, comprising glutaredoxin and omega-glutathione-S-
transferase motifs, that has thiol transferase and dehydroascorbate reductase activities in 
vitro. In order to provide insight into the role of TDR1 in Leishmania parasites, a TDR1 null 
mutant (Δtdr1) was generated. Three rounds of transfection were required, revealing that 
the gene locus is triploid; providing more evidence that the genome of L. donovani has 
plasticity in terms of ploidy. Leishmania virulence or susceptibility to oxidative/nitrosative 
stress was little affected by TDR1 deletion, although an increased sensitivity to trivalent 
antimony and trivalent arsenite was observed. Analysis of parasite’s metabolome revealed 
few but striking differences between Δtdr1 and the wild type parent line, notably in the 
levels of metabolites related to energy and amino acid metabolism (glycerol-3-phosphate, 
proline, argininosuccinic acid and S-adenosylhomocysteine). This metabolic re-
configuration in Δtdr1 implicates TDR1 in regulation through S-glutathionylation of key 
enzymes, an hypothesis supported by the demonstration that recombinant TDR1 has 
deglutathionylation activity towards protein and peptide substrates. The data also confirm 
that metabolic profiling of gene-deletion mutants is a method that allows detailed 
dissection of a protein’s function.  
 
 
 
Submitted for publication to Free Radical Biology & Medicine
4. Objectives and Results 
160 
 
 
4. Objectives and Results 
161 
 
Thiol Dependent Reductase 1 of Leishmania is Implicated in the Regulation 
of Central Metabolism via Deglutathionylation 
 
 
Ana Marta Silva1,2,3, Gareth D. Westrop1, Sylke Müller4, Anabela Cordeiro-da-Silva2,3 and 
Graham H. Coombs1*  
 
 
1Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 
161 Cathedral Street, Glasgow G4 0RE, UK; E-mails: graham.coombs@strath.ac.uk; 
gareth.westrop@strath.ac.uk; amsilva@ibmc.up.pt 
2Instituto de Biologia Molecular e Celular, Universidade do Porto, Rua do Campo Alegre, 
823, 4150-180 Porto, Portugal; E-mail: cordeiro@ibmc.up.pt 
3Laboratório de Ciências Biológicas, Faculdade de Farmácia da Universidade do Porto, R. 
Aníbal Cunha n.º 164, 4050-047 Porto, Portugal;  
4Wellcome Trust Centre for Molecular Parasitology, Institute of Infection, Immunity and 
Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, 
Glasgow, G12 8TA, UK. E-mail: sylke.muller@glasgow.ac.uk 
 
*Corresponding author: E-mail: graham.coombs@strath.ac.uk ; Tel. +44 141 548 2155; 
Fax +44 141 552 2562                   
 
 
Abbreviations: Grx, glutaredoxin; GSH, glutathione; GST, glutathione-S-transferases; 
GSTO, omega class GST; HEDS, 2-hydroxyethyl disulfide; HPLC, high performance liquid 
chromatography; LC-MS, liquid chromatography mass spectrometry; ˙NO, nitric oxide; 
O2˙−, superoxide radical; ONOO−, peroxynitrite; ORF, open reading frame; PBS, 
phosphate buffered saline; ppm, parts per million; RNS, reactive nitrogen species; ROS, 
reactive oxygen species; SbIII, trivalent antimonial; SbV, pentavalent antimonial; SIN-1, 3-
morpholinosydnonimine.HCL; SD, standard deviation; SDS, sodium dodecyl sulfate; 
SNAP, S-nitroso-N-acetylpenicillamine; SSG, sodium stibogluconate; TDR1, thiol 
dependent reductase 1; Trx, thioredoxin; (T(SH)2), trypanothione; UTR, untranslated 
region. 
 
 
4. Objectives and Results 
162 
 
 Abstract  
 
Thiol Dependent Reductase 1 (TDR1) of Leishmania donovani is a parasite-specific 
enzyme with a two domain structure, comprising glutaredoxin and omega-glutathione-S-
transferase motifs, that has thiol transferase and dehydroascorbate reductase activities in 
vitro. In order to provide insight into the role of TDR1 in Leishmania parasites, a TDR1 null 
mutant (Δtdr1) was generated. Three rounds of transfection were required, revealing that 
the gene locus is triploid; providing more evidence that the genome of L. donovani has 
plasticity in terms of ploidy. Leishmania virulence or susceptibility to oxidative/nitrosative 
stress was little affected by TDR1 deletion, although an increased sensitivity to trivalent 
antimony and trivalent arsenite was observed. Analysis of parasite’s metabolome revealed 
few but striking differences between Δtdr1 and the wild type parent line, notably in the 
levels of metabolites related to energy and amino acid metabolism (glycerol-3-phosphate, 
proline, argininosuccinic acid and S-adenosylhomocysteine). This metabolic re-
configuration in Δtdr1 implicates TDR1 in regulation through S-glutathionylation of key 
enzymes, an hypothesis supported by the demonstration that recombinant TDR1 has 
deglutathionylation activity towards protein and peptide substrates. The data also confirm 
that metabolic profiling of gene-deletion mutants is a method that allows detailed 
dissection of a protein’s function.  
 
Keywords: parasite, Leishmania, promastigote, thiol dependent reductase, glutaredoxin, 
glutathione S-transferase, deglutathionylation, redox regulation. 
 
 
Introduction 
 
Leishmania is a protozoan parasite that encounters a variety of different environments 
during its life cycle involving sand fly and mammalian hosts, living within macrophages in 
the latter. It is thus exposed to a series of variations in temperature and pH, reactive 
oxygen (ROS) and nitrogen species (RNS), and the availability of nutrients and oxygen 
[1]. To survive and multiply Leishmania has evolved multiple strategies, including adopting 
various morphological forms which are also, at least in part, metabolically distinct [2-4] 
and contain a variety of antioxidant proteins [5-8]. Rather little is known on how these 
changes are regulated, although clearly this is of vital importance to the parasite. Thus we 
undertook this study with the aim of determining whether thiol dependent reductase 1 
(TDR1), an unusual trypanosomatid-specific enzyme with similarities to glutaredoxins and 
glutathione S-transferases, has roles both in countering redox stresses and in the 
molecular mechanisms of metabolic regulation in Leishmania. We anticipated that the 
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insights obtained could underpin the development of future improved therapies against 
infections caused by Leishmania. 
 
TDR1, a trypanosomatid-specific enzyme first identified in L. major [9], possesses thiol 
transferase and dehydroascorbate reductase enzymatic activities and is present in both 
promastigotes and amastigotes of Leishmania. The enzyme is functional as a trimer of a 
protein with an intriguing two domain nature, with the N-terminal domain containing a 
CysXXCys (CXXC) motif characteristic of glutaredoxin (Grx) and thioredoxin (Trx), while 
the C-terminal active site is characteristic of omega glutathione-S-transferase (GSTO) [9]. 
TDR1 is able to reduce pentavalent antimonials such as sodium stibogluconate (SSG) to 
a trivalent form in vitro, suggesting that it may play a part in the antileishmanial activity of 
antimonial drugs and could account for the parasite-specificity of these drugs [9]. 
Although, the physiological function of TDR1 is unclear, its very unusual structure 
suggests some specific role.  
 
Glutaredoxins (Grxs), members of the Trx superfamily, are small molecular mass, 
glutathione (GSH)-dependent oxidoreductases that play an important part in a cell’s 
defense against oxidative stress and maintenance of redox homeostasis [10]; most cells 
have a specialized set of glutaredoxin isoforms located in various cellular compartments 
and with distinct roles [11-14]. Grxs can have either one or two active site cysteines - 
being classified as dithiol (with a CXXC motif) and monothiol (CXXS) Grxs, respectively. 
Grxs reduce both low molecular weight and protein disulfides using a dithiol mechanism, 
while the reduction of mixed disulfides and glutathionylated proteins occur by a monothiol 
mechanism [15]. However, all the dithiol Grxs known are also able to catalyze monothiol 
reactions - showing the versatility of these proteins, based on the affinity for the GSH 
moiety [15]. Grxs have been implicated in a wide range of biological processes, including 
the reversible S-glutathionylation of proteins [10]. S-glutathionylation can be promoted by 
oxidative stress and through the protection of sensitive thiols of proteins is a means of 
avoiding irreversible modification of a protein’s function; it may also serve as a storage 
mechanism for GSH, which otherwise would be extruded from the cell [16]. However, S-
glutathionylation also occurs under physiological conditions as a mechanism of regulating 
the activity of proteins [16-18]. It can lead to inhibition or activation of an enzyme’s activity 
and the so-called redox regulation of many proteins is achieved via this post-translational 
modification. Deglutathionylation, removing the GSH moiety from the protein mixed 
disulfide, reverses the change [16]. We hypothesized that TDR1, with its Grx-like domain, 
may be responsible for S-glutathionylation or/and deglutathionylation of enzymes in 
Leishmania and so have an important role in regulating metabolism. Leishmania rely on 
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the trypanothione (T(SH)2)/trypanothione reductase system unique to trypanosomatids 
and lack glutathione reductase and thioredoxin reductase [19], which has prompted the 
suggestion that GSH may have little function in the organism apart from as a precursor of 
trypanothione [19]. Our hypothesis, if correct, would mean that there is indeed at least one 
specific role for GSH per se. 
The C-terminal domain of TDR1 has an active site more similar to that present in GSTO 
[9]. The omega class of GSTs is functionally distinct from the other classes of GST 
despite maintenance of the characteristic GST fold. Human GSTO has very low activity 
with 1-chloro-2,4-dinitrobenzene (CDNB)[20]. This is a good substrate for all other classes 
of GSTs, which are able to catalyze the conjugation of free radicals, metals and other 
electrophilic compounds with GSH and play a major role in the detoxification of many 
reactive metabolites. Human GSTO instead has activities similar to Grxs, with thiol 
transferase activity being the most prominent [20]. TDR1 has similarities to human GSTO 
in its activity profile, although the thioltransferase activity is greater and the glutathione-S-
transferase activity with CDNB is lower [9]. Interestingly, there is a report of a GSTO being 
able to carry out deglutathionylation [21] and also another class of GST (GST-P) having 
glutathionylation activity [22]. Thus our hypothesis incorporates the likelihood that the two 
domains of TDR1 complement each other in providing Grx-like activities for Leishmania, 
but the unique two domain arrangement and trimeric functional protein suggests some 
adaptation specific for functions in the parasite. A protein similar to TDR1 occurs in 
another trypanosomatid, Trypanosoma cruzi. This has an activity profile very similar to 
TDR1, although it has substitutions in the active site in the C-terminal domain [23].  
 
To test our hypothesis on the function of TDR1 in Leishmania, we applied a gene 
knockout strategy that allows analysis of the effect of a deletion of the gene of interest on 
the biology of parasite, including its virulence to its host. As a key part of our analyses of 
the phenotype of the null mutant parasite, we have applied a metabolomics approach to 
dissect the effect of the TDR1 gene deletion at a metabolic level. The study of the 
metabolome is an emerging field, mainly due to the fact that better procedures for 
obtaining reliable high resolution data now are available [24-31]. This technology has 
great potential in highlighting phenotypic differences between lines and so the possibility 
of identifying biomarkers for diagnosis and drug therapy [32]. This current study has 
confirmed the potential of metabolomics technologies in such analyses and has provided 
data that support our hypothesis that TDR1 plays a role in regulating the activity of 
enzymes in Leishmania. This idea has been further supported by our demonstration that 
TDR1 catalyses the deglutathionylation of protein-GSH mixed disulfides in vitro. Thus 
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deglutathionylation involving TDR1 may be an important mechanism of enzyme regulation 
in Leishmania. 
 
 
Material and methods 
 
Leishmania parasites 
Leishmania donovani (MHOM/NP/03/BPK206/0clone10) promastigotes had been cloned 
from an isolate from a visceral leishmaniasis patient sensitive to pentavalent antimonials 
in Nepal, as described by Rijal and co-workers [33]. Promastigotes were grown on 
modified Eagle’s medium (designated HOMEM medium, Invitrogen) supplemented with 
20% (v/v) heat inactivated fetal calf serum (FCS, PAA Laboratories) at 26°C. Cultures 
were set up initially at a density of 2.5 x 105 parasites/ml and sub-passaged every 6 days.  
 
Plasmid constructs for targeted gene replacement 
Genomic DNA was isolated from L. donovani promastigotes as described previously [34]. 
The 5’untranslated region (5’UTR) of LdTDR1 (LdBPK_330260.1) (hereafter designated 
as TDR1) was PCR amplified using the following forward (P1) and reverse (P2) primers 
and L. donovani genomic DNA as template. P1 (5’-AAGCTTTGTGCAGCGTTTCTTAGTA 
CCGCTGTGCAGTTTTG-3’) contains a HindIII restriction site (underlined). P2 (5’-
GTCGACCCTCGACGCCAGGCACGCAGTGGCTTATT-3’) contains a SalI restriction site 
(underlined).The design of the primers was based on the L. infantum genome sequence 
available (http://www.genedb.org). The resulting PCR product (1.0 kb) was cloned directly 
at the T/A cloning site of pGEM-T Easy (Promega). The 5’UTR was digested with HindIII 
and SalI and cloned into the corresponding sites of plmcpb-hyg [35], yielding pldtdr1-
hyg5’. The 3’untranslated region (3’UTR) of TDR1 (1.0 kb) was obtained by the same 
procedure used for the 5’UTR with the following forward (P3) and reverse (P4) primers. 
P3 (5’-CCCGGGAGGCTCGTCGAGGGGATCGACGTG-3’) contains a SmaI restriction 
site (underlined). P4 (5’-AGATCTGGGGAGGGAGGGAATGTAGTAGTCCTCTGTGCCTG 
T-3’) contains a BglII restriction site (underlined). The 3’UTR was excised from pGEM-T 
Easy after digestion with SalI-HindIII and ligated to the SalI and HindIII sites of pldtdr1-
hyg5’ to give pldtdr1-hyg5’3’ (construct 1). The hygromycin phosphotransferase resistance 
gene (HYG) was replaced either with bleomycin (BLE) or streptothricin acetyltransferase 
(SAT) resistance genes by digestion with SpeI-BamHI and ligated to the SpeI and BamHI 
sites of pldtdr1-hyg5’3’ yielding pldtdr1-bleo5’3’ (construct 2) and pldtdr1-sat5’3’ (construct 
3), respectively. The HYG-, BLE- and SAT-containing TDR1 gene replacement cassettes 
were excised from the plasmids by HindIII-BglII digestion prior to transfection. For the re- 
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expression experiments, the TDR1 ORF was cloned into the pRIB vector for chromosomal 
integration into a ribosomal RNA locus, where the gene is expressed under the control of 
the rRNA promoter [36]. In addition, TDR1 was expressed from the episomal vector pXG 
[37]. The TDR1 ORF was PCR-amplified using the primers P5 (5’-
GACCCGGGATGGCCGCCCGCGCGCTAAAGCTATAC-3’) and P6 (5’-CTGGATCCTTAC 
CCGCTCTGGGCCCTCCGTTG-3’) (for the episomal add-back) or the primers P7 (5’-
GATCCATATGGCCGCCCGCGCGCTAAAGCTATAC-3’) and P8 (5’-CTACCGGTTTACC 
CGCTCTGGGCCCTCCGTTG-3’) (for the ribosomal add-back) and L. donovani genomic 
DNA as template (restrictions sites for SmaI, BamHI, ClaI and AgeI, respectively, are 
underlined). The PCR products were cloned into pGEM-T Easy before excising fragments 
for subcloning into expression vectors. The episomal add-back plasmid was constructed 
by cloning the SmaI-BamHII-cut TDR1 ORF into pXG [37] and the ribosomal add-back 
plasmid was obtained by cloning the ClaI-AgeI-cut TDR1 ORF into pRIB [36], yielding 
pXG-TDR1 and pRIB-TDR1, respectively. The integration cassette from pRIB-TDR1 was 
excised by digestion with PacI and PmeI before transfection. All PCR-generated products 
were verified by sequencing (Eurofins MWG Operon) and correct orientation of the cloned 
fragments was checked by restriction enzyme digests. 
 
Transfection and selection of L. donovani promastigotes 
For transfection, late logarithmic phase promastigotes were resuspended at 5 x 107 
cells/ml in nucleofector solution (Amaxa nucleofector kit, Lonza). 100 µl of cell suspension 
was either mixed with 10 µg of DNA or 10 µl of water as control and electroporated in a 
disposable cuvette using an Amaxa electroporation device (Lonza). Cells were 
immediately transferred to HOMEM medium supplemented with 20% (v/v) FCS and 24 h 
later the antibiotic required for transfectant selection added as follows: hygromycin B 
(Sigma) at 50 µg/ml; phleomycin (Jena Bioscience) at 20 µg/ml; nourseothricin (Jena 
Bioscience) at 50 µg/ml; neomycin (G418, Sigma) at 50 µg/ml and puromycin 
(Calbiochem) at 100 µg/ml. The TDR1 null mutant was constructed by sequential removal 
of TDR1 alleles by homologous recombination using the three gene replacement 
cassettes (Fig. 1A). Transfection with construct 1 or 3 was performed as described above 
and recombinants were cloned by serial dilution in 96-well plates in medium containing 50 
µg/ml of hygromycin B or 50 µg/ml of nourseothricin. Genomic DNA isolated from these 
cloned parasites was used in Southern blot analyses to confirm the loss of one allele of 
TDR1 and replacement by the hygromycin phosphotransferase or streptothricin 
acetyltransferase resistance cassettes. One clone with the hygromycin 
phosphotransferase resistance gene was subjected to transfection with construct 2, 
selected with 50 µg/ml of hygromycin B plus 20 µg/ml of phleomycin and checked for the 
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replacement of the second allele by the bleomycin resistance cassette. Construct 3 was 
used to replace the third allele of the TDR1 gene and clones resulting from the third round 
of transfection were selected in 50 µg/ml of hygromycin B, 20 µg/ml of phleomycin and 50 
µg/ml of nourseothricin. The clones (designated ∆tdr1) were analyzed for the complete 
removal of TDR1 by Southern blot analysis. Complementation of one Δtdr1 clone was 
achieved by transfection of parasites either with pXG-TDR1 (episomal add-back) or pRIB-
TDR1 (ribosomal add-back) constructs, selected with 50 µg/ml of G418 or 100 µg/ml of 
puromycin, respectively, and protein expression assessed by western blot analysis. 
 
Southern blot analysis 
To verify the correct integration events, genomic DNA from wild type and mutant L. 
donovani promastigotes was analyzed by Southern blot. Briefly, 2 µg DNA were digested 
with XhoI, electrophoresed through a 0.8% agarose gel and blotted onto Hybond-N+ 
membrane (Amersham Bioscience). The 3´UTR of TDR1 generated from genomic DNA 
by PCR with primers P3 and P4 was labelled with the AlkPhos Direct Labelling kit 
(Amersham Bioscience) and used to probe the blot. After overnight hybridization at 55ºC, 
the blot was washed, drained and developed using CDP-Star Detection reagent and 
Hyperfilm ECL (Amersham Biosciences) according to the manufacturer’s instructions. 
 
Western blot analysis 
L. donovani promastigotes were lysed by the addition of 0.25 M sucrose, 0.25% (v/v) 
Triton X-100, 10 mM EDTA, 10 μM E-64, 2 mM 1,10-phenanthroline, 4 μM pepstatin A 
and 1 mM PMSF. Insoluble cellular debris was removed by centrifugation at 12000 x g for 
20 min at 4ºC, proteins separated by SDS-PAGE (12%) and blotted to nitrocellulose for 
Western blot analysis. Western blots were probed with polyclonal sheep anti-TDR1 serum 
or, as a loading control, rabbit anti-LdCS (L. donovani cysteine synthase) and rabbit anti-
sheep or goat anti-rabbit secondary antibodies coupled to peroxidase (Pierce) followed by 
chemiluminescence using ECL detection system (Pierce). 
 
In vitro promastigote susceptibility assays 
The susceptibility of L. donovani promastigotes to oxidative/nitrosative stress and metals 
was assessed by an Alamar Blue assay, as previously described [38] with slight 
modifications. Briefly, promastigotes were diluted in medium to 2 x 106 parasites/ml and 
100 µl of suspension was incubated with 100 µl of S-Nitroso-N-acetylpenicillamine (SNAP, 
Biomol; up to 2000 µM), hydrogen peroxide (H2O2, Sigma; up to 4000 µM), potassium 
antimonyl tartrate (SbIII, Sigma; up to 1000 µg/ml), sodium arsenite (AsIII, Sigma; up to 5 
mM), cadmium chloride (CdII, Sigma; up to 5 mM), copper sulfate (CuIV, Fisher Scientific; 
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up to 5 mM) or 3-morpholinosydnonimine.HCL (SIN-1, Biomol; up to 20 mM), dispensed  
in quadriplicate into 96-well flat-bottom plates at 26°C, and incubated for 72 h (or, with 
SIN-1, 1 h). After incubation, 20 µl of sterile resazurin solution (0.0125% resazurin salt 
(Sigma) in phosphate buffered saline) was added to each well and plates were further 
incubated for 18 h. The fluorescence was then measured using 550 nm excitation and 595 
nm emission wavelengths. IC50 values were determined using GraFit 5 data analysis 
software (Erithacus Software). 
 
Intracellular thiol measurement by HPLC 
The quantification of thiols was carried out as previously described [39] using an HPLC 
method involving the conversion of thiols to fluorescent derivatives by reaction with 
monobromobimane, a fluorescent dye. 
 
In vitro macrophage infections 
Peritoneal macrophages obtained from BALB/c mice were cultured in RPMI medium with 
20% (v/v) FCS at 2 x 104 cells/well in 24-well plates. After overnight incubation at 37ºC 
with 5% CO2, non-adherent cells were removed and macrophages were incubated with 
stationary phase L. donovani promastigotes at a parasite/macrophage ratio of 5:1. After 2 
h of infection, non-internalized parasites were washed off, replaced with fresh RPMI 
medium with 20% (v/v) FCS and incubated at 37ºC with 5% CO2 for up to 3 days. Cells 
were fixed with 100% methanol, stained with Giemsa stain (VWR BDH Prolabo) and the 
parasite infections of the macrophages were assessed at 0, 24 and 72 h post-infection. 
Sensitivity of the intracellular parasites to sodium stibogluconate (SSG) was determined 
using peritoneal macrophages infected with L. donovani promastigotes using a 
promastigote/macrophage ratio of 10:1 (to maximize infection rates). After 24 h of 
incubation at 37ºC with 5% CO2, non-internalized parasites were washed off and the 
medium replaced with fresh RPMI medium with 20% (v/v) FCS containing varying 
concentrations of SSG: 0, 9.5, 19, 38, 75 and 150 µg/ml. After 3 days of incubation at 
37ºC with 5% CO2, cells were fixed with 100% methanol, stained with Giemsa stain and 
the percentage of infected macrophages was determined. Results were normalized, 
taking as 100% the infection rate in the absence of SSG treatment. All assays were 
performed in triplicate for each time point or condition tested. 
 
In vivo infections and assessment of parasite load 
Age-matched female BALB/c mice in-house bred at University of Strathclyde and 
commercially obtained Golden Syrian hamsters (Mesocricetusauratus; Harlan 
Laboratories, U.K.) were used in this study. All animal procedures were undertaken in 
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adherence to experimental guidelines and procedures approved by The Home Office of 
the UK government. All work was covered by Home Office Project Licence PPL60/3929 
entitled ‘Mechanism of control of parasite infection’. All animal protocols received ethical 
approval from the University of Strathclyde Ethics Committee. 
 
BALB/c mice (3 animals per group) were infected by intravenous injection (tail vein) with 2 
x 107 L. donovani promastigotes in 200 µl of PBS. Two and six weeks post-infection, 
spleen and liver were removed and each organ was gently homogenised and 
resuspended in RPMI medium to obtain single cell suspensions for parasite load 
assessment. Golden Syrian hamsters were infected by intravenous injection (tongue vein) 
with 2 x 107 L. donovani promastigotes in 200 µl of PBS and sacrificed 3 months later. The 
spleen from each individual hamster was gently homogenized and resuspended in RPMI 
medium to obtain single cell suspensions for parasite load assessment.  
 
Quantification of the parasite load in the spleens and livers was performed by limiting 
dilution as previously described [40]. Two-fold serial dilutions of the parasite suspensions 
were prepared in flat-bottomed 96-well microtiter plates. After incubation for 15 days at 
26ºC, plates were examined and the positive (presence of motile parasites) and negative 
(absence of motile parasites) wells were determined using an inverted microscope. The 
number of parasites per gram of organ (parasite load) was calculated as follows: parasite 
load = [(geometric mean of reciprocal titer from each quadruplicate cell culture/weight of 
homogenized organ) x reciprocal fraction of the homogenized organ inoculated into the 
first well]. 
 
Leishmania extracts for metabolite analysis  
L. donovani promastigote cultures were initiated at 2.5 x 105 cells/ml in four replicate 10 ml 
cultures in order to obtain cell samples from four independently growing cultures 
(biological replicates). Promastigotes from each culture were harvested at days 5 and 6 
for protein estimation (for normalizing the metabolite data) and metabolite extraction. The 
metabolite extraction was performed as previously described [28]. Briefly, promastigotes 
quenching was performed in a dry ice/ethanol bath with rapid temperature decrease to 
2ºC and then immediate transfer to ice. Two aliquots of 4 x 107 cells were taken from each 
culture flask (technical replicates). After centrifugation at 12000 g for 10 min at 4ºC, the 
supernatant (designated the spent medium) was removed and stored on ice. Cell pellets 
were washed three times in 1 ml of PBS at 4ºC by centrifugation at 12000 g for 10 min at 
4ºC. For cell disruption and metabolite extraction, cell pellets were resuspended in 200 µl 
cold chloroform/methanol/water (20/60/20, v/v/v) and incubated 1 h in a 
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Thermomixer(1400 rpm, 4ºC). After centrifugation at 12000 g for 10 min at 4ºC, the 
supernatant containing the extracted metabolites was recovered and stored at -70ºC until 
analysed. To 75 µl of spent medium was added 300 µl of cold chloroform/methanol 
(20/60, v/v) followed by incubation for 1 h on ice. After centrifugation at 12000 g for 10 min 
at 4ºC, the supernatant was recovered and stored at -70ºC until analysed. 
 
Liquid chromatography mass spectrometry (LC-MS) analysis and data processing 
LC-MS analysis and data processing was carried out generally as described by t’Kindt 
and co-workers [28, 29] also applying subsequently improved analysis software [41]. 
Provisional identification of metabolites was carried out using a mass accuracy difference 
of up to 2 ppm (parts per million) and taking into account retention times. The identity of 
metabolites of interest was confirmed by co-elution with pure standards. The standards 
used to confirm identities of metabolites in this study are listed in Table S1. Intensity level 
ratios were used to compare the different cell lines, with the following criteria being 
applied for differences to be considered of interest and potentially due to TDR1 gene 
deletion: (i) there was at least a 2-fold difference between the WT and Δtdr1; (ii) there was 
at least a 2-fold difference between the Δtdr1 and the episomal add-back line; (iii) there 
was a statistically significant difference (p<0.01) between the cell lines being compared. 
The data are expressed as intensity per 25 μg cell protein. 
 
Recombinant protein expression and purification 
The L. donovani TDR1 (LdTDR1) and the L. infantum dithiol glutaredoxin (LiGRX1) genes 
were amplified from genomic DNA by PCR and cloned into the vector pET15b (Novagen) 
which was modified to incorporate a tobacco etch virus protease site in place of the 
thrombin site in the N-terminal His-Tag [42]. Forward (5’-GCCATATGGCCGCCCGCGCG 
CTAAAGCTATACGTG-3’) and reverse primers (5’-CTGGATCCTTACCCGCTCTGGGCC 
CTCCGTTG-3’) containing NdeI and BamHI restriction sites (underlined), respectively, 
were used to clone LdTDR1 and primers (5’-GCCATATGCTCTCCAGCCGTTTTCTCTAT 
CG-3’ and 5’-ATCCTCGAGTTACGCAAGCTTCGCAGCCAG-3’) containing NdeI and XhoI 
restriction sites (underlined) were used to clone LiGRX1. Nucleotide sequencing 
confirmed that the LdTDR1 is identical to the L. infantum TDR1 (LinJ.33.0260), making 
suitable the comparison between LdTDR1 and LiGRX1 recombinant proteins. The 
LiGRX1 (LinJ.27.0670) is homologous to the T. brucei GRX1 (Tb11.47.0012) 
characterized previously by Ceylan and co-workers [11]. Both LdTDR1 and LiGRX1 were 
expressed in E. coli strain BL21/DE3 for 16 h at 15ºC, following induction with 1 mM 
isopropyl-β-D-thiogalactopyranoside. The recombinant proteins (hereafter designated 
TDR1 and GRX1) from 250 ml cultures were purified to more than 90% homogeneity 
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using nickel nitrilotriacetate (Ni-NTA) agarose (QIAGEN) columns. Cells were harvested 
by centrifugation and resuspended in 5 ml of buffer A (50 mM sodium phosphate buffer, 
300 mM NaCl, pH 8.0) containing 10 mM imidazole. Cell lysates were prepared by 
sonication and cleared by centrifugation at 13,000 x g for 30 minutes at 4ºC. The soluble 
fraction was applied to a 1 ml Ni-NTA column equilibrated with buffer A containing 10 mM 
imidazole. After washing with 10 ml of buffer A containing 20 mM imidazole, the N-
terminally His-tagged protein was eluted with 250 mM imidazole in buffer A. Fractions 
containing TDR1 were pooled and buffer exchanged against 25 mM Tris HCl pH 8.0 
containing 250 mM NaCl using a PD-10 column (GE Healthcare) and stored at -80oC, 
whereas GRX1 fractions were stored at 4ºC without further treatment for up to 1 month. 
20 mg of TDR1 and 7 mg of GRX1 were obtained from 250 ml cultures. 
  
Assays for determining deglutathionylation activity 
Deglutathionylation activities of LdTDR1 and LiGRX1 were measured using 
glutathionylated bovine serum albumin (BSA-SG) and a synthetic glutathionylated peptide 
(Peptide-SG) as substrates.  
 
To prepare BSA-SG, the BSA (Sigma) was reduced, denatured and then glutathionylated 
by incubation with GSH in the presence of an oxidizing agent  as previously described by 
Cheng et al.[43]. Briefly, BSA (10 mg/ml) in 50 mM Tris-HCl, 200 mM NaCl, pH 7.5 
containing 0.1 % (v/v) SDS and 5 mM DTT was heated for 2 min at 100ºC; the SDS and 
DTT were removed using a PD-10 column (GE Healthcare) equilibrated with 50 mM Tris-
HCl, 200 mM NaCl, pH 7.5. The reduced and denatured BSA was then mixed with 1 mM 
GSH and 100 mM H2O2 and incubated for 15 min at 30oC before passing through a PD-10 
column as described above. The protein concentration was determined by measuring the 
absorbance at 280 nm and the total thiol content was quantified using a 5,5’-dithiobis 2-
nitrobenzoic acid assay [44]. The reduced and denatured BSA typically contained 7 
cysteine thiols per molecule whereas only 0.4 thiols were detected after oxidation. This 
shows that the BSA-SG contains a maximum of 7 or 8 glutathionylated cysteine residues 
per molecule but other types of cysteine oxidation are also possible including disulfide 
bond formation. Reduction or deglutathionylation of the BSA-SG was assayed in 200 µl of 
50 mM Tris-HCL, 5 mM EDTA, pH 7.0 containing 200 µM NADPH, 2 U/ml glutathione 
reductase (GR), 1 mM GSH and 120 nM TDR1 or 1.7 µM GRX1. The assay mixture was 
pre-incubated for 5 min at 30ºC before starting the reaction by addition of 30 µM of BSA-
SG. Deglutathionylation activity was quantified by measuring the decrease in absorbance 
at 340 nm due to NADPH oxidation. Specific activities were expressed as µmol/min/mg 
protein and represent the means ± standard deviation of three independent experiments. 
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A peptide with a sequence SQLWCLSN with a GSH residue linked to the cysteine residue 
by a disulfide bond, as used previously in deglutathionylation assays [45, 46], was 
obtained from Peptide Protein Research Ltd. The glutathionylated peptide (Peptide-SG) 
was used to quantify deglutathionylation in a coupled assay with GR as described by 
Bonilla et al. [46]. The assay was carried out in 200 µl of 50 mM Tris-HCl, pH 7.0 
containing 5 mM EDTA, 200 µM NADPH, 2 U/ml GR, 250 µM GSH and 100 nM TDR1 or 
50 nM GRX1. The assay components were incubated for 5 min at 30ºC before starting the 
reaction by addition of Peptide-SG to a final concentration of 100 µM. Deglutathionylation 
activity was quantified by measuring the decrease in absorbance at 340 nm due to 
NADPH oxidation. The Km of TDR1 for Peptide-SG was determined with a fixed 
concentration of GSH (250µM) and 50-600 µM Peptide-SG. The Km of GRX1 was 
determined with 250 µM GSH and 2.5-200 µM Peptide-SG. 
 
Statistical analyses 
Statistical analysis was performed using Student’s T test: a p value smaller than 0.05 
(p<0.05) was considered significant; SPSS Statistics software (IBM) was used to perform 
principal component analysis; GraphPad Prism 4 was used for plotting the graphs and 
VisuMap software (VisuMap Technologies Inc.) was used to visualize the data as 
heatmaps. 
 
 
Results 
 
Generation of mutants lacking TDR1  
To investigate the role of TDR1 in L. donovani, we created a null mutant (designated 
∆tdr1) by homologous gene replacement. Targeted gene replacement is a powerful 
method that has enabled the deletion of many Leishmania genes after two rounds of 
knockout as most Leishmania species are predominantly diploid [47], although recent 
findings have revealed quite extensive aneuploidy especially in L. donovani [48, 49]. Fig. 
1A shows the constructs used to replace the TDR1 alleles in L. donovani by the 
hygromycin phosphotransferase (HYG), bleomycin acetyltransferase (BLE) or 
streptothricin acetyltransferase (SAT) genes flanked at the 5’ and 3’ ends with the 5’ and 
3’ UTRs of the TDR1 gene. After two rounds of transfection, two alleles of the TDR1 gene 
had been replaced by the selection constructs. However, Southern blot analysis, using the 
3’ UTR of TDR1 as the probe, showed that the wild type (WT) gene was still present in the 
genome of these parasite clones (Fig. 1B, lane 3) - which were thus designated 
TDR1/tdr1/tdr1. Several attempts to obtain a null mutant after two rounds of transfection 
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were made, but in all cases they resulted in the generation of parasites in which the WT 
gene remained. TDR1 null mutants of L. major had been obtained after just two rounds of 
transfection, showing that the gene is not essential for this related species (J.C. McGregor 
and G.H. Coombs, unpublished results). We reasoned, therefore, that, as L. major and L. 
donovani are relatively closely related, TDR1 is unlikely to be essential for L. donovani. 
Thus, we hypothesized that the impossibility of deleting the TDR1 gene from L. donovani 
after two rounds of transfection was due to triploidy of the TDR1 gene. After a third round 
of transfection using the SAT construct, we obtained parasites able to grow in the 
presence of all three of the selection drugs and Southern blot analysis confirmed the 
deletion of a third copy of the TDR1 gene (Fig. 1B, lane 4) and so the generation of a null 
mutant (∆tdr1).  
Loss of TDR1 expression in ∆tdr1 was confirmed by western blot analysis using anti-
TDR1 antibody (Fig. 1C, lane 3). To aid in the identification of phenotypic differences 
between the WT parasite and the ∆tdr1 null mutant that directly related to loss of the 
gene, the null mutant was complemented either with an episomal or a ribosomal 
Leishmania expression vector containing TDR1 and these complemented (add-back) lines 
were termed ∆tdr1[pXGTDR1] and ∆tdr1::PRRNATDR1, respectively. Analysis of both lines 
by western blot showed successful re-expression of TDR1 in the null mutant (Fig. 1C, 
lanes 4 and 5). These findings on the generation of the TDR1 null mutant of L. donovani 
provide strong evidence that this isolate of L. donovani is triploid at the TDR1 locus. 
Deletion of TDR1 did not affect the growth of promastigotes in vitro, as the growth rates of 
the WT parasites and the various mutants generated were all similar (Fig. 1D). Thus 
TDR1 is not essential for viability of L. donovani promastigotes. 
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Figure 1. Targeted replacement of the TDR1 gene of L. donovani. (A) Schematic 
representation of the TDR1 locus and the constructs used to replace the gene copies. 
Expected sizes of the XhoI fragments revealed by Southern blot analysis are shown. UTR, 
untranslated region; DHFR, dihydrofolate reductase gene; HYG, hygromycin 
phosphotransferase gene; BLE, bleomycin acetyltransferase gene; SAT, streptothricin 
acetyltransferase gene. (B) Southern blot analysis of genomic DNA digested with XhoI, 
separated on a 0.8% agarose gel and blotted onto a nylon membrane. The membrane 
was hybridized with an alkaline phosphatase-labeled DNA probe comprising the 3’UTR of 
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the TDR1 gene. DNA was from the wild type L. donovani (WT, lane 1), a single allele 
replacement clone (TDR1/TDR1/tdr1, lane 2; a clone with the SAT replacement is shown 
to clarify the genes in ∆tdr1, lane 4), a two allele replacement clone (TDR1/tdr1/tdr1, lane 
3) and the TDR1 null mutant (∆tdr1, lane 4); the positions of the molecular size markers 
(kb) and identity of the bands are shown on the left and on the right, respectively. The box 
below summarizes which genes are present. (C) Western blot analysis of cell lysate from 
stationary phase promastigotes of WT (lane 1), TDR1/tdr1/tdr1 (lane 2), ∆tdr1 (lane 3), 
ribosomal add-back line (∆tdr1::PRRNATDR1, lane 4) and episomal add-back line 
(∆tdr1[pXG TDR1], lane 5). Cell extracts were separated using 12% SDS-PAGE and 
immunoblotted with polyclonal sheep anti-TDR1 serum. Anti-serum raised in rabbit 
against cysteine synthase (CS) was used to confirm equivalent protein loading; molecular 
masses are indicated on the left (kDa) and identity of the bands is shown on the right. (D) 
The effect of TDR1 disruption on the in vitro growth as promastigotes of L. donovani WT, 
TDR1/tdr1/tdr1, ∆tdr1, ∆tdr1::PRRNATDR1 and ∆tdr1[pXG TDR1]. Cultures were seeded at 
2.5 x 105 parasites/ml and counted daily. Log base 10-transformed cell density is shown. 
Δtdr1[pXG TDR1] were grown in the presence of  50 µg/ml G418. 
 
Deletion of TDR1 renders L. donovani promastigotes more sensitive to trivalent 
arsenite and trivalent antimony but not reactive oxygen and nitrogen species 
Leishmania parasites are exposed to a variety of reactive oxygen and nitrogen species 
(ROS and RNS) - from their own metabolism and from the oxidative burst generated 
during phagocytosis by their host macrophage that includes superoxide (O2˙−), H2O2, 
hydroxyl radical (˙OH), nitric oxide (˙NO) and peroxynitrite (ONOO−) (reviewed in [8]). 
Leishmania rely on an antioxidant defense system mainly based on trypanothione [19], 
which is able to suppress macrophage responses [50]. To investigate whether TDR1 may 
also play a role in protection against oxidative and nitrosative stress, we used H2O2, SNAP 
and SIN-1 as reagents that induce stress of a different nature and potentially mimic those 
to which Leishmania is naturally exposed. SNAP releases ˙NO under physiological 
conditions while SIN-1 induces mixed oxidative/nitrosative stress by the generation of both 
O2˙− and ˙NO that spontaneously form ONOO−. Promastigotes were exposed to different 
concentrations of H2O2, SNAP or SIN-1 and their viability assessed by an Alamar Blue 
assay. The data generated (Table 1) show all of the lines were similarly susceptible to the 
oxidative/nitrosative stresses induced.  
 
 
 
4. Objectives and Results 
176 
 
Table 1. Susceptibility of L. donovani promastigotes to oxidative/nitrosative 
stresses 
 
IC50 ± SD (µM) 
Parasite line H2O2 SNAP SIN-1 
WT 477 ± 62 68 ± 12 871± 182 
TDR1/tdr1/tdr1 468 ± 76 41 ± 4 878 ± 183 
∆tdr1 446 ± 42 46 ± 13 904 ± 170 
∆tdr1::PRRNATDR1 482 ± 110 47 ± 9 899 ± 154 
∆tdr1[pXG TDR1] 601 ± 73 42 ± 7 837 ± 137 
 
IC50 represents the concentration of hydrogen peroxide (H202), S-Nitroso-N-acetylpenicillamine (SNAP) or 3-
morpholinosydnonimine.HCl (SIN-1) that inhibited by 50% the growth of the wild type (WT), TDR1 null mutant 
(∆tdr1), ribosomal add-back (∆tdr1::PRRNATDR1) and episomal add-back (∆tdr1[pXG TDR1]) lines. Each value 
is a mean ± standard deviation (SD) of three independent experiments. GraFit 5 software was used to 
calculate the IC50 values. 
 
The susceptibility of the L. donovani promastigotes to metal compounds that can have a 
direct effect through the induction of DNA damage, GSH depletion, and binding to protein 
sulphydryl groups or an indirect one by the generation of ROS and RNS [51] was also 
tested (Table 2). Statistically significant differences were observed between the 
susceptibility of WT parasites and ∆tdr1 to SbIII or AsIII, but not to CdII or CuIV. It is 
noteworthy that the episomal add-back returned the susceptibility to WT levels, whereas the 
ribosomal add-back line was similarly susceptible as ∆tdr1 itself. 
 
The activity of TDR1 involves the use of glutathione as a reducing agent [9] and so it 
appeared possible that the greater susceptibility of the null mutant to metal compounds 
could reflect an interference with the mechanisms for thiol homeostasis. In order to 
evaluate the effect of TDR1 deletion on the parasite’s thiol pool, GSH, T[SH]2 and cysteine 
levels were measured by HPLC for WT, Δtdr1 and Δtdr1[pXGTDR1] promastigotes from 
different days of growth in vitro. No significant differences between lines were observed 
on any of days 4-6 of growth (data not shown).  
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Table 2. TDR1 null mutants display increased susceptibility to trivalent antimony 
and trivalent arsenite 
 
 
IC50 ± SD (µg/ml) 
Parasite line SbIII AsIII CdII CuIV 
WT 70 ± 8 234 ± 15 239 ± 37 194 ± 41 
TDR1/tdr1/tdr1 79 ± 7 198 ± 22 218 ± 24 153 ± 20 
∆tdr1    37 ± 9** 169 ± 5* 161 ± 54 121 ± 3 
∆tdr1::PRRNATDR1  45 ± 7* 136 ± 75 140 ± 50 120 ± 24 
∆tdr1[pXG TDR1]  77 ± 14 366 ± 78 228 ± 12 154 ± 26 
 
IC50 represents the concentration of potassium antimonyl tartrate (SbIII), sodium arsenite (AsIII), cadmium 
chloride (CdII) or copper sulfate (CuIV) that inhibited by 50% the growth of the wild type (WT), TDR1 null 
mutant (∆tdr1), ribosomal add-back (∆tdr1::PRRNATDR1) and episomal add-back (∆tdr1[pXG TDR1]) lines. 
Each value is a mean ± standard deviation (SD) of three independent experiments. GraFit 5 software was 
used to calculate the IC50 values. Statistically significant differences between WT and ∆tdr1 or WT and 
∆tdr1::PRRNATDR1 lines  are indicated: * p<0.05, ** p<0.01. 
 
TDR1 deletion does not affect virulence to macrophages in vitro and to mice  
Stationary phase promastigotes of the different cell lines were assessed for their ability to 
infect and survive in peritoneal macrophages in vitro. The extent of macrophage infection 
was determined at 0, 24 and 72 h post exposure to promastigotes (Fig. 2A). There was a 
decrease in the number of macrophages infected by the null mutant by 72 h, although this 
was not statistically significant when compared with the WT (p = 0.064), and there was no 
difference in the number of parasites per infected macrophage (data not shown).  
 
The ability of promastigotes of the various lines to cause infection in BALB/c mice and in 
hamsters was investigated. All infected, and no differences were observed for the parasite 
loads in the spleen and liver between the WT and null mutant parasites in either host 
(data not shown). 
 
TDR1 does not seem to be involved in susceptibility to pentavalent antimonials 
Pentavalent antimonials (SbV) are pro-drugs that need to be reduced to trivalent 
antimonials (SbIII) in order to be toxic to Leishmania. TDR1 is able to reduce SbV to SbIII in 
vitro [9] and therefore it was postulated to have a role in susceptibility of the parasites to 
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SbV. The reduction of SbV could, however, also work in favor of the parasite, as the SbIII 
form of the drug is readily extruded from the cell when conjugated with thiols [52]. Thus 
TDR1 could potentially have a role in drug susceptibility or drug resistance. In order to 
investigate whether TDR1 plays a part in determining the susceptibility of Leishmania to 
SbV, the relative susceptibility of the WT, ∆tdr1 and the episomal add-back line in 
macrophages to SbV was analysed (Fig. 2B). No statistically significant differences 
between the ∆tdr1 and WT lines were observed. Interestingly, the add-back line appeared 
slightly less susceptible to SbV, although there was no statistically significant difference 
compared with WT. 
 
 
Figure 2. Infectivity to macrophages in vitro of L. donovani Δtdr1 promastigotes 
and susceptibility to sodium stibogluconate. (A) L. donovani WT, Δtdr1 and 
Δtdr1[pXGTDR1] stationary phase promastigotes were used to infect peritoneal 
macrophages at a ratio of 5:1. After 2 h of infection, non-internalized parasites were 
washed off, replaced with fresh medium and incubated at 37ºC. Macrophage infection 
was determined at 0, 24 and 72 h post-infection. Each value is a mean ± standard 
deviation from three replicates and is representative of two independent experiments. (B) 
Stationary phase promastigotes were used to infect peritoneal macrophages at a ratio of 
10:1 and incubated for 24 h. Non-internalized parasites were then washed off and 
replaced with fresh medium containing varying concentrations of sodium stibogluconate 
(SSG): 0, 9.5, 19, 38, 75 and 150 µg/ml. After 3 days of incubation, the percentage of 
infected macrophages was determined and the results normalized - taking as 100% the 
number of infected macrophages in the cultures not treated with SSG. Each value is a 
mean ± standard deviation from three replicates. Statistically significant differences 
between Δtdr1 and Δtdr1[pXG TDR1] groups are indicated: * p<0.05. 
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Analyses of the effect of TDR1 deletion on the parasite’s metabolome 
To obtain insights into the role of TDR1 in the metabolism of L. donovani, we adopted a 
global metabolomics approach to identify differences between the metabolomes of WT 
and ∆tdr1 promastigotes. We applied stringent conditions in experimental design, in 
selecting metabolite differences and confirming the identity of metabolites of interest (see 
methods section), including the requirement that differences between WT and Δtdr1 
needed to be complemented in an add-back line.  
 
As a means of ensuring that observed phenotypic changes between WT and Δtdr1 are the 
result of the gene deletion alone, we generated two add-back cell lines with the re-
expression of TDR1 being from different loci (as described in the methods). Presence of 
the appropriate protein as analysed by western blot is usually taken as successful 
complementation of gene deletion, although the literature indicates that full 
complementation of phenotypic differences is not always observed [53-56]. In this study, 
we compared the metabolic profile of each add-back cell line with the metabolomes of the 
WT and Δtdr1 lines to analyse the effectiveness of the two methods of complementation 
to recover the WT metabolome phenotype. The ribosomal add-back (Δtdr1::PRRNATDR1) 
did not result in reversion of metabolites to levels observed in the WT line as shown in Fig. 
3. Principal component analysis (PCA) is an unsupervised clustering technique that allows 
the reduction of the data into two dimensions (principal component 1 and principal 
component 2), which capture and enable visualization of data variability [57]. The PCA 
analysis shows that replicates samples from Δtdr1::PRRNATDR1 and Δtdr1 cluster closely 
together, indicating a very similar metabolic profile, but removed from the WT which 
clearly demonstrates the separation between these two mutant cell lines and the WT line. 
In contrast, the episomal add-back (Δtdr1[pXGTDR1]) did result in recovery to the WT 
levels for most metabolites (being very similar with respect to principal component 1 which 
accounts for 57.1% of total variance), with there only being variation in the second 
principal component which accounts for just 17.3% of the total variance. Thus surprisingly, 
as expression of TDR1 was similar in both add-backs as determined by western blot 
analysis (Fig. 1C), the ribosomal add-back did not recover any of the metabolite levels 
that differed by 2-fold between Δtdr1 and WT promastigotes, whereas the episomal add-
back was effective in all except 18% of the metabolites (Table S2). The ribosomal add-
back, as an integrative construct, is generally expected to lead to stable and consistent 
expression of the protein and so be more reliable than complementation using episomal 
expression, but our data show unambiguously that this is not the case with our mutant 
lines. Given these results, we only used the episomal add-back line in the remainder of 
the analyses (as indicated in the datasets themselves). 
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Figure 3. Episomal complementation of ∆tdr1 is more effective than with an 
integrative construct. Principal component analysis of all metabolites identified by LC-
MS in cell extracts from L. donovani WT, Δtdr1, Δtdr1::PRRNATDR1 and Δtdr1[pXG TDR1] 
promastigotes on day 5 of growth in vitro. Principal component 1 and principal component 
2 explain 57.1% and 17.3% of the total variance, respectively.  
 
In order to obtain meaningful data, it is important to have an indication of the relative 
intracellular concentrations of metabolites in the different lines. Thus it is necessary to 
take into account changes in cell size that occur during the life cycle of Leishmania (such 
as between different forms of promastigotes that occur in the in vitro cultures – procyclic 
promastigotes and metacyclic promastigotes) and also any changes induced by the 
genetic manipulations. A simple approximate correlate of cell size is protein content and 
we have shown in a previous study that a significant decrease in protein content occurs as 
L. donovani WT promastigotes progress into stationary phase [4]; this correlates with 
metacyclogenesis being initiated in late log phase and resulting in the metacyclic 
promastigotes that  are characterized by a smaller body size [58]. To ensure that 
differences in the sizes of WT and Δtdr1 would not have an impact in the metabolome 
analysis and comparison, we checked for differences in protein content between these 
cell lines after 5 and 6 days in culture. As expected and observed previously [4] there was 
a decrease in protein content between the two time points, however there were no 
significant differences between the protein content of the WT and Δtdr1 promastigotes. To 
enable comparison of the metabolomes of promastigotes on days 5 and 6 of in vitro 
culture, we have expressed the data on metabolite levels per cell protein (rather than cell 
number), as we have reported previously [4]. 
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In order to obtain an extensive metabolic profile of each cell line, promastigote cultures of 
L. donovani WT, Δtdr1 and Δtdr1[pXGTDR1] were set up and harvested at 5 days, which 
corresponds to the transition between logarithmic and stationary phases of growth, and at 
stationary phase (6 days) when the number of mammal-infective metacyclic 
promastigotes are high. The experiments were performed based on four biological 
replicates per cell line to obtain representative data; also during the cell processing from 
each culture two samples (designated technical replicates) were taken to control for 
variation due to technical factors. Analysis of the data for identification of metabolites was 
carried out using a mass accuracy difference of up to 2 part per million (ppm). The initial 
identification of the metabolites was carried out based on the database of metabolites 
detailed by t’Kindt and co-workers [28, 29]. After manual verification of the metabolites 
initially identified by the software using LeishCyc database [59], we had a total of 363 and 
378 putative metabolites for the day 5 and day 6 samples, respectively. The main 
comparison between WT and ∆tdr1 cell extracts was performed based on the ratio of the 
signal intensity for each metabolite identified with the LeishCyc database. The intensities 
of the majority of metabolites identified were unaffected by TDR1 gene deletion, with only 
about 10% of metabolites differing at least by 2-fold between the WT and ∆tdr1 (Fig. 4). 
The putative compounds identified belong to a wide range of metabolic pathways, with 
lipids and amino acids and their derivatives being those identified in highest numbers (Fig. 
5). A general overview of the metabolites within central metabolic pathways that were 
putatively detected is shown in Fig. S1. The full list of putatively identified metabolites at 
days 5 and 6 are detailed in Tables S3 and S4 of Supplementary Material. A comparative 
analysis of the levels of the metabolites identified in WT, ∆tdr1 and ∆tdr1[pXGTDR1] 
promastigotes on days 5 and 6 of in vitro growth is shown in Fig. 5. This highlights that 
there were more differences between ∆tdr1 and WT promastigotes on day 5 as some of 
the most prominent differences observed between the extracts on day 5 were not present 
by day 6. It is noteworthy that, in agreement with the PCA data (Fig. 3), there was a very 
good complementation of the metabolite levels  by the episomal add-back, as verified by 
the values obtained for the ratio (WT/Δtdr1[pXGTDR1]) being between 0.5 and 2 for 
almost all putatively identified metabolites (Tables S3 and S4).  
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Figure 4. TDR1 deletion leads to few changes at a metabolic level. Differences 
detected between the levels of intracellular metabolites in L. donovani WT and Δtdr1 on 
days 5 (A) and 6 (B). Following a logarithmic transformation (base 2) the average signal 
intensity ratios of ∆tdr1/WT for all identified metabolites are plotted. The dotted lines 
represent the fold-change cut-off used in this study for a given metabolite profile being 
considered to be different between WT and Δtdr1: log2 (metabolite intensity ratio) below -1 
or above 1 indicates a 2-fold difference between the cell lines compared. The metabolites 
differing in intensity by at least 2-fold between WT and ∆tdr1 on days 5 and 6 represented 
10.4% and 10.5%, respectively, of all metabolites identified. 
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Figure 5. Comparative levels of all intracellular metabolites identified in L. donovani 
WT, ∆tdr1 and ∆tdr1[pXGTDR1] promastigotes. The heatmap was generated using log 
base 2-transformed fold-changes determined by the average signal intensity ratios of 
∆tdr1/WT (A), ∆tdr1/∆tdr1[pXG TDR1] (B) and WT/∆tdr1[pXG TDR1] (C) for all 
metabolites detected. Metabolites are ordered by compound category shown on the left 
and log values of measurements are color coded as indicated in the scale on the right of 
the heatmap, from green to red. 
 
The criteria that we have used in this study to define whether detected differences in 
intensity levels of a metabolite between the cells lines is of interest are that both ratios 
Δtdr1/WT and Δtdr1/Δtdr1[pXGTDR1] show greater than 2-fold differences and that these 
are statistical significant (p<0.01); thus we have concentrated on the metabolite changes 
for which recovery by the episomal add-back was achieved. Moreover, we have only 
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included in the following analysis metabolites whose identity has been confirmed by using 
standards. Metabolites identified in the data for days 5 and 6 of growth that fulfilled these 
conditions are shown in Fig. 6. Proline, 2-ketoisocaproate, indolelactate, deoxycytidine, 
argininosuccinic acid and CDP-choline were significantly different on both days. Some 
metabolites differed only on one day: histidine, glycerol-3-phosphate and S-
adenosylhomocysteine are metabolites for which the fold change between the Δtdr1 
mutant and WT became lower than 2 on day 6, whilst mevalonate is not shown on day 5 
because the ratio Δtdr1/Δtdr1[pXGTDR1] is lower than 2 - thus that recovery by the 
episomal add-back was not to the level required for inclusion. The identity of metabolites 
in Fig. 6 was confirmed by co-elution with standards. Some metabolites fulfilling the 
criteria of being >2-fold and significantly different between the WT and Δtdr1 were 
excluded from Fig. 6 as we have been unable to confirm their putative identification by co-
elution with standards. These include proline betaine, 10-pentadecenal, valerylglycine, 8-
amino-7-oxo-nonanoic acid, and 4alpha,14alpha-dimethyl-24-methylene-cholest-7,(11)-
dien-3beta-ol.  
 
We also investigated the metabolite changes in the culture medium, as metabolite uptake 
and release are part of the overall metabolic events occurring. Just a few metabolite levels 
differed significantly between the spent media for WT and ∆tdr1 parasites after 6 days of 
growth in vitro (Fig. 7 and Table S5). Only a few met the criteria applied for being 
meaningfully different between the ∆tdr1 and WT lines (Fig. 7C). Interestingly, the 
extracellular proline levels were decreased with ∆tdr1 compared with the WT, as were the 
intracellular levels (Fig. 6). Also, 2-ketoisocaproate levels were increased in the null 
mutant spent medium relatively to the WT spent medium; the concentrations also 
increased intracellularly. The other significant differences (aspartic acid and glutamic acid) 
were not mirrored by intracellular changes that fulfilled our criteria for inclusion as being 
significant.  
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Figure 6. Intracellular metabolites at different levels in L. donovani WT and ∆tdr1 
promastigotes. L. donovani WT, ∆tdr1 and ∆tdr1[pXG TDR1] were harvested after 5 and 
6 days of growth in vitro and cell extracts analyzed by LC-MS. Following a logarithmic 
transformation (base 2), the average signal intensity ratios of ∆tdr1/WT, ∆tdr1/∆tdr1[pXG 
TDR1] and WT/∆tdr1[pXG TDR1] for metabolites at interestingly different levels identified 
on day 5 (A) and day 6 (B) were plotted. Dotted lines represent the adopted cut-off for 
significant changes in a given metabolite profile: log2 (metabolite intensity ratio) below -1 
or above 1 indicates a 2-fold difference between the cell lines compared. All metabolites 
shown were statistically significant different between ∆tdr1 and WT or ∆tdr1[pXG TDR1] 
and their identities were confirmed by co-elution with the respective standard. The 
metabolites are ordered according to mass.  
 
 
 
 
 
4. Objectives and Results 
186 
 
 
 
Figure 7. Changes in extracellular metabolite profile due to TDR1 gene deletion. (A) 
Differences detected between the levels of all metabolites identified in the spent culture 
media of L. donovani WT and Δtdr1 promastigotes on day 6 of growth in vitro. Following a 
logarithmic transformation (base 2), the average signal intensity ratios of ∆tdr1/WT for all 
metabolites was plotted. The metabolites differing at least by 2-fold between the WT and 
∆tdr1 on day 6 represented 9.3% of the all of the metabolites identified. (B) Comparison of 
levels of all extracellular metabolites detected in the spent media of L.donovani WT, ∆tdr1 
and ∆tdr1[pXG TDR1] promastigotes on day 6 of growth in vitro. The heatmap was 
generated using log base 2-transformed average signal intensity ratios of ∆tdr1/WT (a), 
∆tdr1/∆tdr1[pXG TDR1] (b) and WT/∆tdr1[pXG TDR1] (c) for all metabolites identified 
using 2 ppm cut-off. Metabolites are ordered by compound category shown on the left and 
log values of measurements are color-coded as indicated in the scale on the right of the 
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heatmap, from green to red. (C) Metabolites identified at significant different levels in the 
spent media of WT and ∆tdr1 on day 6. Following a logarithmic transformation (base 2), 
the average signal intensity ratios of ∆tdr1/WT, ∆tdr1/∆tdr1[pXG TDR1] and 
WT/∆tdr1[pXG TDR1] were plotted. Dotted lines in A and C represent the adopted cut-off 
for significant changes in a given metabolite profile: log2 (metabolite intensity ratio) below -
1 or above 1 indicates a 2-fold difference between the cell lines compared. All metabolites 
shown in C were statistically significant different between ∆tdr1 and WT or ∆tdr1[pXG 
TDR1] and their identities were confirmed by co-elution with the respective standard. The 
metabolites are ordered according to mass. 
 
Recombinant TDR1 has deglutathionylation activity towards protein and peptide 
substrates 
In order to investigate whether the changes observed in ∆tdr1 parasites at a metabolome 
level could reflect TDR1 having a role in regulation of enzymes via glutathionylation, we 
evaluated the ability of TDR1 to catalyze protein deglutathionylation. TDR1 and GRX1 
were purified as recombinant N-terminally His-tagged proteins and confirmed to catalyse 
the deglutathionylation of a small molecule mixed-disulfide in the 2-hydroxyethyl disulfide 
(HEDS) assay (data not shown) with specific activities that were comparable to those 
reported for L. major TDR1 [9] and T. brucei GRX1 [11]. To determine whether TDR1 and 
GRX1 can also use protein-GSH mixed disulfides as a substrate, BSA was 
glutathionylated chemically by reduction and denaturation followed oxidation in the 
presence of GSH. The specific activity of TDR1 in reducing the glutathionylated BSA 
(BSA-SG) was 3.1 ± 0.7 µmol/min/mg, which was similar to that obtained with GRX1 (1.6 
± 0.4 µmol/min/mg). Kinetic analysis of the protein deglutathionylation reaction was 
performed using a peptide with the sequence SQLWCLSN, synthesised with a GSH linked 
to the cysteine residue by a disulfide bond (Peptide-SG). Peltoniemi and co-workers used 
this glutathionylated peptide in a fluorescence assay, exploiting the observation that the 
disulfide bond quenches the fluorescence of the adjacent tryptophan residue [45]. 
However, in this study it was more convenient to measure peptide deglutathionylation in a 
coupled assay with GR as described by [46]. Table 3 shows a comparison of the kinetic 
parameters obtained with TDR1 and GRX1 in this study, as well as published data for the 
E. coli GRX1 with the same substrate (Peptide-SG) [45] and for T. brucei Grxs (GRX1 and 
GRX2) with glutathionylated tryparedoxin-dependent peroxiredoxin protein (TXNPx-SG) 
as a substrate [11]. The Km for the Peptide-SG was 40-fold higher for TDR1 than for 
GRX1, but the turnover of the glutathionylated peptide by TDR1 was also higher. 
Interestingly, similar differences in these kinetic parameters were observed when T. brucei 
GRX1 and GRX2 were compared [11]. The kcat value obtained with TDR1 in the peptide 
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deglutathionylation was comparable to published values for different glutaredoxins with 
gluthionylated proteins or peptides as substrates [11, 45, 60]. The catalytic efficiency (kcat 
/Km) of GRX1 in reducing peptide-SG is similar to that of its homolog T. brucei GRX1 with 
TXNPx-SG as a substrate, whereas the catalytic efficiency of TDR1 in this assay is more 
similar to that of T. brucei GRX2. 
 
Table 3. Kinetic analysis of peptide deglutathionylation catalysed by TDR1 
 
Enzyme Substrate kcat  
(s-1) 
Km  
(µM) 
kcat/Km  
(M-1s-1) 
Ref. 
 
LdTDR1 Peptide-SG 6.5 ± 1.7 433 ± 175 1.5 x 104 this study 
LiGRX1 Peptide-SG 1.0 ± 0.1 7.6 ± 0.2 1.3 x 105 this study 
EcoGRX1 Peptide-SG 4.4 7.8 5.1 x 105 [45] 
TbGRX1 TXNPx-SG 1.5 21 6.9 x 104 [11] 
TbGRX2 TXNPx-SG 1.0 269 3.8 x 103 [11] 
 
Results for L. donovani TDR1 (LdTDR1) and L. infantum GRX1 (LiGRX1) are the means of 2 independent 
experiments (± 0.5 range). Enzymes: EcoGRX1, E. coli glutaredoxin type 1; TbGRX1, T. brucei glutaredoxin 
type 1; TbGRX2, T. brucei glutaredoxin type 2. T .brucei GRX1 is the homolog of LiGRX1. TbGRX2 has the 
active site motif CQFC and only 25% amino acid identity with TbGRX1 [11]. The Leishmania homolog of 
GRX2 has only one cysteine in the active site (CQFS). Substrates: Peptide-SG, SQLWCLSN with GSH 
linked to the cysteine by a disulfide bond; TXNPx-SG, glutathionylated T. brucei tryparedoxin-dependent 
peroxiredoxin.  
 
 
Discussion 
 
In order to gain insights into the role of TDR1 in Leishmania, we have generated a TDR1 
null mutant using L. donovani promastigotes. To obtain the null mutant it was necessary to 
perform three rounds of transfection, because of the presence of three copies of the gene. 
Although an unexpected finding, recently published studies using new and refined 
methods to sequence Leishmania genomes from different species have shown that 
chromosome copy number variation seems to be widespread and a potential contributor 
for Leishmania genetic plasticity and diversity [48, 49]. Leishmania has been considered 
to be predominantly diploid [47], with the exception of chromosome 1 trisomy [61] and 
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chromosome 31 tetrasomy in L. major [62]. Many previous reports of the emergence of 
aneuploid parasites have been associated with attempts to knockout essential genes [63-
65] or in response to drug pressure [66]. Thus our finding of aneuploidy that was not 
brought about by genetic manipulation or drug pressure but is a genomic feature of the L. 
donovani strain used is unusual but may reflect a situation occurring more commonly than 
reported to date, certainly our finding supports the recently published genome sequencing 
data [48, 49]. It is important to note that the aneuploidy is not a feature of the whole 
genome in this line – we were able to generate a null mutant for cysteine synthase, after 
just two rounds of transfection (L. McCaig, G.H. Coombs and S. Müller, unpublished 
results); thus triploidy and diploidy can clearly occur simultaneously in one cell. Sterkers 
and co-workers [67] described a mechanism that might explain the genomic plasticity 
observed in Leishmania. Their data suggested that every chromosome was observed in at 
least two ploidy stages and also chromosome ploidy distribution was variable among 
clones and strains. This phenomenon, named chromosomal mosaicism, appeared to be 
constitutive and potentially responsible for the generation of phenotypic variability from 
genomic plasticity. Such mosaicism would raise many questions and have implications for 
the methodology that could be used to study Leishmania, as it would make it difficult to 
predict the variability in chromosome copy number. The subsequent findings from genome 
sequencing [48, 49] provide clear evidence of aneuploidy, especially in L. donovani. 
However, the fact that gene null mutants can be obtained, albeit in this study requiring 
three gene deletion events, suggests that the genome is not very variable within a 
population; if it was one would expect there always to remain parasites with an 
endogenous copy of the gene. Thus the data available show convincingly that gene copy 
number varies, but the frequency and rate of change remains to be determined. Such 
gene dose fluctuation may provide significant adaptive advantage to the parasite in coping 
with different environments, including drug pressure, and may be crucial in facilitating the 
development of resistance to antiparasite drugs. 
 
The two domain structure of TDR1, with motifs characteristics of Grxs and GSTO, and the 
ability of the recombinant protein to use GSH as an electron donor to reduce 
dehydroascorbate (DHA) and HEDS, an artificial substrate generally used to measure 
deglutathionylation activity of Grx [9], suggested a possible role of TDR1 in regulation of 
redox-sensitive proteins within the parasite and so an active part in antioxidant defense 
during the parasite’s multi-environment life cycle. Thus, we challenged the TDR1 null 
mutant (∆tdr1) to different compounds known to induce oxidative and nitrosative stress. 
No evidence was obtained for the greater susceptibility of the mutant than WT to these 
stressers, which does not support the suggestion that TDR1 has an involvement in 
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protection of the parasite against this type of stress. Importantly, however, several other 
Leishmania proteins, including ascorbate peroxidase [6] and peroxiredoxins [5], have 
been reported to be central players in the regulation of ROS content in the parasite. For 
instance, recently Wyllie and co-workers demonstrated that L. donovani antimony-
resistant field isolates have higher levels of tryparedoxin and tryparedoxin peroxidase than 
antimony-sensitive isolates, which could comprise an enhanced antioxidant defense to 
protect the parasite from the oxidative stress induced by exposure to the antimonial drug 
[7]. Thus as many enzymes appear to be involved in protecting Leishmania from 
oxidative/nitrosative stress during its life cycle (reviewed in [8]), those stresses generated 
in the different environments and also due to drug pressure, there is probably significant 
redundancy between them. Therefore although the deletion of TDR1 did not lead to a 
change in the overall susceptibility of the living parasite to such stressers, this should not 
be interpreted as confirmation that the enzyme plays no part in protection against 
oxidative/nitrosative stress – it may play a part together with others. Analyses of the 
parasite’s intracellular thiols also showed that these were not significantly affected by 
deletion of TDR1, which is consistent with the parasites being able to cope without TDR1 
in combating many challenges. This conclusion was reiterated by the finding that TDR1 
null mutant promastigotes were able to infect macrophages in vitro and animals as well as 
the WT line. These results show that TDR1 is not vital for these processes and that, 
whatever role it does play, TDR1 clearly it is not essential. 
 
The null mutant promastigotes were more susceptible than WT parasites to trivalent 
antimony and arsenite (Table 2). This is consistent with TDR1 having a role in drug 
detoxification, which has been implicated in drug resistance [52, 68]. Resistance to 
antimonial drugs is thought to be multifactorial but one of the key factors is the 
concentration of active drug (the trivalent form SbIII) within the parasite, which can be 
modulated by decreased uptake and increased inactivation of the drug by the parasite. 
Inactivation can be achieved by the conjugation of SbIII with glutathione or trypanothione, 
leading to extrusion of the drug out of the cell [52]. On the other hand, SbIII leads to an 
imbalance in thiol homeostasis and a consequent accumulation of reactive oxygen 
species [69, 70]. As our evidence is that the presence of TDR1 is not essential for 
protecting the cell against oxidative stress, at least in the conditions tested, it is possible 
that the greater sensitivity of the TDR1 null mutant parasites to trivalent antimonials could 
be explained by TDR1 being involved in the extrusion of the toxic metal out of the cell. 
TDR1 is able to convert the clinically used pentavalent antimonial drugs (SbV) to a 
trivalent form (SbIII) in vitro [9], a reduction that is necessary for the effective action of the 
drug against Leishmania as SbIII is the form that is toxic to the cells. This conversion of 
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SbV to SbIII is thought to occur only in amastigotes, which explains why promastigotes are 
not susceptible to SbV [71]. It is important to note that SbV reduction has also been shown 
to be effected non-enzymatically by thiols, however the reduction is much faster when 
catalyzed by TDR1 [9]. However, neither of these possibilities, that TDR1 could be 
involved in antimonial activation or resistance to the compounds, were supported by the 
finding that there was no change in susceptibility to SbV of the TDR1 null mutant 
compared with the wild type line when they were intracellular in macrophages (Fig. 2B). 
Thus the sensitivity of ∆tdr1 promastigotes to the metals suggests that the trivalent metals 
mediate their toxicity in a way different from SSG and one which is countered by TDR1. 
 
These data confirmed that the absence of TDR1 had some impact upon the parasite and 
thus we used a metabolomics approach in further attempts to elucidate the physiological 
role of TDR1 in Leishmania. The differences that we have detected between the metabolic 
status of ∆tdr1 and the WT parasite have allowed the construction of a novel hypothesis 
on the involvement of TDR1 in Leishmania and provided some evidence to support it. 
Metabolomics is a developing technology that has not yet been applied extensively to 
Leishmania or other parasites although this is now happening [4, 25, 29, 31]. We based 
our procedures upon published protocols [28, 41] that have been validated and used strict 
criteria for inclusion of data, as detailed in the Materials and Methods and Results 
sections. This approach yielded data consistent with there being relatively few large 
differences between the metabolomes of the null mutant and wild type lines (Fig. 4) and it 
is those metabolites that differed greatly and for which we confirmed their identity with 
standards on which we have concentrated in developing ideas on the role of TDR1.  
 
One incidental finding from our study may be of widespread significance for all studies 
involving gene deletion approaches. This was that the two add-back lines generated as 
controls gave very different results. Only the episomal add-back line complemented to a 
large extent the changes observed between the null mutant and WT lines, the integrated 
add-back failing to do so. This finding was surprising, as both add-back approaches 
generated lines expressing a level of TDR1 protein, as analysed by western blot (Fig. 1C), 
similar to that in the WT parent. Our interpretation of these results is that the TDR1 in the 
integrated complementation line is not appropriately active. The generally accepted 
criteria for a satisfactorily complemented line is the presence of a protein band, we 
suggest that this should reconsidered and that the presence of such a band is insufficient 
information on which to judge success of complementation. Comparing the metabolome 
would seem to be far more informative and a reliable analytical method. The literature 
contains many examples of complementation (as judged by protein presence) not 
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restoring well phenotypic changes resulting from gene deletion [53-56]; our data offer an 
explanation for this. 
 
TDR1 gene deletion led to changes in the levels of putative metabolites known to 
participate in a variety of metabolic pathways, many of these are shown in Fig. S1 of 
Supplementary Material. This pictorial representation reiterates that the levels of many 
putative metabolites were not greatly affected, even when in a pathway in which some 
detected metabolites did differ. This is a reflection that the fluxes through pathways are 
controlled at various key steps. The figure also serves as reminder that many metabolites 
were not detected in our analysis. Nevertheless, some distinct differences in confirmed 
metabolite levels were discovered (Fig. 6). The variety of changes resulting from TDR1 
deletion could reflect the involvement of TDR1 in multiple processes in the cell, but it 
could also be indicative of a primary effect and then several secondary effects resulting 
from the primary change. The main challenge in analyzing metabolomics data is to 
integrate all the changes found from a biological point of view.  
 
Several of the metabolites which changed greatly, both within the cells (Fig. 6) and also in 
some cases in the spent medium (Fig. 7), were in the area of amino acid and energy 
metabolism. Leishmania are known to be able to use amino acids, especially proline, as 
energy substrates, although sugar oxidation via glycolysis is also important [3, 30, 72] as 
is hexosamine use [73]. Thus the decreased levels of proline, aspartic acid and glutamic 
acid in the medium and proline intracellularly in the mutant with the concomitant increase 
in intracellular levels of glycerol-3-phosphate could be interpreted as a switch from 
glycolysis to amino acid utilization as energy source. How could TDR1 deletion lead to 
such metabolic re-configuration? These changes in levels of metabolites related with 
energy metabolism, which can be read as a consequence of a change in the carbon 
source used to generate energy, cannot be interpreted as an adaptation in response to 
availability as the TDR1 null mutant and wild type promastigotes were both grown in 
medium rich in sugars and amino acids. However, they could reflect a blockage in the 
pathway responsible for the use of a given energy source; thus the build up of glycerol-3-
phosphate could result from a block towards the final steps in the glycolytic pathway, 
glycerol-3-phosphate being generated as a means of maintaining redox balance.  
 
Regulation of energy metabolism in other organisms involves protein modification, 
including S-glutathionylation in which GSH combines reversibly with a specific protein 
cysteinyl group to form a mixed disulfide [16, 17, 74, 75]. S-glutathionylation can occur in 
the presence of ROS and RNS and is mediated by the formation of reactive thiol 
4. Objectives and Results 
193 
 
derivatives of GSH and the protein cysteinyl group such as sulfenates, thiyl radicals and 
nitrosothiols [15]. This modification results in protein-specific functional changes, that can 
protect a protein’s sensitive thiol from irreversible oxidation during oxidative stress but can 
also occur under physiological conditions as a regulatory mechanism of enzyme activities 
[16] S-glutathionylation is reversed and therefore regulated by deglutathionylation 
catalysed by Grxs [15]. Many enzymes have been identified as being susceptible to this 
type of modification which can lead to activation or inhibition [76] and this so called ‘redox 
regulation’ is increasingly being implicated as an important mechanism of regulation of 
metabolism.  
 
Metabolic re-configuration occurs in many organisms as a response to oxidative stress, 
often through redirection of metabolic flux from glycolysis to the pentose phosphate 
pathway generating NADPH [77]. Oxygen tension has also been implicated in the 
regulation of intermediary metabolism in L. major, with an increase in glycerol formation 
and decrease in glucose consumption being associated with anaerobic conditions [78]. 
Post-translational modification of proteins in Leishmania certainly occurs [79]. Leishmania 
has the enzyme capacity to use S-glutathionylation for redox regulation, encoding two 
glutaredoxins and other thiol-disulfide oxidoreductases including Trx and tryparedoxin 
[19]. Like the Grxs, TDR1 uses GSH as a substrate for the reduction of the mixed disulfide 
formed between GSH and HEDS [9, 11]. Moreover, we found that recombinant TDR1 is 
able to reduce glutathionylated protein and peptide substrates in vitro (Table 3). The BSA-
SG was prepared by an established method [43] and although the structure of the 
substrate was not determined experimentally, BSA-SG is a known substrate of the T. 
brucei GRX1 and other glutaredoxins [11, 60]. The activity of TDR1 detected with BSA-SG 
is therefore likely to represent deglutathionylation of a protein mixed disulfide rather than 
the reduction of a protein disulfide. This is further supported by the observation that TDR1 
has no protein disulfide reductase activity with insulin as a substrate (G.D. Westrop and 
G.H. Coombs, unpublished results). The kcat/Km of TDR1 with the peptide substrate was 
found to be 10-fold lower than that obtained with recombinant Leishmania GRX1. 
However, turnover by TDR1 was 5-fold higher, indicating that TDR1 can efficiently 
catalyse deglutathionylation but has a low affinity for binding this particular peptide. These 
results provide proof in-principle that TDR1 could function as a deglutathionylating 
enzyme and its apparent increase in substrate specificity compared with Leishmania 
glutaredoxin is consistent with a regulatory role for the protein. The T. brucei 
glutaredoxins, GRX1 and GRX2, were similarly reported to have different specificities for a 
glutathionylated peroxiredoxin protein [11]. Also GRX1 and GRX2 from Chlamydomonas 
reinhardtii have been shown to catalyze deglutathionylation at different rates depending 
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on the protein substrate [14], suggesting a certain degree of substrate specificity among 
Grxs that may be crucial for the regulation of cellular processes. There are no previous 
reports on glutathionylation of Leishmania proteins, although the related organism 
Trypanosoma uses glutathione for the glutathionylation of thiol redox proteins [80]. The 
malaria parasite Plasmodium falciparum has also been reported to have proteins redox 
regulated through being targeted by Trx and Grx [81, 82]. Proteins involved in antioxidant 
defense (peroxiredoxins) were identified specifically as potential Trx targets and proteins 
involved in carbohydrate metabolism were also found to interact with Trx, Grx and 
plasmoredoxin (Plrx) proteins [82]. However, TDR1 reduction of other proteins such as 
Trx or tryparedoxin seems unlikely as TDR1 is unable to act as an electron donor for 
tryparedoxin in an insulin reduction assay (G.D. Westrop and G.H. Coombs, unpublished 
results). Thus we interpret our findings to indicate that TDR1 has a regulatory role through 
deglutathionylating key target enzymes, the identity of these, for which TDR1 presumably 
has a relatively high affinity and specificity, remain to be elucidated. 
 
Could such an action of TDR1 explain the data obtained in this study? Most of the 
enzymes involved in glycolysis are sulfhydryl proteins sensitive to redox regulation and 
have been reported, through proteomic approaches in bacteria, plants and mammalian 
cells, as Trx and/or Grx targets [75, 76, 82-87]. S-glutathionylation leads to the inhibition 
of several glycolytic enzymes, notably glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) [74] and triose phosphate isomerase [17]. Our findings are consistent with 
TDR1 playing a role in maintaining the activity of glycolytic enzymes towards the end of 
glycolysis. Pyruvate kinase is known to be glutathionylated in the presence of high 
concentrations of GSSG and the enzyme of Plasmodium falciparum can be enzymatically 
deglutathionylated by PfTrx1, PfGrx1, and PfPlrx. The same was also observed with 
PfGAPDH [81, 82]. Fig. 8 outlines the hypothesis arising from this study and other reports; 
it shows enzymes potentially under regulation through glutathionylation and the levels of 
metabolites in some of the pathways in the WT, ∆tdr1 and add-back line.  
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Figure 8. Schematic representation of central carbon metabolism in Leishmania 
promastigotes. Intensity/25 µg cell protein levels (x 105) are shown for intracellular 
metabolites identified in WT, ∆tdr1 and ∆tdr1[pXGTDR1] promastigotes on day 5 of 
culture in vitro and culture medium from the same day (the latter shown outside the large 
dotted box); metabolites within solid boxes represent metabolites for which at least a 2- 
4. Objectives and Results 
196 
 
fold difference between WT and ∆tdr1 was observed. Grey boxes represent enzymes 
putatively or experimentally identified in other parasites as targets of S-glutathionylation 
modification; dashed arrows represent multiple enzymatic steps; dashed boxes represent 
pathways linked with the ones described. Abbreviations: Glc, glucose; Fru, fructose; 
Fru1,6BP, fructose-1,6-bisphosphate; GlcN, glucosamine; GlcNAc, N-acetyl-glucosamine; 
DHAP, dihydroxyacetone phosphate; GAP, glyceraldehyde-3-phosphate; G1,3P2, 1,3-
biphosphoglycerate; PGA, phosphoglycerate; PEP, phosphoenolpyruvate; Ala, alanine; 
Glu, glutamic acid; Gln, glutamine; Asp, aspartic acid; Pro, proline. Enzymes: 1, 
hexokinase; 2, phosphoglucose isomerase; 3, phosphofructokinase; 4, fructose 
biphosphate aldolase; 5, triosephosphate isomerase; 6, glycerol-3-phosphate 
dehydrogenase; 7, glycerol kinase; 8, glyceraldehyde-3-phosphate dehydrogenase; 9, 
pyruvate kinase; 10, alanine aminotransferase; 11, pyruvate dehydrogenase; 12, acetate-
succinate CoA transferase; 13, glutamate dehydrogenase; 14, glutamine synthetase; 15, 
acetyl-CoA synthethase; 16, malate dehydrogenase; 17, malic enzyme; 18, 
phosphoenolpyruvate carboxykinase; 19, aspartate aminotransferase; 20, pyruvate 
phosphate dikinase; 21, fumarate hydratase; 22, NADH-dependent fumarate reductase; 
23, fructose-1,6-bis-phosphatase; 24, glucosamine-6-phosphate deaminase; 25, N-
acetylglucosamine-6-phosphate deacetylase. 
 
A similar involvement in regulating enzyme activity through S-
glutathionylation/deglutathionylation could also explain some of the other metabolic 
changes observed. Argininosuccinic acid is synthesized from citrulline and aspartic acid 
as part of the urea cycle in mammals. Despite the presence of several genes for enzymes 
of the urea cycle, Leishmania do not seem to have a functional cycle since it lacks the 
genes coding for ornithine carbamoyl transferase and argininosuccinate lyase [88]. 
Argininosuccinate synthase, the enzyme that catalyzes the synthesis of argininosuccinic 
acid from citrulline and aspartic acid, has been reported to be regulated by Trx or/and Grx 
in photosynthetic organisms [85-87]. Inactivation or inhibition of argininosuccinate 
synthase due to lack of deglutathionylation in ∆tdr1 could explain the decrease in 
argininosuccinic acid levels observed in the TDR1 null mutant. Such control would 
suggest some important as yet undiscovered role for argininosuccinic acid in Leishmania 
metabolism. An alternative possibility is that the greater use of amino acids due to the 
purposed metabolic re-configuration in ∆tdr1 would lead to less availability of aspartic acid 
for this reaction, and consequent decrease in argininosuccinic acid levels.  
 
Another interesting change in the TDR1 null mutant was the increase in the intracellular 
levels of S-adenosylhomocysteine (SAH). This is converted to homocysteine and 
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adenosine by S-adenosylhomocysteine hydrolase (SAHH), a crucial enzyme of S-
adenosylmethionine (SAM) metabolism as it prevents the accumulation of this toxic 
metabolite. SAHH is tightly regulated and is, similarly to methionine synthase and SAM 
synthase (two other enzymes involved in SAM metabolism), susceptible to redox 
regulation in, for example, plants and algae [85, 87, 89]. In P. falciparum, SAHH has been 
shown to interact with Grx and Trx [82]. Thus S-glutathionylation is a potential mechanism 
of SAHH regulation, and the increase in the levels of SAH that we found in ∆tdr1 could 
reflect a lack of deglutathionylation of SAHH by TDR1.  
 
Other of the changes found with the TDR1 null mutant could also be rationalized in a 
similar way, through TDR1 being involved, directly or indirectly, in regulating enzyme 
activities via deglutathionylation, although further analyses are required to understand fully 
the mechanisms involved.  
 
 
Conclusions  
 
This study has revealed new insights into how metabolism in Leishmania may be 
regulated via glutathionylation and how TDR1 appears to play a key role in this through its 
deglutathionylation activity. Deletion of TDR1 resulted in specific changes in central 
energy metabolism and also amino acid metabolism. The null mutant lines were also more 
sensitive to metal-induced stress. The unusual structure and parasite-specificity of TDR1 
suggests that it has particular roles and investigating these further is likely to yield new 
detailed information on mechanisms by which metabolism is regulated in Leishmania, 
which could be a determinant in the search for better drugs or even be targeted in drug 
discovery. 
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Supplementary Material 
 
 
Figure S1. Schematic representation of the changes in metabolite levels resulting 
from TDR1 deletion in L. donovani. 100 of the metabolites putatively identified in day 5 
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cell lysates are represented; each is color-coded indicating whether the level differed 
between WT and ∆tdr1 promastigotes (green lower in ∆tdr1, red higher in ∆tdr1). 
 
Table S1. The standards used to verify the identity of metabolites in this study. The 
identity of all of the listed metabolites was confirmed for the extracts of L. donovani 
analysed in this study. 
 
Table S2. Comparison of metabolic profiles resulting from different 
complementation strategies. Metabolites identified below 1 ppm in day 5 samples of 
each of L. donovani WT, ∆tdr1, ∆tdr1::PRRNATDR1 and ∆tdr1[pXGTDR1] are listed in mass 
order. For each metabolite the following information is shown: ionisation mode; detected 
mass; retention time (min); putative metabolite identification; ppm deviation between 
detected mass and theoretical mass of the putative metabolite identified; signal intensity in 
each sample; average signal in each cell line; standard deviation in each cell line; ratio of 
average signal intensity between the different cell lines; Student’s T test ∆tdr1 versus WT, 
∆tdr1 versus ∆tdr1::PRRNATDR1, ∆tdr1 versus ∆tdr1[pXGTDR1]; p value < 0.01 ∆tdr1 
versus WT, ∆tdr1 versus ∆tdr1::PRRNATDR1, ∆tdr1 versus ∆tdr1[pXGTDR1] indicating 
whether or not there was a statistically significant difference; decision on whether or not 
the compound was significantly changed in level based on a two-fold or higher average 
difference in signal intensity and statistical significant (p<0.01) between ∆tdr1/WT, 
∆tdr1/∆tdr1::PRRNATDR1, ∆tdr1/∆tdr1[pXGTDR1]; compound category. 
 
Table S3. Metabolites identified in day 5 samples of L. donovani WT, ∆tdr1 and 
∆tdr1[pXGTDR1]. For each compound the following information is shown: ionisation 
mode; detected mass; retention time (min); putative metabolite identification; ppm 
deviation between detected mass and theoretical mass of the putative metabolite 
identified; signal intensity in each sample; average signal in each cell line; standard 
deviation in each cell line; ratio of average signal intensity between the different cell lines; 
Student’s T test ∆tdr1 versus WT, ∆tdr1 versus ∆tdr1[pXGTDR1]; p value < 0.01 ∆tdr1 
versus WT, ∆tdr1 versus ∆tdr1[pXGTDR1] indicating whether or not there was a 
statistically significant difference; decision on whether or not the compound was 
significantly changed in level based on a two-fold or higher average difference in signal 
intensity and statistical significant (p<0.01) between ∆tdr1/WT, ∆tdr1/∆tdr1[pXGTDR1]; 
compound category. 
 
Table S4. Metabolites identified in day 6 samples of L. donovani WT, ∆tdr1 and 
∆tdr1[pXGTDR1]. The data presented are as described for Table S2. 
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Table S5. Metabolites identified in day 6 samples of spent media from cultures of L. 
donovani WT, ∆tdr1 and ∆tdr1[pXG TDR1]. The data presented are as described for 
Table S2.  
 
 
Tables S1 to S5 are available in the electronic version of the thesis. 
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4.5  Leishmania donovani TDR1, a unique trimeric glutathione transferase 
 evolved by gene duplication then fusion 
 
 
 
Thiol-dependent reductase 1 (TDR1) occurs only in the trypanosomatid parasites 
Trypanosoma cruzi and Leishmania and is thought to contribute to activation of antimonial 
pro-drugs used to treat leishmaniasis. Our structure of L. donovani TDR1 reveals a unique 
trimer of subunits each containing two glutathione-S-transferase (GST) domains. The 
similarities of individual domains, and comparisons with GST classes, suggest that TDR1 
evolved by gene duplication, diversification and gene fusion; an event unknown until now 
in the GST protein superfamily.  
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4. Objectives and Results 
210 
 
 
4. Objectives and Results 
 
Leishmania donovani TDR1, a unique trimeric glutathione transferase 
evolved by gene duplication then fusion 
 
 
Paul K. Fyfe, Gareth D. Westrop#, Ana Marta Silva#, Graham H. Coombs# and William N. 
Hunter* 
 
 
Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University 
of Dundee, DD1 5EH, United Kingdom and #Strathclyde Institute of Pharmacy and 
Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, United Kingdom. 
  
*Correspondence e-mail: w.n.hunter@dundee.ac.uk 
 
 
Abstract 
 
Thiol-dependent reductase 1 (TDR1) occurs only in the trypanosomatid parasites 
Trypanosoma cruzi and Leishmania and is thought to contribute to activation of antimonial 
pro-drugs used to treat leishmaniasis. Our structure of L. donovani TDR1 reveals a unique 
trimer of subunits each containing two glutathione-S-transferase (GST) domains. The 
similarities of individual domains, and comparisons with GST classes, suggest that TDR1 
evolved by gene duplication, diversification and gene fusion; an event unknown until now 
in the GST protein superfamily.   
 
 
The kinetoplastida parasites Leishmania sp. and Trypanosoma cruzi proliferate 
intracellularly within humans and cause the widespread neglected tropical diseases 
leishmaniasis and Chagas Disease. Each parasite is characterized by the presence of a 
trimeric thiol reductase protein known as TDR1 (the T. cruzi enzyme has been called 
Tc52), apparently involved, in the case of Leishmania, in redox regulation and perhaps 
mediating the parasite’s susceptibility to the antimonial pro-drugs Pentostam and 
Glucantime (Denton et al., 2004; Silva AM, Westrop GW, Müller S, Cordeiro-da-Silva A 
and Coombs GH, submitted). Therapeutic activity depends on reduction of the relatively 
inert pentavalent metalloid to the more toxic trivalent species. This reduction occurs slowly 
in the presence of low molecular mass thiols such as glutathione (GSH) or the 
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trypanosomatid specific polyamine conjugate of GSH called trypanothione in vitro, 
especially at low pH such as found in the parasitophorous vacuole in which Leishmania 
resides (Ferreira et al., 2003; Yan et al., 2003). TDR1 catalyses this reduction by acting 
on a metalloid glutathione complex and it has been postulated that it thus mediates the 
key activation of the pro-drug (Denton et al., 2004). The reaction might be considered as a 
de-glutathionylation of an Sb(V)-glutathione adduct during which reduction to Sb(III) 
occurs and thus is a side-activity of the TDR1’s perceived main intracellular function of 
redox regulation via de-glutathionylation of target enzymes (Silva AM, Westrop GW, 
Müller S, Cordeiro-da-Silva A and Coombs GH, submitted). 
 
The structure of the enzyme from L.donovani (LdTDR1), determined by single-
wavelength anomalous dispersion on a SeMet derivative and refined to 2.3 Å resolution 
(Supp. material, Table 1), reveals a new class of trimeric GST. The asymmetric unit 
consists of a homotrimer with D3 symmetry, total mass approximately 150 kDa (Figure 
1A). A few residues, 1-3 in subunit A, 1-4 and 445-450 in subunit B, C1-2 in subunit C are 
omitted from the model due to poor electron density. A high degree of non-
crystallographic symmetry is evident (r.m.s.d. of subunit A with B, 0.24 Å; B with C, 0.30 
Å; A with C, 0.29 Å) therefore subunit A is detailed, unless stated otherwise. 
 
The TDR1 subunit contains two similar domains (domain I residues 1-219 and domain II 
231-450; Figure 1B & C), linked by a short section of ten residues. The domains share a 
sequence identity of 30% and 199 Cα positions overlay with an r.m.s.d of 1.8 Å. Both 
TDR1 domains are closely related to the Ω and τ class glutathione-S-transferases (Board 
et al., 2000; Thom et al., 2002; Axarli et al., 2009). The interface between the domains is 
primarily hydrophobic and of some 680 Å2, or ~6 % of the surface area of each domain. 
 
Cytosolic GST subunits consist of an N-terminal thioredoxin-like sub-domain and a C-
terminal α-helical sub-domain (Figure 1C). Superimposition of the thioredoxin-like 
domains (residues 6-78 and 232-301) from a subunit reveals a sequence identity of 39 % 
and r.m.s.d. 0.95 Å. A larger divergence is noted between the α-helical sub-domains with 
an additional short helix (α4) present in the N-terminal domain. Superimposing the core 
of these sub-domains (residues 95-209 with 319-434) reveals a sequence identity of 
about 25% and r.m.s.d. on Cα atoms of almost 2 Å. This value is strongly influenced by 
differences in α5-α6 of domain I compared to the related α16-α7 of domain II. The short 
link between α5-α6 in domain I contributes to the interface between the two domains in a 
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subunit; the same region in domain II is, however, exposed to solvent far removed from 
any domain:domain interactions. 
 
 
 
Figure 1. The structure of LdTDR1. A. The trimer with glutathione shown in stick 
format. The position of one of the GST-like dimers is indicated by the dotted circle; B. 
TDR1 subunit A, coloured by domain; C. Domain I and domain II separated and 
presented in the same orientation. The thioredoxin-like and helical sub-domains are 
indicated. Glutathione is depicted as VDW spheres colour coded: C yellow, N blue, O 
red, S green. The position of the G- and H-sites are labeled. 
 
The trimeric quaternary structure of TDR1 differs from the dimeric cytosolic GST 
enzymes (Oakley, 2005). Each LdTDR1 subunit is constructed from two GST-like 
domains (Figure 1). The closest structurally related molecule is τ-GST from Glycine max 
(Protein Data Bank (PDB) code 3FHS, Axarli et al., 2007). Comparison of the LdTDR1 
trimer against the 3FHS model reveals a typical GST-dimeric structure is formed, with 
each subunit contributing one domain to form a dimer with the alternate GST-domain 
from the neighboring subunit (Figure 1A). The trimer presents three GST-like dimers 
generated through inter- rather than intra-subunit interactions. 
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The domain I – II subunit interface regions have an average surface accessible area 
(ASA) of 1030 Å2, or ~5 % of the total ASA of a subunit. This is towards the lower end of 
the range (~1000 Å2 to ~1700 Å2) found in GSTs. Hydrogen bonds are made between the 
side chain of Lys189 to the backbone carbonyls of Ala141 and Ala142; Tyr321 OH and 
the backbone amide of Phe69, the Asn329 and Arg52 side chains and there are also salt 
bridges involving Glu322 - Arg66 and Glu358 - Arg52. 
 
TDR1 lacks the N-terminal extension widely observed in τ and Ω GST classes (Board et 
al, 2000). However, one τ and Ω class specific feature (Thom et al., 2002) present in 
TDR1 is a F-F-G-G motif in the α17 – α18 loop on domain II. In domain I the 
phenylalanine residues are replaced by tyrosines and the glycines are replaced by a 
cysteine aspartate combination. This is the case in all three Leishmania TDR1 sequences 
as well as Tc52 from T. cruzi. In domain I this loop is solvent exposed on the surface of a 
subunit whereas in domain II it contributes significantly to the subunit:subunit interface. 
 
Each subunit contains two glutathione binding or G-sites (Suppl. Figure S1) and nearby, 
about 10 Å distant, ligand or substrate binding sites that in GSTs are predominantly 
hydrophobic and usually termed the H-site (Figure 1C). The sites are designated G-I/H-I 
and G-II/H-II within TDR1 domains I and II, respectively. G-I and G-II binding sites 
contain four distinctive, highly conserved GST family features related to substrate 
binding. Firstly, a cis-proline (Pro56, Pro281) occurs in an α – β loop and supports the 
formation of a hydrogen bond from the backbone of the neighboring valine (Val55, 
Val280) to the cysteinyl moiety of glutathione (Dirr, et al., 1994). Secondly, 
Ramachandran outliers Glu70 and Glu293 form hydrogen bonds to bind the glutathione 
γ-glutamyl moiety. Mutation of this highly conserved glutamate has a profoundly 
deleterious effect on activity and stability of GSTs (Allocati et al., 2002; Winayanuwattikun 
& Ketterman, 2004). The active site cysteines (Cys14, Cys240) at the N-terminus of an α-
helix interact with the glutathione thiol and the helix dipole is expected to enhance 
cysteine nucleophilicity (Kortemme & Creighton, 1995). Finally the phenylalanine in the 
C-P-F-C active site motif stacks over the aliphatic backbone of the glutamyl moiety of 
GSH. A large hydrophobic residue always occupies this position, contributing van der 
Waals interactions to stabilize the complex. 
 
Although the G-I and G-II sites and interactions formed with glutathione are highly 
conserved, there are distinctive features (Suppl. Figure S2, S3). In both substrate binding 
sites the cysteinyl moiety forms mixed thiol-disulfide species with the active site cysteines 
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(Cys14 in G-I; Cys240 in G-II). The C-P-F-C motif in G-I mirrors that found in glutaredoxin 
and thioredoxin, with the proline crucial to ensure the proper alignment of three thiols 
from GSH, Cys14 and Cys17, such that the latter is available to stabilize the Cys14 
thiolate. In subunit B, there is a mixed thiol-disulfide formed between Cys14 and Cys17 
but in the other subunits the sulfur atoms of Cys14 and Cys17 are 3.4 Å and 3.6 Å apart. 
In G-II Cys17 is replaced by Val243 so the mixed disulfide configuration is not possible. 
 
In the G-I site, hydrogen bonds occur between glutathione and Val55, Glu70, Arg39 and 
Ser71. Similar associations are noted in the G-II site involving Val280, Glu293 Ser294. 
Other than the cysteine to valine change in the G-II site compared to G-I, the alterations 
are restricted to the region in the pocket responsible for binding the glycyl moiety of 
glutathione. Here a hydrogen bond with the main chain of an arginine (Arg39) in G-I is 
replaced by a hydrogen bond to Gln267 NE2 in G-II. The position of Arg39 in G-I 
corresponds to His265 in G-II, while the position of Gln267 important in G-II is Glu41 in 
G-I. 
 
In most GSTs the glutathione binding site is a relatively open cleft but in TDR1, as in Ω 
and τ-GSTs, the presence of an α-helix (α2  results in a smaller, partially occluded H-site 
the entrance of which is about 6.5 Å in diameter (Suppl. Figure S4). The pocket is 
partially formed by the almost ubiquitous Pro-Phe (often Tyr) motif following on from the 
active site cysteine. The H-I pocket is reduced in size due to the presence of His114 and 
Tyr215 at the base of the cleft, the side chains of which are linked by a hydrogen bond 
(data not shown).  
 
In the H-II pocket, Met338 and Ile440 replace His114 and Tyr215, respectively, resulting 
in a different shape and the loss of a hydrogen bond linking two helical sections together 
may allow α20 to adopt a configuration giving rise to a more open cavity (Suppl. Figure 
S5). The H-II site, which is guarded by Pro241, Met338, Ile342, Arg443 and His439, 
extends 6 Å in one direction, nearly 10Å in another with a depth of some 14 Å away from 
the GSH thiol. Neither H-I nor H-II fit the hydrophobic descriptor, due to the presence of 
basic residues (His, Arg). The electrostatic properties of the pocket suggest that the 
natural substrates of TDR1 are acidic rather than hydrophobic. 
 
The C-terminal domain G-II site, carries the dehydroascorbate reductase (DHAR) activity 
and treatment with iodoacetamide confirms that cysteine is important for the DHAR 
activity (Denton et al., 2004). However, treatment of TDR1 with sodium arsenite or 
potassium antimonyl tartrate does not reduce DHAR activity – these reagents would be 
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expected to block the two cysteines found in the C-P-F-C motif of G-I, but not the C-P-F-
V motif of G-II. The C-terminal domain was also cloned and expressed, and shown to 
carry DHAR activity. 
 
The LdTDR1 domains were treated as a single GST for sequence comparisons, large-
scale alignments and tree calculations (Figure 2B). The introduction of L. mexicana and 
L. infantum TDR1 sequences along with Tc52 indicates two new branches in the GST 
phylogenetic tree, which correspond to a separation of domain I from domain II. That 
these two groupings are then more closely related to one another suggests the origin of 
TDR1/Tc52 is a gene duplication followed by a gene fusion event. Diversification has 
likely occurred after gene duplication leading to C-X-X-C motif in one domain and a C-X-
X-S motif in the other. There is no other example where such a combination of events 
has occurred in a GST. Multiplication of the gene encoding GSTs has frequently occurred 
but not allied to a fusion. A fortuitous consequence of LdTDR1 evolution is the presence 
of an activating agent that supports the successful deployment of antimonial pro-drugs. 
 
 
Figure 2A. Sequence alignment of domain I and domain II from L. donovani TDR1. 
Secondary structure elements are identified by cyan arrows for β-strands and yellow 
cylinders for α-helices, and labeled. Selected residues involved in binding glutathione are 
indicated by purple, for domain I, and green, for domain II, stars. Strictly conserved 
residues are encased in black, acidic residues in red and basic in blue. The alignment 
was performed using MUSCLE15 and the figure produced with ALINE.16 The purple and 
green stars mark residues from domain I and II respectively that interact with glutathione. 
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Figure 2B. Circular cladogram of GST family members. All marked assignments taken 
from database entries. TDR1 and Tc52 are considered as domains I and II for the 
analysis. Alignments were prepared using MUSCLE and the tree calculated through 
average distance using BLOSUM62 in Jalview.17 The branch carrying TDR1 and Tc52 is 
coloured red. 
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Supplemental Material 
 
 
Materials and Methods 
 
Sample preparation and crystallization 
The L. donovani TDR1 gene was cloned into pET15bTEV to add a tobacco etch virus 
(TEV) protease cleavable histidine tag as an aid for purification of the recombinant 
protein (LdTDR1). A selenomethionine (SeMet) derivative was prepared in the 
methionine auxotroph Escherichia coli strain B834 (DE3), using selenomethionine 
medium (Molecular Dimensions, UK), supplemented with 40 mg mL-1 selenomethionine. 
A purification protocol commonly used in our laboratory was applied (Dawson et al., 
2008). In summary, the first stage involved nickel affinity chromatography with a 5 mL Ni-
NTA column (Qiagen). A linear concentration gradient was applied to elute the product, 
which was then incubated for two hours with His-tagged TEV protease at 30 °C, before 
dialysis at room temperature against 20 mM Tris-HCl, pH 7.8, 150 mM for one hour. The 
resulting mixture was applied to the Ni-NTA column, which bound the cleaved His-tag, 
the protease and uncleaved LdTDR1. The LdTDR1, from which the His-tag had been 
cleaved, was in the flow-through. Fractions were analyzed using sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and those containing LdTDR1 were 
pooled. The protein was further purified by size exclusion chromatography using a 
calibrated Superdex 200 26/60 column (GE Healthcare) equilibrated with 20 mM Tris-
HCl, 150 mM NaCl pH 7.8. This final purification stage also indicated that LdTDR1 
formed a stable trimer in solution (data not shown). The high level of LdTDR1 purity was 
confirmed by SDS-PAGE and matrix-assisted laser desorption/ionization-time-of-flight 
mass spectrometry. The latter technique also confirmed full incorporation of SeMet. The 
sample was dialyzed into 10 mM HEPES pH 7.8, 50 mM NaCl then concentrated using a 
Vivaspin 20 (Sartorius) to provide a stock solution for crystallization. A theoretical 
extinction coefficient of 56185 M-1 cm-1 at 280 nm, was used to estimate protein 
concentration (PROTPARAM, Gasteiger et al., 2005); the theoretical mass of one subunit 
of the SeMet derivative is 50872 Da. 
 
LdTDR1 was crystallized at 20 °C by the hanging drop vapor diffusion method using 0.75 
μL of protein solution at a concentration of 5 mg mL-1 containing 1 mM glutathione, mixed 
with 0.75 μL of reservoir containing 12 % polyethylene glycol (PEG) 8000, 0.1 M HEPES 
buffer pH 7.0, 8 % (v/v) ethylene glycol. Monoclinc rods, with approximate dimensions of 
1.0 x 0.2 x 0.2 mm, grew over 1-2 days. The concentration of PEG 8000 and ethylene 
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glycol in the mother liquor provided sufficient cryo-protection that crystals could be placed 
in a stream of cold N2 gas directly and characterized in-house using a Rigaku HF007 
rotating anode X-ray generator coupled to an RAXIS IV++ image plate detector. The 
crystals were monoclinic in space group C2 with unit cell lengths a = 197.5, b = 58.4, c = 
160.4 Å with β = 111.8°. Crystals were stored in liquid N2 for data collection at a 
synchrotron. Attempts to obtain crystals of the apo-form, and of complexes with 
glutathionylspermidine or trypanothione were unsuccessful. 
 
X-ray data collection, processing, structure solution and refinement 
Single-wavelength anomalous diffraction (SAD) data were measured from a SeMet 
derivative on beam line I02 of the Diamond Light Source using an ADSC Q315 CCD 
detector. Data were indexed and integrated using MOSFLM (Leslie, 2006) and scaled 
using SCALA (Evans, 2006). The SAD data were collected near the Se K-absorption 
edge f” maximum, determined using X-ray Absorption Near Edge Structure spectroscopy. 
Initial phases were obtained by SAD-phasing within the CCP4 pipeline CRANK (Ness et 
al., 2004; Pannu et al., 2011). Substructure detection and refinement were performed 
using AFRO (Pannu, unpublished), CRUNCH2 (de Graff et al., 2001) and BP3 (Pannu et 
al., 2003), and identified the positions of all 39 selenium atoms present. The initial figure-
of-merit was 0.49. Hand determination followed by density modification was performed 
using SOLOMON (Abrahams & Leslie, 1996) with an estimated solvent content of 55 %, 
and this improved the figure-of-merit to 0.71. Automated map interpretation with 
BUCCANEER (Cowtan, 2006) produced a partial model consisting of 1335 residues in 15 
polypeptide chains giving an Rwork and Rfree values of 33.5 % and 36.9 % respectively. 
The model was then extended in COOT (Emsley & Cowtan, 2004). 
 
Refinement was performed in REFMAC5 (Murshudov et al., 1997) utilizing 
Translation/Libration/Screw refinement (Winn et al., 2000), and alternated with rounds of 
electron and difference density map inspection and model manipulation together with 
ligand incorporation using COOT. Non-crystallographic symmetry (NCS) restraints were 
not employed. MOLPROBITY (Chen et. al., 2010) was used to investigate model 
geometry in combination with the validation tools provided in COOT. Crystallographic 
statistics are presented in Table 1. Analyses of surface areas and interactions were made 
using the PISA server (Krissinel & Henrick, 2007) and figures were prepared with PyMOL 
(DeLano, 2002). Amino acid sequence alignments were carried out using the program 
MUSCLE (Edgar, 2004) and structural superimposition performed with SSM (Krissinel & 
Henrick, 2004). The PDBeFold server (http://www.ebi.ac.uk/msd-srv/ssm; Krissinel & 
Henrick (2004)) was used to performing a search of the protein structural database.  
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Table S1. Crystallographic statistics 
 
Data Collection 
Space group C2
Wavelength 0.9795 Å 
Unit cell parameters  
a, b, c, (Å) 
 β (°) 
 
197.5, 58.4, 160.4  111.8  
Resolution Range (Å) 29.8 – 2.3 
Unique reflections 74,464 
Completeness (%)a 97.9 (98.7) 
<I/s(I)> 12.6 (3.9) 
Multiplicity 4.0 (4.2) 
Rmerge (%)b 5.9 (25.9) 
Refinement 
Resolution Range (Å) 30.0 – 2.3 
No. of used reflections 70,625 
Rworkc, Rfree 14.9, 20.8 
Protein atoms 11,011 
Glutathione / ethylene glycol / water 6, 15, 1165 
R.m.s. deviations from ideal geometry  
bond lengths (Å) 0.015 
bond angles (°) 1.418 
Thermal parameters (Å2)  
Wilson B 42.9 
Mean B  
subunit A, B, C 
 
55.2 / 60.5 / 55.9 
GSH, water, ethylene glycol 46.8 / 60.2 / 72.7 
Ramachandran plot (%) 
favoured/allowed 
98.3 / 1.2 / 0.5 
 
a. Values in parentheses refer to the highest resolution bin of width approx. 0.1 Å; b. Rmerge = 
∑h∑i||(h,i) - <I(h)> ∑h∑i I(h,i); c. Rwork = ∑hkl||Fo|-|Fc||/∑|Fo|, where Fo is the observed structure 
factor and Fc the calculated structure factor; d. Rfree is the same as R-work except calculated 
using 5% of the data that are not included in any refinement calculations. 
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Figure S1. Stereoview comparison of TDR1 inter-subunit (A-C) dimer with the 
dimer formed by the closest structurally related tau class GST dimer (PDB code: 
3FHS21). The polypeptide trace of 3FHS is shown in dark grey, superimposed on domain 
I from subunit A (purple) and domain II from subunit C (green), which generate the TDR1 
GST-like dimer. The bound glutathione molecules are depicted sticks colored with yellow 
C atoms for the TDR1 model, grey for the 3FHS model. 
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Figure S2. Stereoview images of the two glutathione binding sites within subunit A. 
A. G-I - the domain I glutathione binding site; B. G-II - the domain II binding site. Atomic 
positions are color coded: N blue, O red, S green, C grey for the ligands and yellow for 
the protein. Water molecules are shown as cyan spheres. Dotted lines represent potential 
hydrogen bonding interactions. Glutathione has been modeled as a 50:50 mixture of 
reduced and oxidized forms. 
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Figure S3. The electrostatic properties of the G-I and G-II binding sites. TDR1 is 
depicted as van der Waals surface colored with blue representing positive charge, red 
negative and grey neutral. Although many structural features are conserved between the 
two glutathione binding sites are distinct with G-II displaying a much greater basic 
character than G-I.  
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Figure S4. Stereoimage showing an overlay of the hydrophobic (H-sites) from 
domain I (H-I, green) and domain II (H-II, orange) from subunit A. The Cys-Pro-Phe 
motif is conserved in both near the GSH binding site, but there is conservation in the H-
site itself. The H-I pocket is restricted by the positioning of Tyr215 and His114 and with 
the movement of α12 to narrow the pocket. 
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4.6  Metabolic variation during development in culture of Leishmania 
 donovani promastigotes  
 
 
 
The genome sequencing of several Leishmania species has provided immense amounts 
of data and allowed the prediction of the metabolic pathways potentially operating. 
Subsequent genetic and proteomic studies have identified stage-specific proteins and 
putative virulence factors but many aspects of the metabolic adaptations of Leishmania 
remain to be elucidated. In this study, we have used an untargeted metabolomics 
approach to analyze changes in the metabolite profile as promastigotes of L. donovani 
develop during in vitro cultures from logarithmic to stationary phase. The results show that 
the metabolomes of promastigotes on days 3-6 of culture differ significantly from each 
other, consistent with there being distinct developmental changes. Most notable were the 
structural changes in glycerophospholipids and increase in the abundance of 
sphingolipids and glycerolipids as cells progress from logarithmic to stationary phase. 
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Introduction
Leishmaniasis remains one of the major infectious diseases with
350 million people at risk in 88 countries worldwide and 2 million
estimated new cases every year [1]. The lack of effective
chemotherapy and emergence of drug resistance (reviewed in
[2]) highlights the need for an improved knowledge of the
parasite’s cell biology to discover peculiarities that could
potentially be explored as drug targets.
The Leishmania life cycle involves several developmental stages
and alternates between sand fly and mammalian hosts. A major
developmental difference is the occurrence as intracellular
amastigotes in mammalian macrophages and as extracellular
promastigotes in the sand fly. However, multiple forms of
promastigotes have been identified based on morphology,
location, infectivity, growth rate, ability to divide, and specific
features such as expression of surface molecules [3–8]. It is
believed that the parasite’s occurrence in different developmental
forms is a mechanism whereby it adapts to survive and persist in
the various environmental conditions in which it is confronted
with variations in temperature, pH, nutrient and oxygen
availability and exposure to reactive oxygen (ROS) and nitrogen
species (RNS) [9]. Despite the extensive investigations on various
features of Leishmania over many years and the recent pioneering
application of metabolomics technologies to studies on the parasite
[10–13], particularly the elucidation of ways in which amastigotes
differ from promastigotes [13–16], currently relatively little is
known about the detail of the metabolic variation that happens
during this developmental sequence in the sand fly.
The developmental sequence in the sand fly vector, which
terminates in transformation to the metacyclic form infective to a
mammalian host, appears to be mimicked, at least in part, during
growth axenically in vitro; this comprises multiplication of
procyclic promastigote forms and then differentiation to the
metacyclic form, a process known as metacyclogenesis which is
accompanied by morphological changes, including reduction in
size of the cell body and a relatively longer flagellum, and some
known biochemical changes such as lipophosphoglycan (LPG) and
surface protein expression [5–7,17–20]. Thus the in vitro system
provides an opportunity to investigate the metabolome changes
that accompany and perhaps underpin the developmental
sequence of the promastigote. In the present study, we have
applied state-of-the-art metabolomics approaches to analyse the
changes in the metabolome of promastigotes of Leishmania donovani
during culture in vitro. The results show that there is distinct
variation in the metabolome, especially in the lipid composition.
Methods
Leishmania parasites
Leishmania donovani (MHOM/NP/03/BPK206/0clone10) promas-
tigotes had been cloned from an isolate from a visceral leishmaniasis
patient sensitive to pentavalent antimonials in Nepal, as described by
Rijal and co-workers [21]. Promastigotes were grown on modified
Eagle’s medium (designated HOMEM medium, Invitrogen) supple-
mented with 20% (v/v) heat inactivated fetal calf serum (FCS, PAA
Laboratories) at 26uC. Cultures were set up initially at a density of
2.56105 parasites/ml and sub-passaged every 6 days.
Leishmania extracts for metabolite analysis
L. donovani promastigote cultures were initiated at 2.56105 cells/
ml in 16610 ml cultures in order to obtain cell samples from four
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independently growing cultures (biological replicates) on each day.
Promastigotes from each culture were harvested at days 3, 4, 5 and
6 for metabolite extraction. The metabolite extraction was
performed as previously described [11]. Briefly, promastigotes
quenching was performed in a dry ice/ethanol bath with rapid
temperature decrease to 2uC and then immediate transfer to ice.
Two aliquots of 46107 cells were taken from each culture flask
(technical replicates). Cell pellets were obtained by centrifugation
at 12000 g for 10 min at 4uC, and washed 3 times in 1 ml of PBS.
For cell disruption and metabolite extraction, cell pellets were
resuspended in 200 ml cold chloroform/methanol/water (20/60/
20, v/v/v) and incubated for 1 h in a Thermomixer (1400 rpm,
4uC). After centrifugation at 12000 g for 10 min at 4uC, the
supernatant containing the extracted metabolites was recovered
and stored at 270uC until analysed.
Liquid chromatography mass spectrometry (LC-MS)
analysis and data processing
LC-MS analysis and data processing was done as described by
t’Kindt and co-workers [11,12]. Metabolite level comparisons
between the time points analyzed (after 3, 4, 5 and 6 days of in
vitro growth) were performed based on the ratio between the
intensity on each day and the mean intensity level for the 4 day
period, that is x/X3–6. The following criteria were applied to
assign differences in metabolite levels among the time points
analyzed as being potentially interesting and so worthy of inclusion
in the full analysis: (i) there was at least a 2-fold difference between
at least one of the time points when compared with the mean
intensity level; and (ii) there was a statistically significant difference
(p,0.05) between the time points being compared. The data are
expressed as intensity per 25 mg cell protein.
Statistical analysis
Statistical analysis was performed using Analysis of Variance
(ANOVA), which allowed the simultaneous comparison of all time
point analyzed: a p value smaller than 0.05 (p,0.05) was
considered significant; SPSS Statistics software (IBM) was used
to perform principal component analysis; GraphPad Prism 4 was
used for plotting the graphs and VisuMap software (VisuMap
Technologies Inc.) was used to visualise the data as heatmaps.
Results
In order to obtain detailed information about the metabolic
changes that occur during the development of promastigotes
under defined conditions in vitro, we have applied an untargeted
metabolomics approach. Promastigotes were collected after 3, 4, 5
and 6 days of in vitro growth (thus including different proportions
of various promastigote forms, including procyclic promastigotes
which dominate during logarithmic growth and the non-dividing
metacyclic forms that start to be formed at late stages of
logarithmic phase) and analyzed by LC-MS. We used four parallel
cultures (designated biological replicates) to obtain representative
data and during the cell processing from each culture two samples
were taken (designated technical replicates) to control for variation
due to technical factors. Analysis of a parasite’s metabolome needs
to take into account the changes in cell volume that occur during
development and growth. Measurement of the protein content of
the cells showed that transformation to the metacyclic form at late
logarithmic phase of growth was accompanied by a decrease in
protein content, which is thought to correlate with the decrease in
cell size (Figure 1). There was a great difference in protein content
between the cells on days 3 and 6 (p,0.0028) but also a significant
difference between the cells on days 3 and 4 (p,0.025) and days 5
and 6 (p,0.034). To assure that the metabolome analysis of the
parasite would reflect the changes observed in cell size, we have
expressed the data as intensity per cell protein (rather than per cell
number), thus facilitating meaningful comparison of the metabo-
lite levels in cells of differing volume. This method of normaliza-
tion had significant effects, for instance the general decreases in
metabolite intensity when expressed per cell number that were
observed between promastigotes on day 3 and day 6 were almost
abolished when data were expressed as intensity/mg cell protein.
Indeed the summed total of the metabolite intensities normalized
Author Summary
Leishmania infections are considered neglected tropical
diseases as the parasites affect millions of people
worldwide but there are limited research efforts aimed at
obtaining vaccines and new drugs. Leishmania has a
digenetic life cycle alternating between promastigote
forms, which develop in the sand-fly, the vector of the
disease, and an amastigote form, which grows in mammals
after being bitten by an infected sand-fly. In vitro studies
with the promastigote forms are routinely used to gain
insights about the parasite’s cell biology. Little is known
about how the different promastigotes forms are meta-
bolically adapted to their particular micro-environment in
the host or how they are pre-adapted metabolically for
infecting a mammal, thus we have undertaken a study of
the metabolite profile of L. donovani promastigotes in
order to gain an understanding of the changes that occur
during promastigote development. The analysis has
revealed that the changes in promastigotes’ metabolome
between days 3 and 6 take place in a progressive manner;
however major differences were observed when compar-
ing the promastigotes on days 3 and 6. An increase in lipid
abundance as promastigote development occurred was
notable and is likely to reflect remodelling of the parasite’s
surface in readiness for infecting a mammal.
Figure 1. Relantionship between protein content and cell
density during in vitro growth of L. donovani promastigotes. L.
donovani promastigotes were seeded at 2.56105 parasites/ml, counted
daily and harvested at days 3, 4, 5 and 6. Protein content was
determined by the Lowry method. Each value is a mean 6 standard
deviation from four cultures. Statistically significant differences
observed between the days evaluated: days 3 and 4, p,0.05; days 5
and 6, p,0.05; days 4 and 6, p,0.05; days 3 and 6, p,0.01.
doi:10.1371/journal.pntd.0001451.g001
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to cell protein were relatively constant over the four days whereas
when expressed as intensity/cell number it declined 33% on day 6.
We believe that this method of taking into account the changes in
cell size during growth is currently optimal and provides a means
of generating data that are meaningful and can be interpreted with
confidence.
In order to understand better the metabolic fluctuations as the
promastigotes developed over the four days, we compared the
profiles of metabolites levels (Figures 2A and 3). The analysis
shown in Figure 2A (in which the metabolite intensity level on
each day is compared with the mean level over the 4 day period)
highlights that, of the total metabolites identified, the levels of the
majority remained rather similar throughout although 26.9%
differed by at least 2-fold on one of the days when compared with
the mean. The day 3 levels were the most different from the others
(22% being at least 2-fold different from the centered-mean for the
period analyzed) and with just some metabolites differing greatly at
other times. This is consistent with there being a progressive
change in many metabolite levels over the four day period.
However, comparison between the metabolite intensities on days 3
and 6 revealed that 48.4% of all the metabolites identified differed
by more than 2-fold (Figure 2B), suggesting a significant difference
in metabolic profile between promastigote populations in loga-
rithmic (mainly procyclic promastigotes) and stationary phases
(containing many metacyclic promastigotes).
The metabolic profile was also analysed by principal component
analysis (PCA). PCA is an unsupervised clustering technique that
allows the reduction of the data into two dimensions (principal
component 1 [PC1] and principal component 2 [PC2]), which
capture and enable visualization of data variability; this method is
generally applied to large sets of data, such as those resulting from
microarray or metabolomic analyses, as a way of obtaining a
summary or overview of all samples, to find clusters and trends,
and to identify the outliers. It is recommended as a starting point
for analysis of multivariate data [22]. The PCA score plots
(Figure 4) of the LC-MS data show clearly the identification of four
distinct clusters, each one corresponding to one of the groups of
samples analyzed on a particular day of growth. PC1 and PC2
account for more than 81% of the variables which shows the clear
metabolic differences between the samples. Moreover, the tight
clustering within each group indicates good reproducibility. The
data in Figure 4 show that promastigotes on days 4 and 5 are
aligned closely with each other indicating that they have a similar
metabolic profile that is clearly distinguished from those on days 3
and 6 (which explains 59.0% of total variance given by the second
principal component). These data are consistent with there being
metabolic changes as the promastigotes develop from procyclic
promastigotes to metacyclic promastigotes, and the relatively large
number of metabolites that differ in levels significantly between
days 3 and 6.
The identity of the metabolites was carried out based on the
databases detailed by t’Kindt and co-workers [11,12]. We were
able to identify 368 putative metabolites (267 at ,1 parts per
million [ppm] deviation and 101 at the 1–2 ppm deviation level).
The compounds identified belong to a wide range of metabolic
pathways and include amino acids, nucleosides, carbohydrates,
fatty acyls, sterols and glycerophospholipids among others, as
shown in Figure 3. The full list of putatively identified
metabolites at days 3, 4, 5 and 6 at below 1 ppm and between
1–2 ppm deviation are provided in Tables S1 and S2 of
supplementary data, respectively. The majority of the metabo-
lites remained at a relatively constant level. Indeed, the overall
sum of intensities of the identified metabolites in the samples
from the different days show that there is little apparent variation
in the total metabolome identified, with the only difference being
between day 3 and day 4 (Figure S1); clearly, however, such data
have to be used with caution as not all of the parasite’s
metabolites are included in the dataset and the method is not
fully quantitative. There were, however, some apparent varia-
tions within each group of metabolites (Figure S2). Lipids, in
general, increased substantially from day 3 to day 6. Carbohy-
drates and nucleosides similarly apparently increase in abun-
dance, whereas other groups of metabolites including amino
acids and derivatives, organic acids and alcohols remain at
relatively constant levels.
All metabolites that differed from the mean for the 4-day period
by at least a 2-fold on one or more days and were statistically
different between the time points analyzed (p,0.05) are repre-
sented in heatmap format to visualize the main changes that occur
during transformation of promastigotes in logarithmic phase to
those in stationary phase (Figure 5) and the intensity levels are
provided on Table S3. This group (97 in total, 26% of the total
number of metabolites putatively identified) includes metabolites
representative of all of the compound categories shown in Figure 3
with the exception of organic acids and alcohols. It was possible to
distinguish five general patterns by which metabolites fluctuated
during the 4-day period analyzed (Figure S3 and Table S3). The
levels of some metabolites continually increased from day 3 to day
6 (pattern 1, 74% of the 97 varying metabolites), while the
opposite happened with others (pattern 3, 9%). Other metabolites
showed peak levels on days 4 or 5 which then declined (pattern 2,
9%), while others decreased from day 3 to day 4 and then
increased (pattern 4, 2%). Some metabolites had a fluctuating
profile showing an increase followed by a decrease and then
another increase (pattern 5, 6%).
A more detailed analysis of each of the categories of metabolites
suggests specific variation potentially related with the cell stage.
For instance, analysis of structural properties of the fatty acyl side
chains of phosphatidylethanolamine (PE) and phosphatidylcholine
(PC) lipids revealed that there was an increased abundance of the
PC lipids with lower unsaturated fatty acyl chains as the
promastigotes developed from day 3 to day 6 (Figure 6 and S4
in supplementary data); this seems also to happen in PE lipids, but
less so than with PC lipids. These data suggest that there are
changes in the composition of membranes with development from
procyclic to metacyclic promastigotes. Another class of metabolites
showing striking differences depending on the cell stage were the
sphingolipids (SLs). In Leishmania, SLs are not essential for growth
but they are for differentiation, probably due to the high demand
in vesicular trafficking required for parasite remodeling [23]. The
abundance of these metabolites in general increased on day 5 and
greatly on day 6, such that for some of the SLs identified, such as
N-(eicosanoyl)-sphinganine, N-(hexadecanoyl)-sphinganine and
heptadecasphinganine, the day 6 intensity amounted to more
than 70% of the total amount detected over the four days
(Figure 7A). A similar situation was seen with some of the
identified glycerolipids, with the diacylglycerol putatively identified
as DAG(42:3) being especially increased on day 6 (Figure 7B). The
abundance of sterols, prenol lipids and fatty acyl metabolites
generally increased during growth and thus were more abundant
on days 5 and 6, although there were exceptions such as N-(11Z-
eicosaenoyl)-ethanolamine and N-(11Z,14Z-eicosaenoyl)-ethanol-
amine (Figures S5 and S6).
In contrast to the lipids, amino acids and derivatives in general
did not differ greatly during the four day period, although some
were less abundant on day 6 (proline, glutamate-semialdehyde,
homocysteine, carnitine and cystathionine among others) while
others were increased (for example N-butyrylglycine, lysine,
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Figure 2. Overview of intracellular metabolite levels in L. donovani promastigotes during in vitro growth. (A) Relative levels of
intracellular metabolites in L. donovani promastigotes detected from day 3 to day 6. Metabolite intensity levels on each day were compared with the
mean level over the 4-day period. Following a logarithmic transformation (base 2), the relative level of each metabolite was plotted. Dotted lines
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valerylglycine, acetyl-lysine, and N-acetyl-arginine) (Table S3 and
Figure S7). A higher abundance of carbohydrates, such as
maltohexose among others, was observed as cells reach stationary
phase (Table S3 and Figure S8). The intensity variation for
hypoxanthine and xanthine over the 4 days had a clearly distinct
pattern from the other nucleosides or nucleoside conjugates, with a
large increase in the abundance of these metabolites on day 6,
while, for example, cytosine and deoxycytidine decreased in
abundance on day 6 (Table S3 and Figure S9). The great increase
in the abundance of hypoxanthine and xanthine at day 6 is
responsible for the large change observed in the overall abundance
of all metabolites included in this group (Figure S2); the overall
abundance of this group was relatively unchanged over the 4 day
period of analysis if these two metabolites were not included. None
of the metabolites included in the organic acids group accomplish
the criteria defined, despite, for example, the statistically
significant difference observed in the levels of mevalonate on day
6 (Figure S10). A marked decrease in abundance on day 6 was also
observed for 5-methyl-THF, dihydrobiopterin and N-acetylpu-
trescine (Table S3 and Figure S11).
Figure 3. Intracellular metabolic fluctuations during in vitro development of L. donovani promastigotes. Profiles of all intracellular
metabolites identified below 2 ppm deviation in relative levels. Metabolite levels on each day were compared with the mean level over the 4-day
period. Following a logarithmic transformation (base 2), the relative level of each metabolite is shown; log2 (x/X3–6) below 21 or above 1 indicates a
2-fold change; x, time point analyzed (day 3, 4, 5 or 6). Metabolite profiles are ordered by compound category shown on the left and log values of
measurements are color-coded as indicated in the scale on the right of the heat map, from green to red.
doi:10.1371/journal.pntd.0001451.g003
represent the fold-change cut-off considered as significantly different between the day analyzed and the mean level of the 4-day period: log2 (dx/
X3–6) below or above 1 indicates a 2-fold change; dx, time point analyzed (day 3, 4, 5 or 6). The metabolites differing at least by 2-fold on one of the
days when compared with the mean were 26.9% of the all of the metabolites identified. (B) Comparison between day 6 (d6) and day 3 (d3) intensity
ratios for each identified metabolite. All metabolites within the 2 ppm cut-off are included and following a logarithmic transformation (base 2) the
average signal intensity ratios of d6/d3 for all metabolites were plotted. Dotted lines represent the fold-change cut-off in this study for a given
metabolite profile being considered to be significantly different between day 6 and day 3: log2 (metabolite intensity ratio) below 21 or above 1
indicates a 2-fold change between time points compared. The metabolites differing at least by 2-fold between day 6 and day 3 were 48.4% of the
total number of metabolites identified.
doi:10.1371/journal.pntd.0001451.g002
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Discussion
Leishmania promastigotes development in the sand fly includes a
wide range of modifications in order to prepare the parasite for
transmission to a mammalian host. The number of distinct
developmental stages that occur is uncertain for although many
have been named and identified based on morphology [3,4] most
have not been sufficiently characterized to be certain that they are
truly distinct developmental stages. As expected, in vitro we were
able to observe various morphological forms of L. donovani
promastigotes but the major clear difference was the appearance
of small morphs as the culture reached stationary phase, when
metacyclic forms are predominant. This reflects the remodeling of
cell shape during life cycle transitions and involved a decrease in
protein content (Figure 1). This was taken into consideration in
analyzing the metabolite dataset and indeed the data were
normalized to protein content as a means of taking into account
changes in cell size.
Analysis of metabolome during in vitro growth of promastigotes
revealed that whereas the overall metabolite abundance remained
relatively constant there were variations in the levels of individual
metabolites, suggesting that parasite differentiation from procyclic
to metacyclic forms takes place in a progressive manner and
involves changes in certain individual or groups of metabolites.
This study reinforces the idea that there are multiple forms of
promastigotes that are adapted differently at the metabolic level,
presumably reflecting the differing challenges that they face
naturally in the sand fly. It has been postulated previously from
studies on morphology of Leishmania promastigotes in sand flies
and in vitro cultures that the parasite undergoes similar
developmental transitions in vitro as occur in the sand fly host
[24], despite the absence of the host pressure. This has been
interpreted as the parasite being genetically pre-adapted to survive
in the sand fly. The biochemical changes that accompany these
morphological/developmental changes are not fully known,
although some characteristics of the metacyclic promastigote of
L. major have been reported. Differentiation to the infective
metacyclic promastigote form involves modifications in LPG
structure [6,25], which have been shown to occur both in in vitro
culture and during in vivo development in the sand fly [26].
HASPB and SHERP are stage-specific proteins present in the
infective stages, with SHERP being exclusively present in the
metacyclic forms; the stage-specific expression of both has been
observed in vitro as well as during the development in the vector
[8]. Other surface molecules, including the metallopeptidase
GP63, also undergo changes in expression pattern as the
promastigotes development progresses [27]. The LPG modifica-
tions are essential for parasite infectivity and occur in vitro and in
vivo demonstrating that in the absence of the host this essential
processes still occurs; these findings are suggestive that other
changes similarly also occur in vitro and the data of our current
study show that indeed this is the case.
Metacyclogenesis is marked by a great increase in membrane
trafficking and remodeling [28] and previous studies have shown
that the organization of Leishmania membrane differs between
procyclic and metacyclic promastigotes, in part due to the
distribution of LPG into lipid rafts during differentiation [29].
Phospholipids (PLs) account for ,70% of total cellular lipids in
Leishmania, with PC, the most abundant glycerophospholipid,
predominantly present in a diacyl form [30] with unusually long
and unsaturated fatty acid species [31]. These properties, the acyl
length and degree of unsaturation, may play an important role in
the fluidity of Leishmania membrane, thus they are likely to be
regulated throughout parasite development in its hosts. Indeed,
our data show that promastigote phospholipid composition
changed remarkably in terms of the unsaturation levels observed
in the fatty acid chains, in particular of PC lipids. Promastigotes in
stationary phase (day 6) presented a higher abundance of PC lipids
with lower levels of unsaturation than those observed on day 3
(Figure 6), revealing a shift towards lower unsaturation of PC lipids
and consequently a decrease in membrane fluidity with metacyclic
promastigote generation. These observed changes in membrane
Figure 4. L. donovani promastigote development is accompanied by significant changes in the metabolome. Principal component
analysis of all metabolites identified by LC-MS in cell extracts from L. donovani promastigotes harvested on days 3, 4, 5 and 6 of in vitro growth; each
datapoint corresponds to the analysis of one biological replicate. Principal component 1 and principal component 2 explain 59.0% and 22.3% of the
total variance, respectively.
doi:10.1371/journal.pntd.0001451.g004
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fluidity may be a mechanism whereby the parasite becomes pre-
adapted for survival upon infecting a mammalian host, at which
time it is confronted by a dramatic increase in temperature. Thus
perhaps the change in membrane composition enables the parasite
to maintain an appropriate membrane fluidity even at the higher
temperature encountered. It is well known that the well-being of
organisms is dependent upon the maintenance of optimal level of
membrane fluidity [32]. In yeast, changes in the degree of
unsaturation of fatty acids has been reported as a response to
changes in the environmental temperature and complements other
mechanisms such as modifications in fatty acid chain length,
branching and cellular fatty acid content [33]. A recent study by
Turk and co-workers [34] have related membrane fluidity to the
adaptation level of different yeast to environmental stresses and to
their growth temperature range, demonstrating that plasma-
membrane fluidity can be used as an indicator of fitness for
survival in extreme environments [34]. Changes in membrane
fluidity in plants was also suggested to be crucial in sensing and
influencing gene expression during temperatures fluctuations [35].
Alterations in membrane fluidity have been associated with the
occurrence of drug resistance in Leishmania; it is thought that
membrane lipid composition may influence drug-membrane
interactions and interfere with drug uptake by the amastigotes
residing in the mammalian host [36–38]. Indeed, comparison of
promastigotes derived from clinical L. donovani isolates with
different antimonial sensitivity has shown a shift towards higher
unsaturation of PC lipids in drug-resistant clones, suggesting an
increase in membrane fluidity that may be related to the changes
in uptake ability observed in the drug-resistant cell lines [12].
Another group of lipids that notably increased in abundance
during L. donovani promastigotes development in vitro were the SLs
(Figure 7A). SLs are not required for growth of Leishmania, since
parasites that completely lack SLs grew normally in logarithmic
phase and were still able to make ‘‘lipid rafts’’. However, deletion
of spt2-, the gene that encodes the key de novo biosynthetic
enzyme serine palmitoyltransferase subunit 2, resulted in parasites
deficient in de novo SLs synthesis that once in the stationary phase
were not able to differentiate into metacyclic forms [23]. The
increase in SLs during stationary phase we have found in this study
is consistent with the requirement of these metabolites for
differentiation to metacyclic froms. SLs are considered essential
membrane components in all eukaryotes, mediating many
signaling pathways including those key for apoptosis, growth and
differentiation [39]. However, in Leishmania the primary role of SLs
appears to be the provision of ethanolamine, as ethanolamine
supplementation was able to overcome the phenotype observed in
the SL-deficient mutant parasites [40]. Ethanolamine and choline
are essential nutrients, and when available exogenously they can
be salvaged by Leishmania via membrane transporters [41,42].
Thus the significance of SL biosynthesis is likely to be stage-
specific, being important in those stages in the sand fly that cannot
rely upon salvaged ethanolamine. Indeed, amastigotes deficient in
de novo SLs synthesis recovered from a mammalian host showed
normal levels of inositolphosphoryl ceramide (IPC) and thus
amastigotes seems to be able to perform SLs salvage [43].
Glycerolipids, represented by diacylglycerols (DAG) and
triacylglycerols (TAG), also increased in abundance as L. donovani
promastigote development progressed (Figure 7B). PC and PE
lipids are synthesized by conjugation of a lipid anchor such as
DAG with either CDP-choline or CDP-ethanolamine, the last step
of the in de novo biosynthesis of phospholipids (the Kennedy
pathway) (reviewed in [44]). Thus the observed increase in neutral
lipids correlates well with the changes observed in Leishmania
membrane lipid composition during promastigote development.
Sterol and prenol lipids also increased with time in culture,
although the changes during L. donovani promastigotes develop-
ment were not so accentuated as for SLs and glycerolipids. Sterols
are the target of the important antileishmanial drug amphotericin
B [36] and they may also play a significant role in the activity of
miltefosine against the parasite, as sterol depletion led to a
decrease in susceptibility [45]. Effectiveness of these drugs is
mainly dependent on their interaction with the Leishmania
membrane, thus it is clear that the ability of the parasite to
change its lipid membrane composition, which occurs inherent
during its life cycle, should be taken into consideration when
considering new drug formulations.
Leishmania parasites are auxotrophic for many amino acids and
must scavenge essential amino acids from their hosts. Besides the
use in protein biosynthesis, some amino acids, notably proline, can
be used as major energy sources [46]. Recently, Saunders and co-
workers have reported that aspartate, alanine and glutamate are
internalized by L. mexicana promastigotes and incorporated into the
TCA cycle, revealing the importance of this pathway in glutamate,
glutamine and proline synthesis and demonstrating that the TCA
cycle in Leishmania is not only a catabolic pathway [47]. One
notable feature in the levels of amino acids and amino acid
conjugates during growth of promastigotes in vitro was a large
increase in metabolites of fatty acids named acyl glycines
(valerylglycine, tiglyglycine, N-butyrylglycine). Increases in levels
of acyl glycines in higher eukaryotes is associated with mitochon-
drial energy metabolism disorders, indeed the measurement of
these metabolites is used as a diagnostic tool. Glycine conjugation
is considered to be an important detoxification system, preventing
the accumulation of acyl-CoA esters in several inherited metabolic
disorders of humans [48]. Moreover, valerylglycine was found to
be increased in urine of Plasmodium vivax-infected individuals,
which indicates an alteration in the fatty acid metabolism during
infection [49]. These changes in acylglycines abundance during
promastigote development could reflect changes in mitochondrial
metabolism, but caution needs to be exercised as increased levels
of this group of compounds was also found in drug-resistant
parasites [12] and also in genetically manipulated mutants (A.M.
Silva et al., unpublished results) – which indicates that the levels of
these metabolites may be disturbed in a variety of situations.
Leishmania also take up from their environment other essential
nutrients, such as purines and growth factors. Biopterin and folate
uptake has been shown to decrease when promastigote have
entered stationary phase [50], which is consistent with our findings
that there was a decrease in abundance of 5-methyl-THF and
dihydrobiopterin in L. donovani promastigotes at day 6 of in vitro
growth. Indeed, low levels of tetrahydrobiopterin were associated
Figure 5. Heatmap depicting significant fluctuations in L. donovani promastigotes intracellular metabolome during in vitro
development. Profiles over 4 days of intracellular metabolites that differed at least by 2-fold from the mean levels in at least one of the time points
analyzed. Metabolite intensity levels on each day were compared with the mean level over the 4 day period. Following a logarithmic transformation
(base 2), the relative level of each metabolite is shown; log2 (x/X3–6) below21 or above 1 indicates a 2-fold change; x, time point analyzed (day 3, 4, 5
or 6). Metabolites labelled with * represent peaks with multiple potential identifications, for which just one is shown in this figure but the full list is
given in the Supporting Information; metabolite profiles are ordered by compound category shown on the left and log values of ratios are color-
coded as indicated in the scale on the right of the heat map, from green to red.
doi:10.1371/journal.pntd.0001451.g005
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with increased differentiation of L. major into the infective
metacyclic form and thus postulated to be an important factor
controlling this process [51]. Leishmania parasites are not able to
synthesize purines de novo and need to acquire either nucleosides
or nucleobases [52]. Hypoxanthine uptake by L. major promas-
tigotes is greatly reduced in stationary phase compared with
logarithmic growth phase. This was shown to correlate with
down-regulation of expression of the NT3 permease as
promastigotes reach stationary phase [53] and it was reasoned
that these changes reflected the fact that at this stage the
population is mainly composed by non-dividing cells, the
metacyclic promastigotes, that do not require purines for mitosis.
Our findings of an increase in the levels of hypoxanthine and
xanthine at day 6 of L. donovani promastigotes in vitro growth
Figure 6. Comparative analysis of phosphatidylcholines and phosphatidylethanolamines in L. donovani promastigotes on days 3
and 6. Fatty acyl structure properties in (A) phosphatidylcholines (PC) and (B) phosphatidylethanolamines (PE) for each phospholipid detected on
day 6 and day 3. The x-axis shows the total number of unsaturated bonds present in the 2 fatty acyl chains, while the y-axis shows the length of the
fatty acyl chains in total number of carbon units. Data are shown as ratios of signal intensity, day 6/day 3, after a logarithmic transformation (base 2)
and represented by a color code as indicated in the scale on the right of the heat map, from green to red, where green represents a decrease and a
red an increase in abundance of the given phospholipid on day 6.
doi:10.1371/journal.pntd.0001451.g006
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Figure 7. Stage specific increase of sphingolipids and glycerolipids abundance during L. donovani promastigotes development in
vitro. (A) Sphingolipids and sphingoid base and (B) glycerolipid metabolites abundance is represented for each day as a percentage of the total
abundance detected, which comprises the sum of the total metabolite intensity on each of the 4 days analysed. Metabolites labelled with * represent
peaks with multiple potential identifications, for which just one is shown in this figure but the full list is given in the Supporting Information. DAG,
diacylglycerol; TAG, triacylglycerol.
doi:10.1371/journal.pntd.0001451.g007
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explain why less uptake is required at this stage. Moreover, one
can speculate that these higher levels in the metacyclic forms are
beneficial in enabling the subsequent differentiation events after
infection of a mammal, a transition phase that occurs in the
parasitophorous vacuole of a macrophage where availability of
some nutrients may be limiting [54,55].
Overall the results of this study have provided convincing data
that promastigotes of Leishmania at different stages of culture in
vitro differ from each other significantly in terms of the
composition of their metabolome, whereas the total metabolite
abundance appears to remain relatively constant as the promas-
tigotes develop from day 3 to day 6. The study has provided
insights into the overall changes that occur, which adds to the
many previous reports on changes in individual metabolites,
groups of metabolites and enzymatic reactions involved in
metabolite production (see, for example, [16,46,56–58]). Our
data are consistent in particular with previous findings obtained
using other approaches, such as changes observed in the content of
sphingolipids and other lipids that may contribute to successful
parasite survival in the mammalian host [23,57]. These changes
observed undoubtedly reflect adaptations to differing conditions
that Leishmania encounters in its two hosts, but the full
understanding of how these adaptations function require addi-
tional data on the environments themselves (the detailed content of
the parasitophorous vacuole in a macrophage and the intestinal
tract of the sand fly, and how these change with time, are largely
unknown) as well as more complete analyses of metabolism of
individual promastigote forms and if possible integration of the
generated data with those arising from other –omics approaches.
However, understanding the variation in metabolism of promas-
tigotes will be informative in elucidating more fully the metabolic
capabilities of Leishmania and hopefully highlight unusual features
that can be exploited in novel approaches to designing therapies.
Supporting Information
Figure S1 Overall metabolite levels remain similar
during L. donovani promastigotes development in vitro.
Sum of total metabolite intensities from L. donovani promastigotes
identified by LC-MS analysis at days 3, 4, 5 or 6 of in vitro growth.
(PDF)
Figure S2 Overall metabolite levels for each compound
category during L. donovani promastigotes development
in vitro. Sum of total metabolite intensities from L. donovani
promastigotes identified by LC-MS analysis at days 3, 4, 5 or 6 of
in vitro growth grouped by compound categories.
(PDF)
Figure S3 Patterns of metabolite variation in level
during L. donovani promastigote in vitro growth from
day 3 to day 6. Analysis of L. donovani promastigotes metabolome
at day 3, 4, 5 and 6 allowed the distinction of 5 patterns (1–5)
based on the metabolic profile for each metabolite that differed in
intensity by 2-fold or more from the mean levels in at least one of
the time points analyzed (a total of 97 metabolites). The relative
level of each metabolite is shown, following logarithmic transfor-
mation (base 2); log2 (x/X 3–6) below 21 or above 1 indicates a 2-
fold change; x, time point analyzed (day 3, 4, 5 or 6). (A) Pattern 1
(74% of all metabolites considered) and (C) pattern 3 (9%) include
metabolites that increased or decreased, respectively, continuously
during all the whole period analyzed; (B) pattern 2 (9%) include
metabolites which had peak levels on days 4 or 5 but which then
declined; (D) pattern 4 (2%) metabolite levels decreased from day 3
to day 4 and then increased and (E) pattern 5 (6%) include
metabolites that showed an increase followed by a decrease and
then another increase.
(PDF)
Figure S4 Glycerophospholipids abundance during L.
donovani promastigotes development in vitro. Glycer-
ophospholipids abundance is represented for each metabolite on
each day as a percentage of the total abundance detected, which
comprises the sum of the total metabolite intensity during the 4-
day period of analysis.
(PDF)
Figure S5 Sterol and prenol lipids abundance during L.
donovani promastigotes development in vitro. Sterol and
prenol lipids abundance is represented for each metabolite on each
day as a percentage of the total abundance detected, which
comprises the sum of the total metabolite intensity during the 4-
day period of analysis. Metabolites labelled with * represent peaks
with multiple potential identifications, for which just one is shown
in this figure but the full list is given in Tables S1 and S2.
(PDF)
Figure S6 Fatty acyls abundance during L. donovani
promastigotes development in vitro. Fatty acyls abundance
is represented for each metabolite on each day as a percentage of
the total abundance detected, which comprises the sum of the total
metabolite intensity during the 4-day period of analysis. Metab-
olites labelled with * represent peaks with multiple potential
identifications, for which just one is shown in this figure but the full
list is given in Tables S1 and S2.
(PDF)
Figure S7 Amino acids and amino acids conjugates
abundance during L. donovani promastigotes develop-
ment in vitro. Amino acids and amino acids conjugates
abundance is represented for each metabolite on each day as a
percentage of the total abundance detected, which comprises the
sum of the total metabolite intensity during the 4-day period of
analysis. Metabolites labelled with * represent peaks with multiple
potential identifications, for which just one is shown in this figure
but the full list is given in Tables S1 and S2.
(PDF)
Figure S8 Carbohydrates and carbohydrate conjugates
abundance during L. donovani promastigotes develop-
ment in vitro. Carbohydrates and carbohydrate conjugates
abundance is represented for each metabolite on each day as a
percentage of the total abundance detected, which comprises the
sum of the total metabolite intensity during the 4-day period of
analysis. Metabolites labelled with * represent peaks with multiple
potential identifications, for which just one is shown in this figure
but the full list is given in Tables S1 and S2.
(PDF)
Figure S9 Nucleosides and nucleoside conjugates abun-
dance during L. donovani promastigotes development in
vitro. Nucleosides and nucleoside conjugate metabolites abun-
dance is represented for each metabolite on each day as a
percentage of the total abundance detected, which comprises the
sum of the total metabolite intensity during the 4-day period of
analysis. Metabolites labelled with * represent peaks with multiple
potential identifications, for which just one is shown in this figure
but the full list is given in Tables S1 and S2.
(PDF)
Figure S10 Organic acids abundance during L. dono-
vani promastigotes development in vitro. Organic acids
abundance is represented for each metabolite on each day as a
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percentage of the total abundance detected, which comprises the
sum of the total metabolite intensity during the 4-day period of
analysis. Metabolites labelled with * represent peaks with multiple
potential identifications, for which just one is shown in this figure
but the full list is given in Tables S1 and S2.
(PDF)
Figure S11 Vitamins and cofactors, ketones and alde-
hydes, heterocyclic molecules, amines and alcohols
abundance during L. donovani promastigotes develop-
ment in vitro. Vitamins and cofactors, ketones and aldehydes,
heterocyclic molecules, amines and alcohols abundance is
represented for each metabolite on each day as a percentage of
the total abundance detected, which comprises the sum of the total
metabolite intensity during the 4-day period of analysis. Metab-
olites labelled with * represent peaks with multiple potential
identifications, for which just one is shown in this figure but the full
list is given in Tables S1 and S2.
(PDF)
Table S1 Metabolites identified below 1 ppm deviation
in samples of L. donovani promastigotes from day 3 to
day 6 of in vitro growth. For each compound the following
information is shown: ionisation (ESI) mode; detected mass;
retention time (min); putative metabolite identification; ppm
deviation between detected mass and theoretical mass of the
putative metabolite identified; intensity per 25 mg cell protein for
each sample; average intensity per 25 mg cell protein in each time-
point analyzed (3D, 4D, 5D or 6D); standard deviation in each
time point analyzed; log base 2 of ratio of the average signal
intensity in each time point against the mean intensity level during
the 4 day period; F test statistics and p values obtained by analysis
of variance (ANOVA), indicating whether or not there was a
statistically significant difference between the time points analyzed;
decision on whether or not the compound was significantly
changed in level based on a two-fold or higher average difference
in signal intensity in at least one of the time points analyzed and
statistical significance (p,0.05); compound category.
(XLS)
Table S2 Metabolites identified between 1–2 ppm devi-
ation in samples of L. donovani promastigotes from day
3 to day 6 of in vitro growth. The data presented are as
described for Table S1.
(XLS)
Table S3 Intensity levels of metabolites that differ
significantly during L. donovani promastigote develop-
ment in vitro. Metabolites are ordered by compound category;
for each metabolite is shown the average intensity per 25 mg cell
protein at days 3, 4, 5 and 6 and the respective metabolic profile
pattern (analysis shown in Figure S2). Metabolites labelled with *
represent peaks with multiple potential identifications, for which
just one is shown in this figure but the full list is given in Table S1
and S2.
(PDF)
Acknowledgments
We thank: Malcolm McConville and colleagues (Melbourne) for excellent
guidance on the methods of sample preparation for the metabolomics
analyses; Ruben t’Kindt (ITM, Antwerp, and Strathclyde) for assistance
with the sample preparation method for the metabolomics analyses; Dave
G. Watson and Alex Zhang (Strathclyde) for help with the LC-MS
technology.
Author Contributions
Conceived and designed the experiments: AMS AC GHC. Performed the
experiments: AMS. Analyzed the data: AMS GHC. Wrote the paper:
AMS AC GHC.
References
1. Kedzierski L (2010) Leishmaniasis Vaccine: Where are We Today? J Glob Infect
Dis 2: 177–185.
2. Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in leishmaniasis. Clin
Microbiol Rev 19: 111–126.
3. Gossage SM, Rogers ME, Bates PA (2003) Two separate growth phases during
the development of Leishmania in sand flies: implications for understanding the
life cycle. Int J Parasitol 33: 1027–1034.
4. Kamhawi S (2006) Phlebotomine sand flies and Leishmania parasites: friends or
foes? Trends Parasitol 22: 439–445.
5. McConville MJ, Blackwell JM (1991) Developmental changes in the glycosylated
phosphatidylinositols of Leishmania donovani. Characterization of the promas-
tigote and amastigote glycolipids. J Biol Chem 266: 15170–15179.
6. McConville MJ, Turco SJ, Ferguson MA, Sacks DL (1992) Developmental
modification of lipophosphoglycan during the differentiation of Leishmania
major promastigotes to an infectious stage. EMBO J 11: 3593–3600.
7. Sacks DL, Pimenta PF, McConville MJ, Schneider P, Turco SJ (1995) Stage-
specific binding of Leishmania donovani to the sand fly vector midgut is
regulated by conformational changes in the abundant surface lipophosphogly-
can. J Exp Med 181: 685–697.
8. Sadlova J, Price HP, Smith BA, Votypka J, Volf P, et al. (2010) The stage-
regulated HASPB and SHERP proteins are essential for differentiation of the
protozoan parasite Leishmania major in its sand fly vector, Phlebotomus
papatasi. Cell Microbiol 12: 1765–1779.
9. Burchmore RJ, Barrett MP (2001) Life in vacuoles–nutrient acquisition by
Leishmania amastigotes. Int J Parasitol 31: 1311–1320.
10. De Souza DP, Saunders EC, McConville MJ, Likic VA (2006) Progressive peak
clustering in GC-MS Metabolomic experiments applied to Leishmania parasites.
Bioinformatics 22: 1391–1396.
11. t’Kindt R, Jankevics A, Scheltema RA, Zheng L, Watson DG, et al. (2010)
Towards an unbiased metabolic profiling of protozoan parasites: optimisation of
a Leishmania sampling protocol for HILIC-orbitrap analysis. Anal Bioanal
Chem 398: 2059–2069.
12. t’Kindt R, Scheltema RA, Jankevics A, Brunker K, Rijal S, et al. (2010)
Metabolomics to unveil and understand phenotypic diversity between pathogen
populations. PLoS Negl Trop Dis 4: e904.
13. Saunders EC, Ng WW, Chamber JM, Ng M, Naderer T, et al. (2011)
Isoptopomer profiling of Leishmania mexicana promastigotes reveals important
roles for succinate fermentation and aspartate uptake in TCA cycle anaplerosis,
glutamate synthesis and growth. J Biol Chem.
14. Naderer T, Heng J. McConville MJ Evidence that intracellular stages of
Leishmania major utilize amino sugars as a major carbon source. PLoS Pathog 6:
e1001245.
15. McConville MJ, Naderer T (2011) Metabolic Pathways Required for the
Intracellular Survival of Leishmania. Annu Rev Microbiol.
16. Saunders EC, DP DES, Naderer T, Sernee MF, Ralton JE, et al. Central carbon
metabolism of Leishmania parasites. Parasitology 137: 1303–1313.
17. Rogers ME, Chance ML, Bates PA (2002) The role of promastigote secretory gel
in the origin and transmission of the infective stage of Leishmania mexicana by
the sandfly Lutzomyia longipalpis. Parasitology 124: 495–507.
18. Davies CR, Cooper AM, Peacock C, Lane RP, Blackwell JM (1990) Expression
of LPG and GP63 by different developmental stages of Leishmania major in the
sandfly Phlebotomus papatasi. Parasitology 101 Pt 3: 337–343.
19. Schneider P, Rosat JP, Bouvier J, Louis J, Bordier C (1992) Leishmania major:
differential regulation of the surface metalloprotease in amastigote and
promastigote stages. Exp Parasitol 75: 196–206.
20. Pimenta PF, Saraiva EM, Sacks DL (1991) The comparative fine structure and
surface glycoconjugate expression of three life stages of Leishmania major. Exp
Parasitol 72: 191–204.
21. Rijal S, Yardley V, Chappuis F, Decuypere S, Khanal B, et al. (2007) Antimonial
treatment of visceral leishmaniasis: are current in vitro susceptibility assays
adequate for prognosis of in vivo therapy outcome? Microbes Infect 9: 529–535.
22. Wishart DS (2010) Computational approaches to metabolomics. Methods Mol
Biol 593: 283–313.
23. Zhang K, Showalter M, Revollo J, Hsu FF, Turk J, et al. (2003) Sphingolipids are
essential for differentiation but not growth in Leishmania. EMBO J 22: 6016–6026.
24. Bates PA, Rogers ME (2004) New insights into the developmental biology and
transmission mechanisms of Leishmania. Curr Mol Med 4: 601–609.
25. Sacks DL, Brodin TN, Turco SJ (1990) Developmental modification of the
lipophosphoglycan from Leishmania major promastigotes during metacyclogen-
esis. Mol Biochem Parasitol 42: 225–233.
Metabolome of Leishmania Promastigotes
www.plosntds.org 12 December 2011 | Volume 5 | Issue 12 | e1451
26. Saraiva EM, Pimenta PF, Brodin TN, Rowton E, Modi GB, et al. (1995)
Changes in lipophosphoglycan and gene expression associated with the
development of Leishmania major in Phlebotomus papatasi. Parasitology
111(Pt 3): 275–287.
27. Yao C, Donelson JE, Wilson ME (2003) The major surface protease (MSP or
GP63) of Leishmania sp. Biosynthesis, regulation of expression, and function.
Mol Biochem Parasitol 132: 1–16.
28. Besteiro S, Williams RA, Morrison LS, Coombs GH, Mottram JC (2006)
Endosome sorting and autophagy are essential for differentiation and virulence
of Leishmania major. J Biol Chem 281: 11384–11396.
29. Denny PW, Smith DF (2004) Rafts and sphingolipid biosynthesis in the
kinetoplastid parasitic protozoa. Mol Microbiol 53: 725–733.
30. Wassef MK, Fioretti TB, Dwyer DM (1985) Lipid analyses of isolated surface
membranes of Leishmania donovani promastigotes. Lipids 20: 108–115.
31. Zufferey R, Allen S, Barron T, Sullivan DR, Denny PW, et al. (2003) Ether
phospholipids and glycosylinositolphospholipids are not required for amastigote
virulence or for inhibition of macrophage activation by Leishmania major. J Biol
Chem 278: 44708–44718.
32. Beney L, Gervais P (2001) Influence of the fluidity of the membrane on the
response of microorganisms to environmental stresses. Appl Microbiol
Biotechnol 57: 34–42.
33. Suutari M, Liukkonen K, Laakso S (1990) Temperature adaptation in yeasts: the
role of fatty acids. J Gen Microbiol 136: 1469–1474.
34. Turk M, Plemenitas A, Gunde-Cimerman N (2011) Extremophilic yeasts:
plasma-membrane fluidity as determinant of stress tolerance. Fungal Biol 115:
950–958.
35. Wahid A, Gelani S, Ashraf M, Foolad MR (2007) Heat tolerance in plants: An
overview. Environmental and Experimental Botan 61: 199–223.
36. Mbongo N, Loiseau PM, Billion MA, Robert-Gero M (1998) Mechanism of
amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob
Agents Chemother 42: 352–357.
37. Cauchetier E, Loiseau PM, Lehman J, Rivollet D, Fleury J, et al. (2002)
Characterisation of atovaquone resistance in Leishmania infantum promasti-
gotes. Int J Parasitol 32: 1043–1051.
38. Rakotomanga M, Saint-Pierre-Chazalet M, Loiseau PM (2005) Alteration of
fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani
promastigotes and consequences for drug-membrane interactions. Antimicrob
Agents Chemother 49: 2677–2686.
39. Hannun YA, Obeid LM (2008) Principles of bioactive lipid signalling: lessons
from sphingolipids. Nat Rev Mol Cell Biol 9: 139–150.
40. Zhang K, Pompey JM, Hsu FF, Key P, Bandhuvula P, et al. (2007) Redirection
of sphingolipid metabolism toward de novo synthesis of ethanolamine in
Leishmania. EMBO J 26: 1094–1104.
41. Zufferey R, Mamoun CB (2002) Choline transport in Leishmania major
promastigotes and its inhibition by choline and phosphocholine analogs. Mol
Biochem Parasitol 125: 127–134.
42. Rifkin MR, Fairlamb AH (1985) Transport of ethanolamine and its
incorporation into the variant surface glycoprotein of bloodstream forms of
Trypanosoma brucei. Mol Biochem Parasitol 15: 245–256.
43. Zhang K, Hsu FF, Scott DA, Docampo R, Turk J, et al. (2005) Leishmania
salvage and remodelling of host sphingolipids in amastigote survival and
acidocalcisome biogenesis. Mol Microbiol 55: 1566–1578.
44. Gibellini F, Smith TK. The Kennedy pathway–De novo synthesis of
phosphatidylethanolamine and phosphatidylcholine. IUBMB Life 62: 414–428.
45. Saint-Pierre-Chazalet M, Ben Brahim M, Le Moyec L, Bories C,
Rakotomanga M, et al. (2009) Membrane sterol depletion impairs miltefosine
action in wild-type and miltefosine-resistant Leishmania donovani promasti-
gotes. J Antimicrob Chemother 64: 993–1001.
46. Opperdoes FR, Coombs GH (2007) Metabolism of Leishmania: proven and
predicted. Trends Parasitol 23: 149–158.
47. Saunders EC, Ng WW, Chamber JM, Ng M, Naderer T, et al. Isoptopomer
profiling of Leishmania mexicana promastigotes reveals important roles for
succinate fermentation and aspartate uptake in TCA cycle anaplerosis,
glutamate synthesis and growth. J Biol Chem.
48. Bonafe L, Troxler H, Kuster T, Heizmann CW, Chamoles NA, et al. (2000)
Evaluation of urinary acylglycines by electrospray tandem mass spectrometry in
mitochondrial energy metabolism defects and organic acidurias. Mol Genet
Metab 69: 302–311.
49. Sengupta A (2010) A Urine IH NMR based Metabonomic Approach to
Understand the Host Metabolic Response towards Plasmodium vivax Infection.
Proceedings of 2010 International Conference on Systems in Medicine and
Biology.
50. Cunningham ML, Beverley SM (2001) Pteridine salvage throughout the
Leishmania infectious cycle: implications for antifolate chemotherapy. Mol
Biochem Parasitol 113: 199–213.
51. Cunningham ML, Titus RG, Turco SJ, Beverley SM (2001) Regulation of
differentiation to the infective stage of the protozoan parasite Leishmania major
by tetrahydrobiopterin. Science 292: 285–287.
52. Landfear SM, Ullman B, Carter NS, Sanchez MA (2004) Nucleoside and
nucleobase transporters in parasitic protozoa. Eukaryot Cell 3: 245–254.
53. Ortiz D, Sanchez MA, Pierce S, Herrmann T, Kimblin N, et al. (2007)
Molecular genetic analysis of purine nucleobase transport in Leishmania major.
Mol Microbiol 64: 1228–1243.
54. Naderer T, McConville MJ (2008) The Leishmania-macrophage interaction: a
metabolic perspective. Cell Microbiol 10: 301–308.
55. McConville MJ, de Souza D, Saunders E, Likic VA, Naderer T (2007) Living in
a phagolysosome; metabolism of Leishmania amastigotes. Trends Parasitol 23:
368–375.
56. Rosenzweig D, Smith D, Opperdoes F, Stern S, Olafson RW, et al. (2008)
Retooling Leishmania metabolism: from sand fly gut to human macrophage.
FASEB J 22: 590–602.
57. Zhang K, Beverley SM (2010) Phospholipid and sphingolipid metabolism in
Leishmania. Mol Biochem Parasitol 170: 55–64.
58. Colotti G, Ilari A (2011) Polyamine metabolism in Leishmania: from arginine to
trypanothione. Amino Acids 40: 269–285.
Metabolome of Leishmania Promastigotes
www.plosntds.org 13 December 2011 | Volume 5 | Issue 12 | e1451
4. Objectives and Results 
 
246 
 
Supporting Information 
 
 
 
 
 
Figure S1. Overall metabolite levels remain similar during L. donovani promastigotes 
development in vitro. Sum of total metabolite intensities from L. donovani promastigotes 
identified by LC-MS analysis at days 3, 4, 5 or 6 of in vitro growth. 
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Figure S2. Overall metabolite levels for each compound category during L. donovani 
promastigotes development in vitro. Sum of total metabolite intensities from L. donovani 
promastigotes identified by LC-MS analysis at days 3, 4, 5 or 6 of in vitro growth grouped by 
compound categories. 
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Figure S3. Patterns of metabolite variation in level during L. donovani promastigote in 
vitro growth from day 3 to day 6. Analysis of  L. donovani promastigotes metabolome at 
day 3, 4, 5 and 6 allowed the distinction of 5 patterns (1-5) based on the metabolic profile for 
each metabolite that differed in intensity by 2-fold or more from the mean levels in at least 
one of the time points analyzed (a total of 97 metabolites). The relative level of each 
metabolite is shown, following logarithmic transformation (base 2); log2 (x/Χ 3-6) below -1 or 
above 1 indicates a 2-fold change; x, time point analyzed (day 3, 4, 5 or 6). (A) Pattern 1 
(74% of all metabolites considered) and (C) pattern 3 (9%) include metabolites that 
increased or decreased, respectively, continuously during all the whole period analyzed,; (B) 
pattern 2 (9%) include metabolites which had peak levels on days 4 or 5 but which then 
declined;  (D) pattern 4 (2%) metabolite levels decreased from day 3 to day 4 and then 
increased and  (E) pattern 5 (6%) include metabolites that showed an increase followed by a 
decrease and then another increase. 
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Figure S4. Glycerophospholipids abundance during L. donovani promastigotes 
development in vitro. Glycerophospholipids abundance is represented for each metabolite 
on each day as a percentage of the total abundance detected, which comprises the sum of 
the total metabolite intensity during the 4-day period of analysis. 
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Figure S5. Sterol and prenol lipids abundance during L. donovani promastigotes 
development in vitro. Sterol and prenol lipids abundance is represented for each metabolite 
on each day as a percentage of the total abundance detected, which comprises the sum of 
the total metabolite intensity during the 4-day period of analysis. Metabolites labelled with * 
represent peaks with multiple potential identifications, for which just one is shown in this 
figure but the full list is given in Tables S1 and S2. 
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Figure S6. Fatty acyls abundance during L. donovani promastigotes development in 
vitro. Fatty acyls abundance is represented for each metabolite on each day as a 
percentage of the total abundance detected, which comprises the sum of the total metabolite 
intensity during the 4-day period of analysis. Metabolites labelled with * represent peaks with 
multiple potential identifications, for which just one is shown in this figure but the full list is 
given in Tables S1 and S2. 
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Figure S7. Amino acids and amino acids conjugates abundance during L. donovani 
promastigotes development in vitro. Amino acids and amino acids conjugates abundance 
is represented for each metabolite on each day as a percentage of the total abundance 
detected, which comprises the sum of the total metabolite intensity during the 4-day period of 
analysis. Metabolites labelled with * represent peaks with multiple potential identifications, for 
which just one is shown in this figure but the full list is given in Tables S1 and S2. 
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Figure S8. Carbohydrates and carbohydrate conjugates abundance during L. donovani 
promastigotes development in vitro. Carbohydrates and carbohydrate conjugates 
abundance is represented for each metabolite on each day as a percentage of the total 
abundance detected, which comprises the sum of the total metabolite intensity during the 4-
day period of analysis. Metabolites labelled with * represent peaks with multiple potential 
identifications, for which just one is shown in this figure but the full list is given in Tables S1 
and S2. 
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Figure S9. Nucleosides and nucleoside conjugates abundance during L. donovani 
promastigotes development in vitro. Nucleosides and nucleoside conjugate metabolites 
abundance is represented for each metabolite on each day as a percentage of the total 
abundance detected, which comprises the sum of the total metabolite intensity during the 4-
day period of analysis. Metabolites labelled with * represent peaks with multiple potential 
identifications, for which just one is shown in this figure but the full list is given in Tables S1 
and S2. 
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Figure S10. Organic acids abundance during L. donovani promastigotes development 
in vitro. Organic acids abundance is represented for each metabolite on each day as a 
percentage of the total abundance detected, which comprises the sum of the total metabolite 
intensity during the 4-day period of analysis. Metabolites labelled with * represent peaks with 
multiple potential identifications, for which just one is shown in this figure but the full list is 
given in Tables S1 and S2. 
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Figure S11. Vitamins and cofactors, ketones and aldehydes, heterocyclic molecules, 
amines and alcohols abundance during L. donovani promastigotes development in 
vitro. Vitamins and cofactors, ketones and aldehydes, heterocyclic molecules, amines and 
alcohols abundance is represented for each metabolite on each day as a percentage of the 
total abundance detected, which comprises the sum of the total metabolite intensity during 
the 4-day period of analysis. Metabolites labelled with * represent peaks with multiple 
potential identifications, for which just one is shown in this figure but the full list is given in 
Tables S1 and S2. 
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Table S1 – Metabolites identified below 1 ppm deviation in samples of L. donovani 
promastigotes from day 3 to day 6 of in vitro growth. For each compound the following 
information is shown: ionisation (ESI) mode; detected mass; retention time (min); putative 
metabolite identification; ppm deviation between detected mass and theoretical mass of the 
putative metabolite identified; intensity per 25 µg cell protein for each sample; average 
intensity per 25 µg cell protein in each time-point analyzed (3D, 4D, 5D or 6D); standard 
deviation in each time point analyzed; log base 2 of ratio of the average signal intensity in 
each time point against the mean intensity level during the 4 day period; F test statistics and 
p values obtained by analysis of variance (ANOVA), indicating whether or not there was a 
statistically significant difference between the time points analyzed; decision on whether or 
not the compound was significantly changed in level based on a two-fold or higher average 
difference in signal intensity in at least one of the time points analyzed and statistical 
significance (p<0.05); compound category. 
 
Table S2 – Metabolites identified between 1-2 ppm deviation in samples of L. donovani 
promastigotes from day 3 to day 6 of in vitro growth. The data presented are as 
described for Table S1. 
 
 
Tables S1 and S2 are available in the electronic version of the thesis. 
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Table S3 – Intensity levels of metabolites that differ significantly during L. donovani 
promastigote development in vitro 
 Average intensity per 25µg cell protein  
 day 3 day 4 day 5 day 6 pattern 
amines 
N-acetylputrescine 2.53E+05 3.69E+05 1.42E+06 2.42E+05 2 
amino acids and amino acids conjugates 
proline 2.95E+08 3.07E+08 2.45E+08 1.10E+08 2 
2-amino-3-oxobutanoic acid* 2.29E+05 3.69E+05 5.77E+05 6.99E+05 1 
glutamate-semialdehyde 1.36E+07 1.09E+07 8.36E+06 1.89E+06 3 
homocysteine 2.56E+05 2.26E+05 1.18E+05 7.34E+04 3 
N-butyrylglycine 1.28E+05 4.13E+05 1.11E+06 5.04E+06 1 
lysine 5.54E+06 1.31E+07 2.01E+07 2.75E+07 1 
tiglylglycine* 7.76E+04 1.70E+05 2.41E+05 6.00E+05 1 
valerylglycine 1.64E+05 7.21E+05 2.16E+06 8.90E+06 1 
carnitine 1.89E+06 1.16E+06 7.44E+05 4.24E+05 3 
N-acetylleucine* 8.48E+04 1.97E+05 3.19E+05 6.26E+05 1 
acetyl-lysine* 1.37E+05 2.11E+05 3.01E+05 9.75E+05 1 
N-acetyl-arginine 7.16E+04 9.36E+04 2.82E+05 6.45E+05 1 
cystathionine 7.54E+07 6.69E+07 3.76E+07 2.15E+07 3 
prolylhydroxyproline 3.64E+06 9.33E+05 4.89E+05 4.28E+05 3 
malonylcarnitine 3.10E+05 3.29E+05 3.02E+05 1.33E+05 2 
aspartyl-aspartic acid 2.44E+05 4.27E+05 6.60E+05 1.08E+06 1 
aspartyl-phenylalanine 1.20E+07 9.04E+06 5.29E+06 3.64E+06 3 
glutathione disulfide 4.47E+04 5.03E+04 7.74E+04 1.74E+05 1 
trypanothione 1.32E+06 1.25E+06 2.09E+06 2.55E+05 2 
carbohydrates and carbohydrate conjugates 
trehalose* 4.18E+04 5.29E+04 1.18E+05 1.87E+05 1 
maltotriose 1.30E+05 2.21E+05 4.06E+05 8.18E+05 1 
maltotetraose* 2.15E+05 3.97E+05 7.31E+05 1.50E+06 1 
maltopentaose* 5.27E+05 9.24E+05 1.61E+06 3.84E+06 1 
maltohexaose 7.40E+04 1.46E+05 2.78E+05 5.75E+05 1 
fatty acyls 
10-pentadecenal 8.05E+05 1.99E+06 3.95E+06 5.07E+06 1 
9, 12, 15-octadecatrienal* 4.12E+05 7.24E+05 7.89E+05 1.40E+06 1 
aminohexadecanoic acid 1.24E+06 3.28E+06 4.95E+06 6.42E+06 1 
linoleic acid 4.13E+05 6.35E+05 8.33E+05 1.42E+06 1 
N-(11Z, 14Z-eicosadienoyl)-ethanolamine 1.25E+06 2.24E+06 3.32E+05 1.66E+06 5 
N-(11Z-eicosaenoyl)-ethanolamine 4.26E+05 6.65E+05 1.71E+05 5.46E+05 5 
glycerolipids 
DAG(36:5) 2.75E+05 6.27E+05 9.69E+05 1.49E+06 1 
DAG(36:4) 2.41E+05 6.16E+05 1.10E+06 2.08E+06 1 
DAG(36:3) 2.01E+05 4.02E+05 6.79E+05 1.24E+06 1 
DAG(42:3)* 2.07E+05 1.87E+05 2.28E+05 3.74E+06 4 
DAG(46:7) 1.18E+06 3.49E+06 5.64E+06 7.39E+06 1 
TAG(54:7) 9.96E+04 1.76E+05 2.99E+05 5.63E+05 1 
TAG(54:6) 9.75E+04 2.42E+05 2.75E+05 5.33E+05 1 
TAG(54:5) 1.05E+05 1.34E+05 2.41E+05 4.09E+05 1 
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 Average intensity per 25µg cell protein  
 day 3 day 4 day 5 day 6 pattern 
glycerophospholipids 
GPC(14:1) 1.63E+05 3.07E+05 3.41E+05 5.07E+05 1 
lysoPE(18:2/1) 5.44E+05 1.00E+06 1.29E+06 2.60E+06 1 
GPE(18:1/1) 4.08E+05 6.25E+05 8.82E+05 1.96E+06 1 
GPP(20:0/2) 1.08E+05 2.45E+05 1.83E+05 3.76E+05 5 
GPC(17:0/1) 1.35E+05 2.05E+05 3.70E+05 8.45E+05 1 
GPC(18:3/1) 1.80E+06 3.66E+06 4.16E+06 7.79E+06 1 
GPC(18:2/-1) 2.57E+06 9.45E+06 1.41E+07 3.00E+07 1 
GPC(18:1/-1) 1.03E+06 1.96E+06 4.49E+06 1.22E+07 1 
GPC(18:0/1) 2.37E+06 3.32E+06 5.71E+06 1.58E+07 1 
lysoPC(20:3/1) 4.60E+05 9.64E+05 1.44E+06 2.59E+06 1 
lysoPC (20:2/1) 2.17E+05 8.20E+05 1.52E+06 3.65E+06 1 
GPC(22:5/1) 1.60E+06 2.76E+06 3.20E+06 5.78E+06 1 
GPI(18:1/1) 7.03E+05 1.28E+06 2.15E+06 6.64E+06 1 
GPC(32:3/1) 5.42E+06 1.17E+07 1.58E+07 2.41E+07 1 
GPC(32:1//1)* 7.21E+06 1.48E+07 1.86E+07 2.55E+07 1 
GPC(32:4/2)* 7.73E+06 2.72E+06 1.47E+06 8.56E+05 3 
GPC(34:3/1)* 1.94E+06 3.61E+06 5.38E+06 9.75E+06 1 
GPC(34:1)* 1.81E+06 4.36E+06 6.10E+06 9.81E+06 1 
GPS(34:1/2) 4.93E+04 9.19E+04 1.56E+05 2.73E+05 1 
GPC(36:3/1) 8.31E+05 1.36E+06 2.05E+06 3.16E+06 1 
DMGPE(36:2/2)* 3.04E+06 7.00E+06 1.02E+07 1.38E+07 1 
GPE(38:1/2)* 7.82E+05 1.12E+06 1.93E+06 2.91E+06 1 
GPC(36:7/2) 1.77E+07 8.26E+06 3.54E+06 1.61E+06 3 
GPC(36:2/2) 3.92E+07 8.97E+07 1.31E+08 1.80E+08 1 
GPC(36:1/2) 7.42E+06 1.42E+07 2.57E+07 4.08E+07 1 
GPC(37:2/2)* 4.74E+05 1.07E+06 1.59E+06 2.52E+06 1 
GPT(36:1/2) 1.11E+06 2.89E+06 2.61E+06 3.58E+06 5 
GPC(38:2/2) 1.46E+06 3.34E+06 6.01E+06 9.48E+06 1 
GPC(40:10/2) 1.61E+07 6.25E+06 2.41E+06 1.31E+06 3 
GPC(42:3) 2.29E+05 3.68E+05 5.41E+05 7.63E+05 1 
GPC(42:0/2) 1.61E+05 7.04E+04 1.37E+05 2.74E+05 4 
GPC(44:2/2) 3.37E+05 1.17E+06 1.90E+06 2.36E+06 1 
GPC(46:2/2) 8.51E+04 1.72E+05 3.58E+05 4.09E+05 1 
heterocyclic molecules 
indolelactate 2.40E+05 4.93E+05 9.25E+05 1.08E+06 1 
dihydrobiopterin 1.61E+06 4.21E+06 1.46E+07 2.49E+06 2 
ketones and aldehydes 
aminoacetone* 6.33E+05 1.66E+06 2.54E+06 4.79E+06 1 
nucleosides and nucleoside conjugates 
cytosine 4.23E+05 6.16E+05 1.04E+06 2.74E+05 2 
hypoxanthine 1.97E+05 4.06E+05 8.04E+06 3.92E+07 1 
deoxycytidine 2.58E+05 5.26E+05 6.69E+05 1.37E+05 2 
others 
diphosphate 2.29E+05 8.11E+05 8.09E+05 6.86E+05 2 
N-methylpelletierine 6.41E+04 1.19E+05 2.23E+05 8.01E+05 1 
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 Average intensity per 25µg cell protein  
 day 3 day 4 day 5 day 6 pattern 
sphingolipids and sphingoid bases 
1-deoxy-sphinganine 7.66E+05 1.78E+06 2.56E+06 4.22E+06 1 
heptadecasphinganine 2.03E+05 3.77E+05 6.85E+05 1.59E+06 1 
dehydrosphinganine 5.47E+05 1.62E+06 2.57E+06 3.41E+06 1 
SP(2-amino-14, 16-dimethyloctadecan-3-ol) 1.97E+05 3.43E+05 5.10E+05 7.92E+05 1 
4-hydroxysphinganine 1.54E+05 4.09E+05 5.08E+05 5.61E+05 1 
N, N-dimethylsphing-4-enine 1.66E+05 4.56E+05 3.60E+05 6.02E+05 5 
SP(2S-dimethylaminooctadecane-1, 3R-diol) 9.15E+05 1.77E+06 2.59E+06 3.07E+06 1 
N-(hexadecanoyl)-sphing-4-enine 4.60E+06 1.08E+07 2.28E+07 4.17E+07 1 
N-(hexadecanoyl)-4S-hydroxysphinganine 1.99E+06 6.10E+06 1.36E+07 2.24E+07 1 
N-(octadecanoyl)-sphing-4-enine 1.41E+05 4.74E+05 1.46E+06 2.87E+06 1 
sterol and prenol lipids 
retinol acetate* 3.05E+05 4.31E+05 7.13E+05 1.16E+06 1 
(5Z, 7E)-(1S, 3R)-23, 24-dinor-9, 10-seco…* 2.00E+05 3.37E+05 5.79E+05 1.07E+06 1 
dehydrosqualene 4.84E+05 9.31E+05 1.65E+06 2.19E+06 1 
epoxysqualene* 2.21E+05 3.80E+05 5.52E+05 6.77E+05 1 
30,32-dihydroxy-2b-methyl-bishomohopane 1.40E+05 8.12E+05 3.36E+06 7.48E+06 1 
vitamins and cofactors 
5-methyl-THF 1.31E+05 4.47E+05 5.24E+05 1.49E+05 2 
 
Metabolites are ordered by compound category; for each metabolite is shown the average intensity per 25 µg cell 
protein at days 3, 4, 5 and 6 and the respective metabolic profile pattern (analysis shown in Figure S2). 
Metabolites labelled with * represent peaks with multiple potential identifications, for which just one is shown in 
this figure but the full list is given in Table S1 and S2. 
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4.7  Comparative metabolomic analyses of Leishmania donovani and  
Leihmania major reveal specificity in tryptophan metabolism 
 
 
 
We have undertaken a comparative analysis of the metabolomes of promastigotes of L. 
donovani and L. major, species that cause visceral and cutaneous leishmaniasis, 
respectively. 30.7% of the identified metabolites differed between the two species, 
although the overall abundance of all identified metabolites was similar. Large differences 
were detected in some amino acids, peptides and amines, as well as with some lipids.  A 
particularly notable finding was the differing utilization of tryptophan. The data provide 
clear evidence on the value of metabolomics in detecting species-specific metabolic 
features of Leishmania, thus application of this technology should aid in obtaining a better 
understanding of the parasite’s cell biology and also contribute to novel drug and vaccine 
discovery. 
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Abstract 
 
We have undertaken a comparative analysis of the metabolomes of promastigotes of L. 
donovani and L. major, species that cause visceral and cutaneous leishmaniasis, 
respectively. 30.7% of the identified metabolites differed between the two species, 
although the overall abundance of all identified metabolites was similar. Large differences 
were detected in some amino acids, peptides and amines, as well as with some lipids.  A 
particularly notable finding was the differing utilization of tryptophan. The data provide 
clear evidence on the value of metabolomics in detecting species-specific metabolic 
features of Leishmania, thus application of this technology should aid in obtaining a better 
understanding of the parasite’s cell biology and also contribute to novel drug and vaccine 
discovery. 
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Introduction 
 
Leishmaniasis, caused by the protozoan parasite Leishmania, is an important global 
health problem with an estimated 2 million new cases annually and some 350 million 
people at risk worldwide [1]. More than 20 different Leishmania species can cause 
disease [2], which ranges from self-healing cutaneous lesions to fatal visceral infections 
[1]. The clinical outcome of Leishmania infection is mainly dependent on the infecting 
species, but other factors such as the host immune status also play a role [2-4]. Visceral 
leishmaniasis is caused by L. donovani complex parasites while species resulting in 
cutaneous leishmaniasis include L. major, L. tropica and L. mexicana;  L. braziliensis and 
L. panamensis are examples of species that can cause the especially debilitating 
condition known as mucocutaneous leishmaniasis [5]. Although the characteristics of the 
various forms of leishmaniasis are well known, the mechanisms underlying the differing 
clinical outcomes resulting from infections with the various species are not well 
understood. The pathogenicity of Leishmania is thought to be mainly determined by the 
parasite species itself, thus understanding how species differ at the metabolic level should 
provide insights into not only the innate biological variation between species but also how 
each is adapted for its own niche within its host.   
 
Comparative genomics analysis of different Leishmania species has revealed strong 
conservation of gene content and synteny, with relatively few species-specific genes 
among L. major, L. braziliensis and L. infantum [6] even though the species have clear 
biological differences. Recent new sequencing technology has greatly facilitated the 
analyses of the L. donovani and L. mexicana genomes [7,8]; simultaneously details of the 
reference genomes of L. major, L. braziliensis and L. infantum were also refined [8]. 
These new data confirm the very small number of species-specific genes [7,8], as 
described before [6]. It was anticipated that discovery of species-specific genes would 
provide a key understanding of the differing ability of species to infect and survive in 
different tissues and hosts and the differing pathogenicity. A2 is one example of a 
species-specific gene that is required for L. donovani visceral infection in mice [9] and 
which, upon introduction into L. major , did impart some properties with respect to tissue 
tropism [10]. However, the results so far suggest that the phenotypic differences between 
the various species must be brought about through differential regulation of gene 
expression and protein function rather than simply the possession of different genes.  
Whilst genomics has a major role to play in revealing differences between the genomes of 
Leishmania species, it is limited in providing contextual and integrative information that is 
necessary to decipher the mechanisms of cellular function. In contrast, metabolites are 
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key in linking together the web of complex interactions, cellular pathways, molecular 
participants and environmental stimuli. Thus studies on the metabolomes of the various 
species should aid greatly in gaining an understanding of the adaptations of the individual 
species. The advent of improved methods for detecting and identifying metabolites has 
meant that the technology of ‘metabolomics’ now allows the measurement at high 
resolution of a cell’s metabolites. Thus it is being applied increasingly in drug discovery, 
disease diagnostics and treatment [11] and is now also beginning to be applied in 
research on parasites [12-15]. In this study, we have used an untargeted metabolomics 
approach to compare promastigotes of L. donovani and L. major. The data presented 
show that indeed there are some large differences in the levels of individual metabolites in 
the two species, whereas there is a high similarity between the two species in the overall 
metabolite profile.  
 
 
Material and Methods 
 
Leishmania parasites 
L. donovani (MHOM/NP/03/BPK206/0clone10) and L. major (MHOM/IL/80/Friedlin) were 
used in this study. L. donovani promastigotes had been cloned from an isolate from a 
visceral leishmaniasis patient sensitive to pentavalent antimonials in Nepal, as described 
by Rijal and co-workers [16]. L. donovani and L. major promastigotes were grown in 
modified Eagle’s medium (designated HOMEM medium, Invitrogen) supplemented with 
20% or 10% (v/v) heat inactivated fetal calf serum (PAA Laboratories) and at 26°C or 
27ºC, respectively. Cultures were set up initially at a concentration of 2.5 x 105 
parasites/ml and L. donovani was sub-passaged every 6 days, while L. major was sub-
passaged every 7 days. 
 
Leishmania extracts for metabolite analysis  
Promastigotes cultures were initiated at 2.5 x 105 cells/ml in 4 x 10 ml cultures in order to 
obtain cell samples from four independently growing cultures (biological replicates). 
Promastigotes from each culture were harvested at day 5 for metabolite extraction. The 
metabolite extraction was performed as previously described [12]. Briefly, promastigotes 
quenching was performed in a dry ice/ethanol bath with rapid temperature decrease to 
2ºC and then immediate transfer to ice. Two aliquots of 4 x 107 cells were taken from each 
culture flask (technical replicates). After centrifugation at 12000 g for 10 min at 4ºC, the 
supernatant (designated the spent medium) was removed and stored on ice. Cell pellets 
were washed 3 times in 1 ml of PBS at 4ºC by centrifugation at 12000 g for 10 min at 4ºC. 
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For cell disruption and metabolite extraction, cell pellets were resuspended in 200 µl cold 
chloroform/methanol/water (20/60/20, v/v/v) and incubated 1 h in a Thermomixer (1400 
rpm, 4ºC). After centrifugation at 12000 g for 10 min at 4ºC, the supernatant containing 
the extracted metabolites was recovered and stored at -70ºC until analysed. To 75 µl of 
spent medium was added 300 µl of cold chloroform/methanol (20/60, v/v) followed by 
incubation for 1 h on ice. After centrifugation at 12000 g for 10 min at 4ºC, the supernatant 
was recovered and stored at -70ºC until analysed. 
 
Liquid chromatography mass spectrometry (LC-MS) analysis and data processing 
LC-MS analysis and data processing was done as described by t’Kindt and co-workers 
[12,13] except that the intensity levels of each identified peak were normalized against the 
protein content of the cells used in order to take into account the differing cell volumes. 
Intensity level ratios were used to compare the different cell lines, with the following 
criteria being applied for differences to be considered of interest: (i) there was at least a 2-
fold difference between the L. donovani and L. major; (ii) there was a statistically 
significant difference (p<0.05) between the cell lines being compared. The metabolite data 
are expressed as intensity per 25 µg cell protein.   
 
Statistical analysis 
Statistical analysis was performed using Student’s T test: a p value smaller than 0.05 
(p<0.05) was considered significant; GraphPad Prism 4 was used for plotting the graphs.  
 
 
Results and Discussion 
 
L. donovani and L. major cause leishmaniasis with different clinical manifestations, 
visceral and cutaneous, and associated pathology [4]. Some distinct differences between 
the two species are known, for instance the lipophosphoglycan on the surface of the 
promastigotes is species-specific and is thought to account for differences in the 
attachment to sand fly midgut and play a role in the transmission to the mammalian host 
[17,18]. However, genomic and transcriptomic analyses have not yet provided 
explanations for the distinct species-specific biology of the two species [6,19]. Thus we 
undertook this study in the anticipation that identification of differences between the 
metabolomes of the species would provide greater insights into the individual 
characteristics of each. The results have yielded some key details on metabolic 
differences between the species which start to provide a framework for understanding 
how each is adapted for its particular biological niche. 
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In analyzing the intracellular metabolites of L. donovani and L. major promastigotes after 5 
days of in vitro culture, the metabolite intensity levels resulting from the LC-MS analysis 
were normalized against the protein content of the cells as this clearly differed between 
the two species (Table 1) reflecting differences in cell volumes.  
 
Table 1 – Comparison between L. major and L. donovani protein content and cell 
density at day 5 of in vitro growth 
 
Cell density 
(× 107/ml) 
Protein content 
(mg/108 cells) 
L. donovani 3.39 ± 0.138 0.371 ± 0.0023 
L. major 3.94 ± 0.147 **     0.284 ± 0.0017 *** 
 
L. donovani and L. major cell lines were seeded at 2.5 x 105 parasites/ml, counted daily 
and harvested at day 5. Protein content was determined by the Lowry method. Each 
value is a mean ± standard deviation from four cultures. Statistically significant 
differences between cell lines are indicated: ** p<0.01, *** p<0.001. 
 
Analysis of the intracellular metabolites of L. donovani and L. major lead to the putative 
identification of 208 metabolites (147 at <1 ppm deviation and 61 at 1-2 ppm deviation), of 
which 9 were only detected in one species. Fig. 1 shows the comparative intensity ratio 
between L. donovani and L. major for each metabolite putatively identified; 68 metabolites 
(34.2% of the total number of metabolites identified in both species) differed in intensity at 
least 2-fold between L. donovani and L. major, although the overall intensities in the two 
species was similar (1.33 x 109 and 1.46 x109, respectively).  
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Figure 1. Overview of intracellular metabolite levels comparison between L. 
donovani and L. major promastigotes. L. donovani and L. major promastigotes were 
harvested after 5 days of in vitro growth and cell extracts analyzed by LC-MS. All 
metabolites within the 2 ppm cut-off are included and following a logarithmic 
transformation (base 2) the average signal intensity ratios of L. donovani / L. major for all 
metabolites were plotted. Dotted lines represent the fold-change cut-off in this study for a 
given metabolite profile being considered to be significantly different between L. donovani 
and L. major: log2 (metabolite intensity ratio) below -1 or above 1 indicates a 2-fold 
change between cell lines compared. The metabolites differing at least by 2-fold between 
L. donovani and L. major promastigotes were 34.2% of the metabolites identified.  
 
Metabolites from a wide range of categories were detected, with glycerophospholipids and 
amino acids being the most represented, followed by sterols and prenol lipids, fatty acyls 
and carbohydrates (Fig. 2). Glycerolipids is the only group of compounds for which the 
overall intensity differs remarkably between L. donovani and L. major promastigotes (4-
fold higher in L. major) (Fig. S1). The full list of putatively identified metabolites are 
provided in Tables S1 and S2.  
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Figure 2. Distribution of the identified intracellular metabolites by compound 
category. L. donovani and L. major promastigotes were harvested after 5 days of in vitro 
growth and cell extracts analyzed by LC-MS. All identified intracellular metabolites were 
grouped by compound category. For each category compound is indicated the % of 
compounds identified.  
 
In analyzing the differences between L. donovani and L. major, we concentrated upon the 
metabolites that differed by at least 2-fold between the two species and for which a 
statistical significant difference (p<0.05) was observed. From a total of 61 metabolites that 
met these criteria (30.7% of all the metabolites identified in both species), 67.2% were due 
to a higher abundance in L. donovani.  The two categories of compounds most 
represented in this group of metabolites were glycerophospholipids and amino acids (Fig. 
3).  
 
 
Figure 3. Metabolites significant different between L. donovani and L. major. L. 
donovani and L. major promastigotes were harvested after 5 days of in vitro growth and 
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cell extracts analyzed by LC-MS. Differences between L. donovani and L. major 
promastigotes were based on average intensity per 25 μg cell protein ratios between the 
two cell lines, with a 2-fold difference being required for inclusion in the dataset. 
 
The significant differences observed between L. donovani and L. major are detailed in Fig. 
4. Large differences were found between the two species in the abundance of some lipids, 
amino acids and derivatives. All glycerophospholipids identified as differing between the 
two species were present in higher levels in L. donovani, while the majority of significant 
metabolites identified as sterol or prenol lipids were detected in higher levels in L. major. 
Some of the most interesting differences detected concern amino acids and their 
metabolites. For example, proline, arginine and tryptophan were detected in higher levels 
in L. major than in L. donovani while homoserine, glutamine, aspartic acid and numerous 
aspartyl peptides were more abundant in L. donovani. Intracellular proline levels were 
higher in L. major than in L. donovani, the reverse being the case for glutamine; but there 
were no differences in the intracellular levels of glutamate (Fig. 4). Related to this, it was 
found that the levels of glutamic acid in the spent media were remarkably lower for L. 
major than for L. donovani (Table 2). Recent data for L. mexicana promastigotes suggest 
that glutamate uptake is minimal under standard in vitro culture conditions; the same 
study also suggested that the internalized glutamic acid is primary used for anabolic than 
catabolic functions as a precursor of other amino acids such as proline and glutamine 
[20]. Proline, however, can also be oxidized to glutamic acid and used as an energy 
substrates in Leishmania [21].  Thus our study has demonstrated clearly that there are 
some distinct species differences in amino acid metabolism and this suggests that further 
analysis should be undertaken to understand fully the subtlety of the species-specific 
metabolism of proline and glutamate. The higher levels of intracellular arginine and 
ornithine detected in L. major when compared to L. donovani (Fig. 4) may reflect 
differences in polyamines requirements and/or a higher rate of polyamines production in 
L. major. Arginine, as a polyamine biosynthesis precursor, is an essential amino acid [22] 
and Leishmania needs to acquire it  from the medium. The finding that L. major 
promastigotes uptake more arginine from the culture medium than do L. donovani 
promastigotes (Table 2) is consistent with the higher intracellular levels of arginine and 
ornithine and also a potential difference in the production of polyamines and 
trypanothione.  
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A 
B 
 
Figure 4. Intracellular metabolites with significantly different profiles between L. 
donovani and L. major promastigotes. The average signal intensity ratio of L. donovani 
/ L. major for metabolites at significantly different levels identified using 1 ppm deviation 
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cut-off  (A) or identified between 1 to 2 ppm deviation (B) were plotted following a 
logarithmic transformation (base 2). Metabolites labeled with * represent peaks with 
multiple potential identifications, for which just one is shown in this figure but the full list is 
given in the Supporting Information. Dotted lines represent the adopted cut-off for 
significant changes in a given metabolite profile: log2 (metabolite intensity ratio) below -1 
or above 1 indicates a 2-fold change between the cell lines compared. All metabolites 
shown were statistically significant different between L. donovani and L. major.  
 
Table 2 - Comparison of metabolites levels detected both in spent medium and 
culture medium of L. donovani and L. major promastigotes at day 5 of in vitro 
growth 
 
 
 Average signal intensity  
 Cm Sm log2 (Sm / Cm) 
 L. donovani L. major L. donovani L. major L. donovani L.major 
glutamine 5.01E+06 5.34E+06 3.08E+06 3.73E+06 -0.70 -0.52 
glutamic acid 2.62E+06 1.95E+06 7.45E+05 2.57E+04 -1.82 -6.24 
arginine 8.99E+06 9.10E+06 6.66E+06 3.81E+06 -0.43 -1.26 
tryptophan 4.51E+06 4.49E+06 3.44E+06 1.89E+04 -0.39 -7.90 
L. donovani and L. major cell lines were seeded at 2.5x105 parasites/ml and 5 days after in vitro growth spent 
culture medium (Sm) was harvested and analyzed by LC-MS. The data are the intensities obtained from the 5 µl 
samples of extracted supernant analyses as described in Material and Methods. Metabolite levels detected in 
Sm were compared with intensity levels detected in the initial culture medium (Cm); log2 (Sm/Cm) below -1 or 
above 1 indicates a 2-fold change between the samples compared. 
 
Another interesting observation was the facts that L. major promastigotes had higher 
amounts of intracellular tryptophan and, remarkably, there was 180-fold lower level of this 
amino acid in the spent culture medium (Sm) of L. major compared with that of L. 
donovani (Table 2 and Fig. 5). Comparison with the culture medium (Cm) itself shows that 
tryptophan appears to be taken up extensively by L. major but not at all by L. donovani. 
Tryptophan is an essential amino acid in mammals but little is known about its metabolism 
in Leishmania. It was reported that it is not used as a carbon energy source by L. 
donovani but that it is catabolised to indole-3-lactate [23], the latter pathway was also 
predicted from the genome analysis of L. major [21]. Indole-3-lactate levels were, 
however, very similar in L. major and L. donovani and also in their Sm (Fig. 5). Another 
major catabolic route for tryptophan in some cells is via kynurenine to generate kynurenic 
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acid, anthranilate or NAD [24,25]. However, these metabolites also were at similar levels 
in the two species and their Sm.  Indeed, a recent report has shown that L. infantum is a 
NAD+ auxotroph and relies on the environmental supply of exogenous precursors to 
synthesize NAD+ by a salvage pathway [26]. They showed that the parasite cannot 
perform de novo synthesis and that addition of exogenous tryptophan had no effect on the 
intracellular NAD+ content [26]. Our data, however, showing different metabolic patterns 
for L. donovani and L. major (Table 2 and Fig. 5) reveal some marked differences in the 
uptake or release of the metabolites by the two species. Most dramatic is the finding that 
the tryptophan levels in the Sm of L. major were about 240-fold lower than  in the initial 
culture medium, while no significant changes were detected for L. donovani (1.3-fold 
lower).  Thus there was a remarkable uptake of tryptophan by L. major promastigotes. 
These two metabolites were also higher in L. major cell extracts compared with those of L. 
donovani (Fig. 4). Furthermore, differences between the lines were found for metabolites 
that potentially are produced from tryptophan (Fig. 5), suggesting possible differences in 
the route used by the parasites to metabolize this amino acid. Kynurenine and 
anthranilate were present in lower levels in L. major Sm while indole-3-lactate and 
kynurenic acid were at greater levels in L. major Sm (Fig. 5). These data strongly suggest 
that there are species differences in this area of metabolism with L. major having greater 
metabolic capacity than L. donovani or L. infantum, however further analysis is required to 
obtain a full understanding of this variation. 
 
Overall the differences in the amino acids levels in L. donovani and L. major presumably 
reflect the differing metabolism of the species, but this also will be affected by the 
conditions. Snapshot data such as those obtained in this study always have to be 
interpreted carefully and the recent demonstration that de novo synthesis of serine, 
glycine and  proline was repressed in the presence of exogenous amino acids provides a 
good example of the complex interplay that exists  [20]. However, the data that we have 
generated so far provide a framework within which to conduct the further studies.  
 
Another interesting difference detected between the two species in this analysis is the 
higher abundance of aspartyl dipeptides in L. donovani than in L. major (Fig. 4). The 
explanation for this is unclear, but it seems likely that they result from the activity of 
dipeptidases about which little is known currently but presumably they may be important 
components of the hydrolysis of proteins and the differing levels between the two species 
suggest that these are not identical in the two species.   
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Figure 5. Comparison of tryptophan and derivative metabolite levels between L. 
donovani and L. major promastigotes. L. donovani and L. major promastigotes were 
harvested after 5 days of in vitro growth and cell extracts (E) or spent media (Sm) 
analyzed by LC-MS; initial culture medium (Cm) was also analyzed by LC-MS. Intensity 
levels of tryptophan and derivatives (indole-3-lactate, kynurenine, anthranilate, NAD, 
kynurenic acid) are shown. Graphs within boxes represent metabolites for which at least a 
2-fold difference between L. donovani and L. major was observed. Key: dotted line, 
multiple steps; dotted arrow, not reported in Leishmania; values above the bars 
correspond to the average intensity ratio between L. donovani and L. major following 
logarithmic transformation (base 2) for E, Sm or Cm. Data are means from four biological 
replicates ± standard deviation. 
 
 
Much of the current knowledge about Leishmania metabolic pathways has been inferred 
from the genome sequences and is based on what occurs in other organisms, so it is 
necessary to obtain experimental evidences to confirm the functioning of the described 
pathways or gain insights into possible new ones. This study is a step towards this goal 
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although further analyses, especially involving amastigotes, are required in order to 
discover all of the crucial components of each Leishmania species that lead to the 
distinctive clinical outcomes. 
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Supporting Information 
 
 
 
Figure S1. Overall intracellular metabolite levels for each compound category in L. 
donovani and L. major promastigotes. Sum of total intracellular metabolite intensities 
from L. donovani  and L. major promastigotes identified by LC-MS analysis at day 5 of in 
vitro growth grouped by compound categories: vitamins and cofactors, sterol and prenol 
lipids, sphingolipids (SL) and sphingoid bases, organic acids, nucleosides and nucleoside 
conjugates, ketones and aldehydes, heterocyclic molecules, glycerophospholipids, 
glycerolipids, fatty acyls, carbohydrates and carbohydrate conjugates, amino acids and 
amino acid conjugates. 
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Table S1 – Metabolites identified below 1 ppm deviation in samples of L. donovani 
and L. major promastigotes at day 5 of in vitro growth. For each compound the 
following information is shown: ionisation (ESI) mode; detected mass; retention time (min); 
putative metabolite identification; ppm deviation between detected mass and theoretical 
mass of the putative metabolite identified; intensity per 25 μg cell protein for each sample; 
average intensity per 25 μg cell protein in each cell line ; standard deviation in each cell 
line; ratio of average intensity per 25 µg cell protein between the different cell lines; 
Student’s T test L. donovani versus L. major indicating whether or not there was a 
statistically significant difference; decision on whether or not the compound was 
significantly changed in level based on a two-fold or higher average difference in signal 
intensity and statistical significant (p<0.05) between L. donovani and L. major; compound 
category. 
 
Table S2 – Metabolites identified between 1-2 ppm deviation in samples of L. 
donovani and L. major promastigotes at day 5 of in vitro growth. The data presented 
are as described for Table S1. 
 
Tables S1 and S2 are available in the electronic version of the thesis. 
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Leishmaniasis, a vector-borne parasitic disease that affects millions of people, mainly the 
world’s poorest ones, is considered a neglected tropical disease, together with other 
infections such as Chagas disease and schistosomiasis. The fact that the number of 
annual deaths does not mirror the impact in the populations is the main reason why 
neglected tropical diseases have been neglected as important public health threats. 
Although, taking into account that this group of diseases elicits chronic morbidity without 
causing death, leading to millions of disabled people, the level of importance is equivalent 
to other diseases such as malaria or HIV/AIDS. The lack of economic opportunity offered 
by neglected tropical diseases to multinational pharmaceutical companies, as the 
diseases occur almost exclusively in developing countries, has contributed to the slow 
progress in the development of new diagnostic tools, drugs and vaccines that could lead 
ultimately to the eradication of the diseases558. Thus as an aid to tackling these 
devastating diseases, researchers have embarked on the study of the parasites’ cell 
biology and evaluation of the strategies and requirements necessary for the parasites to 
invade successfully, survive and persist inside mammalian hosts.  
 
In the recent years many progresses have been achieved in Leishmania research, both 
due to the annotation of the genome sequence of different Leishmania species203, 204, 210 
and the development of tools such as proteomics and metabolomics and the application of 
these to the study of the parasite559, 560. The primary goal underlying the comparison of 
Leishmania genomes has been the search for species-specific genes that could explain 
the differences in the clinical outcome induced by visceral and cutaneous species. 
Surprisingly, however, just a few species-specific genes were identified202, highlighting the 
fact that Leishmania parasites possess other means such as regulation of protein 
expression by post-translational modifications that are crucial for adaptation to different 
environments during its life cycle281, 282. In addition, the recent genome analyses describe 
other ways by which Leishmania species can differ rather than by the absence or 
presence of certain genes. Variations in chromosome copy number or gene dosage are 
potential contributors for Leishmania genetic plasticity and diversity203, 204. Leishmania 
genome plasticity had been previosuly experienced during attempts to delete essential 
genes252-254, 426, 561-564 or in drug resistance strains255, 256, but aneuploidy was recently 
reported as a natural genomic feature in different Leishmania species203, 204. As the 
parasite regulates protein expression mainly at post-transcriptional levels, proteomics 
should provide insights into the mechanisms of differentiation, virulence and drug 
resistance. Indeed, proteomics analysis has been used to compare the protein expression 
profiles of different Leishmania developmental stages221, 227, 242, 244, 245, to investigate 
protein secretion565, to carry out serum protein profiling during visceral leishmaniasis566, to 
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identify novel antigens for development of new diagnostic tools and vaccines and to 
investigate the changes in protein expression in attenuated or drug-resistant cell lines 567-
569. However, the methods need to be developed further since using the current ones 
results in membrane proteins being under represented and the lack of sensitivity leads to 
the over-representation of the most abundant proteins560. Metabolomics, now seen as an 
emergent area in the study of parasites, mainly due to the development of new methods 
and use of better technology201, 206-209, 559, 570-572, has been quite extensively applied to 
study other diseases, such as cancer, with the aim of identifying disease biomarkers for 
establishing preventative or therapeutic approaches205. Since the interaction between 
metabolites and specific targets is dynamic, an integrated analysis of metabolomics and 
other -omics may provide an excellent opportunity to detect changes not possible to 
determine when studying just one component of the cell by itself. It is thought that 
metabolomics approaches will allow the detection of subtle changes in the cell biology of 
the parasite that are crucial for its adaptation and survival but that would not be detected 
by other means. Although, the challenges posed by an integrative analysis are enormous, 
mainly due to the high flux and rapid turnover of metabolites, the potential of this kind of 
approach for improving the understanding of Leishmania cell biology are also huge, since 
it is expected to provide a “real time picture” of “what is happening” in a cell under different 
situations.  
 
On the other hand, recent advances in understanding the parasite-host interaction have 
elucidated the role of different cells and molecules of the immune system during the early 
phase of Leishmania infection, this is particularly important as the nature of the early 
parasite-host interactions will influence the parasite-specific adaptive immune responses 
and ultimately the outcome of the disease (reviewed by Kaye P. and Scott P.573 ). 
Furthermore, the generation of transgenic parasites expressing firefly luciferase and/or 
fluorescent proteins have expanded the capacity to detect and quantify the parasite in 
different experimental situations, in particularly the in vivo imaging of the transgenic 
parasites in a live host 574, 575, which can be used to screen potential chemotherapy drugs 
and vaccines. Vaccines formulations comprising the whole live, killed, attenuated or 
genetically modified parasites and also recombinant proteins have been evaluated, alone 
or in the presence of adjuvants and using different delivery systems. Even though 
considerable progresses in the understanding of the mechanisms involved in protective 
immunity have been made, the lack of correlation between vaccine efficacy in the mouse 
model and humans is still a major problem. Experimental vaccines have frequently failed 
to confer significant protection against natural exposure in people, suggesting that the 
parameters considered such as the generation of Th1 responses and the reduction of 
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lesion size and/or parasite number following mice infection may not necessarily mimic the 
requirements for protection against natural transmission in humans.  
 
Advances in the understanding of Leishmania cell biology and the nature of the parasite-
host interactions have been great in recent years, nevertheless there is no human vaccine 
currently available and chemotherapy is far from being satisfactory, with associated high 
costs and an alarming increase in drug resistance84-86.  
 
In this study were used different approaches to gain insights into the role of TDR1 in 
visceral species of Leishmania, L. infantum and L. donovani. TDR1, first identified in L. 
major, shows high conservation within the different Leishmania species, suggestive of an 
important role in the parasite. TDR1 possesses an unusual two domain nature with active 
sites characteristic of Grx and GSTO and is able to use GSH as the reductant to catalyze 
thiol transferase and dehydroascorbate reductase activities. The enzyme was implicated 
in the activation of pentavalent antimonials by its reduction to the toxic form, although this 
was not shown to occur in vivo90. Indeed, analysis of TDR1 gene expression in L. 
braziliensis and L. guanyensis parasites isolated from patients with different antimonial 
treatment outcomes showed no differences in the expression levels576, although this result 
should be interpreted with caution as mRNA levels often do not mirror protein expression 
in Leishmania. Another enzyme identified in L. major, an arsenate reductase known as 
ACR2, was reported to be involved also in pentavalent antimonial reduction and 
expression in L. infantum promastigotes led to an increase in the sensitivity of intracellular 
amastigotes to the drug91. The ability to reduce pentavalent antimonials clearly could only 
be a side-activity of TDR1’s main role in the cell. There is high similarity between TDR1 
and a T. cruzi enzyme named Tc52, which was previously reported as an 
excreted/secreted protein able to modulate the host’s immune response to infection and 
consequently considered a virulence factor555, 577. Moreover, deletion of both Tc52 alleles 
was not possible showing the essentiality of the gene for parasite survival578. These 
findings led us to investigate whether TDR1 could have a similar role in Leishmania 
parasites, through the evaluation of the immune response induced by the recombinant 
protein and its potential to elicit protection in Balb/c mice from infection with L. infantum 
promastigotes. In addition, in order to get definitive data on the role of TDR1 in visceral 
Leishmania species (L. infantum and L. donovani), we attempted to generate TDR1 null 
mutants by homologous recombination, a strategy commonly used to delete Leishmania 
genes249 to study their role. This is the most common approach with this parasite, as 
interference RNA (RNAi) does not operate in these parasites, apart from L. braziliensis, 
due to the lack of RNAi machinery579. 
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As reported previously for L. major90, TDR1 expression in L. infantum parasites is higher 
in the amastigote forms, which could indicate a specific role for the protein in the 
intracellular stage of the parasite [Chapter 4, section 4.2]. Moreover, we have detected 
TDR1 in L. infantum promastigotes and amastigotes spent medium, which could suggest 
a role for TDR1 in the interaction with the host. Recently was shown that Leishmania 
release exosomes which contain a surprisingly large number of proteins from a wide 
range of cellular pathways279 and thus TDR1 may be included in these structures although 
it was not found in the study279. Balb/c immunization with rTDR1 led to an increase in 
CD8-T cell splenic population and a decrease in IL-10 production in the chronic phase of 
infection; however this was not sufficient to elicit high levels of protection. The high levels 
of IgG1 in the serum of rTDR1-immunized mice suggest a dominance of Th2 response, 
resulting in weak protection against infection, although the role of antibodies in 
Leishmania infection is still controversial. In many cases, purified antigens are weak 
immunogens and the immune response generated is not of a sufficient magnitude to 
confer immunity. We have attempted to enhance the levels of protection induced by TDR1 
through the use of an adjuvant, CpG, and a DNA vaccine encoding the protein, which lead 
to the expression of Leishmania antigens folded in its native conformation, potentially with 
unaltered antigenicity, stimulating both cellular and humoral immune reponses due to the 
ability of DC to present the encoded antigen in the context of MHC class I and MHC class 
II117, 147. However, neither immunization of rTDR1 in the presence of CpG or delivery as a 
DNA vaccine improved the levels of protection obtained with the protein alone [Chapter 4, 
section 4.2]. Clearly TDR1 does not have a significant effect on the immune response to 
infection as that observed for T.cruzi Tc52, whose similarity led us to perform this study, 
showing that it has a different role in the parasite and host-parasite interaction. 
 
The generation of viable L. infantum and L. donovani TDR1 null mutants has shown that 
the gene is not essential in either species [Chapter 4, sections 4.3 and 4.4] and 
highlighted a “new reality” in the genomic plasticity and diversity of Leishmania parasites, 
which clearly demonstrates the existence of aneuploidy as a natural genomic feature 
more common than reported previously; indeed the Leishmania genome has been 
considered to be predominantly diploid. Deletion of L. donovani TDR1 was only achieved 
after 3 rounds of transfection due to the presence of three copies of the gene, while L. 
infantum TDR1 null mutants were obtained after 2 and 4 rounds, suggesting variable 
ploidy in the L. infantum population. Previous studies have reported aneuploidy during 
attempts to delete genes by homologous recombination, described as a strategy used by 
Leishmania parasites to maintain essential genes252-254; clearly not the case of TDR1 
gene; with exceptions of L. major chromosome 1 trisomy250 and chromosome 31 
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tetraploidy56. Leishmania genomic plasticity through chromosome copy number variation 
as a natural genomic feature was not suggested until Sterkers and co-workers264 
described a phenomenon, named chromosomal moisacism, in which every chromosome 
was observed in at least 2 ploidy states. Subsequently, genome sequence analysis of L. 
donovani and L. braziliensis as well as new refined versions of L. major, L. infantum and 
L. braziliensis genomes, using improved technologies, allowed the detection of genomic 
features not described in the previous genome sequence analysis202, 210 and provided 
evidence for natural aneuploidy203, 204. The consequences of chromosome and gene copy 
number variations are not yet fully understood, but this feature of the Leishmania genome 
shows that evolution is driven by large structural changes, which are generally detrimental 
for other organisms. Clearly this is not so for Leishmania, which copes well with 
aneuploidy and presumably takes advantage from it. This unusual variation is not only 
observed between species but also among strains and is likely to be important in the 
ability of Leishmania to cause disease and also be involved in drug resistance203, 204.  
 
Generation of the L. donovani TDR1 null mutant and respective add-back cell lines, 
necessary to control for any phenotypic changes not due to the gene deletion, allowed the 
analysis of L. donovani phenotype in the absence of TDR1 [Chapter 4, section 4.4]. Based 
on TDR1 in vitro activities and similarities to GSTO, a natural approach was to test the 
susceptibility of TDR1 null mutant parasites to oxidative and nitrosative stress as well as 
to metal-related compounds. GSTs play a key role in the detoxification of a wide range of 
toxic molecules, including products resulting from oxidative stress as well as exogenous 
products such drugs, through the conjugation with GSH431-433, 435. In order to survive, 
Leishmania parasites need to cope with the macrophage oxidative burst, thus it could be 
predicted that an enzyme with such characteristics as TDR1 would play an important role 
in the parasite’s survival against this. However, TDR1’s similarity with GSTO lead us to 
predict that TDR1 may have another role in the cell, as this class of GSTs possess 
characteristics of Grxs437. Indeed, TDR1 null mutants did not show an increase in 
susceptibility to oxidative and nitrosative stress, demonstrating that TDR1 is not involved 
in the parasite’s defense against this kind of stresser. In fact this result was not 
unexpected since the parasite has a wide range of proteins, such as tryparedoxins, 
tryparedoxin peroxidase, trypanothione S-transferase, ascorbate peroxidase, and also low 
molecular mass thiols, which have a crucial role in the parasite antioxidant defense364, 580. 
Although, TDR1 null mutants were more sensitivity to trivalent antimony and trivalent 
arsenite than the WT parent cell line, which could suggest an involvement of TDR1 in drug 
detoxification, no differences were detected in the susceptibility of Leishmania infected 
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macrophages to treatment with SSG and thus the results did not support the role of TDR1 
in drug reduction and activation nor as a detoxifying enzyme. 
 
The opportunity to evaluate the changes induced by TDR1 deletion in L. donovani 
promastigotes through the use of an untargeted metabolomics approach facilitated the 
detection of changes that suggested TDR1’s involvement in the redox regulation of 
enzymes. As mentioned above, untargeted metabolomics provides a “real time picture” of 
the cell and thus changes that would not be detect by other techniques or not considered 
as a hypothesis are likely to be identified. This is particularly relevant to situations in which 
major phenotypic differences are not observed after gene deletion due to the fact that the 
cell is able to cope with the subtle changes and the approach has a lot to offer in 
understanding how cells adapt to different challenges. 
 
Analyses of the TDR1 null mutant metabolome revealed few but specific changes in the 
levels of metabolites participating in Leishmania energy and amino acid metabolism, 
consistent with a possible role of TDR1 in enzyme redox regulation. In other organisms, 
metabolic reconfiguration has been attributed to the inactivation of enzymes through S-
glutathionylation, a post-translational modification which is promoted and readily reversed 
by Grxs and GSTs464, 507, 540, 581. S-glutathionylation induces functional changes in target 
proteins, either activation or inhibition, leading to alteration of cellular pathways in 
response to oxidative stress. Moreover, S-glutathionylation can occur under physiological 
conditions as a redox-regulatory mechanism502, 582, 583. The use of protein post-
translational modifications by Leishmania parasites fits well with the fact that the parasite 
seems genetically pre-adapted to the different life stages, supported by the high degree of 
genome conservation and synteny between the different Leishmania species and the 
identification of few species-specific genes despite the distinct clinical outcomes202. 
Rosenzweig and co-workers have reported the use of post-translational modifications 
such as phosphorylation and methylation during L. donovani differentiation281. Thus, it is 
seems entitrely feasible that the parasite uses S-glutathionylation to regulate the 
expression of certain enzymes, depending on the environmental conditions, as a 
mechanism to cope with changes in nutrient availability, temperature and pH among 
others, and to survive successfully in different hosts. Although S-glutathionylation has 
been extensively reported to occur in mammals516, 517, 529, 584, plants518, 524, yeast585, green 
algaes586 and also in P. falciparum587 and T. brucei419, the effect of S-glutathionylation on 
enzyme activity and subsequently cellular function in vivo remains to be elucidated and 
this type of modification has not yet been reported in Leishmania. Indeed, we were able to 
add experimental support to our metabolomics driven hypothesis, by the demonstration 
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that TDR1 is able to catalyse the reduction of glutathionylated protein and peptide 
substrates in vitro. Although, TDR1 can efficiently catalyze deglutathionylation, the low 
affinity for the peptide used in this study compared with Leishmania Grx1, suggests 
substrate specificity and thus the involvement of TDR1 in the regulation of specific 
enzymes, a characteristic already reported for T. brucei and Chlamydomonas reinhardtii 
Grxs. This may explain why many organisms have a specialized set of glutaredoxin 
isoforms located in various cellular compartments and with distinct roles496, 540, 588, 589. 
 
The fact that the TDR1 null mutant was able to infect macrophages in vitro and mice as 
well as the WT parent line shows that the gene is not essential for parasite virulence and 
survival, even though changes at a metabolome level were detected. Indeed, the growth 
conditions used for the L. donovani TDR1 null mutant (a rich medium, where both glucose 
and amino acids are abundant) may have masked the effect of gene deletion, and the 
metabolic re-configuration that we discovered as an adaptation mechanism for survival 
may not be possible in the natural Leishmania environment, when glucose or amino acids 
are scarce. 
 
Throughout the development of the work presented in this thesis, metabolomics analysis 
applied to Leishmania parasites undertook an enormous evolution which involved 
improvements in the experimental protocols enabling the extraction of Leishmania 
promastigotes metabolites, together with the increase in sensitivity and resolution of LC-
MS and also the development of software to help in the identification of Leishmania 
metabolites201, 206, 207, 570. Despite not initially being part of the thesis work plan, the 
opportunity to apply this new methodology to characterize the TDR1 null mutants, as 
described above, brought clear advantages to the study. Thus, we have carried out the 
characterization of L. donovani WT promastigotes development in vitro [Chapter 4, section 
4.6] as well as a comparison between a visceral (L. donovani) and a cutaneous (L. major) 
Leishmania species [Chapter 4, section 4.7] at a metabolome level, although the latter is 
still work in progress.  
 
Analysis of L. donovani promastigotes during in vitro growth, particularly following the 
changes that occur as the parasite differentiates from procyclic (logarithimic phase) to 
metacyclic forms (stationary phase), should provide valuable information on the 
requirements for the development of Leishmania infective forms and consequently lead to 
a better understanding of the mechanisms underlying a successful differentiation into the 
intracellular amastigote forms. Indeed, we were able to show that the metabolome of L. 
donovani promastigotes undergo significant changes, supporting the existence of different 
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developmental promastigotes stages590, related with adaptations to the nutrient availability 
and also metacyclogenesis, which includes some known biochemical changes such as 
lipophosphoglycan and surface protein expression, vital for a successful transmission to 
the mammalian host7, 591-594. Promastigotes in logarithmic phase were significantly distinct 
from stationary phase parasites reflecting, as expected, two different populations from 
active to non-dividing cells. Parasite remodelling was highlighted by the significant 
structural changes observed in glycerophospholipids and increase in sphingolipids, 
already shown to be essential for parasite differentiation335. Furthermore, it was possible 
to link some of metabolome data with previous results obtained either through genomic or 
proteomic analysis, increasing our knowledge about the changes underlying 
promastigotes development. The data that were obtained clearly support the concept of 
studying Leishmania and other parasites through the use of an -omics integrative 
approach. 
 
Overall, the study detailed in this thesis has generated important information about the 
potential role of TDR1 in vivo and also the application of new metabolomes approaches to 
characterize Leishmania null mutants as well as different developmental stages of the 
parasite. 
 
Following this work, further investigation should address the importance of TDR1 as a 
deglutathionylating enzyme in vivo, through the identification of TDR1-specific target 
proteins and the effect of TDR1 on the target proteins’ activities. This will elucidate 
whether Leishmania employs S-glutathionylation for regulatory or protection purposes. 
This has not yet been reported for Leishmania, but has been reported to occur in a wide 
range of organisms including P. falciparum and T. brucei parasites. Such analyses would 
also be likely to prove a new role for the considerable levels of free glutathione that occur 
in trypanosomatids. These organisms differ form others in possessing trypanothione as 
their main low molecular weight thiol. This leads to the inevitable question, yet to be 
resolved, of whether trypanothione can form a mixed-disulfide bridge with an accessible 
free thiol on a protein, protecting specific cysteine residues from irreversible oxidation, or 
modulating protein activities. 
 
Undoubtedly a better understanding of how the parasite regulates many cellular 
processes through the use of post-translational modifications such as S-glutathionylation 
will lead to a rethink of the ways in which we can challenge the parasite through exploiting 
new drug targets.  
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